0001213900-23-092268.txt : 20231204 0001213900-23-092268.hdr.sgml : 20231204 20231201214305 ACCESSION NUMBER: 0001213900-23-092268 CONFORMED SUBMISSION TYPE: 6-K/A PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20231204 DATE AS OF CHANGE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fresh2 Group Ltd CENTRAL INDEX KEY: 0001786511 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FILING VALUES: FORM TYPE: 6-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39137 FILM NUMBER: 231461164 BUSINESS ADDRESS: STREET 1: 650 FIFTH AVENUE STREET 2: SUITE 2416 CITY: NEW YORK STATE: NY ZIP: 10019-6108 BUSINESS PHONE: 1 917-397-6890 MAIL ADDRESS: STREET 1: 650 FIFTH AVENUE STREET 2: SUITE 2416 CITY: NEW YORK STATE: NY ZIP: 10019-6108 FORMER COMPANY: FORMER CONFORMED NAME: AnPac Bio-Medical Science Co., Ltd. DATE OF NAME CHANGE: 20190826 6-K/A 1 ea189176-6ka1_fresh2.htm AMENDMENT NO. 1 TO FORM 6-K

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K/A

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2023

 

Commission File Number: 001-39137

 

Fresh2 Group Limited

 

650 5TH AVE STE 2416

NEW YORK, NY 10019-6108

United States

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒     Form 40-F  ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Form 6-K/A is being filed as an amendment to the Form 6-K dated November 9, 2023 (the “Original Form 6-K”). The purpose of this Form 6-K/A is to amend Exhibits 99.1 and 99.2 of the Original Form 6-K. The amendments made in this document are as follows:

 

  Numerical and Wording Revisions: We have made necessary corrections to certain numerical data and wording to ensure accuracy and clarity. These revisions do not materially alter the financial condition or results of operations previously reported.
       
    1. We corrected disclosures regarding loss from disposal of Changwei on page F-18.
       
    2. We corrected disclosures regarding revenues from related parties and third parties for the six months ended June 30, 2023 on page F-18.
       
    3. We corrected disclosures regarding B. Liquidity and Capital Resources on page 5:
       
      1) we changed the working capital deficit as of June 30, 2023 from RMB32,482 million to RMB32.5 million;
         
      2) we changed the value of convertible notes from US$2,000 million to US$2 million;
         
      3) we changed the two tranches of convertible notes sold from US$400 and US$1,600 to US$400,000 and US$1,600,000, respectively;
         
      4) we changed the first payment received from RMB1,697 (US$234) to RMB1,697,000 (US$234,000).
         
    4. We corrected the disclosures regarding capital expenditures for the six months ended June 30, 2022 and 2023 on page 6.

 

Additional Disclosures:

 

  1. We added and corrected disclosures regarding the GISN acquisition on page F-16 and page F-32, specific changes were made to 1) correct the disclosure to note the GISN acquisition is not from a related party, 2) correct the fair value of the assets acquired and liabilities assumed table to include ROU which was missed previously and added the omitted disclosure about revenue contributed by GISN for the six months ended June 30, 2023.

 

2.We added Information pertaining to recent dispositions to provide a more comprehensive understanding of our financial activities.

 

Accounting Policy Modifications: Changes have been made to reflect updates in accounting policy after the adoption of ASU 2017-04 in 2022 on page F-9.

 

Revision of Product Warranty and Return Policy Description: We have updated the descriptions of our product warranty and return policy to better reflect current practices and ensure transparency on page F-12.

 

Except as described herein, no other changes have been made to the Original Form 6-K.

 

1

 

 

EXHIBIT INDEX

 

Exhibit   Description
99.1   Unaudited Condensed Consolidated Financial Statements as of June 30, 2023
99.2   Management’s Discussion and Analysis of Results of Operations
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Fresh2 Group Limited
   
  By: /s/ Haohan Xu
  Name:  Haohan Xu
  Title: Chief Executive Officer
     
Dated: December 1, 2023    

 

 

3

 

 

EX-99.1 2 ea189176ex99-1_fresh2.htm UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023

Exhibit 99.1

 

FRESH2 GROUP LIMITED

 

INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Unaudited Condensed Consolidated Financial Statements   F-1
Unaudited Condensed Consolidated Balance Sheets as of December 31, 2022 and June 30, 2023   F-2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023   F-3
Unaudited Condensed Consolidated Statements of Equity (Deficit) for the Six Months ended June 30, 2022 and 2023   F-4
Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2022 and 2023   F-5
Notes to Unaudited Condensed Consolidated Financial Statements   F-6 – F-33

 

F-1

 

 

FRESH2 GROUP LIMITED 

(FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.)  

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”), except for number of shares and per share data)

 

   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
ASSETS            
Current assets:            
Cash and cash equivalents   16    495    68 
Prepayment   1,050    3,948    544 
Accounts receivable, net       270    37 
Accounts receivable-related party       11,450    1,579 
Amounts due from related parties, net       864    119 
Inventories, net       135    19 
Other current assets, net       414    57 
Current assets held for sale   12,633    9,777    1,348 
Total current assets   13,699    27,353    3,771 
                
Long term -prepayment       4,678    645 
Property and equipment, net       4,309    594 
Intangible assets, net       45,169    6,229 
Goodwill       36,503    5,034 
Right of use assets       223    31 
Long-term investments, net       39,783    5,486 
Noncurrent assets held for sale   26,770    20,193    2,785 
TOTAL ASSETS.   40,469    178,211    24,575 
                
LIABILITIES AND EQUITY/(DEFICIT)               
Current liabilities:               
Short-term debts   15    16    2 
Accounts payable       420    56 
Advance from customers       479    66 
Amounts due to related parties   1,214    592    82 
Lease liability-current       148    20 
Accrued expenses and other current liabilities   7,535    24,759    3,414 
Current liabilities held for sale   33,514    33,421    4,609 
Total current liabilities   42,278    59,835    8,249 
Deferred tax liabilities       2,938    405 
Lease liability-non-current       37    5 
Other long-term liabilities       903    125 
Noncurrent liabilities held for sale   7,595    2,434    336 
TOTAL LIABILITIES   49,873    66,147    9,120 
                
Commitments and contingencies   
 
    
 
    
 
 
                
Shareholders’ equity (deficit):               
Class A Ordinary shares ((US$0.01 par value per share; 2,400,000,000 shares authorized, 79,536,589 and 176,070,465 shares issued and outstanding as of December 31, 2022 and June 30, 2023, respectively)   5,494    12,181    1,680 
Class B Ordinary shares ((US$0.01 par value per share; 30,000,000 authorized, 3,573,100 and 3,573,100 shares issued and outstanding as of December 31, 2022 and June 30, 2023)   240    240    33 
Treasury shares (1)   (11,003)        
Additional paid-in capital   564,869    715,327    98,648 
Accumulated deficit   (577,539)   (648,303)   (89,405)
Accumulated other comprehensive income   4,263    13,079    1,804 
Total Fresh2 Group Limited shareholders’ equity (deficit)   (13,676)   92,524    12,760 
Non-controlling interest   4,272    19,540    2,695 
Total equity (deficit)   (9,404)   112,064    15,455 
                
TOTAL LIABILITIES AND EQUITY (DEFICIT)   40,469    178,211    24,575 

 

(1): 12,492,283 shares Class A Ordinary shares were held as treasury shares.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

F-2

 

 

FRESH2 GROUP LIMITED 

(FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.)  

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE LOSS

(Amounts in thousands of RMB and US$, except for number of shares and per share data)

 

   Six Months Ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Total revenues   
    4,936    681 
Cost of revenues   
    (4,039)   (557)
Gross Profit   
    897    124 
Operating expenses:               
Selling and marketing expenses   (463)   (6,070)   (837)
General and administrative expenses   (8,167)   (35,680)   (4,920)
Research and development expenses   
    (2,303)   (318)
Loss from operations   (8,630)   (43,156)   (5,951)
Non-operating income and expenses:               
Interest expense, net   (31)   (309)   (43)
Foreign exchange loss, net   (513)   
    
 
Share of net loss in equity method investments   
    (95)   (13)
Change in fair value of convertible debt   139    
    
 
Other income, net   
    21    3 
Loss from continuing operations before income taxes   (9,035)   (43,539)   (6,004)
Income tax benefit   
    79    11 
Loss from continuing operations   (9,035)   (43,460)   (5,993)
Loss from discontinued operations, net of taxes   (39,780)   (27,945)   (3,854)
Net loss   (48,815)   (71,405)   (9,847)
Net loss from discontinued operations attributable to noncontrolling interests   (740)   (641)   (88)
Net loss attributable to ordinary shareholders   (48,075)   (70,764)   (9,759)
                
Other comprehensive (loss) income, net of tax:               
Foreign currency translation differences   (162)   8,816    1,216 
Total comprehensive loss   (48,977)   (62,589)   (8,631)
Total comprehensive loss attributable to noncontrolling interests   (740)   (641)   (88)
Total comprehensive loss attributable to ordinary shareholders   (48,237)   (61,948)   (8,543)
                
Amounts attributable to ordinary shareholders:               
Net loss from continuing operations   (9,035)   (43,460)   (5,993)
Net loss from discontinued operations   (39,040)   (27,304)   (3,766)
Net loss attributable to ordinary shareholders   (48,075)   (70,764)   (9,759)
                
Loss per Class A and B ordinary shares - basic and diluted               
Continuing operations
   (0.38)   (0.35)   (0.05)
Discontinued operations
   (1.66)   (0.22)   (0.03)
Net Loss
   (2.04)   (0.57)   (0.08)
                
Weighted average shares outstanding used in calculating basic and diluted loss per share               
Class A and Class B ordinary shares - basic and diluted
   23,603,709    124,374,140    124,374,140 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

 

FRESH2 GROUP LIMITED

(FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

SHAREHOLDERS’ EQUITY/(DEFICIT)

(Amounts in thousands of RMB and US$, except for number of shares and per share data)

 

   Class A
Ordinary Shares
   Class B
Ordinary Shares
   Treasury shares   Additional
Paid-in
   Accumulated   Accumulated
Other
(Loss)
   Total
Fresh2 Group
Limited
Shareholders’
Equity
   Non-controlling   Total
Equity
 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Income   (Deficit)   interest   (Deficit) 
Balance at January 1, 2022   16,604,402    1,096    2,773,100    185            465,334    (475,646)   4,532    (4,499)   5,817    1,318 
Net loss                               (48,075)       (48,075)   (740)   (48,815)
Issuance of shares in private placements, net of offering costs   14,382,693    961                    30,028            30,989        30,989 
Issuance shares for exercise of share option   417,702    27                    (27)                    
Issuance shares reserved for convertible loan   6,000,000    381                    (381)                    
Issuance shares for service   187,094    13                    (13)                    
Conversion of convertible loans                           27,739            27,739        27,739 
Share based compensation                           4,528            4,528        4,528 
Foreign currency translation differences                                   (162)   (162)       (162)
Balance at June 30, 2022 (unaudited)   37,591,891    2,478    2,773,100    185            527,208    (523,721)   4,370    10,520    5,077    15,597 

 

   Class A
Ordinary Shares
   Class B
Ordinary Shares
   Treasury shares   Additional
Paid-in
   Accumulated   Accumulated
Other
(Loss)
   Total
Fresh2 Group
Limited
Shareholders’
Equity
   Non-controlling   Total
Equity
 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Income   (Deficit)   interest   (Deficit) 
Balance at January 1, 2023   79,536,589    5,494    3,573,100    240    (12,492,283)   (11,003)   564,869    (577,539)   4,263    (13,676)   4,272    (9,404)
Net loss                               (70,764)       (70,764)   (641)   (71,405)
Issuance of shares in private placements, net of offering costs   62,885,707    4,355                    77,541            81,896        81,896 
Issuance shares for exercise of share options   663,900    46                    182            228        228 
Issuance shares for exercise of warrants   7,584,900    528                    6,383            6,911        6,911 
Issuance shares for acquisition   31,891,652    2,174                    66,788            68,962        68,962 
Issuance shares for service   3,500,000    243                    6,142            6,385        6,385 
Shares issued in private placement, cancelled subsequently   2,500,000    178                    (178)                    
Canceled treasure shares   (12,492,283)   (837)           12,492,283    11,003    (10,166)                    
Share based compensation                           3,766            3,766        3,766 
Disposition of Changwei                                           15,909    15,909 
Foreign currency translation differences                                   8,816    8,816        8,816 
Balance at June 30, 2023 (unaudited)   176,070,465    12,181    3,573,100    240            715,327    (648,303)   13,079    92,524    19,540    112,064 
Balance at June 30, 2023 (US$)   176,070,465    1,680    3,573,100    33            98,648    (89,405)   1,804    12,760    2,695    15,455 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

FRESH2 GROUP LIMITED

(FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

CASH FLOWS

(Amounts in thousands of RMB and US$, except for number of shares and per share data)

 

   Six Months Ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Operating activities:            
Net loss   (48,815)   (71,405)   (9,847)
Less: net loss from discontinued operations   (39,780)   (27,945)   (3,854)
Net loss from continuing operations   (9,035)   (43,460)   (5,993)
Adjustments to reconcile net loss to net cash provided by operating activities:               
Depreciation and amortization       2,960    408 
Share of net loss in equity method investments       95    13 
Share-based compensation       2,872    396 
Amortization of right of use assets       68    9 
Change in fair value of convertible debt   (139)        
Deferred tax benefits       (79)   (11)
Changes in operating assets and liabilities:               
Prepayment   (9,034)   (699)   (96)
Accounts receivable       (154)   (21)
Accounts receivable-related party       962    133 
Inventories       (129)   (18)
Other current assets   658    742    102 
Accounts payable       (569)   (78)
Advance from customers       458    63 
Accrued expenses and other current liabilities   (155)   1,384    191 
Lease liabilities       (60)   (8)
Net cash used in operating activities – continuing operations   (17,705)   (35,609)   (4,910)
Net cash used in operating activities –discontinued operations   (13,497)   (1,669)   (230)
Net cash used in operating activities   (31,202)   (37,278)   (5,140)
                
Investing activities:               
Purchases of property and equipment       (2,355)   (325)
Purchases of intangible assets       (8,980)   (1,238)
Cash acquired from acquisition       1,130    156 
Long-term investment       (38,106)   (5,255)
Net cash used in investing activities – continuing operations       (48,311)   (6,662)
Net cash (used in) provided by investing activities –discontinued operations   (817)   2,095    289 
Net cash used in investing activities   (817)   (46,216)   (6,373)
                
Financing activities:               
Proceeds from private placement   30,989    81,643    11,259 
Proceeds from exercising of warrants       6,911    953 
Proceeds from exercising of options       228    31 
Other long-term liabilities       982    135 
Payment to related parties   (160)   (549)   (76)
Net cash provided by financing activities – continuing operations   30,829    89,215    12,302 
Net cash used in financing activities –discontinued operations   (1,589)   (2,799)   (386)
Net cash provided by financing activities   29,240    86,416    11,916 
                
Effect of exchange rate changes on cash and cash equivalents   (362)   (2,443)   (337)
Net increase (decrease) in cash and cash equivalents   (3,141)   479    66 
Cash and cash equivalents at beginning of period   3,152    16    2 
Cash and cash equivalents at end of period   11    495    68 
                
Supplemental disclosure of non-cash activities:            
Conversion of convertible loans   27,739         
Right of use assets obtained in exchange for lease liabilities   8,954         
Receivable from issuance shares for private placement       253    35 
Issuances of shares for services       6,385    881 
Issuances of shares for acquisitions       68,962    9,510 
Additions to intangible assets through accrued expenses and other current liabilities       1,851    255 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-5

 

 

FRESH2 GROUP LIMITED

(FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.)

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in thousands of RMB and US$, except for number of shares and per share data)

 

1. ORGANIZATION AND PRINCIPAL ACTIVITIES

 

Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., the “Company”) was incorporated in the British Virgin Islands (“the BVI”) in January 2010. The Company incorporated a new subsidiary, Fresh2 Technology Inc. (“Fresh2”) on October 4, 2022. On February 1, 2023, the Group acquired GISN (HK) LIMITED (“GISN”), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commerce operations. On February 8, 2023, the Group acquired Fresh 2 Ecommerce Inc. (“Fresh2 Ecommerce”), a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants and other retail customers in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as food companies, manufacturers, agents, importers, and wholesalers to restaurants and other retail customers. On March 31, 2023, the Group closed an asset purchase with Easy Hundred Inc. (“Easy Hundred”), a U.S.-based e-commerce startup company in the foodservice industry. On July 17, 2023, the Group entered into a definitive Share Purchase Agreement to purchase 51% of Roxe Holding Inc. (“Roxe”). On July 27, 2023, Roxe entered into a Share Purchase Agreement with SpeedIn INC (“SpeedIn”) to purchase 100% of the shares of SpeedIn. Due to its poor operating results, on October 9, 2023, Roxe sold SpeedIn to Immensus LLC, a company owned by our CEO. On November 4, 2023 the Company and Fresh2 Technology entered into a definitive Share Purchase Agreement to purchase 38.61% of the common stock of Roxe.

 

The Company and its subsidiaries (collectively, the “Group”) provides a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants and other retail customers in the U.S.

 

Effective on July 28, 2023, the Group disposed its multi-cancer screening and detection test business (the “CDA Business”) in the People’s Republic of China (the “PRC” or “China”). The Group determined that the disposal of the CDA Business met the criteria to be classified as a discontinued operation (see Note 4) and, as a result, the CDA business’s historical financial results are reflected in the Group’s unaudited condensed consolidated financial statements as a discontinued operation.

 

As of June 30, 2023, the details of the Group’s principal subsidiaries are as follows:

 

Major subsidiaries  Percentage of
Ownership
  

Date of
Incorporation/

Acquisition

  Place of
Incorporation
  Major Operation
Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. *    100%  March 2010  the PRC  Cancer screening and detection tests
AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”) *

   100%  October 2012  the PRC  Cancer screening detection tests and device manufacturing
AnPac Bio-Medical Technology (Shanghai) Co., Ltd.*   100%  April 2014  the PRC  Cancer screening and detection tests
AnPac Technology USA Co., Ltd. (“AnPac US”) *

   100%  September 2015  the U.S.  Clinical trials for research on cancer screening and detection tests
Lishui AnPac Medical Laboratory Co., Ltd.*   100%  July 2016  the PRC  Cancer screening and detection tests
Shiji (Hainan) Medical Technology Ltd.*   100%  March 2013  the PRC  Cancer screening and detection research
Shanghai Muqing AnPac Health Technology Co., Ltd. (“AnPac Muqing”) (i)*   51%  March 2019  the PRC  Cancer screening and detection tests
Anpai (Shanghai) Healthcare Management and Consulting Co., Ltd.*   60%  August 15, 2021  the PRC  Cancer screening and detection tests
Fresh 2 Group Inc   100%  December 27, 2022  the U.S.  B2B e-commerce
Fresh 2 Technology Inc (“Fresh2”)   100%  October 4, 2022  the U.S.  B2B e-commerce
Fresh 2 Logistics Inc.   100%  February 22, 2023  the U.S.  B2B e-commerce
Fresh 2 HF Inc   100%  February 21, 2023  the U.S.  B2B e-commerce
Foodbase Group Inc   100%  January 19, 2023  the U.S.  B2B e-commerce
Fresh 2 EZ Inc   100%  March 3, 2023  the U.S.  B2B e-commerce
Fresh 2 information Inc (ii)   100%  April 12, 2023  the U.S.  B2B e-commerce
Fresh 2 Ecommerce (“Fresh2 Ecommerce”)   100%  February 8, 2023  the U.S.  B2B e-commerce
GISN (HK) Limited (“GISN”)   100%  February 1, 2023  Hongkong, PRC,  B2B e-commerce
Hua You Sheng Future (Beijing) Technology Co., Ltd.   100%  February 1, 2023  PRC  B2B e-commerce
Guanshi Technology (Beijing) Co., Ltd.   100%  February 1, 2023  PRC  Software development

 

* Subsidiaries that were sold subsequent to June 30, 2023.
(i) AnPac Muqing closed business in March 2023
(ii) On April 12, 2023, the Company, through its subsidiary, Fresh 2 EZ Inc to acquire 100% of equity interest in Fresh 2 information Inc from Roxe Holding Inc, a company controlled by Mr. Haohan Xu, with a nominal price. Fresh 2 information Inc has not begun operation yet.

F-6

 

 

2. LIQUIDITY AND GOING CONCERN UNCERTAINTIES

 

The Group’s principal sources of liquidity have been cash generated from financing and operating activities. As of June 30, 2023, the Group had RMB495 (US$68) of cash and cash equivalents and a working capital deficit of RMB34,148 (US$4,710). For the six months ended June 30, 2023, the Group incurred a loss from continuing operations of RMB43,460(US$5,993). For the six months ended June 30, 2023, net cash used in continuing operating activities was RMB35,609 (US$4,910). The above-mentioned facts raise substantial doubt about the Group’s ability to continue as a going concern. In assessing its liquidity, management monitors and analyzes the Group’s cash on-hand, its ability to generate sufficient revenue sources in the future, and its operating and capital expenditure commitments. With respect to capital funding requirements, the Group budgeted capital spending based on ongoing assessments of needs to maintain adequate cash. The Group intends to finance its future working capital requirements and capital expenditures from financing activities until the Group’s operating activities generate positive cash flows, if ever. Management expects continued capital financing through debt or equity issuances to support its working capital requirements.

 

On September 25, 2023, the Company entered into an agreement with an institutional investor to purchase up to US$2,000 of convertible notes, the convertible notes will be sold in two tranches (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at an exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at an exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment of RMB1,697(US$234) from this offering, excluding related financing costs.

 

The Group can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to the Group, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material adverse effect on the Group and its financial statements.

 

The unaudited condensed consolidated financial statements have been prepared assuming that the Group will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty.

 

3. SUMMARY OF PRINCIPAL ACCOUNTING POLICIES

 

(a) Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial reporting and pursuant to the applicable rules and regulations of the SEC pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

 

In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2023 and 2022 are not necessarily indicative of the results that may be expected for the full year. The information included in this report should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Group’s annual financial statements for the fiscal year ended December 31, 2022 filed with the SEC on May 16, 2023.

 

(b) Principles of consolidation

 

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Group. All inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power, has the power to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of the board of directors, or has the power to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders.

 

F-7

 

 

(c) Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Areas where management uses subjective judgement include, but are not limited to allowance for doubtful accounts, share-based compensation, deferred tax and uncertain tax position, useful lives of intangible assets and property and equipment, impairment of long-lived assets, goodwill and long-term investments and the purchase price allocation with respect to business combinations. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences could be material to the unaudited condensed consolidated financial statements. 

 

(d) Cash and cash equivalents

 

Cash and cash equivalents consist of cash on hand and demand deposits placed with banks which are unrestricted as to withdrawal or use and have original maturities less than three months. All highly liquid investments with a stated maturity of 90 days or less from the date of purchase are classified as cash equivalents.

 

(e) Accounts receivable and allowance for credit losses

 

Accounts receivable represents the amounts that the Group has an unconditional right to consideration and is recorded net of allowance for credit losses.

In 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The Group has adopted this ASC Topic 326 and several associated ASUs on January 1, 2023 using a modified retrospective approach. The adoption has no material impact to the Company’s consolidated financial statements. The Group estimated allowance for credit losses to reserve for potentially uncollectible receivable amounts periodically, considering factors in assessing the collectability of its accounts receivable, such as historical distribution of the age of the amounts due, payment history, creditworthiness, forward-looking factor, historical collections data of the customers, to assess the credit risk characteristics. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Group also makes specific allowance in the period in which a loss is determined to be probable. Accounts receivable are considered impaired and written-off when it is probable that all contractual payments due will not be collected after all collection efforts have been exhausted.

 

(f) Convenience translation

 

Amounts in US$ are presented for the convenience of the reader and are translated at the noon buying rate of US$1.00 to RMB7.2513 on June 30, 2023, representing the noon buying rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be converted, realized or settled into US$ at such rate or at any other rate.

 

(g) Long-term investments

 

The Group’s long-term investments include equity method investments and equity investments without readily determinable fair values.

 

Investments in entities in which the Group can exercise significant influence but does not own a majority equity interest or control are accounted for using the equity method of accounting in accordance with ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Under the equity method, the Group initially records its investment at cost and the difference between the cost of the equity investee and the amount of the underlying equity in the net assets of the equity investee is accounted for as if the investee were a consolidated subsidiary. The share of earnings or losses of the investee are recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Equity method adjustments include the Group’s proportionate share of investee income or loss, adjustments to recognize certain differences between the Group’s carrying value and its equity in net assets of the investee at the date of investment, impairments, and other adjustments required by the equity method. The Group assesses its equity investment for other-than-temporary impairment by considering factors as well as all relevant and available information including, but not limited to, current economic and market conditions, the operating performance of the investees including current earnings trends, the general market conditions in the investee’s industry or geographic area, factors related to the investee’s ability to remain in business, such as the investee’s liquidity, debt ratios, and cash burn rate and other company-specific information.

 

F-8

 

 

Investments in equity securities without readily determinable fair values are measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. No impairment on its long-term investments was recognized for the six months ended June 30, 2022 and 2023.

 

(h) Business combinations

 

The cost of an acquisition is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued. The costs directly attributable to the acquisition are expensed as incurred. Identifiable assets, liabilities and contingent liabilities acquired or assumed are measured separately at their fair value as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total of the cost of the acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the fair value of the identifiable net assets of the acquiree, the difference is recognized directly in earnings.

 

The determination and allocation of fair values to the identifiable net assets acquired, liabilities assumed and noncontrolling interest is based on various assumptions and valuation methodologies requiring considerable judgment. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determines discount rates to be used based on the risk inherent in the acquiree’s current business model and industry comparisons. Although the Group believes that the assumptions applied in the determination are reasonable based on information available at the date of acquisition, actual results may differ from forecasted amounts and the differences could be material.

 

(i) Asset Acquisition

 

We evaluate acquisitions pursuant to ASC 805, “Business Combinations,” to determine whether the acquisition should be classified as either an asset acquisition or a business combination. Acquisitions for which substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets are accounted for as an asset acquisition.

 

For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Common stock issued as consideration in an asset acquisition is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. However, as of the date of acquisition, if certain assets are carried at fair value under other applicable GAAP, the consideration is first allocated to those assets with the remainder allocated to the non-monetary identifiable assets based on relative fair value basis.

 

(j) Goodwill

 

Goodwill is the cost of acquired companies in excess of the fair value of identifiable net assets at acquisition date. Goodwill is not subject to amortization, but rather is evaluated for impairment at least annually. The Group evaluates its goodwill for impairment during the fourth quarter of its fiscal year or more frequently if indicators of potential impairment exist, in accordance with ASC 350, Intangibles - Goodwill and Other. Goodwill impairment is determined by comparing the estimated fair value of a reporting unit (generally defined as the businesses for which financial information is available and reviewed regularly by management) with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not deemed to be impaired. However, if the estimated fair value is below carrying value, further analysis is required to determine the amount of the impairment.

 

In the course of evaluating the potential impairment of goodwill, the Group may perform either a qualitative or a quantitative assessment. The Group’s qualitative assessment of potential impairment may result in the determination that a quantitative impairment analysis is not necessary. Under this elective process, the Group assesses qualitative factors to determine whether the existence of events or circumstances leads the Company to determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then performing a quantitative analysis is not required. However, if the Group concludes otherwise, then the Group performs a quantitative impairment analysis.

 

If the Group either chooses not to perform a qualitative assessment, or the Group chooses to perform a qualitative assessment but is unable to qualitatively conclude that no impairment has occurred, then the Group performs a quantitative evaluation. In the case of a quantitative assessment, the Group estimates the fair value of the reporting unit with which the goodwill that is subject to the quantitative analysis is associated and compares it to the carrying value. If the estimated fair value of a reporting unit is less than its carrying value, the excess is recorded as a goodwill impairment, which is limited to the total amount of goodwill allocated to that reporting unit.

 

F-9

 

 

For the six months ended June 30, 2022 and 2023, the Group performed a qualitative assessment for the reporting unit. Based on the requirements of ASC 350-20, the Group evaluated all relevant qualitative and quantitative factors, weighed all factors in their entirety and concluded that it was not more-likely-than-not that the fair value of the reporting unit was less than its carrying amount. Therefore, no goodwill impairment was recognized for the six months ended June 30, 2022 and 2023.

 

(k) Discontinued operations

 

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity’s financial results and operations. Included in the unaudited condensed consolidated statements of income and comprehensive income, result from discontinued operations is reported separately from the income and expenses from continuing operations and prior periods are presented on a comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

 

(l) Fair value of financial instruments

 

The Group applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements.

 

ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. 

 

Level 2—Other inputs that are directly or indirectly observable in the marketplace. 

 

Level 3—Unobservable inputs which are supported by little or no market activity.

 

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

  

The Group’s financial instruments include cash and cash equivalents, accounts receivables, accounts payable, other receivables, other payables and short-term debt. The carrying values of these financial instruments approximate their fair values due to their short-term maturities.

 

The Group elected the fair value option to account for its convertible loans. The Group engaged an independent valuation firm to perform the valuation. The fair value of the convertible loans as of December 31, 2022 and June 30, 2023 was RMB15 and RMB16 (US$2) calculated using the binomial tree model. The convertible loans are classified as level 3 instruments as the valuation was determined based on unobservable inputs which are supported by little or no market activity and reflect the Group’s own assumptions in measuring fair value. Significant estimates used in developing the fair value of the convertible loans include time to maturity, risk-free interest rate, straight debt discount rate, probability to convert and expected timing of conversion. Refer to Note 11 for additional information.

 

As the inputs used in developing the fair value for level 3 instruments are unobservable, and require significant management estimate, a change in these inputs could result in a significant change in the fair value measurement.

 

F-10

 

 

The following is a reconciliation of the beginning and ending balances for convertible loans measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of December 31, 2022 and June 30, 2023:

 

   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
Opening balance   27,859    15    2 
Conversion of convertible loans   (27,739)   
    
 
Loss (gain) on change in fair value of convertible loan   (144)   
    
 
Other comprehensive income -foreign exchange translations   39    1    
 
Total   15    16    2 

 

(m) Property and equipment

 

Property and equipment are stated at cost less accumulated depreciation and any recorded impairment. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, as follows:

 

Category  Estimated useful life
Furniture, fixtures and equipment  3-5 years
Motor vehicles  5 years

 

(n) Intangible assets

 

The Company’s intangible assets mainly include acquired software from business acquisition and asset acquisition. In business combinations, identifiable intangible assets acquired are measured separately at their fair value as of the acquisition date. For asset acquisitions, the cost of the asset acquisition is allocated to identifiable assets acquired based on a relative fair value basis. Intangible assets with finite lives are carried at cost less accumulated amortization. All intangible assets with finite lives are amortized using the straight-line method over the estimated useful lives.

 

Intangible assets have estimated useful lives from the date of purchase as follows:

 

Category  Estimated useful life
Software  5-10 years

 

(o) Impairment of Long-Lived Assets

 

The Company evaluates the recoverability of its long-lived assets, including property and equipment and the intangible assets and for impairment whenever events or changes in circumstances indicate that the carrying amount of its asset may not be fully recoverable. When these events occur, the Company measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the asset and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the asset, the Company recognizes an impairment loss based on the excess of the carrying amount of the asset over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the asset when the market prices are not readily available. The adjusted carrying amount of the asset is the new cost basis and is depreciated over the asset’s remaining useful life. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. No impairment of long-lived assets was recognized for the six months ended June 30, 2022 and 2023, respectively.

 

(p) Treasury shares

 

The Company accounts for treasury share using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account on the unaudited condensed consolidated balance sheets. At retirement of the treasury shares, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is allocated between additional paid in capital (up to the amount credited to the additional paid in capital upon original issuance of the shares) and retained earnings.

 

F-11

 

 

(q) Revenue recognition

 

The Group applies the ASU 2014-09, Revenue from Contracts with Customers — Topic 606 for its revenue recognition for all periods presented. The majority of the Group’s revenue comes from product sales of Asia food and consumable through its software application (“APP”). Revenue is recognized when the Group satisfies the performance obligations in an amount of consideration to which the Group expects to be entitled to in exchange for those goods. The Group evaluates the presentation of revenue on a gross or net basis based on whether it controls the goods provided to customers and is the principal (i.e., “gross”), or the Group arranges for other parties to provide the goods to the customers and is an agent (i.e., “net”).

 

The Group sells food and consumable products through its own APP. The Group utilizes external delivery service providers to deliver goods to its customers. The customers pay for the goods in advance. The Group recognizes product sales made through APP on a gross basis because the Group is acting as a principal in these transactions as the Company (i) is responsible for fulfilling the promise to provide the specified goods, (ii) takes on inventory risk and (iii) has discretion in establishing price. Revenues are recognized when control is transferred, which typically happens upon delivery. The Group’s contracts with customer are primarily on a fixed-price basis. Discounts and allowances provided to customers are recognized as a reduction in net sales as control of the products is transferred to customers.

 

The Group generally allows customers to return non-food items within 30 days of receipt of proof that the products are unused and included in the original package. For food products, the Group does not accept returns. Customers may be qualified to receive a refund for food products received with unacceptable quality within 2 to 30 days from the date of delivery. The Group estimates returns of the products and refund, which are deducted from sales in the period in which the related revenue is recognized. The determination of the Group’s product returns and refund accruals is based on historical experience with the sales of such products. The Group estimates and adjusts these accruals at each balance sheet date in accordance with changes in these factors

 

Contract balances

 

Contract assets relate to the Group’s conditional right to consideration for completed performance obligations under the contract. Accounts receivable are recorded when the right to consideration becomes unconditional. The Group does not have contract assets for the periods presented. In instances where the timing of revenue recognition differs from the timing of invoicing, the Group has determined that its contracts generally do not include a significant financing component.

 

Contract liabilities represent considerations received from customers in advance of satisfying the Group’s performance obligations under the contract, which are presented in “advance from customers” in the unaudited condensed consolidated balance sheets. The Group classifies contract liabilities as current based on the timing of when we expect to recognize revenue, which typically occurs within one year. Revenue recognized that was included in contract liabilities at the beginning of the period was nil for the six months ended June 30, 2022 and 2023, respectively. As of December 31, 2022 and June 30, 2023, contract liabilities amounted to nil and RMB479 (US$66), respectively.

 

Practical expedients

 

The Group has applied the following practical expedients:

 

(i) The transaction price allocated to the performance obligations that are unsatisfied, or partially unsatisfied has not been disclosed, as substantially all of the Group’s contracts have a duration of one year or less.

 

(ii) The Group recognizes incremental costs to obtain a contract as expenses when incurred because the amortization period would be one year or less. These costs are recorded within sales and marketing expenses.

  

(r) Research and development expenses

 

Research and development expenses primarily are comprised of costs incurred in performing research and development activities, including related personnel and consultant’s compensation, benefits, share-based compensation and related materials and supplies costs. The Group expenses research and development expenses as they are incurred.

 

F-12

 

 

(s) Leases

 

The Group adopted ASU No. 2016-02—Leases (Topic 842) as of January 1, 2022, using a modified retrospective transition method permitted under ASU No. 2018-11. This transition approach provides a method for recording existing leases only at the date of adoption and does not require previously reported balances to be adjusted. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional lease assets and lease liabilities on the consolidated balance sheets. The standard did not materially impact our unaudited condensed consolidated net earnings and cash flows.

 

Right-of-use (“ROU”) assets represent the Group’s rights to use underlying assets for the lease term and lease liabilities represent the Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, reduced by lease incentives received, plus any initial direct costs, using the discount rate for the lease at the commencement date. As the implicit rate in lease is not readily determinable for the Group’s operating leases, the Group generally use the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The Group’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Group will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Group accounts for lease and non-lease components separately. the Group has no finance leases for any of the periods presented.

 

Prior to the adoption of ASU No. 2016-02, leases were classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exist: (a) ownership is transferred to the lessee by the end of the lease term, (b) there is a bargain purchase option, (c) the lease term is at least 75% of the property’s estimated remaining economic life, or (d) the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an occurrence of an obligation at the inception of the lease. The Group has no capital leases for the six months ended June 30, 2022 and 2023.

 

(t) Warrants

 

The Group accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Group’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Group’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annual period end date while the warrants are outstanding.

 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. All warrants outstanding as of June 30, 2023 and December 31, 2022 do not meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815 and therefore, classified as equity.

 

(u) Share-based compensation

 

The Group accounts for share-based compensation in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). In accordance with ASC 718, the Group determines whether an award should be classified and accounted for as a liability award or an equity award. All the Group’s share-based awards were classified as equity awards and are recognized in the unaudited condensed consolidated financial statements based on their grant date fair values.

 

The Group has elected to recognize share-based compensation using the straight-line method for all share-based awards granted with graded vesting based on service conditions. The Group accounts for forfeitures as they occur in accordance with ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvement to Employee Share-based Payment Accounting. The Black-Scholes Model were applied in determining the estimated fair value of the options granted to employees and non-employees.

 

(v) Income taxes

 

The Group follows the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.

 

F-13

 

 

The Group accounted for uncertainties in income taxes in accordance with ASC 740. Interest and penalties related to unrecognized tax benefit recognized in accordance with ASC 740 are classified in the unaudited condensed consolidated statements of operations and comprehensive loss as income tax expenses.

 

For the six months ended June 30, 2022 and 2023, the Group did not have any significant unrecognized uncertain tax positions or any unrecognized liabilities, interest or penalties associated with unrecognized tax benefits. The Group does not believe that its uncertain tax benefits position will materially change over the next twelve months.

 

(w) Comprehensive loss

 

Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group’s comprehensive loss includes net loss and foreign currency translation differences, and is presented in the unaudited condensed consolidated statements of operations and comprehensive loss.

  

(x) Segment reporting

 

After the Group discontinued CDA business, the Group operates and manages its business as a single segment and the Group’s primary revenue are generated in the U.S. The Group has only one reportable segment for the six months ended June 30, 2023, in accordance with ASC 280, Segment Reporting. The Group’s Chief Executive Officer is the chief operating decision-maker that review the unaudited condensed consolidated financial results when making decisions about allocating resources and assessing the performance of the Group as a whole.

 

(y) Loss per share

 

Loss per share is calculated in accordance with ASC 260, Earnings per Share. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.

 

Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the share options, using the treasury share method. Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Group’s unaudited condensed consolidated statements of operations and comprehensive loss.

 

The rights, including the liquidation and dividend rights, of the holders of our Class A and Class B ordinary shares are identical, except with respect to voting. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to ten votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares under any circumstances. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis. For the six months ended June 30, 2022 and 2023, the net loss per share amounts are the same for Class A and Class B common ordinary shares because the holders of each class are entitled to equal per share dividends or distributions in liquidation.

 

The Group did not include share options, convertible debt and warrants in the computation of diluted earnings per share for the six months ended June 30, 2022 and 2023, because those were anti-dilutive for loss per share.

 

(z) Risks, Uncertainties and Concentrations

 

Concentration of credit risk

 

Financial instruments that potentially subject the Group to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivables. As of December 31, 2022 and June 30, 2023, the aggregate amounts of cash and cash equivalents of RMB14 and RMB62 (US$9), respectively, were held at major financial institutions located in the PRC and RMB1 and RMB268 (US$37), respectively, were deposited at banks located in U.S. and covered by the FDIC insurance program. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. There is a RMB 500,000 deposit insurance limit for a legal entity’s aggregated balance at each PRC bank.

 

F-14

 

 

As of December 31, 2022, no customer accounted for more than 10% of total accounts receivables. As of June 30, 2023, four customers accounted for 37%, 20%, 19% and 16% of total accounts receivables. The risk is mitigated by credit evaluations the Group performs on its customers.

 

Business, customer, supplier, political and economic risks

 

The Group’s e-commerce food-related business has a limited operating history. The recently acquired operations are subject to all of the risks inherent in the initial expenses, challenges, complications, and delays frequently encountered in connection with the formation of any new business.

 

The Group participates in a dynamic industry and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in industry standards; changes in certain strategic relationships or customer relationships; regulatory considerations; intellectual property considerations; and risks associated with the Group’s ability to attract and retain employees necessary to support its growth.

 

For the six months ended June 30, 2022, no customer accounted for more than 10% of the total revenues, respectively. For the six months ended June 30, 2023, the Group had one customer that accounted for 16% of total revenues.

 

For the six months ended June 30, 2022, no supplier accounted for more than for 10% of total cost of revenues. For the six months ended June 30, 2023, two suppliers that accounted for 22% and 22% of total cost of revenues, respectively.

 

As of December 31, 2022, no supplier accounted for more than 10% of total accounts payables As of June 30, 2023, three suppliers accounted for 25%, 14%and 12% of total accounts payables, respectively.

  

(aa) Recent accounting pronouncements

 

The Group is an emerging growth company (“EGC”) as defined by the Jumpstart Our Business Startups Act (“JOBS Act”). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Group. Early adoption is permitted. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the unaudited condensed consolidated financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, “‘Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). This ASU requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The amendments are effective for fiscal years beginning after December 15, 2023, and are applied prospectively to business combinations that occur after the effective date. The Group does not expect the adoption of ASU 2021-04 will have a material effect on the unaudited condensed consolidated financial statements.

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Group adopts as of the specified effective date. Unless otherwise discussed, the Group does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.

 

F-15

 

 

4. ACQUSITIONS

 

Business Combinations

 

The Group accounted the following acquisitions as business combinations in accordance with ASC 805. Acquisition-related costs incurred for the acquisitions are not material.

 

GISN acquisition

 

On January 28, 2023, the Company, through its subsidiary Fresh2, entered into a Share Purchase Agreement to acquire GISN (HK) LIMITED, a Hong Kong corporation (“GISN”). GISN and its subsidiaries provide technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Group’s efficiency in its e-commerce operations. The acquisition closed on February 1, 2023. The Company issued 8,785,530 Class A ordinary shares with fair value of RMB25,938 (US$3,848) to purchase all the issued and outstanding equity interest of GISN.

 

The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:

 

   Amount 
   RMB 
     
Total consideration   25,938 
      
Assets acquired and liabilities assumed:     
Cash acquired   1,028 
Accounts receivable   100 
Accounts receivable-related parties   12,073 
Other current assets   123 
Right of use assets   

283

 
Property and equipment   1,573 
Intangible assets   11,233 
Advance from customer   (1,013)
Accrued expenses and other current liabilities   (13,705)
Lease liabilities   (239)
Deferred tax liability   (2,808)
Total net assets acquired   8,648 
Goodwill   17,290 

 

The intangible assets are mainly attributable to software acquired through the acquisition, which are amortized over 10 years.

 

The following unaudited pro forma summary presents consolidated information of the Group as of the business combination had occurred on January 1, 2022.

 

   Unaudited Pro Forma 
   For the six months
ended June 30,
 
   2022   2023 
   RMB   RMB 
Revenue   10,149    4,936 
           
Net losses   51,322    (71,405)

 

For the six months ended June 30, 2023, the revenue contributed by GISN was RMB677 (US$93), which was included in the Group’s consolidated statement of operation and comprehensive loss.

 

F-16

 

 

Fresh2 acquisition

 

On February 7, 2023, the Company, through its subsidiary Fresh2, entered into a Share Purchase Agreement (the “Ecommerce Agreement”) to acquire Fresh 2 Ecommerce Inc, a Delaware corporation (“Fresh2 Ecommerce”), from Mr. Haohan Xu, the Company’s Co-CEO and Co-Chairman of the board of directors. Fresh2 Ecommerce is a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants well as other retail customers in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as food companies, manufacturers, agents, importers, and wholesalers to restaurants and other retail customers. The acquisition was closed on February 8, 2023. The Company issued 5,440,420 Class A ordinary shares with fair value of RMB17,304 (US$2,549) to acquire all the issued and outstanding equity interests in Fresh2 Ecommerce.

 

The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:

 

   Amount 
   RMB 
     
Total consideration   17,304 
      
Assets acquired and liabilities assumed:     
Cash acquired   71 
Other current assets   938 
Accounts payables   (950)
Accrued expenses and other current liabilities   (72)
Total net assets acquired   (13)
Goodwill   17,317 

 

None of the goodwill is expected to be deductible for income tax purposes. For the six months ended June 30, 2023, Fresh2 Ecommerce contributed revenue of 199 and loss of 86 to the group from February 8, 2023 to June 30, 2023. Pro forma results reflecting this transaction were not presented because it is not significant to the Group’s consolidated financial results.

 

Asset acquisition

 

On March 31, 2023, the Group closed an asset purchase with Easy Hundred Inc. (“Easy Hundred”), a U.S.-based e-commerce startup company in the foodservice industry. Pursuant to the Asset Purchase Agreement (the “EZ Agreement”), the Group acquired certain fixed assets of Easy Hundred and Easy Hundred’s intellectual property relating to ez100, 2Supply and 100WAY systems with total consideration consisting of RMB5,013(US$730) in cash and 17,665,702 Class A ordinary shares of the Company. The fair value of the shares issued was RMB25,720 (US$3,745).

 

The following table summarizes the fair value of the identifiable assets:

 

   Amount 
   RMB 
Property and equipment- furniture, fixtures and equipment   160 
Property and equipment- motor vehicles   434 
Intangible assets- software*   30,139 
Total consideration   30,733 

 

*Intangible assets refer to intellectual property relating to ez100, 2Supply and 100WAY systems.

 

F-17

 

 

5. DISCONTINUED OPERATION

 

In July, 2023, the Board approved the sale of its early cancer screening and detection business (the “CDA Business”), comprised of (i) AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”), a subsidiary based in Lishui, China, (ii) Anpac Technology USA CO., LTD. (“AnPac USA”), a subsidiary based in Pennsylvania and California, and (iii) Changhe Bio-Medical Technology (Yangzhou) Co., Ltd.(“Changhe”), a subsidiary based in Yangzhou, China. Accordingly, on July 28, 2023, the Group entered into Share purchase agreements with New-Horizon Bio-Medical Science Co., Ltd. (“New-Horizon”), a Hong Kong company focused on bio-medical technology, under which the Group agreed to sell 100% of the shares of AnPac Lishui and AnPac USA, which had experienced significant financial losses in its operations and are not expected to achieve a breakeven point in the immediate future, to New-Horizon in consideration of nil and nil, respectively. In addition, on July 28, 2023, the Group entered into a share purchase agreement with Ningkasai Technology (Shanghai) Co., Ltd. (“Ningkasai”), a PRC high-tech company specialized in nanotechnologies for life science applications, under which the Group agreed to sell 100% of the shares of Changhe, to Ningkasai for no consideration. The closing is expected to take place in November 2023.

 

The Group determined that the disposal of CDA Business met the criteria to be classified as a discontinued operation and, as a result, CDA business’s historical financial results are reflected in the Group’s unaudited condensed consolidated financial statements as a discontinued operation. The disposal of CDA Business represents a strategic shift that has a significant effect on the Group’s operations and financial results, which trigger discontinued operations accounting in accordance with ASC 205-20-45. The assets and liabilities related to the discontinued operations were retroactively classified as assets/liabilities held for sale, while results of operations related to the discontinued operations, including comparatives, were retroactively reported as income (loss) from discontinued operations for the six months ended June 30, 2022 and 2023, respectively.

 

In connection with the disposal of CDA business, the Group also sold its 70% equity interest in Changwei System Technology (Shanghai) Co., Ltd (“Changwei”) to Jiaxing Changxin Enterprise Management, LLP (“Changxin”) in consideration of US$350 (RMB2,538) and sold the remaining 29% equity interest in Changwei to Shanghai Yiyou Investment Management Co., LTD (“Yiyou”) in consideration of US$150 (RMB1,088). Yiyou further entered into an arrangement with Changxin and Ms. Ruoou Ying, pursuant to which the Group agreed to transfer 29% of Changwei’s shares to Changxin and 1% of the shares to Ms. Ruoou Ying (the “Changwei disposal”). The Group received the consideration in aggregated of RMB3,626 (US$500) from the Changwei disposal. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company. Loss from disposal of Changwei amounted to RMB16,724 (US$2,307) and was included in net loss from discontinued operations. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company.

 

The results of discontinued operations for the six months ended June 30, 2022 and 2023 were as follows:

 

   Six Months Ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Revenues:            
Revenues-third parties   3,972    2,937    405 
Revenues-related parties   1,241    91    13 
Total revenues   5,213    3,028    418 
Cost of revenues   (1,832)   (1,292)   (178)
Gross Profit   3,381    1,736    240 
Operating expenses:               
Selling and marketing expenses   (4,894)   (3,872)   (534)
General and administrative expenses   (15,629)   (8,593)   (1,185)
Research and development expenses   (4,330)   (3,438)   (474)
Impairment of intangible assets   (7,911)   
    
 
Impairment of goodwill   (12,758)   
    
 
Loss from operations   (42,141)   (14,167)   (1,953)
Non-operating income and expenses:               
Interest expense, net   (161)   (81)   (11)
Foreign exchange gain, net   7    9    1 
Share of net loss in equity method investments   (87)   (88)   (12)
Other income, net   472    3,106    428 
Loss from operations for discontinued operations   (41,910)   (11,221)   (1,547)
Loss from disposal of a subsidiary   
    (16,724)   (2,307)
Loss from discontinued operations before income taxes   (41,910)   (27,945)   (3,854)
Income tax benefit   2,130    
    
 
Net Loss from discontinued operations   (39,780)   (27,945)   (3,854)

 

F-18

 

 

Assets and liabilities of the discontinued operations:

 

   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
ASSETS            
Current assets:            
Cash and cash equivalents   1,854    319    44 
Prepayment   2,692    1,334    184 
Accounts receivable, net   2,235    3,318    458 
Amounts due from related parties, net   2,194    684    94 
Inventories, net   210    178    25 
Other current assets, net   3,448    3,944    543 
Total current assets held for sale   12,633    9,777    1,348 
                
Property and equipment, net   17,182    15,746    2,171 
Land use rights, net   1,111    1,097    151 
Intangible assets, net   185    271    37 
Goodwill               
Right of use assets   7,213    2,088    288 
Long-term investments, net   1,079    991    138 
Total noncurrent assets held for sale   26,770    20,193    2,785 
TOTAL ASSETS HELD FOR SALE   39,403    29,970    4,133 
                
LIABILITIES               
Current liabilities:               
Short-term debts   5,000    5,000    690 
Accounts payable   2,108    2,012    277 
Advance from customers   4,956    7,800    1,076 
Amounts due to related parties   2,280    1,079    149 
Lease liability-current   784    1,042    144 
Accrued expenses and other current liabilities   18,386    16,488    2,273 
Total current liabilities held for sale   33,514    33,421    4,609 
Deferred tax liabilities               
Lease liability-non-current   6,515    1,368    189 
Other long-term liabilities   1,080    1,066    147 
Total noncurrent liabilities held for sale   7,595    2,434    336 
TOTAL LIABILITIES HELD FOR SALE   41,109    35,855    4,945 

 

6. ACCOUNTS RECEIVABLE, NET

 

Accounts receivable as of December 31, 2022 and June 30, 2023 were as follows:

 

   December 31     
   2022   June 30 2023 
   RMB   RMB   US$ 
             
Accounts receivable   
    270    37 
Allowance for credit losses   
    
    
 
Balance at end of year   
    270    37 

 

F-19

 

 

7. OTHER CURRENT ASSETS, NET

 

Other current assets consist of the following:

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Deposits   
    154    21 
Receivable from private placement investors   
    260    36 
Loan to third-parties   422    444    61 
Total   422    858    118 
Allowance for credit losses   (422)   (444)   (61)
Other current assets, net   
    414    57 

 

8. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consists of the following:

 

   December 31,     
   2022   June 30 2023 
   RMB   RMB   US$ 
Furniture, fixtures and equipment   
    3,255    448 
Motor vehicles   
    2,007    277 
Total   
    5,262    725 
Less: accumulated depreciation   
    (953)   (131)
Property and equipment, net   
    4,309    594 

 

Depreciation expense was nil and RMB449 (US$62) for the six months ended June 30, 2022 and June 30, 2023, respectively. No impairment charges were recognized on the property and equipment for the six months ended June 30, 2022 and 2023.

 

9. INTANGIBLE ASSETS, NET

 

Intangible assets, net consist of the following:

 

   December 31,     
   2022   June 30 2023 
   RMB   RMB   US$ 
Software   
    47,798    6,592 
Total   
    47,798    6,592 
Less: accumulated amortization   
    (2,629)   (363)
Intangible assets, net   
    45,169    6,229 

 

F-20

 

 

Amortization expense for six months ended June 30, 2022 and 2023 amounted to nil and RMB2,511 (US$346), respectively. The estimated aggregate amortization expense for each of the five succeeding years is as follows:

 

Twelve months ending June 30,  RMB 
2024   8,351 
2025   8,351 
2026   8,351 
2027   8,351 
2028   6,226 
Thereafter   5,539 
Total   45,169 

 

10. LONG-TERM INVESTMENTS, NET

 

Long-term investments, net consisted of the following:

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Equity method investments               
Advanced Life Therapeutics Co., Ltd. (“Advanced Life”)   
    
    
 
Nassau Enterprises LLC (“Nassau”).   
    39,783    5,486 
Total   
    39,783    5,486 
Less: Impairment   
    
    
 
Long-term investments, net   
    39,783    5,486 

 

Equity method investments

 

Advanced Life

 

On May 15, 2021, the Company and other third parties established Advanced Life Therapeutics Co., Ltd. (“Advanced Life”), of which the Company owned a 40% equity interest in its registered capital. The Company has not made any capital contribution as yet because Advanced Life has not commenced its intended operations. The Group accounts for Advanced Life as long-term investment under the equity method, there’s no carrying value of this investment. Subsequently, the Board has approved the disposition of the 40% of equity interest in Advanced Life to a company controlled by Mr. Chris Yu at a nominal price on October 18, 2023.

 

Nassau

 

On May 24, 2023, the Company, through its subsidiary Foodbase Group Inc. (“Foodbase”), entered into a purchase agreement (the “Nassau Investment Agreement”) with Mr. Haohan Xu (“Mr. Xu”), the CEO of the Company, and Nassau Enterprises LLC, a Delaware limited liability company that was established to engage in real estate development (“Nassau”). Mr. Xu was the sole shareholder and CEO of Nassau prior to the Company’s investment. The Group’s investment in Nassau consisted of a capital injection of RMB39,882 (US$5,500) and a nominal payment to Mr. Xu to acquire 19.64% of the equity interests in Nassau. The transaction closed on May 24, 2023. After the closing, Mr. Xu holds 8,036 voting units in Nassau, representing 80.36% of the outstanding equity interests in Nassau. The Group can exercise significant influence on the management and operation of Nassau. The Group accounts for its investment in Nassau as long-term investment under the equity method. Nassau through its subsidiary intends to develop, market and sell real estate in Savannah Lakes Village (“SLV Project”) and to utilize an EB-5 program to finance the development of the SLV Project, which is expected to provide alternative financing for the Company’s growth.

 

The Group recorded its share of loss in this investment of RMB95 (US$13) for the six months ended June 30, 2023.

  

F-21

 

 

11. SHORT-TERM DEBTS

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Convertible loan (“CL”) (i)   15    16    2 
Total   15    16    2 

 

(i)On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were originally due in one year and bear interest of 0% per annum if the conversion feature is not triggered. Pursuant to the agreement, the conversion price is lower of (i) US$15 or (ii) the lower of 82% of the closing bid price or 80% of VWAP of the Company’s ADSs during the ten consecutive trading days immediately preceding conversion, but not lower than a Floor Price of US$1 (the “floor price”). Due to significant drop of the ADS market price in 2022, the debenture holders and the Company renegotiated the Floor Price. On February 5, 2022, the Company entered into an amendment agreement, pursuant to which the Floor Price was reduced to US$0.10 per Class A Ordinary Share. The Company has elected to recognize the Convertible Debentures at fair value and therefore there was no further evaluation of embedded features for bifurcation. The Convertible Debentures were partially converted into 114,234 shares on December 10, 2021. The fair value of the Convertible Debentures loan immediately prior to conversion was assessed at RMB1,321. Substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares (refer to Note 14) on March 16, 2022. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).

 

For the six months ended June 30, 2022 and 2023, the Company recognized change in fair value of the Convertible Debenture of RMB139 and nil, respectively.

 

12. LEASES

 

The Group has several operating leases for offices. The Group’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

 

Effective on January 1, 2022, the Group adopted the new lease accounting standard using a modified retrospective transition method which allowed the Group not to recast comparative periods presented in its consolidated financial statements. In addition, the Group elected the package of practical expedients, which allowed the Group to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Group has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. The Group combines the lease and non-lease components in determining the ROU assets and related lease obligation. Adoption of this standard resulted in the recording of operating lease ROU assets and corresponding operating lease liabilities as disclosed below and had no impact on accumulated deficit as of January 1, 2022. ROU assets and related lease obligations are recognized at commencement date based on the present value of remaining lease payments over the lease term.

 

Supplemental balance sheet information related to operating leases was as follows:

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
             
Right-of-use assets, net   
    223    31 
                
Operating lease liabilities - current   
    148    20 
Operating lease liabilities - non-current   
    37    5 
Total operating lease liabilities   
    185    25 

 

F-22

 

 

The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of June 30, 2023:

 

Weighted average remaining lease term (years)   1.51 
Weighted average discount rate   4.75%

 

The following is a schedule of maturities of lease liabilities are as follows:

 

Twelve months ending June 30,  RMB 
2024   150 
2025   37 
Total future minimum lease payments   187 
Less: imputed interest   (2)
Total   185 

 

13. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

 

   December 31     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Salary and welfare payable   1,740    9,312    1,283 
Accrued expenses (1)   5,762    9,057    1,249 
Payable for property and equipment   
    2,301    318 
Other payables   33    4,089    564 
Total   7,535    24,759    3,414 

 

(1):the accrued expenses mainly consist of accrued professional fees.

 

14. SHAREHOLDERS’ EQUITY

 

Ordinary Shares

 

On October 14, 2022, the Company amended and restated its memorandum and articles of association to increase the maximum number of authorized shares to 150,000,000 shares divided into 120,000,000 class A ordinary shares with a par value of US$0.01 each and 30,000,000 class B ordinary shares with a par value of US$0.01 each.

 

On February 14, 2023, the Company amended and restated its memorandum and articles of association to increase the maximum number of authorized shares from 150,000,000 shares to 2,430,000,000 shares divided into 2,400,000,000 Class A Ordinary Shares with a par value of US$0.01 each and 30,000,000 Class B Ordinary Shares with a par value of US$0.01 each.

 

As of December 31, 2022 and June 30, 2023, 79,536,589 and 176,070,465 Class A ordinary shares were issued and outstanding, respectively. As of December 31, 2022 and June 30, 2023, 3,573,100 and 3,573,100 Class B ordinary shares were issued and outstanding.

 

Completion of IPO

 

On January 30, 2020, the Company completed its IPO on the Nasdaq Share Exchange. In November 2022, the Company adopted an ordinary share / ADS ratio change from one (1) Class ‘A’ ordinary share being equal to one (1) ADS to 20 Class ‘A’ ordinary shares being equal to one (1) ADS).

 

F-23

 

 

Conversion of convertible loans

 

On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were partially converted into 114,234 Class ‘A’ ordinary shares on December 10, 2021. On March 16, 2022, substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).

 

On May 31, 2021, the Company issued a convertible note in the principal amount of RMB4,479 to Ascent Investor Relations Inc., (“Ascent”) for public relations services rendered. The convertible note was fully converted into 3,232,397 Class A ordinary shares with conversion prices ranging from US$0.16-0.33 per share by April 27, 2022. The fair value of the convertible note immediately prior to conversion was assessed at RMB5,502.

 

Shares issued for services

 

On June 1, 2022, the Company entered into a service agreement with a public relations firm. Pursuant to the service agreement, the Group was required to pay US$50 as compensation for the public relations services. On June 10, 2022, the Company issued 187,094 class A ordinary shares for the services. The fair value of the PR services was RMB359 (US$54) determined based on the Company’s ADS market price on June 10, 2022.

 

On August 31, 2022, the Company granted 140,000 class A ordinary shares to two employees as bonuses that vested immediately upon grant. On September 16, 2022, the Company issued the 140,000 class A ordinary shares. The fair value of the bonuses was RMB1,341 (US$195) determined based on the Company’s ADS market price on August 31, 2022.

 

On April 20, 2023, the Company entered into a service agreement with a finance service firm, Pursuant to the service agreement, the Company was required to pay 3,500,000 Class A ordinary shares for the service. On May 11, 2023, the Company issued 3,500,000 Class A ordinary shares to the finance service firm. The fair value of the services was RMB6,385 (US$919) determined based on the Company’s ADS market price on May 11, 2023.

 

Shares issued for reserve

 

As of December 31, 2022, the Group had 1,322,853 Class A ordinary shares held in an escrow account as reserve solely for potential convertible loans conversion. During the six months ended June 30, 2023, of 22,000,000 Class A ordinary shares issued in a private placement on June 9, 2023, 2,500,000 class A ordinary shares were subsequently recalled and cancelled on October 30, 2023 due to the inability to timely collect the funds from the investor. Such 2,500,000 class A ordinary shares were included as the shares held as a reserve and not included in the calculation of loss per share. As of June 30, 2023, 3,822,853 Class A ordinary shares were held in an escrow account as a reserve.

 

Private placements

 

On March 16, 2022, the Company entered into a share subscription agreement with a third-party investor, pursuant to which the Company issued 1,235,788 Class A ordinary shares at price of US$0.2563 per share to the investor (the “March 16, 2022 private placement”). In addition, the Company also issued pre-funded warrants to purchase an aggregate of 4,226,135 of Class A ordinary shares for US$0.2563 per share to the investor, equal to the exercise price minus US$0.00001 for the pre-funded warrants. Total gross proceeds of RMB9,395 (US$1,400) was received on May 19, 2022. 2,584,900 pre-funded warrants were exercised during the six months ended June 30, 2023; the remaining pre-funded warrants were exercised on July 13, 2023.

 

On March 29, 2022, the Company entered into a share subscription agreement with a third-party Chinese investor, pursuant to which the Company issued 654,622 Class A ordinary shares at price of US$0.35 to the investor and received gross proceeds of RMB1,500 (US$232) on March 30, 2022.

 

F-24

 

 

On May 27, 2022, the Company entered into investment agreements with nine third-party investors. The investors agreed to invest up to RMB20,094 (US$3,000) to purchase Class A ordinary shares, at a purchase price of the lower of (i) $0.30 per ADS (the equivalent of 1 Class A ordinary share) and (ii) 80% of the average ten-day trading closing price of the ADSs (the equivalent of 1 Class A ordinary share) for the ten consecutive day trading period ended on the date of investment agreement. On May 27, 2022 and May 30, 2022, the Company issued 6,229,235 and 6,263,048 Class A ordinary shares to the investors, respectively. In addition, warrants to purchase (i) an aggregate of 3,000,000 Class A ordinary shares for US$0.4 per share, (ii) an aggregate of 1,200,000 Class A ordinary shares for US$0.75 per share (ADS), and (iii) an aggregate of 750,000 Class A ordinary shares (ADS) for US$1.2 per share were issued to the investors. No warrants were excised during the year ended December 31, 2022. On September 2, 2022, three of the investors in the Company’s May 2022 private placements filed an action against the Company in the State of Delaware Court of Chancery captioned Chen Wenge, et al. v. Fresh2 Group Limited, C.A. No. 2022-0779-PAF. The Plaintiffs sued the Company for breaches of the investment agreements. The plaintiffs claimed that the entry into certain investment agreements and a merger agreement breached or would breach the terms of the plaintiffs’ (and several other investors’) securities purchase agreements, including a right of first refusal and a prohibition against certain acquisitions and changes of business. The Court issued a temporary restraining order concerning enforcement of the private placements on September 3, 2022, amended the temporary restraining order on September 9, 2022, and further amended the temporary restraining order on September 23, 2022 (“TRO”). In order to settle the litigation, the Company entered into a share repurchase agreement with the three plaintiffs, and all the other investors in the May 2022 private placements on October 15, 2022. The Company agreed to repurchase 12,492,283 Class A ordinary shares and warrants to purchase a total of 2,475,000 Class A ordinary shares from the nine investors for total consideration of RMB11,003(US$1,507). The Company fully settled the litigation on October 27, 2022. In connection with the settlement, Yuyang Cui and Jiawen Kang resigned from our board of directors of the Company and Yuyang Cui resigned as Co-CEO of the Company. The repurchased warrants were canceled and the repurchased Class A ordinary shares are treated a treasury shares as of December 31, 2022. The treasury shares were canceled on January 19, 2023.

 

On September 2, 2022, the Company entered into investment agreements with three third-party investors (the “September 2, 2022 private placement”). The investors agreed to purchase an aggregate of 5,000,000 Class A ordinary shares at price of US$0.1 per share and warrants to purchase an aggregate of 5,000,000 Class A ordinary shares at an exercise price of US$0.4 per share for RMB3,613. The warrants are exercisable within 2 years from the date of issuance. Total gross proceeds of RMB3,613 was received in September, 2022. No warrants were excised during the year ended December 31, 2022 and six months ended June 30, 2023.

 

On September 26, 2022, the Company entered into investment agreements with nine third-party investors, pursuant to which the Company issued 36,729,613 Class A ordinary Shares at price of US$0.10 per share to the investors and received gross proceeds of RMB26,410 (US$3,660) during the period October 2022 to November 2022.

 

In December 2022 and March 2023, the Company signed investment agreements with several third-party investors (the “March 2023 private placement”) to sell 30,885,707 Class A ordinary shares of the Company at a price of US$0.175 per share for a total purchase price of US$5,405. Proceeds of RMB36,608 (US$5,369) were received by June 30, 2023 and the remaining balance subsequently was received on August 10, 2023. For each Class A ordinary share purchased, the investors received two warrants with each warrant to purchase one Class A ordinary share at an exercise price of US$0.21 per share. The warrants are exercisable within 2 years from the date of issuance. No warrants were exercised during the six months ended June 30, 2023.

 

On April 6, 2023, the Company closed a registered direct offering (the “April 2023 private placement”), the Company sold to the institutional investors a total of 12,500,000 Class A ordinary shares priced at $0.2 per ordinary share, pre-funded warrants exercisable for 2,500,000 Class A ordinary shares and warrants exercisable for 15,000,000 Class A ordinary shares. The purchase price of each pre-funded warrant is equal to the offering price per Class A ordinary shares, minus $0.00005, and the exercise price of each pre-funded warrant is equal $0.00005 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The warrants are immediately exercisable and expire five (5) years from the original issuance date and have an exercise price of $0.2 per Class A ordinary shares. The Company also issued to Univest Securities, LLC, which acted as the sole placement agent for the offering, warrants exercisable for 750,000 Class A ordinary shares, with an exercise price of $0.24 per share. The net proceeds to the Company from the registered direct offering were RMB17,238 (US$2,510) after deducting the placement agent’s fees and other offering expenses. No pre-funded warrants were exercised during the six months ended June 30, 2023, and 5,000,000 warrants were exercised with proceeds of RMB6,911(US$1,000) during the six months ended June 30, 2023.

 

F-25

 

 

On June 2, 2023, the Company entered into an agreement with an investor, under which the investor agreed to purchase 22,000,000 Class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares at an aggregate purchase price of US$4,400 (the “June 2023 private placement”). The warrants are exercisable within 2 years from the date of issuance and have an exercise price of US$0.21 per share. On June 9, 2023, the Company issued 22,000,000 Class A ordinary shares to the investor, proceeds of RMB27,797 (US$3,900) were received by June 30, 2023. Due to inability to timely collect the remaining proceeds of RMB3,564(US$500) from the investor, the corresponding 2,500,000 shares was recalled and cancelled on October 30, 2023, subsequently. No warrants were exercised during the six months ended June 30, 2023.

 

Shares issued for acquisitions

 

In connection with the GISN acquisition on February 1, 2023, the Company issued 8,785,530 Class A shares to the original shareholders of GISN as consideration of 100% equity interest. The fair value of the shares issued amounted to RMB25,938(US$3,848).

 

In connection of the Fresh2 acquisition on February 8, 2023, the Company issued 5,440,420 Class A shares to the original shareholders of Fresh ecommerce as consideration of 100% equity interest. The fair value of the shares issued amounted to RMB17,304(US$2,549).

 

In connection of the assets acquisition from Easy Hundred on March 31, 2023, the Company issued 17,665,702 Class A shares to Easy Hundred as consideration. The fair value of the shares issued amounted to RMB25,720(US$3,745).

 

Warrants

 

As of June 30, 2023, there were 103,702,658 warrants outstanding. A summary of warrants activity for the six months ended June 30 2023 was as follows:

 

       Weighted
average
exercise
price per
share
   Weighted    
  

Number of

warrants

   US$ per
share
   average life
Years
 

Expiration

dates 

Balance of warrants outstanding and exercisable as of December 31, 2022   9,266,135    0.24   1.85 to unlimited  August 31, 2024 to unlimited
—warrants issued in connection with the March 2023 private placement   61,771,423    0.21   1.58 to 1.96  February 3, 2025 to June 16, 2025
—warrants issued in connection with the April 2023 private placement   18,250,000    0.00001-0.24   1.75 to Unlimited  March 31, 2025 to unlimited
—warrants issued in connection with the June 2023 private placement   22,000,000    0.21   1.95  June 9, 2025
Exercised   (7,584,900)   0.00001-0.2       
Balance of warrants outstanding and exercisable as of June 30, 2023   103,702,658    0.21   1.96 to unlimited  August 31, 2024 to unlimited

 

F-26

 

 

15. SHARE BASED COMPENSATION

 

On October 31, 2019, the Board and the Company’s shareholders approved the 2019 Share Incentive Plan (“2019 Plan”) which authorized the compensation committee or such other committee to grant share options to purchase 1,105,300 Class A ordinary shares to directors, service providers, advisors, employees and consultants of the Group. On July 5, 2021, the Board and the Compensation Committee of the Board approved the Amended and Restated 2019 Plan increasing the number of Class A ordinary shares subject to the 2019 Plan to 1,885,300 shares. As of June 30, 2023, no shares remain available to be issued under the Amended and Restated 2019 Plan. On April 14, 2022, the Company’s Board approved and adopted the 2022 Share Incentive Plan (the “2022 Plan”) providing for the grant of options to purchase 2,800,000 Class A ordinary shares. On August 28, 2022, the Board and the Compensation Committee of the Board approved the Amended and Restated 2022 Plan increasing the number of Class A ordinary shares subject to the 2022 Plan to 4,700,000 shares. These options were granted to employees and professionals during 2022 and 2023 and will vest over four years. As of June 30, 2023, options to purchase 182,593 Class A ordinary shares remain available to be issued under the 2022 Plan.

 

On January 6, 2023, the Company’s Board approved and adopted the 2023 Share Incentive Plan (the “2023 Plan”) providing for the grant of restricted share unit (“RSU”) of 4,000,000 Class A ordinary shares. On March 10, 2023, the Board and the Compensation Committee of the Board approved an amended to the 2023 Plan increasing the number of Class A ordinary shares subject to the 2023 Plan to 13,000,000 shares. On August 23, 2023, the Board and the Compensation Committee of the Board further approved a further amendment to 2023 Plan increasing the number of Class A ordinary shares subject to the 2023 Plan to 41,000,000 shares These RSU are to be granted to employees and professionals. During the six months ended June 30, 2023, the Company issued 12,779,670 RSUs to that can be converted to Class A ordinary shares upon vesting to employees, directors and officers the Group under the 2023 Plan. The aggregate fair value of the RSUs granted was RMB32,310 (US$4,456). These RSUs vest over 1-4 years based on the related granted agreements. During six months ended June 30, 2023, 458,452 RSUs was forfeited and none vested. As of June 30, 2023, the Company had 12,321,218 RSUs outstanding. For the six months ended June 30, 2023, the Company recorded related share-based compensation expense of RMB2,872 (US$396).

 

Employees-options

 

The options granted to employees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards and contain only service vesting conditions. The following table summarized the Group’s employee share option activities:

 

               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
   Number of   Exercise   Grant date   Contractual   Intrinsic 
   Options   Price   Fair Value   Term   Value 
       US$ per   US$ per         
       option   option   Years   US$ 
Share options outstanding at December 31, 2022   2,334,906    1.69    5.08    8.05    452 
Granted   
    
    
    
    
 
Exercised   (13,900)   0.05    0.05    0.22    
 
Share options outstanding at June 30, 2023   2,321,006    1.70    2.32    7.54    306 
Vested and exercisable at June 30, 2023   2,199,006    1.41    2.08    7.54    306 

 

The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date for those awards that had exercise price below the estimated fair value of the relevant Class A ordinary shares.

 

For the six months ended June 30, 2022 and 2023, the total fair value of the equity awards vested were RMB2,962 and RMB894 (US$123) respectively. As of June 30, 2023, there was RMB2,525 (USD$348) in total unrecognized employee share-based compensation expense related to unvested options, that may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost may be recognized over a weighted-average period of 0.6 years.  

 

F-27

 

 

Nonemployees-options

 

The options granted to nonemployees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards with service and/or performance vesting conditions. The following table summarized the Group’s nonemployee share option activity:

 

               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
   Number of   Exercise   Grant date   Contractual   Intrinsic 
   Options   Price   Fair Value   Term   Value 
       US$ per   US$ per         
       option   option   Years   US$ 
Share options outstanding at December 31, 2022   2,651,700    0.86    0.85    9.27    532 
Granted   
    
    
    
    
 
Exercised   (650,000)   0.05    0.05    0.22    
 
Forfeited   (20,000)   
    
    
    
 
Share options outstanding at June 30, 2023   1,981,700    1.13    1.04    8.74    315 
Vested and exercisable at June 30, 2023   1,981,700    1.13    1.00    8.74    315 

 

The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant Class A ordinary shares.

 

The total fair value of the equity awards vested during the six months ended June 30, 2022 and 2023 were RMB1,566 and nil, respectively. There was no unrecognized nonemployee share-based compensation expenses as of June 30, 2023.

 

Fair value of options

 

The Group used the Black-Scholes simplified method for the valuation of new options issued during the six months ended June 30, 2022 and 2023. The assumptions used to value the share options granted to employees and nonemployee were as follows:

 

   For the six months ended
June 30,
 
   2022   2023 
Risk-free interest rate   0.34%   
%
Expected volatility range   100.2%   
%
Fair market value per ordinary share as at grant dates   US$0.29    
 

  

The following table sets forth the amount of share-based compensation expense included in each of the relevant financial statement line items:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Selling and marketing expenses   705    1,712    236 
Research and development expenses   1,263    818    113 
General and administrative expenses   2,560    1,236    170 
Total share-based compensation expenses   4,528    3,766    519 

 

F-28

 

 

16. INCOME TAXES

 

BVI

 

The Company is incorporated in the BVI and conducts its primary business operations through the subsidiaries in the U.S. and PRC Under the current laws of the BVI, the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Company to its shareholders, no BVI withholding tax will be imposed.

 

Hong Kong

 

GISN (HK) Limited is a holding company registered in Hong Kong and had no operating profit and no taxable income for the six months ended June 30, 2023.

 

PRC

 

The Group’s subsidiaries in the PRC are subject to tax at the statutory rate of 25%, in accordance with the Enterprise Income Tax law (the “EIT Law”), which was effective since January 1, 2008. Hua You Sheng Future (Beijing) Technology Co., Ltd. is entitled to a preferential income tax treatment as they qualify as small and micro-sized enterprises. For the six months ended June 30, 2022 and 2023, if the annual taxable income of small and micro- profit enterprises does not exceed RMB 1,000, 12.5% shall be included in the taxable income and the enterprise income tax rate shall be 20%; if the annual taxable income exceeds RMB 1,000 but does not exceed RMB 3,000, 25% shall be included in the taxable income and the enterprise income tax shall be paid at the rate of 20%.

 

Dividends, interests, rent and royalties payable by the Group’s PRC subsidiaries, to non-PRC resident enterprises, and proceeds from any such non-resident enterprise investor’s disposition of assets (after deducting the net value of such assets) shall be subject to 10% withholding tax, unless the respective non-PRC resident enterprise’s jurisdiction of incorporation has a tax treaty or arrangements with PRC that provides for a reduced withholding tax rate or an exemption from withholding tax.

 

United States

 

The Group’s subsidiaries in the U.S. are subject to the U.S. federal corporate income tax and New York as well as Delaware state income tax at a rate of 21%, 6.5% and 8.7%, respectively, for the six months ended June 30, 2022 and 2023.

 

The Group’s Chinese subsidiaries tax returns filed with Chinese governments for the years after 2019 remain open for statutory examination by PRC tax authorities. The Group’s US subsidiaries tax returns filed with governments remain open for statutory examination by tax authorities in the future.

 

The Group’s loss before income taxes consisted of:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Non-US   (9,035)   (23,507)   (3,241)
US   
    (20,032)   (2,763)
Total   (9,035)   (43,539)   (6,004)

 

F-29

 

 

The current and deferred components of income tax benefit appearing in the unaudited condensed consolidated statements of comprehensive income are as follows:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Current tax expense   
    
    
 
Deferred tax benefit   
    79    11 
Total   
    79    11 

 

The reconciliation of tax computed by applying the federal statutory income tax rate of 21% for the six months ended June 30, 2022 and 2023 applicable to the U.S. operations to income tax benefit were as follows:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Loss before income taxes   (9,035)   (43,539)   (6,004)
Income tax benefit computed at the statutory income tax rate at 21%   (1,897)   9,142    1,261 
International rate differences   1,897    (4,726)   (652)
Change in valuation allowance       (4,337)   (598)
Income tax benefit       79    11 

 

Deferred Taxes

 

The significant components of deferred taxes were as follows:

 

   As of December 31, 
   December 31,   June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Deferred tax assets:            
Net loss carryforward   1,900    9,608    1,325 
Valuation allowance   (1,900)   (9,608)   (1,325)
Total deferred tax assets.   
    
    
 
                
Deferred tax liabilities:               
Long-lived assets arising from acquisitions   
    2,938    405 
Total deferred tax liabilities.   
    2,938    405 

 

The Group operates through several subsidiaries. Valuation allowance is considered for each of the entities.

 

Realization of the net deferred tax assets is dependent on factors including future reversals of existing taxable temporary differences and adequate future taxable income, exclusive of reversing deductible temporary differences and tax loss carry forwards. The Group evaluates the potential realization of deferred tax assets on an entity-by-entity basis. As of December 31, 2022 and June 30, 2023, the Company and all of its subsidiaries were in a cumulative loss position, valuation allowances were provided against deferred tax assets in entities where it was determined it was more likely than not that the benefits of the deferred tax assets will not be realized.

 

F-30

 

 

As of June 30, 2023, the Group had PRC net operating losses of RMB10,342 (US$ 1,426), which will expire from 2023 to 2027 if not utilized. As of June 30, 2023, the Group had Hongkong net operating losses of RMB 307 (US$42) that can be carried forward indefinitely for deduction in future periods. As of June 30, 2023, the Group had U.S. net operating losses of RMB33,198 (US$4,578) for U.S. federal and state income tax purposes. The Group files state tax returns in both New York and Delaware. U.S. federal net operating losses are limited to 80% and can be utilized indefinitely. State net operating losses can be carried forward for 20 years and will begin to expire from 2038 to 2042.

 

17. RELATED PARTY TRANSACTIONS AND BALANCES

 

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. The related parties that had transactions in the six months ended June 30, 2022 and 2023 or balances with the Group as of December 30, 2022 and June 30, 2023 consisted of:

 

Related Party   Nature of the party   Relationship with the Group
Haohan Xu   Individual   Chief Executive Officer
Apifiny Inc.   Investment management   Controlled by Haohan Xu
Roxe Holding Inc.   Investment management   Controlled by Haohan Xu
Dr. Chris Chang Yu*   Individual   Co-Founder and shareholder
CRS Holdings Inc.   Investor   Controlled by Dr. Chris Chang Yu
Jiaxing Zhijun Sihang Investment Partnership Enterprises (limited partnership) (“Jiaxing Zhijun”)   Private equity investment   Shareholder, due to diluted equity interest, no longer a related party for the six months ended June 30 2023

 

*Dr. Yu resigned from his position as the Chief Executive Officer (“CEO”) of the Company and Chairman of the Board on April 6, 2022 and was appointed as Co-Chairman and Co-CEO in May 2022. On May 17, 2023, Dr. Yu resigned as the Co-Chief Executive Officer of the Company.

 

Related party balances

 

   As of
December 31,
   As of June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Due from related parties:            
Apifiny Inc.   
    211    29 
Roxe Holding Inc.   
    363    50 
Dr. Chris Chang Yu   
    290    40 
Due from related parties, net   
    864    119 

 

   As of
December 31,
  

As of June 30,

 
   2022   2023   2023 
   RMB   RMB   US$ 
Due to related parties:            
CRS Holdings Inc.   287    592    82 
Jiaxing Zhijun   927    
    
 
Due to related parties   1,214    592    82 

 

F-31

 

 

   As of
December 31,
  

As of June 30,

 
   2022   2023   2023 
   RMB   RMB   US$ 
Accounts receivables-related parties:            
Apifiny Inc.   
    3,525    486 
Roxe Holding Inc.   
    7,925    1,093 
Accounts Receivables-related parties, net   
    11,450    1,579 

 

Accounts receivables-related parties represented receivables from Apifiny Inc. and Roxe Holding Inc. for research and development services provided by the Group’s subsidiaries before the GISN acquisition.

 

Related party transactions

 

For the six months ended June 30, 2022 and 2023, related party transactions consisted of the following:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Fixed assets purchased from Apifiny Inc.   
    970    134 
Consulting service received from Roxe Holding Inc.   
    464    64 
Rent expense incurred with Apifiny Inc.   32    624    86 

 

Acquisition, investment and divestitures

 

The Group completed one acquisition from a related party – Mr. Xu (details refer to Note 4) and completed divestiture transaction with a related party Dr. Chris Yu on July 28, 2023 (details refer to Note 5). On May 24, 2023, the Group completed equity investment in Nassau, controlled by a related party - Mr. Xu (details refer to Note 10).

 

18. COMMITMENTS AND CONTINGENCIES

 

Litigation

 

In the ordinary course of the business, the Group is subject to periodic legal or administrative proceedings. As of December 31, 2022 and June 30, 2023, there was no contingent liability accrued relating to legal or administrative proceedings.

 

19. SUBSEQUENT EVENTS

 

Recent Development

 

The Company announced that as of June 30, 2023, it no longer qualified as a Foreign Private Issuer, as defined in Rule 405 of Regulation C under the Securities Act of 1933 and Rule 3b-4 under the Securities Exchange Act of 1934. The Company will take all necessary actions to comply with the requirements for a domestic issuer under the federal securities laws, as of January 1, 2024.

 

On July 21, 2023, the Company appointed Mr. Yidong Hu as the Chief Strategy Officer of the Company.

 

On August 25, 2023, Mr. Edwards Jinqiu Tang resigned as the Co-Chief Financial Officer of the Company. Mr. Tang’s resignation did not result from any disagreement with the Company or its management.

 

F-32

 

 

Divestiture

 

On July 28, 2023, the Group entered into agreements to sell its CDA Business (details refer to Note 5).

 

Acquisition

 

On July 17, 2023, the Group entered into a definitive share purchase agreement with Immensus LLC, Zero2First Capital Limited, Future Capital Tech Pte. Ltd (Singapore), River Hill China Capital Ltd (collectively, the “Sellers”) and Roxe Holding Inc. (“Roxe”) under which Fresh2 Technology purchased 51% of the common share of Roxe (the “Roxe Shares”). As consideration for the purchase of the Roxe Shares, the Company issued an aggregate of 110,476,291 Class A Ordinary Shares of the Company to the Sellers, based on Roxe’s valuation of US$60,000 and the average trading price of the Company’s ADSs for the prior 90 trading days (each ADS represents 20 Class A Ordinary Shares). The closing took place simultaneously with the execution of the Share Purchase Agreement. Unaudited Pro-forma condensed combined financial information in connection with the above acquisition was included in the Company’s filling in a Form 6-K with the SEC on August 21, 2023. On July 27, 2023, Roxe entered into a share purchase agreement with SpeedIn INC (“SpeedIn”), a delivery service provider, and its shareholders, under which Roxe agreed to purchase 100% of the shares of SpeedIn from the Sellers with a nominal price. The closing took place simultaneously with the execution of the share purchase agreement. Due to badly performance, the Board have approved the disposition of SpeedIn to a company controlled by Mr. Haohan Xu on October 9, 2023.

 

On July 28, 2023, the Company, through its subsidiary, Foodbase Group Inc. agreed to acquire 100% of the equity interest in Windfall SLV Development LLC and SLV Windfall Management LLC, from XHome Group Inc, a company controlled by Mr. Haohan Xu, for a nominal price. Windfall SLV Development LLC and SLV Windfall Management LLC have not begun operations as yet.

 

On November 4, 2023 the Company and Fresh2 Technology entered into a definitive Share Purchase Agreement to purchase 38.61% of the common stock of Roxe.

 

Financing activities

 

On September 25, 2023, the Company entered into an agreement with an institutional investor to purchase up to US$2,000 of convertible notes, the convertible notes will be sold in two tranches (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date  and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment RMB1,697(US$234) from this offering, excluding related financing costs.

 

 

F-33

 

 

0.05 0.35 0.38 0.03 0.22 1.66 0.08 0.57 2.04 124374140 124374140 23603709 true --12-31 Q2 2023-06-30 0001786511 0001786511 2023-01-01 2023-06-30 0001786511 2022-12-31 0001786511 2023-06-30 0001786511 us-gaap:RelatedPartyMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember 2023-06-30 0001786511 us-gaap:CommonClassAMember 2022-12-31 0001786511 us-gaap:CommonClassAMember 2023-06-30 0001786511 us-gaap:CommonClassBMember 2022-12-31 0001786511 us-gaap:CommonClassBMember 2023-06-30 0001786511 2022-01-01 2022-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001786511 us-gaap:TreasuryStockCommonMember 2021-12-31 0001786511 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001786511 us-gaap:RetainedEarningsMember 2021-12-31 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2021-12-31 0001786511 us-gaap:NoncontrollingInterestMember 2021-12-31 0001786511 2021-12-31 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001786511 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2022-01-01 2022-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2022-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001786511 us-gaap:RetainedEarningsMember 2022-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2022-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2022-06-30 0001786511 2022-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001786511 us-gaap:TreasuryStockCommonMember 2022-12-31 0001786511 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001786511 us-gaap:RetainedEarningsMember 2022-12-31 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2022-12-31 0001786511 us-gaap:NoncontrollingInterestMember 2022-12-31 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001786511 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2023-01-01 2023-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2023-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001786511 us-gaap:RetainedEarningsMember 2023-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2023-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2023-06-30 0001786511 us-gaap:SubsequentEventMember 2023-07-17 2023-07-17 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember us-gaap:SubsequentEventMember 2023-07-17 2023-07-17 0001786511 srt:ScenarioForecastMember 2023-11-01 2023-11-06 0001786511 2023-04-12 2023-04-12 0001786511 anpc:ChangweiSystemTechnologyShanghaiCoLtdMember 2023-06-30 0001786511 anpc:ChangweiSystemTechnologyShanghaiCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyLishuiCoLtdAnPacLishuiMember 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyLishuiCoLtdAnPacLishuiMember 2023-01-01 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyShanghaiCoLtdMember 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyShanghaiCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:AnPacTechnologyUSACoLtdAnPacUSMember 2023-06-30 0001786511 anpc:AnPacTechnologyUSACoLtdAnPacUSMember 2023-01-01 2023-06-30 0001786511 anpc:LishuiAnPacMedicalLaboratoryCoLtdMember 2023-06-30 0001786511 anpc:LishuiAnPacMedicalLaboratoryCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:ShijiHainanMedicalTechnologyLtdMember 2023-06-30 0001786511 anpc:ShijiHainanMedicalTechnologyLtdMember 2023-01-01 2023-06-30 0001786511 anpc:ShanghaiMuqingAnPacHealthTechnologyCoLtdAnPacMuqingMember 2023-06-30 0001786511 anpc:ShanghaiMuqingAnPacHealthTechnologyCoLtdAnPacMuqingMember 2023-01-01 2023-06-30 0001786511 anpc:AnpaiShanghaiHealthcareManagementAndConsultingCoLtdMember 2023-06-30 0001786511 anpc:AnpaiShanghaiHealthcareManagementAndConsultingCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2GroupIncMember 2023-06-30 0001786511 anpc:Fresh2GroupIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2TechnologyIncFresh2Member 2023-06-30 0001786511 anpc:Fresh2TechnologyIncFresh2Member 2023-01-01 2023-06-30 0001786511 anpc:Fresh2LogisticsIncMember 2023-06-30 0001786511 anpc:Fresh2LogisticsIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2HFIncMember 2023-06-30 0001786511 anpc:Fresh2HFIncMember 2023-01-01 2023-06-30 0001786511 anpc:FoodbaseGroupIncMember 2023-06-30 0001786511 anpc:FoodbaseGroupIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2EZIncMember 2023-06-30 0001786511 anpc:Fresh2EZIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2InformationIncMember 2023-06-30 0001786511 anpc:Fresh2InformationIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2EcommerceFresh2EcommerceMember 2023-06-30 0001786511 anpc:Fresh2EcommerceFresh2EcommerceMember 2023-01-01 2023-06-30 0001786511 anpc:GSINHKLimitedGISNMember 2023-06-30 0001786511 anpc:GSINHKLimitedGISNMember 2023-01-01 2023-06-30 0001786511 anpc:HuaYouShengFutureBeijingTechnologyCoLtdMember 2023-06-30 0001786511 anpc:HuaYouShengFutureBeijingTechnologyCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:GuanshiTechnologyBeijingCoLtdMember 2023-06-30 0001786511 anpc:GuanshiTechnologyBeijingCoLtdMember 2023-01-01 2023-06-30 0001786511 srt:ScenarioForecastMember 2023-09-25 0001786511 srt:MinimumMember 2023-01-01 2023-06-30 0001786511 srt:MaximumMember 2023-01-01 2023-06-30 0001786511 2022-12-31 2022-12-31 0001786511 anpc:OneSuppliersMember 2022-01-01 2022-06-30 0001786511 us-gaap:OtherCustomerMember 2023-01-01 2023-06-30 0001786511 anpc:TwoSuppliersMember 2022-01-01 2022-06-30 0001786511 anpc:TwoCustomersMember 2023-01-01 2023-06-30 0001786511 anpc:ThreeCustomersMember 2023-01-01 2023-06-30 0001786511 anpc:ThreeSuppliersMember 2022-01-01 2022-06-30 0001786511 anpc:TwoSuppliersMember 2023-01-01 2023-06-30 0001786511 anpc:FourSuppliersMember 2023-01-01 2023-06-30 0001786511 anpc:ThreeSuppliersMember 2023-01-01 2023-06-30 0001786511 2022-01-01 2022-12-31 0001786511 srt:MinimumMember anpc:FurnitureFixturesAndEquipmentMember 2023-06-30 0001786511 srt:MaximumMember anpc:FurnitureFixturesAndEquipmentMember 2023-06-30 0001786511 anpc:MotorVehiclesMember 2023-06-30 0001786511 srt:MinimumMember 2023-06-30 0001786511 2008-09-30 0001786511 anpc:GISNAcquisitionMember us-gaap:CommonClassAMember 2023-06-30 0001786511 anpc:GISNAcquisitionMember us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember us-gaap:CommonClassAMember 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember anpc:ProFormMember 2023-01-01 2023-06-30 0001786511 anpc:AssetAcquisitionMember 2023-01-01 2023-06-30 0001786511 anpc:GISNAcquisitionMember 2023-01-01 2023-06-30 0001786511 anpc:GISNAcquisitionMember 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember 2023-06-30 0001786511 anpc:FurnitureFixturesAndEquipmentMember 2023-06-30 0001786511 anpc:MotorVehiclesMember 2023-06-30 0001786511 anpc:SoftwareMember 2023-06-30 0001786511 anpc:RevenuesThirdPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-06-30 0001786511 anpc:RevenuesThirdPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-06-30 0001786511 anpc:RevenuesRelatedPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-06-30 0001786511 anpc:RevenuesRelatedPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-06-30 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-06-30 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-06-30 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2022-12-31 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2023-06-30 0001786511 2022-07-01 2022-12-31 0001786511 us-gaap:SoftwareDevelopmentMember 2022-12-31 0001786511 us-gaap:SoftwareDevelopmentMember 2023-06-30 0001786511 anpc:AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember 2021-05-01 2021-05-15 0001786511 2023-05-24 0001786511 anpc:NassauEnterprisesLLCNassauMember 2023-06-30 0001786511 anpc:NassauEnterprisesLLCNassauMember 2023-05-24 0001786511 anpc:AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember 2022-12-31 0001786511 anpc:AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember 2023-06-30 0001786511 anpc:NassauEnterprisesLLCNassauMember 2022-12-31 0001786511 anpc:NassauEnterprisesLLCNassauMember 2023-06-30 0001786511 2021-07-22 0001786511 2021-07-22 2021-07-22 0001786511 srt:MaximumMember 2021-07-22 2021-07-22 0001786511 srt:MinimumMember 2021-07-22 2021-07-22 0001786511 us-gaap:CommonClassAMember 2022-02-05 0001786511 2021-12-10 0001786511 2021-12-10 2021-12-10 0001786511 2022-03-16 2022-03-16 0001786511 2019-10-14 0001786511 us-gaap:CommonClassAMember 2019-10-01 2019-10-14 0001786511 us-gaap:CommonClassBMember 2019-10-01 2019-10-14 0001786511 srt:MinimumMember 2023-02-14 0001786511 srt:MaximumMember 2023-02-14 0001786511 us-gaap:CommonClassAMember 2023-02-14 2023-02-14 0001786511 us-gaap:CommonClassBMember 2023-02-14 2023-02-14 0001786511 us-gaap:CommonClassAMember 2021-12-10 2021-12-10 0001786511 us-gaap:CommonClassAMember 2022-03-16 2022-03-16 0001786511 2023-03-31 2023-03-31 0001786511 us-gaap:CommonClassAMember 2023-03-31 0001786511 srt:MinimumMember 2023-03-31 2023-03-31 0001786511 2022-04-27 2022-04-27 0001786511 2023-06-01 0001786511 us-gaap:CommonClassAMember 2022-06-10 2022-06-10 0001786511 2022-06-10 2022-06-10 0001786511 us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001786511 us-gaap:CommonClassAMember 2022-09-16 0001786511 2022-08-31 0001786511 us-gaap:CommonClassAMember 2020-07-28 2020-07-28 0001786511 us-gaap:CommonClassAMember 2023-05-11 2023-05-11 0001786511 2023-05-11 2023-05-11 0001786511 us-gaap:CommonClassAMember 2022-12-31 2022-12-31 0001786511 us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001786511 us-gaap:CommonClassAMember 2023-06-01 2023-06-09 0001786511 srt:ScenarioForecastMember us-gaap:CommonClassAMember 2023-10-01 2023-10-30 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-16 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2023-06-30 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-16 2022-03-16 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-05-19 2022-05-19 0001786511 us-gaap:PrivatePlacementMember 2023-01-01 2023-06-30 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-29 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-30 2022-03-30 0001786511 2022-05-01 2022-05-27 0001786511 2022-05-27 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-05-27 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-05-30 0001786511 us-gaap:WarrantMember 2022-12-31 0001786511 anpc:NineInvestorsMember us-gaap:CommonClassAMember 2022-12-31 0001786511 us-gaap:CommonClassAMember 2022-01-01 2022-12-31 0001786511 2022-09-02 2022-09-02 0001786511 2022-09-02 0001786511 us-gaap:CommonClassAMember 2022-09-02 2022-09-02 0001786511 us-gaap:PrivatePlacementMember 2022-09-02 0001786511 us-gaap:CommonClassAMember 2022-09-26 0001786511 us-gaap:CommonClassAMember 2022-09-02 0001786511 2022-09-26 2022-09-26 0001786511 2022-03-16 0001786511 us-gaap:CommonClassAMember 2022-03-01 2022-03-16 0001786511 2023-08-10 0001786511 us-gaap:CommonClassAMember 2023-08-10 0001786511 2023-02-01 2023-02-01 0001786511 2023-02-08 2023-02-08 0001786511 us-gaap:WarrantMember 2023-03-31 0001786511 2022-12-30 0001786511 us-gaap:CommonClassAMember 2019-10-01 2019-10-31 0001786511 us-gaap:CommonClassAMember 2021-07-05 0001786511 us-gaap:CommonClassAMember 2022-04-01 2022-04-14 0001786511 2022-08-01 2022-08-28 0001786511 2023-01-01 2023-01-31 0001786511 2023-03-10 0001786511 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001786511 anpc:EmployeesMember 2022-01-01 2022-06-30 0001786511 anpc:EmployeesMember 2023-01-01 2023-06-30 0001786511 anpc:NonEmployeesMember 2022-01-01 2022-06-30 0001786511 anpc:NonEmployeesMember 2023-01-01 2023-06-30 0001786511 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-06-30 0001786511 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-06-30 0001786511 anpc:NonEmployeesMember 2022-12-31 0001786511 anpc:NonEmployeesMember 2023-06-30 0001786511 srt:MinimumMember 2022-01-01 2022-06-30 0001786511 anpc:PRCMember 2023-01-01 2023-06-30 0001786511 us-gaap:InterestIncomeMember 2023-01-01 2023-06-30 0001786511 anpc:PRCMember 2023-01-01 2023-06-30 0001786511 country:US 2023-01-01 2023-06-30 0001786511 country:US 2022-01-01 2022-06-30 0001786511 stpr:NY 2023-01-01 2023-06-30 0001786511 stpr:NY 2022-01-01 2022-06-30 0001786511 stpr:DE 2023-01-01 2023-06-30 0001786511 stpr:DE 2022-01-01 2022-06-30 0001786511 anpc:Fresh2TechnologiesIncMember 2023-01-01 2023-06-30 0001786511 country:HK 2023-01-01 2023-06-30 0001786511 anpc:NonPRCMember 2023-01-01 2023-06-30 0001786511 us-gaap:InternalRevenueServiceIRSMember 2023-01-01 2023-06-30 0001786511 anpc:NonPRCMember 2022-01-01 2022-06-30 0001786511 country:US 2022-01-01 2022-06-30 0001786511 country:US 2023-01-01 2023-06-30 0001786511 anpc:HaohanXuMember 2023-01-01 2023-06-30 0001786511 anpc:ApifinyIncMember 2023-01-01 2023-06-30 0001786511 anpc:RoxeHoldingIncMember 2023-01-01 2023-06-30 0001786511 anpc:DrChrisChangYuMember 2023-01-01 2023-06-30 0001786511 anpc:CRSHoldingsIncMember 2023-01-01 2023-06-30 0001786511 anpc:JiaxingZhijunSihangInvestmentPartnershipEnterprisesMember 2023-01-01 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:ApifinyIncMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:ApifinyIncMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:RoxeHoldingIncMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:RoxeHoldingIncMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:DrChrisChangYuMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:DrChrisChangYuMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:CRSHoldingsIncMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:CRSHoldingsIncMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:JiaxingZhijunInvestmentManagementCoLtdZhijunMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:JiaxingZhijunInvestmentManagementCoLtdZhijunMember 2023-06-30 0001786511 anpc:AnPacBeijingMember 2022-01-01 2022-06-30 0001786511 anpc:AnPacBeijingMember 2023-01-01 2023-06-30 0001786511 anpc:XUdongDuMember 2022-01-01 2022-06-30 0001786511 anpc:XUdongDuMember 2023-01-01 2023-06-30 0001786511 us-gaap:SubsequentEventMember 2023-07-01 2023-07-27 0001786511 srt:ScenarioForecastMember anpc:OneIndividualMember us-gaap:CommonClassAMember 2023-09-29 0001786511 us-gaap:SubsequentEventMember 2023-09-25 2023-09-25 iso4217:CNY iso4217:USD iso4217:USD xbrli:shares xbrli:shares iso4217:CNY xbrli:shares xbrli:pure
EX-99.2 3 ea189176ex99-2_fresh2.htm MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS

Exhibit 99.2

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

A Operating Results

 

The following discussion and analysis of our financial condition as of June 30, 2023 and results of operations for the six months ended June 30, 2023 and June 30, 2022 should be read together with our condensed interim consolidated financial statements and related notes included elsewhere in this filing and our audited consolidated financial statements included in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (“SEC”) on May 16, 2023 (the “2022 Form 20-F”). The following discussion contains forward-looking statements that reflect our current plans, estimates and beliefs and involve risks and uncertainties. Our actual results may differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include those discussed below and elsewhere in this filing and in our Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.

 

Introduction

 

In late 2022 we began to transition our business to build a comprehensive B2B e-commerce platform with a focus on assisting restaurant owners in selecting Asian food suppliers more efficiently with the ultimate goal of providing one-stop fulfillment services from food sourcing to last-mile delivery. We primarily sources consumables and fresh food items from wholesale distributors, reselling them to restaurants nationwide. We were incorporated in the British Virgin Islands in January 2010 as AnPac Bio-Medical Science Co., Ltd. and changed our name to Fresh2 Group Limited to reflect our current business.

 

Unless otherwise indicated or unless the context otherwise requires, references to “Fresh2,” “we,” “us,” “our company,” “the Company,” the “Group” and “our” refers to Fresh2 Group Limited, a British Virgin Islands company and its subsidiaries:

 

Recent Developments

 

Acquisitions

 

In October 2022 we incorporated a new subsidiary, Fresh2 Technology Inc. (“Fresh2”) to serve as the operating company for our B2B business. On February 1, 2023, we acquired GISN (HK) LIMITED (“GISN”), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises, from Mr. Haohan Xu, our then Co-CEO and Co-Chairman of the board of directors. This acquisition was a critical initiative for the Company in order to improve the efficiency of its e-commerce operations.

 

On February 8, 2023, we acquired Fresh 2 Ecommerce Inc, a Delaware corporation (“Fresh2 Ecommerce”), from Mr. Xu. Fresh2 Ecommerce is a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as manufacturers, agents, importers, and wholesalers to restaurants and other retail customers.

 

On July 17, 2023, we purchased 51% of the common stock of Roxe Holding Inc. (“Roxe”), a development stage Delaware corporation with several New York based operating subsidiaries. Roxe, which has over than 100 independent contractors and employees, has used Blockchain technology to develop a peer-to-peer online payment program. The Roxe Instant Settlement Network (RISN) has been designed to enable financial institutions to provide cost efficient payments and near instant settlement. Roxe’s technology will enable multi asset payments and instant settlement in any supported currency. At present, Roxe has the ability to support transactions in over 100 countries and support more than 50 currencies and intends to allow users to accept payments in multiple assets. It has signed up 42 financial institutions and other organizations who intend to use Roxe’s technology. Roxe’s business is designed to support and interact with third party B2B e-commerce businesses to facilitate seamless payment transactions that take place on these platforms, enabling these businesses to achieve near real-time settlement. This interaction is intended to ensure quicker payment processing, reduced transaction fees, and enhanced cash flow for B2B transactions.

 

 

 

 

Roxe also intends to sign up e-commerce restaurants which could utilize Roxe’s payment technology for more efficient payment processing. Roxe intends to provide these businesses with the option of engaging Roxe to analyze their data points, such as menus, payment systems, and ingredient procurement and offer customized solutions.

 

On July 27, 2023, Roxe purchased SpeedIn Inc., which is focused on last mile deliveries, utilizing independent contractors, for a nominal price, from our CEO, Mr. Haohan Xu. Due to its disappointing performance, we sold SpeedIn back to Mr. Xu for the same nominal amount as paid.

 

We recently acquired a 19.64% interest in Nassau Enterprises LLC (“Nassau”). Nassau intends to develop, market and sell real estate in Savannah Lakes Village (the “SLV Project”) and to utilize an EB-5 program to finance the development of the SLV Project. This activity is expected to provide alternative financing for the Company’s growth.

 

Divestitures

 

In July, 2023, the Board approved the sale of its early cancer screening and detection business (the “CDA Business”), comprised of (i) AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”), a subsidiary based in Lishui, China, (ii) Anpac Technology USA CO., LTD. (“AnPac USA”), a subsidiary based in Pennsylvania and California, and (iii) Changhe Bio-Medical Technology (Yangzhou) Co., Ltd.(“Changhe”), a subsidiary based in Yangzhou, China. Accordingly, on July 28, 2023, the Group entered into Share purchase agreements with New-Horizon Bio-Medical Science Co., Ltd. (“New-Horizon”), a Hong Kong company focused on bio-medical technology, under which the Group agreed to sell 100% of the shares of AnPac Lishui and AnPac USA, which had experienced significant financial losses in its operations and are not expected to achieve a breakeven point in the immediate future, to New-Horizon in consideration of nil and nil, respectively. In addition, on July 28, 2023, the Group entered into a share purchase agreement with Ningkasai Technology (Shanghai) Co., Ltd. (“Ningkasai”), a PRC high-tech company specialized in nanotechnologies for life science applications, under which the Group agreed to sell 100% of the shares of Changhe, to Ningkasai for no consideration. The closing is expected to take place in November 2023.

 

Going Concern Uncertainties

 

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.

 

As reflected in the accompanying unaudited condensed consolidated financial statements for the six months ended June 30, 2023, we incurred net losses from continuing operations of approximately RMB43.5 million (US$6.0 million), net cash used in continuing operating activities of RMB43.7 million (US$6.0 million). As of June 30, 2023, we had an accumulated deficit of RMB648.3 million (US$89.4 million). Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months. The continuation of our company as a going concern through the next twelve months is dependent upon (1) the continued financial support from our shareholders or external financing. While we believe in the viability of our strategy to enter the e-commerce food distribution business will allow us to reduce our losses and improve our ability to raise additional funds, there can be no assurance to that effect, nor that our company will be successful in securing sufficient funds to sustain the operations.

 

These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.

 

2 

 

 

Results of Operations

 

Effective on July 28, 2023, we disposed of our ownership interests in our multi-cancer screening and detection test business (the “CDA Business”)which was primarily based in the People’s Republic of China (the “PRC” or “China”). The Group determined that the disposal of the CDA Business met the criteria to be classified as a discontinued operation and, as a result, the CDA business’s historical financial results are reflected in the Group’s unaudited condensed consolidated financial statements as a discontinued operation.

 

The following table summarizes our results of operations for the periods indicated. This information should be read together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this annual report. The operating results in any period are not necessarily indicative of the results that may be expected for any future period.

 

   For the six months ended
June 30,
   Amount
Increase
   Percentage
Increase
 
   2022   2023   (Decrease)   (Decrease) 
   RMB   RMB         
(In thousands of RMB, except for percentages)
Revenues       4,936    4,936    %
Cost of revenues       (4,039)   (4,039)   %
Gross Profit       897    897    %
Operating expenses:                    
Selling and marketing expenses   (463)   (6,070)   (5,607)   1,211.0%
General and administrative expenses   (8,167)   (35,680)   (27,513)   336.9%
Research and development expenses       (2,303)   (2,303)   %
Loss from operations   (8,630)   (43,156)   (34,526)   400.1%
Non-operating income and expenses:                   %
Interest expense, net   (31)   (309)   (278)   896.8%
Foreign exchange loss, net   (513)       513    (100.0)%
Share of net loss in equity method investments       (95)   (95)   %
Change in fair value of convertible debt   139        (139)   (100.0)%
Other income, net       21    21    %
Loss from continuing operations before income taxes   (9,035)   (43,539)   (34,504)   381.9%
Income tax benefit       79    79    %
Loss from continuing operations   (9,035)   (43,460)   (34,425)   381.0%
Loss from discontinuing operations, net of taxes   (39,780)   (27,945)   11,835    (29.8)%
Net loss   (48,815)   (71,405)   (22,590)   46.3%
Net loss from discontinuing operations attributable to noncontrolling interests   (740)   (641)   99    (13.4)%
Net loss attributable to ordinary shareholders   (48,075)   (70,764)   (22,689)   47.2%

 

Six months ended June 30, 2022 Compared to Six months ended June 30, 2023

 

Revenues

 

After the acquisition of GISN, Fresh2 Ecommerce and Easy Hundred during the first quarter 2023, the Group started to operate a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants and other retail customers in the U.S.

 

Our total revenues from continuing operations amounted to RMB4.9 million (US$681,000) for the six months ended June 30, 2023, primarily representing the revenue from sales of food and consumable products through our own APP in U.S. market. We did not have revenues from this source in the same period of last year.

 

Cost of Revenues

 

Our cost of revenues from continuing operations amounted to RMB4.0 million (US$557,000) for the six months ended June 30, 2023 as compared to nil for the same period of 2022, which mainly represented the cost of merchandise sold during the period.

 

Gross Profit

 

Our gross profit from continuing operations amounted to RMB897,000 (US$124,000) for the six months ended June 30, 2023 as compared to nil for the same period of 2022. Gross margin was18.2% for the six months ended June 30, 2023.

 

3 

 

 

Operating Expenses

 

Selling and marketing expenses

 

Our selling and marketing expenses from continuing operations increased by 1,211.0% to RMB6.1 million (US$837,000) for the six months ended June 30, 2023 from RMB463,000 for the same period of 2022, primarily due to more promotions and selling expenses incurred in promoting our platform. We also incurred additional sales and marketing staff salaries, share base compensation and shipping expenses during the first half of 2023.

 

General and administrative expenses

 

Our general and administrative expenses from continuing operations increased by 336.9% to RMB35.7 million (US$4.9 million) for the six months ended June 30, 2023 from RMB8.2 million for the same period of 2022, primarily due to increased professional consulting fees and employee salaries and the amortization of intangible assets as new business start.

 

Research and development expenses

 

Our research and development expenses from continuing operations amounted to RMB2.3 million (US$318,000) for the six months ended June 30, 2023 as compared to nil for the same period of 2022, primarily due to the inclusion of the operations of GISN which was acquired in February 2023. Our research and development expense incurred in the 2022 were mainly related to our discontinued CDA business.

 

Interest expense, net

 

Our net interest expense from continuing operations increased to RMB309,000 (US$43,000) for the six months ended June 30, 2023 from RMB31,000 for the same period of 2022, primarily due to increased interest paid on installment financings used for the purchases of fixed assets during the six months ended June 30, 2023. No such financings were made in the same period of 2022.

 

Net Loss

 

As a result of the foregoing, our net loss from continuing operations amounted to RMB43.5 million (US$6.0 million) for the six months ended June 30 2023 compared to RMB9.0 million for the same period of 2022.

 

Net loss from the discontinued CDA business amounted to RMB27.9 million (US$3.9 million) for the six months ended June 30 2023 compared to a net loss of RMB39.8 million for the same period of 2022.

 

4 

 

 

B. Liquidity and Capital Resources

 

Our principal sources of liquidity have been cash generated from financing and operating activities. Management expects that we will require continuous debt or equity financings to support our working capital. As of June 30, 2023, the Group had RM495,000 (US$68,000) of cash and cash equivalents and a working capital deficit of RMB32.5 million (US$4.5 million). For the six months ended June 30, 2023, the Group incurred losses from continuing operations of RMB43.5 million (US$6.0 million) and incurred RMB35.6 million (US$4.9 million) of negative cash flows from continuing operations. In assessing its liquidity, management monitors and analyzes the Group’s cash on-hand, its ability to generate sufficient revenue sources in the future, and its operating and capital expenditure commitments. With respect to capital funding requirements, the Group budgeted capital spending based on ongoing assessments of its need to maintain adequate cash.

 

Our unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty.

 

Based on the above assessment, we are uncertain as to when we will be able to obtain the financings necessary to fund our working capital requirements during the next 12 months from date of this report. As a result, the substantial doubt about the Company’s ability to continue as a going concern remains as of the date of this report.

 

On September 25, 2023, we entered into an agreement with an institutional investor to purchase up to US$2 million of convertible notes. The convertible notes will be sold in two tranches of (i) US$400,000 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600,000 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. We received the first payment of RMB1,697,000 (US$234,000) from this offering, excluding related financing costs.

 

We intend to finance our future working capital requirements and capital expenditures from cash generated from funds raised from financing activities until operating activities generate positive cash flows, if ever. We may, however, also require additional cash due to changing business conditions or other future developments, including any investments or acquisitions we may decide to pursue. If our existing cash is insufficient to meet our requirements, we may seek to issue debt or equity securities or obtain additional credit facilities. Financing may be unavailable in the amounts we need or on terms acceptable to us, if at all. Issuance of additional equity securities or equity-linked securities, including convertible debt securities, will dilute its earnings per share. The incurrence of debt would divert cash for working capital and capital expenditures to service debt obligations and could result in operating and financial covenants that restrict its operations and its ability to pay dividends to our shareholders.

 

We can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to us, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material adverse effect on us and our financial statements.

 

The following table sets forth selected cash flow statement information for the periods indicated:

 

   For the six months ended
June 30,
 
   2022   2023   2023 
   RMB   RMB   US$ 
   (in thousands) 
Net cash used in operating activities – continuing operations   (17,705)   (35,609)   (4,910)
Net cash used in operating activities – discontinuing operations   (13,497)   (1,669)   (230)
Net cash used in operating activities   (31,202)   (37,278)   (5,140)
Net cash used in investing activities – continuing operations       (48,311)   (6,662)
Net cash (used in) provided by investing activities – discontinuing operations   (817)   2,095    289 
Net cash used in investing activities   (817)   (46,216)   (6,373)
Net cash provided by financing activities – continuing operations   30,829    89,215    12,302 
Net cash used in financing activities – discontinuing operations   (1,589)   (2,799)   (386)
Net cash provided by financing activities   29,240    86,416    11,916 
Effect of exchange rate changes on cash and cash equivalents   (362)   (2,443)   (337)
Net increase (decrease) in cash and cash equivalents   (3,141)   479    66 
Cash and cash equivalents at beginning of period   3,152    16    2 
Cash and cash equivalents at end of period   11    495    68 

 

5 

 

 

Operating Activities

 

Net cash used in operating activities for the six months ended June 30, 2023 was RMB37.3 million (US$5.1 million), which was primarily attributable to our net loss from continuing operations of RMB43.5 million (US$6.0 million), adjusted by the non-cash items of RMB3.0 million (US$408,000) of depreciation and amortization expense and RMB2.9 million (US$396,000) of share based compensation, as well as operating cash used in our discontinued CDA business of RMB1.7 million (US$230,000).

 

Net cash used in operating activities for the six months ended June 30, 2022 was RMB31.2 million, which was primarily attributable to operating cash used in our discontinued CDA business of RMB13.5 million and net loss from continuing operations of RMB9.0 million as well as an increase of RMB9.0 million in deposits and prepayments made to our venders.

 

Investing Activities

 

Net cash used in investing activities for the six months ended June 30,2023 was RMB46.2 million (US$6.4 million), which was primarily attributable to our investment of RMB38.1 million (US$5.3 million) to acquire a 19.64% equity interest in Nassau Enterprises LLC (“Nassau”) in May 2023, and purchase intangible assets and property and equipment of RMB11.3 million (US$1.6 million).

 

Net cash used in investing activities for the six months ended June 30, 2022 was RMB0.8 million, which was primarily related to operating cash used in our discontinued CDA business.

 

Financing Activities

 

Net cash provided by financing activities for the six months ended June 30, 2023 was RMB86.4 million (US$11.9 million), which was primarily attributable to proceeds from a private placement of RMB81.6 million (US$11.3) million and proceeds from the exercise of warrants and options of RMB7.1 million (US$1.0 million).

 

Net cash provided by financing activities for the six months ended June 30, 2022 was RMB29.2 million, which was primarily attributable to the proceeds of RMB31.0 million private placements, offset by operating cash used in our discontinued CDA business of RMB1.6 million.

 

Capital Expenditures

 

Our capital expenditures were nil and RMB11.3 million for the six months ended June 30, 2022 and 2023, respectively. In 2022, these capital expenditures included the purchases of property and equipment and intangible assets related to our discontinued CDA business. We expect to increase the capital expenditures in our e-commerce business to meet the needs of our expected growth.

 

C. Critical Accounting Policies and Estimates

 

We prepare our unaudited condensed consolidated financial statements in conformity with U.S. GAAP, which requires us to make judgments, estimates and assumptions that affect our reported amount of assets, liabilities, revenue, costs and expenses, and any related disclosures. Although there were no material changes made to the accounting estimates and assumptions in the past three years, we continually evaluate these estimates and assumptions based on the most recently available information, our own historical experience and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from our expectations as a result of changes in our estimates.

 

We believe that the following accounting policies involve a higher degree of judgment and complexity in their application and require us to make significant accounting estimates: business combination, goodwill, impairment of long-lived assets other than goodwill, share-based compensation and revenue recognition. These accounting policies and estimates are described in Note 2 of our Unaudited Condensed Financial Statements.

 

 

6

 

 

EX-101.SCH 4 anpc-20230630.xsd XBRL SCHEMA FILE 001 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Alternate 0 link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Unaudited Condensed Consolidated Statements of Shareholders’ Equity/(Deficit) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Principal Activities link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Liquidity and Going Concern Uncertainties link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Summary of Principal Accounting Policies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Acqusitions link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Discontinued Operations link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Accounts Receivable, Net link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Other Current Assets, Net link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Intangible Assets, Net link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Long-Term Investments, Net link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Short-Term Debts link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Share Based Compensation link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Related Party Transactions and Balances link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Organization and Principal Activities (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Summary of Principal Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Acqusitions (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Accounts Receivable, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Other Current Assets, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Long-Term Investments, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Short-Term Debts (Tables) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Share Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Related Party Transactions and Balances (Tables) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Organization and Principal Activities (Details) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Organization and Principal Activities (Details) - Schedule of Group’s Principal Subsidiaries link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Liquidity and Going Concern Uncertainties (Details) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Summary of Principal Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Acqusitions (Details) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Acqusitions (Details) - Schedule of Pro Forma of Group Business Combination link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Discontinued Operations (Details) link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Discontinued Operations (Details) - Schedule of Results of Discontinued Operations link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Other Current Assets, Net (Details) - Schedule of Other Current Assets link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:definitionLink link:calculationLink 060 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net Consists link:presentationLink link:definitionLink link:calculationLink 061 - Disclosure - Intangible Assets, Net (Details) link:presentationLink link:definitionLink link:calculationLink 062 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible Assets Net link:presentationLink link:definitionLink link:calculationLink 063 - Disclosure - Intangible Assets, Net (Details) - Schedule of Estimated Aggregate Amortization Expense link:presentationLink link:definitionLink link:calculationLink 064 - Disclosure - Long-Term Investments, Net (Details) link:presentationLink link:definitionLink link:calculationLink 065 - Disclosure - Long-Term Investments, Net (Details) - Schedule of Long-Term Investments link:presentationLink link:definitionLink link:calculationLink 066 - Disclosure - Short-Term Debts (Details) link:presentationLink link:definitionLink link:calculationLink 067 - Disclosure - Short-Term Debts (Details) - Schedule of Short-Term Debts link:presentationLink link:definitionLink link:calculationLink 068 - Disclosure - Leases (Details) - Schedule of Operating Leases link:presentationLink link:definitionLink link:calculationLink 069 - Disclosure - Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates link:presentationLink link:definitionLink link:calculationLink 070 - Disclosure - Leases (Details) - Schedule of Maturities of Lease Liabilities link:presentationLink link:definitionLink link:calculationLink 071 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities link:presentationLink link:definitionLink link:calculationLink 072 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 073 - Disclosure - Shareholders' Equity (Details) - Sechedule of Warrants Activity link:presentationLink link:definitionLink link:calculationLink 074 - Disclosure - Share Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 075 - Disclosure - Share Based Compensation (Details) - Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument link:presentationLink link:definitionLink link:calculationLink 076 - Disclosure - Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument link:presentationLink link:definitionLink link:calculationLink 077 - Disclosure - Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued link:presentationLink link:definitionLink link:calculationLink 078 - Disclosure - Share Based Compensation (Details) - Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense link:presentationLink link:definitionLink link:calculationLink 079 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 080 - Disclosure - Income Taxes (Details) - Schedule of Loss Before Income Taxes link:presentationLink link:definitionLink link:calculationLink 081 - Disclosure - Income Taxes (Details) - Schedule of Current and Deferred Components of Income Tax Benefit link:presentationLink link:definitionLink link:calculationLink 082 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate link:presentationLink link:definitionLink link:calculationLink 083 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 084 - Disclosure - Income Taxes (Details) - Schedule of Significant Components of Deferred Taxes link:presentationLink link:definitionLink link:calculationLink 085 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational link:presentationLink link:definitionLink link:calculationLink 086 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Party Balances link:presentationLink link:definitionLink link:calculationLink 087 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Accounts Receivables link:presentationLink link:definitionLink link:calculationLink 088 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 089 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 anpc-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 anpc-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 7 anpc-20230630_lab.xml XBRL LABEL FILE EX-101.PRE 8 anpc-20230630_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
6 Months Ended
Jun. 30, 2023
Document Information Line Items  
Entity Registrant Name Fresh2 Group Limited
Document Type 6-K/A
Current Fiscal Year End Date --12-31
Amendment Flag true
Amendment Description This Form 6-K/A is being filed as an amendment to the Form 6-K dated November 9, 2023 (the “Original Form 6-K”). The purpose of this Form 6-K/A is to amend Exhibits 99.1 and 99.2 of the Original Form 6-K. The amendments made in this document are as follows:   ● Numerical and Wording Revisions: We have made necessary corrections to certain numerical data and wording to ensure accuracy and clarity. These revisions do not materially alter the financial condition or results of operations previously reported.             1. We corrected disclosures regarding loss from disposal of Changwei on page F-18.             2. We corrected disclosures regarding revenues from related parties and third parties for the six months ended June 30, 2023 on page F-18.             3. We corrected disclosures regarding B. Liquidity and Capital Resources on page 5:               1) we changed the working capital deficit as of June 30, 2023 from RMB32,482 million to RMB32.5 million;                 2) we changed the value of convertible notes from US$2,000 million to US$2 million;                 3) we changed the two tranches of convertible notes sold from US$400 and US$1,600 to US$400,000 and US$1,600,000, respectively;                 4) we changed the first payment received from RMB1,697 (US$234) to RMB1,697,000 (US$234,000).               4. We corrected the disclosures regarding capital expenditures for the six months ended June 30, 2022 and 2023 on page 6. ●Additional Disclosures:   1. We added and corrected disclosures regarding the GISN acquisition on page F-16 and page F-32, specific changes were made to 1) correct the disclosure to note the GISN acquisition is not from a related party, 2) correct the fair value of the assets acquired and liabilities assumed table to include ROU which was missed previously and added the omitted disclosure about revenue contributed by GISN for the six months ended June 30, 2023. 2.We added Information pertaining to recent dispositions to provide a more comprehensive understanding of our financial activities. ●Accounting Policy Modifications: Changes have been made to reflect updates in accounting policy after the adoption of ASU 2017-04 in 2022 on page F-9. ●Revision of Product Warranty and Return Policy Description: We have updated the descriptions of our product warranty and return policy to better reflect current practices and ensure transparency on page F-12. Except as described herein, no other changes have been made to the Original Form 6-K.
Entity Central Index Key 0001786511
Document Period End Date Jun. 30, 2023
Document Fiscal Year Focus 2023
Document Fiscal Period Focus Q2
Entity File Number 001-39137
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Condensed Consolidated Balance Sheets
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Current assets:      
Cash and cash equivalents ¥ 495 $ 68 ¥ 16
Prepayment 3,948 544 1,050
Accounts receivable, net 270 37
Amounts due from related parties, net 864 119
Inventories, net 135 19
Other current assets, net 414 57
Current assets held for sale 9,777 1,348 12,633
Total current assets 27,353 3,771 13,699
Long term -prepayment 4,678 645
Property and equipment, net 4,309 594
Intangible assets, net 45,169 6,229
Goodwill 36,503 5,034
Right of use assets 223 31
Long-term investments, net 39,783 5,486
Noncurrent assets held for sale 20,193 2,785 26,770
TOTAL ASSETS. 178,211 24,575 40,469
Current liabilities:      
Short-term debts 16 2 15
Accounts payable 420 56
Advance from customers 479 66
Lease liability-current 148 20
Accrued expenses and other current liabilities 24,759 3,414 7,535
Current liabilities held for sale 33,421 4,609 33,514
Total current liabilities 59,835 8,249 42,278
Deferred tax liabilities 2,938 405
Lease liability-non-current 37 5
Other long-term liabilities 903 125
Noncurrent liabilities held for sale 2,434 336 7,595
TOTAL LIABILITIES 66,147 9,120 49,873
Commitments and contingencies
Shareholders’ equity (deficit):      
Treasury shares [1] (11,003)
Additional paid-in capital 715,327 98,648 564,869
Accumulated deficit (648,303) (89,405) (577,539)
Accumulated other comprehensive income 13,079 1,804 4,263
Total Fresh2 Group Limited shareholders’ equity (deficit) 92,524 12,760 (13,676)
Non-controlling interest 19,540 2,695 4,272
Total equity (deficit) 112,064 15,455 (9,404)
TOTAL LIABILITIES AND EQUITY (DEFICIT) 178,211 24,575 40,469
Class A Ordinary Shares      
Shareholders’ equity (deficit):      
Ordinary shares 12,181 1,680 5,494
Class B Ordinary Shares      
Shareholders’ equity (deficit):      
Ordinary shares 240 33 240
Related Party      
Current assets:      
Accounts receivable-related party 11,450 1,579
Amounts due from related parties, net 864 119
Current liabilities:      
Amounts due to related parties ¥ 592 $ 82 ¥ 1,214
[1] 12,492,283 shares Class A Ordinary shares were held as treasury shares.
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Class A Ordinary Shares    
Ordinary shares, shares par value (in Dollars per share) $ 0.01 $ 0.01
Ordinary shares, shares authorized 2,400,000,000 2,400,000,000
Ordinary shares, shares issued 176,070,465 79,536,589
Ordinary shares, shares outstanding 176,070,465 79,536,589
Class B Ordinary Shares    
Ordinary shares, shares par value (in Dollars per share) $ 0.01 $ 0.01
Ordinary shares, shares authorized 30,000,000 30,000,000
Ordinary shares, shares issued 3,573,100 3,573,100
Ordinary shares, shares outstanding 3,573,100 3,573,100
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
¥ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
CNY (¥)
¥ / shares
shares
Income Statement [Abstract]      
Total revenues ¥ 4,936 $ 681
Cost of revenues (4,039) (557)
Gross Profit 897 124
Operating expenses:      
Selling and marketing expenses (6,070) (837) (463)
General and administrative expenses (35,680) (4,920) (8,167)
Research and development expenses (2,303) (318)
Loss from operations (43,156) (5,951) (8,630)
Non-operating income and expenses:      
Interest expense, net (309) (43) (31)
Foreign exchange loss, net (513)
Share of net loss in equity method investments (95) (13)
Change in fair value of convertible debt 139
Other income, net 21 3
Loss from continuing operations before income taxes (43,539) (6,004) (9,035)
Income tax benefit 79 11
Loss from continuing operations (43,460) (5,993) (9,035)
Loss from discontinued operations, net of taxes (27,945) (3,854) (39,780)
Net loss (71,405) (9,847) (48,815)
Net loss from discontinued operations attributable to noncontrolling interests (641) (88) (740)
Net loss attributable to ordinary shareholders (70,764) (9,759) (48,075)
Other comprehensive (loss) income, net of tax:      
Foreign currency translation differences 8,816 1,216 (162)
Total comprehensive loss (62,589) (8,631) (48,977)
Total comprehensive loss attributable to noncontrolling interests (641) (88) (740)
Total comprehensive loss attributable to ordinary shareholders (61,948) (8,543) (48,237)
Amounts attributable to ordinary shareholders:      
Net loss from continuing operations (43,460) (5,993) (9,035)
Net loss from discontinued operations (27,304) (3,766) (39,040)
Net loss attributable to ordinary shareholders ¥ (70,764) $ (9,759) ¥ (48,075)
Loss per Class A and B ordinary shares - basic and diluted      
Continuing operations basic (in Dollars per share and Yuan Renminbi per share) | (per share) ¥ (0.35) $ (0.05) ¥ (0.38)
Discontinued operations basic (in Dollars per share and Yuan Renminbi per share) | (per share) (0.22) (0.03) (1.66)
Net Loss basic (in Dollars per share and Yuan Renminbi per share) | (per share) ¥ (0.57) $ (0.08) ¥ (2.04)
Weighted average shares outstanding used in calculating basic and diluted loss per share      
Class A and Class B ordinary shares - basic (in Shares) 124,374,140 124,374,140 23,603,709
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)
6 Months Ended
Jun. 30, 2023
$ / shares
shares
Jun. 30, 2023
¥ / shares
shares
Jun. 30, 2022
¥ / shares
shares
Income Statement [Abstract]      
Continuing operations diluted | (per share) $ (0.05) ¥ (0.35) ¥ (0.38)
Discontinued operations diluted | (per share) (0.03) (0.22) (1.66)
Net Loss diluted | (per share) $ (0.08) ¥ (0.57) ¥ (2.04)
Class A and Class B ordinary shares - diluted (in Shares) 124,374,140 124,374,140 23,603,709
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Condensed Consolidated Statements of Shareholders’ Equity/(Deficit)
¥ in Thousands, $ in Thousands
Class A
Ordinary Shares
CNY (¥)
shares
Class A
Ordinary Shares
USD ($)
shares
Class A
shares
Class B
Ordinary Shares
CNY (¥)
shares
Class B
Ordinary Shares
USD ($)
shares
Treasury shares
CNY (¥)
shares
Treasury shares
USD ($)
shares
Additional Paid-in Capital
CNY (¥)
Additional Paid-in Capital
USD ($)
Accumulated Deficit
CNY (¥)
Accumulated Deficit
USD ($)
Accumulated Other (Loss) Income
CNY (¥)
Accumulated Other (Loss) Income
USD ($)
Total Fresh2 Group Limited Shareholders’ Equity (Deficit)
CNY (¥)
Total Fresh2 Group Limited Shareholders’ Equity (Deficit)
USD ($)
Non-controlling interest
CNY (¥)
Non-controlling interest
USD ($)
CNY (¥)
USD ($)
Balance at June 30, 2023 (US$) (in Dollars) ¥ 1,096     ¥ 185     ¥ 465,334   ¥ (475,646)   ¥ 4,532   ¥ (4,499)   ¥ 5,817   ¥ 1,318  
Balance at June 30, 2023 (US$) (in Shares) | shares 16,604,402 16,604,402   2,773,100 2,773,100                            
Balance at Dec. 31, 2021 ¥ 1,096     ¥ 185     465,334   (475,646)   4,532   (4,499)   5,817   1,318  
Balance (in Shares) at Dec. 31, 2021 | shares 16,604,402 16,604,402   2,773,100 2,773,100                            
Net loss           (48,075)     (48,075)   (740)   (48,815)  
Issuance of shares in private placements, net of offering costs ¥ 961         30,028       30,989     30,989  
Issuance of shares in private placements, net of offering costs (in Shares) | shares 14,382,693 14,382,693                                  
Issuance shares for exercise of share option ¥ 27         (27)            
Issuance shares for exercise of share option (in Shares) | shares 417,702 417,702                                  
Issuance shares reserved for convertible loan ¥ 381         (381)            
Issuance shares reserved for convertible loan (in Shares) | shares 6,000,000 6,000,000                                  
Issuance shares for service ¥ 13         (13)            
Issuance shares for service (in Shares) | shares 187,094 187,094                                  
Conversion of convertible loans         27,739       27,739     27,739  
Share based compensation         4,528       4,528     4,528  
Foreign currency translation differences             (162)   (162)     (162)  
Balance at Jun. 30, 2022 ¥ 2,478     ¥ 185     527,208   (523,721)   4,370   10,520   5,077   15,597  
Balance (in Shares) at Jun. 30, 2022 | shares 37,591,891 37,591,891   2,773,100 2,773,100                            
Balance at June 30, 2023 (US$) (in Dollars) ¥ 2,478     ¥ 185     527,208   (523,721)   4,370   10,520   5,077   15,597  
Balance at June 30, 2023 (US$) (in Shares) | shares 37,591,891 37,591,891   2,773,100 2,773,100                            
Balance at June 30, 2023 (US$) (in Dollars) ¥ 5,494     ¥ 240   ¥ (11,003)   564,869   (577,539)   4,263   (13,676)   4,272   (9,404)  
Balance at June 30, 2023 (US$) (in Shares) | shares 79,536,589 79,536,589   3,573,100 3,573,100 (12,492,283) (12,492,283)                        
Balance at Dec. 31, 2022 ¥ 5,494     ¥ 240   ¥ (11,003)   564,869   (577,539)   4,263   (13,676)   4,272   (9,404)  
Balance (in Shares) at Dec. 31, 2022 | shares 79,536,589 79,536,589   3,573,100 3,573,100 (12,492,283) (12,492,283)                        
Net loss           (70,764)     (70,764)   (641)   (71,405) $ (9,847)
Issuance of shares in private placements, net of offering costs ¥ 4,355         77,541       81,896     81,896  
Issuance of shares in private placements, net of offering costs (in Shares) | shares 62,885,707 62,885,707                                  
Issuance shares for exercise of share option ¥ 46         182       228     228  
Issuance shares for exercise of share option (in Shares) | shares 663,900 663,900                                  
Issuance shares for exercise of warrants ¥ 528         6,383       6,911     6,911  
Issuance shares for exercise of warrants (in Shares) | shares 7,584,900 7,584,900                                  
Issuance shares for acquisition ¥ 2,174         66,788       68,962     68,962  
Issuance shares for acquisition (in Shares) | shares 31,891,652 31,891,652                                  
Issuance shares for service ¥ 243         6,142       6,385     6,385  
Issuance shares for service (in Shares) | shares 3,500,000 3,500,000 3,822,853                                
Shares issued in private placement, cancelled subsequently ¥ 178         (178)              
Shares issued in private placement, cancelled subsequently (in Shares) | shares 2,500,000 2,500,000                                  
Canceled treasure shares ¥ (837)       ¥ 11,003   (10,166)            
Canceled treasure shares (in Shares) | shares (12,492,283) (12,492,283)       12,492,283 12,492,283                        
Share based compensation         3,766       3,766     3,766  
Disposition of Changwei                 15,909   15,909  
Foreign currency translation differences             8,816   8,816     8,816  
Balance at Jun. 30, 2023 ¥ 12,181 $ 1,680   ¥ 240 $ 33 715,327 $ 98,648 (648,303) $ (89,405) 13,079 $ 1,804 92,524 $ 12,760 19,540 $ 2,695 112,064 15,455
Balance (in Shares) at Jun. 30, 2023 | shares 176,070,465 176,070,465   3,573,100 3,573,100                        
Balance at June 30, 2023 (US$) (in Dollars) ¥ 12,181 $ 1,680   ¥ 240 $ 33 ¥ 715,327 $ 98,648 ¥ (648,303) $ (89,405) ¥ 13,079 $ 1,804 ¥ 92,524 $ 12,760 ¥ 19,540 $ 2,695 ¥ 112,064 $ 15,455
Balance at June 30, 2023 (US$) (in Shares) | shares 176,070,465 176,070,465   3,573,100 3,573,100                        
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Unaudited Condensed Consolidated Statements of Cash Flows
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Operating activities:      
Net loss ¥ (71,405) $ (9,847) ¥ (48,815)
Less: net loss from discontinued operations (27,945) (3,854) (39,780)
Net loss from continuing operations (43,460) (5,993) (9,035)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization 2,960 408
Share of net loss in equity method investments 95 13
Share-based compensation 2,872 396
Amortization of right of use assets 68 9
Change in fair value of convertible debt (139)
Deferred tax benefits (79) (11)
Changes in operating assets and liabilities:      
Prepayment (699) (96) (9,034)
Accounts receivable (154) (21)
Accounts receivable-related party 962 133
Inventories (129) (18)
Other current assets 742 102 658
Accounts payable (569) (78)
Advance from customers 458 63
Accrued expenses and other current liabilities 1,384 191 (155)
Lease liabilities (60) (8)
Net cash used in operating activities – continuing operations (35,609) (4,910) (17,705)
Net cash used in operating activities –discontinued operations (1,669) (230) (13,497)
Net cash used in operating activities (37,278) (5,140) (31,202)
Investing activities:      
Purchases of property and equipment (2,355) (325)
Purchases of intangible assets (8,980) (1,238)
Cash acquired from acquisition 1,130 156
Long-term investment (38,106) (5,255)
Net cash used in investing activities – continuing operations (48,311) (6,662)
Net cash (used in) provided by investing activities –discontinued operations 2,095 289 (817)
Net cash used in investing activities (46,216) (6,373) (817)
Financing activities:      
Proceeds from private placement 81,643 11,259 30,989
Proceeds from exercising of warrants 6,911 953
Proceeds from exercising of options 228 31
Other long-term liabilities 982 135
Payment to related parties (549) (76) (160)
Net cash provided by financing activities – continuing operations 89,215 12,302 30,829
Net cash used in financing activities –discontinued operations (2,799) (386) (1,589)
Net cash provided by financing activities 86,416 11,916 29,240
Effect of exchange rate changes on cash and cash equivalents (2,443) (337) (362)
Net increase (decrease) in cash and cash equivalents 479 66 (3,141)
Cash and cash equivalents at beginning of period 16 2 3,152
Cash and cash equivalents at end of period 495 68 11
Supplemental disclosure of non-cash activities:      
Conversion of convertible loans 27,739
Right of use assets obtained in exchange for lease liabilities 8,954
Receivable from issuance shares for private placement 253 35
Issuances of shares for services 6,385 881
Issuances of shares for acquisitions 68,962 9,510
Additions to intangible assets through accrued expenses and other current liabilities ¥ 1,851 $ 255
XML 16 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Principal Activities
6 Months Ended
Jun. 30, 2023
Organization and Principal Activities [Abstract]  
ORGANIZATION AND PRINCIPAL ACTIVITIES

1. ORGANIZATION AND PRINCIPAL ACTIVITIES

 

Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., the “Company”) was incorporated in the British Virgin Islands (“the BVI”) in January 2010. The Company incorporated a new subsidiary, Fresh2 Technology Inc. (“Fresh2”) on October 4, 2022. On February 1, 2023, the Group acquired GISN (HK) LIMITED (“GISN”), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commerce operations. On February 8, 2023, the Group acquired Fresh 2 Ecommerce Inc. (“Fresh2 Ecommerce”), a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants and other retail customers in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as food companies, manufacturers, agents, importers, and wholesalers to restaurants and other retail customers. On March 31, 2023, the Group closed an asset purchase with Easy Hundred Inc. (“Easy Hundred”), a U.S.-based e-commerce startup company in the foodservice industry. On July 17, 2023, the Group entered into a definitive Share Purchase Agreement to purchase 51% of Roxe Holding Inc. (“Roxe”). On July 27, 2023, Roxe entered into a Share Purchase Agreement with SpeedIn INC (“SpeedIn”) to purchase 100% of the shares of SpeedIn. Due to its poor operating results, on October 9, 2023, Roxe sold SpeedIn to Immensus LLC, a company owned by our CEO. On November 4, 2023 the Company and Fresh2 Technology entered into a definitive Share Purchase Agreement to purchase 38.61% of the common stock of Roxe.

 

The Company and its subsidiaries (collectively, the “Group”) provides a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants and other retail customers in the U.S.

 

Effective on July 28, 2023, the Group disposed its multi-cancer screening and detection test business (the “CDA Business”) in the People’s Republic of China (the “PRC” or “China”). The Group determined that the disposal of the CDA Business met the criteria to be classified as a discontinued operation (see Note 4) and, as a result, the CDA business’s historical financial results are reflected in the Group’s unaudited condensed consolidated financial statements as a discontinued operation.

 

As of June 30, 2023, the details of the Group’s principal subsidiaries are as follows:

 

Major subsidiaries  Percentage of
Ownership
  

Date of
Incorporation/

Acquisition

  Place of
Incorporation
  Major Operation
Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. *    100%  March 2010  the PRC  Cancer screening and detection tests
AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”) *

   100%  October 2012  the PRC  Cancer screening detection tests and device manufacturing
AnPac Bio-Medical Technology (Shanghai) Co., Ltd.*   100%  April 2014  the PRC  Cancer screening and detection tests
AnPac Technology USA Co., Ltd. (“AnPac US”) *

   100%  September 2015  the U.S.  Clinical trials for research on cancer screening and detection tests
Lishui AnPac Medical Laboratory Co., Ltd.*   100%  July 2016  the PRC  Cancer screening and detection tests
Shiji (Hainan) Medical Technology Ltd.*   100%  March 2013  the PRC  Cancer screening and detection research
Shanghai Muqing AnPac Health Technology Co., Ltd. (“AnPac Muqing”) (i)*   51%  March 2019  the PRC  Cancer screening and detection tests
Anpai (Shanghai) Healthcare Management and Consulting Co., Ltd.*   60%  August 15, 2021  the PRC  Cancer screening and detection tests
Fresh 2 Group Inc   100%  December 27, 2022  the U.S.  B2B e-commerce
Fresh 2 Technology Inc (“Fresh2”)   100%  October 4, 2022  the U.S.  B2B e-commerce
Fresh 2 Logistics Inc.   100%  February 22, 2023  the U.S.  B2B e-commerce
Fresh 2 HF Inc   100%  February 21, 2023  the U.S.  B2B e-commerce
Foodbase Group Inc   100%  January 19, 2023  the U.S.  B2B e-commerce
Fresh 2 EZ Inc   100%  March 3, 2023  the U.S.  B2B e-commerce
Fresh 2 information Inc (ii)   100%  April 12, 2023  the U.S.  B2B e-commerce
Fresh 2 Ecommerce (“Fresh2 Ecommerce”)   100%  February 8, 2023  the U.S.  B2B e-commerce
GISN (HK) Limited (“GISN”)   100%  February 1, 2023  Hongkong, PRC,  B2B e-commerce
Hua You Sheng Future (Beijing) Technology Co., Ltd.   100%  February 1, 2023  PRC  B2B e-commerce
Guanshi Technology (Beijing) Co., Ltd.   100%  February 1, 2023  PRC  Software development

 

* Subsidiaries that were sold subsequent to June 30, 2023.
(i) AnPac Muqing closed business in March 2023
(ii) On April 12, 2023, the Company, through its subsidiary, Fresh 2 EZ Inc to acquire 100% of equity interest in Fresh 2 information Inc from Roxe Holding Inc, a company controlled by Mr. Haohan Xu, with a nominal price. Fresh 2 information Inc has not begun operation yet.
XML 17 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Liquidity and Going Concern Uncertainties
6 Months Ended
Jun. 30, 2023
Liquidity and Going Concern Uncertainties [Abstract]  
LIQUIDITY AND GOING CONCERN UNCERTAINTIES

2. LIQUIDITY AND GOING CONCERN UNCERTAINTIES

 

The Group’s principal sources of liquidity have been cash generated from financing and operating activities. As of June 30, 2023, the Group had RMB495 (US$68) of cash and cash equivalents and a working capital deficit of RMB34,148 (US$4,710). For the six months ended June 30, 2023, the Group incurred a loss from continuing operations of RMB43,460(US$5,993). For the six months ended June 30, 2023, net cash used in continuing operating activities was RMB35,609 (US$4,910). The above-mentioned facts raise substantial doubt about the Group’s ability to continue as a going concern. In assessing its liquidity, management monitors and analyzes the Group’s cash on-hand, its ability to generate sufficient revenue sources in the future, and its operating and capital expenditure commitments. With respect to capital funding requirements, the Group budgeted capital spending based on ongoing assessments of needs to maintain adequate cash. The Group intends to finance its future working capital requirements and capital expenditures from financing activities until the Group’s operating activities generate positive cash flows, if ever. Management expects continued capital financing through debt or equity issuances to support its working capital requirements.

 

On September 25, 2023, the Company entered into an agreement with an institutional investor to purchase up to US$2,000 of convertible notes, the convertible notes will be sold in two tranches (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at an exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at an exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment of RMB1,697(US$234) from this offering, excluding related financing costs.

 

The Group can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to the Group, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material adverse effect on the Group and its financial statements.

 

The unaudited condensed consolidated financial statements have been prepared assuming that the Group will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty.

XML 18 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Principal Accounting Policies
6 Months Ended
Jun. 30, 2023
Summary of Principal Accounting Policies [Abstract]  
SUMMARY OF PRINCIPAL ACCOUNTING POLICIES

3. SUMMARY OF PRINCIPAL ACCOUNTING POLICIES

 

(a) Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial reporting and pursuant to the applicable rules and regulations of the SEC pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

 

In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2023 and 2022 are not necessarily indicative of the results that may be expected for the full year. The information included in this report should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Group’s annual financial statements for the fiscal year ended December 31, 2022 filed with the SEC on May 16, 2023.

 

(b) Principles of consolidation

 

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Group. All inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power, has the power to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of the board of directors, or has the power to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders.

 

(c) Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Areas where management uses subjective judgement include, but are not limited to allowance for doubtful accounts, share-based compensation, deferred tax and uncertain tax position, useful lives of intangible assets and property and equipment, impairment of long-lived assets, goodwill and long-term investments and the purchase price allocation with respect to business combinations. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences could be material to the unaudited condensed consolidated financial statements. 

 

(d) Cash and cash equivalents

 

Cash and cash equivalents consist of cash on hand and demand deposits placed with banks which are unrestricted as to withdrawal or use and have original maturities less than three months. All highly liquid investments with a stated maturity of 90 days or less from the date of purchase are classified as cash equivalents.

 

(e) Accounts receivable and allowance for credit losses

 

Accounts receivable represents the amounts that the Group has an unconditional right to consideration and is recorded net of allowance for credit losses.

In 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The Group has adopted this ASC Topic 326 and several associated ASUs on January 1, 2023 using a modified retrospective approach. The adoption has no material impact to the Company’s consolidated financial statements. The Group estimated allowance for credit losses to reserve for potentially uncollectible receivable amounts periodically, considering factors in assessing the collectability of its accounts receivable, such as historical distribution of the age of the amounts due, payment history, creditworthiness, forward-looking factor, historical collections data of the customers, to assess the credit risk characteristics. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Group also makes specific allowance in the period in which a loss is determined to be probable. Accounts receivable are considered impaired and written-off when it is probable that all contractual payments due will not be collected after all collection efforts have been exhausted.

 

(f) Convenience translation

 

Amounts in US$ are presented for the convenience of the reader and are translated at the noon buying rate of US$1.00 to RMB7.2513 on June 30, 2023, representing the noon buying rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be converted, realized or settled into US$ at such rate or at any other rate.

 

(g) Long-term investments

 

The Group’s long-term investments include equity method investments and equity investments without readily determinable fair values.

 

Investments in entities in which the Group can exercise significant influence but does not own a majority equity interest or control are accounted for using the equity method of accounting in accordance with ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Under the equity method, the Group initially records its investment at cost and the difference between the cost of the equity investee and the amount of the underlying equity in the net assets of the equity investee is accounted for as if the investee were a consolidated subsidiary. The share of earnings or losses of the investee are recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Equity method adjustments include the Group’s proportionate share of investee income or loss, adjustments to recognize certain differences between the Group’s carrying value and its equity in net assets of the investee at the date of investment, impairments, and other adjustments required by the equity method. The Group assesses its equity investment for other-than-temporary impairment by considering factors as well as all relevant and available information including, but not limited to, current economic and market conditions, the operating performance of the investees including current earnings trends, the general market conditions in the investee’s industry or geographic area, factors related to the investee’s ability to remain in business, such as the investee’s liquidity, debt ratios, and cash burn rate and other company-specific information.

 

Investments in equity securities without readily determinable fair values are measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. No impairment on its long-term investments was recognized for the six months ended June 30, 2022 and 2023.

 

(h) Business combinations

 

The cost of an acquisition is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued. The costs directly attributable to the acquisition are expensed as incurred. Identifiable assets, liabilities and contingent liabilities acquired or assumed are measured separately at their fair value as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total of the cost of the acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the fair value of the identifiable net assets of the acquiree, the difference is recognized directly in earnings.

 

The determination and allocation of fair values to the identifiable net assets acquired, liabilities assumed and noncontrolling interest is based on various assumptions and valuation methodologies requiring considerable judgment. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determines discount rates to be used based on the risk inherent in the acquiree’s current business model and industry comparisons. Although the Group believes that the assumptions applied in the determination are reasonable based on information available at the date of acquisition, actual results may differ from forecasted amounts and the differences could be material.

 

(i) Asset Acquisition

 

We evaluate acquisitions pursuant to ASC 805, “Business Combinations,” to determine whether the acquisition should be classified as either an asset acquisition or a business combination. Acquisitions for which substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets are accounted for as an asset acquisition.

 

For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Common stock issued as consideration in an asset acquisition is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. However, as of the date of acquisition, if certain assets are carried at fair value under other applicable GAAP, the consideration is first allocated to those assets with the remainder allocated to the non-monetary identifiable assets based on relative fair value basis.

 

(j) Goodwill

 

Goodwill is the cost of acquired companies in excess of the fair value of identifiable net assets at acquisition date. Goodwill is not subject to amortization, but rather is evaluated for impairment at least annually. The Group evaluates its goodwill for impairment during the fourth quarter of its fiscal year or more frequently if indicators of potential impairment exist, in accordance with ASC 350, Intangibles - Goodwill and Other. Goodwill impairment is determined by comparing the estimated fair value of a reporting unit (generally defined as the businesses for which financial information is available and reviewed regularly by management) with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not deemed to be impaired. However, if the estimated fair value is below carrying value, further analysis is required to determine the amount of the impairment.

 

In the course of evaluating the potential impairment of goodwill, the Group may perform either a qualitative or a quantitative assessment. The Group’s qualitative assessment of potential impairment may result in the determination that a quantitative impairment analysis is not necessary. Under this elective process, the Group assesses qualitative factors to determine whether the existence of events or circumstances leads the Company to determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then performing a quantitative analysis is not required. However, if the Group concludes otherwise, then the Group performs a quantitative impairment analysis.

 

If the Group either chooses not to perform a qualitative assessment, or the Group chooses to perform a qualitative assessment but is unable to qualitatively conclude that no impairment has occurred, then the Group performs a quantitative evaluation. In the case of a quantitative assessment, the Group estimates the fair value of the reporting unit with which the goodwill that is subject to the quantitative analysis is associated and compares it to the carrying value. If the estimated fair value of a reporting unit is less than its carrying value, the excess is recorded as a goodwill impairment, which is limited to the total amount of goodwill allocated to that reporting unit.

 

For the six months ended June 30, 2022 and 2023, the Group performed a qualitative assessment for the reporting unit. Based on the requirements of ASC 350-20, the Group evaluated all relevant qualitative and quantitative factors, weighed all factors in their entirety and concluded that it was not more-likely-than-not that the fair value of the reporting unit was less than its carrying amount. Therefore, no goodwill impairment was recognized for the six months ended June 30, 2022 and 2023.

 

(k) Discontinued operations

 

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity’s financial results and operations. Included in the unaudited condensed consolidated statements of income and comprehensive income, result from discontinued operations is reported separately from the income and expenses from continuing operations and prior periods are presented on a comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

 

(l) Fair value of financial instruments

 

The Group applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements.

 

ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. 

 

Level 2—Other inputs that are directly or indirectly observable in the marketplace. 

 

Level 3—Unobservable inputs which are supported by little or no market activity.

 

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

  

The Group’s financial instruments include cash and cash equivalents, accounts receivables, accounts payable, other receivables, other payables and short-term debt. The carrying values of these financial instruments approximate their fair values due to their short-term maturities.

 

The Group elected the fair value option to account for its convertible loans. The Group engaged an independent valuation firm to perform the valuation. The fair value of the convertible loans as of December 31, 2022 and June 30, 2023 was RMB15 and RMB16 (US$2) calculated using the binomial tree model. The convertible loans are classified as level 3 instruments as the valuation was determined based on unobservable inputs which are supported by little or no market activity and reflect the Group’s own assumptions in measuring fair value. Significant estimates used in developing the fair value of the convertible loans include time to maturity, risk-free interest rate, straight debt discount rate, probability to convert and expected timing of conversion. Refer to Note 11 for additional information.

 

As the inputs used in developing the fair value for level 3 instruments are unobservable, and require significant management estimate, a change in these inputs could result in a significant change in the fair value measurement.

 

The following is a reconciliation of the beginning and ending balances for convertible loans measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of December 31, 2022 and June 30, 2023:

 

   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
Opening balance   27,859    15    2 
Conversion of convertible loans   (27,739)   
    
 
Loss (gain) on change in fair value of convertible loan   (144)   
    
 
Other comprehensive income -foreign exchange translations   39    1    
 
Total   15    16    2 

 

(m) Property and equipment

 

Property and equipment are stated at cost less accumulated depreciation and any recorded impairment. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, as follows:

 

Category  Estimated useful life
Furniture, fixtures and equipment  3-5 years
Motor vehicles  5 years

 

(n) Intangible assets

 

The Company’s intangible assets mainly include acquired software from business acquisition and asset acquisition. In business combinations, identifiable intangible assets acquired are measured separately at their fair value as of the acquisition date. For asset acquisitions, the cost of the asset acquisition is allocated to identifiable assets acquired based on a relative fair value basis. Intangible assets with finite lives are carried at cost less accumulated amortization. All intangible assets with finite lives are amortized using the straight-line method over the estimated useful lives.

 

Intangible assets have estimated useful lives from the date of purchase as follows:

 

Category  Estimated useful life
Software  5-10 years

 

(o) Impairment of Long-Lived Assets

 

The Company evaluates the recoverability of its long-lived assets, including property and equipment and the intangible assets and for impairment whenever events or changes in circumstances indicate that the carrying amount of its asset may not be fully recoverable. When these events occur, the Company measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the asset and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the asset, the Company recognizes an impairment loss based on the excess of the carrying amount of the asset over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the asset when the market prices are not readily available. The adjusted carrying amount of the asset is the new cost basis and is depreciated over the asset’s remaining useful life. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. No impairment of long-lived assets was recognized for the six months ended June 30, 2022 and 2023, respectively.

 

(p) Treasury shares

 

The Company accounts for treasury share using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account on the unaudited condensed consolidated balance sheets. At retirement of the treasury shares, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is allocated between additional paid in capital (up to the amount credited to the additional paid in capital upon original issuance of the shares) and retained earnings.

 

(q) Revenue recognition

 

The Group applies the ASU 2014-09, Revenue from Contracts with Customers — Topic 606 for its revenue recognition for all periods presented. The majority of the Group’s revenue comes from product sales of Asia food and consumable through its software application (“APP”). Revenue is recognized when the Group satisfies the performance obligations in an amount of consideration to which the Group expects to be entitled to in exchange for those goods. The Group evaluates the presentation of revenue on a gross or net basis based on whether it controls the goods provided to customers and is the principal (i.e., “gross”), or the Group arranges for other parties to provide the goods to the customers and is an agent (i.e., “net”).

 

The Group sells food and consumable products through its own APP. The Group utilizes external delivery service providers to deliver goods to its customers. The customers pay for the goods in advance. The Group recognizes product sales made through APP on a gross basis because the Group is acting as a principal in these transactions as the Company (i) is responsible for fulfilling the promise to provide the specified goods, (ii) takes on inventory risk and (iii) has discretion in establishing price. Revenues are recognized when control is transferred, which typically happens upon delivery. The Group’s contracts with customer are primarily on a fixed-price basis. Discounts and allowances provided to customers are recognized as a reduction in net sales as control of the products is transferred to customers.

 

The Group generally allows customers to return non-food items within 30 days of receipt of proof that the products are unused and included in the original package. For food products, the Group does not accept returns. Customers may be qualified to receive a refund for food products received with unacceptable quality within 2 to 30 days from the date of delivery. The Group estimates returns of the products and refund, which are deducted from sales in the period in which the related revenue is recognized. The determination of the Group’s product returns and refund accruals is based on historical experience with the sales of such products. The Group estimates and adjusts these accruals at each balance sheet date in accordance with changes in these factors

 

Contract balances

 

Contract assets relate to the Group’s conditional right to consideration for completed performance obligations under the contract. Accounts receivable are recorded when the right to consideration becomes unconditional. The Group does not have contract assets for the periods presented. In instances where the timing of revenue recognition differs from the timing of invoicing, the Group has determined that its contracts generally do not include a significant financing component.

 

Contract liabilities represent considerations received from customers in advance of satisfying the Group’s performance obligations under the contract, which are presented in “advance from customers” in the unaudited condensed consolidated balance sheets. The Group classifies contract liabilities as current based on the timing of when we expect to recognize revenue, which typically occurs within one year. Revenue recognized that was included in contract liabilities at the beginning of the period was nil for the six months ended June 30, 2022 and 2023, respectively. As of December 31, 2022 and June 30, 2023, contract liabilities amounted to nil and RMB479 (US$66), respectively.

 

Practical expedients

 

The Group has applied the following practical expedients:

 

(i) The transaction price allocated to the performance obligations that are unsatisfied, or partially unsatisfied has not been disclosed, as substantially all of the Group’s contracts have a duration of one year or less.

 

(ii) The Group recognizes incremental costs to obtain a contract as expenses when incurred because the amortization period would be one year or less. These costs are recorded within sales and marketing expenses.

  

(r) Research and development expenses

 

Research and development expenses primarily are comprised of costs incurred in performing research and development activities, including related personnel and consultant’s compensation, benefits, share-based compensation and related materials and supplies costs. The Group expenses research and development expenses as they are incurred.

 

(s) Leases

 

The Group adopted ASU No. 2016-02—Leases (Topic 842) as of January 1, 2022, using a modified retrospective transition method permitted under ASU No. 2018-11. This transition approach provides a method for recording existing leases only at the date of adoption and does not require previously reported balances to be adjusted. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional lease assets and lease liabilities on the consolidated balance sheets. The standard did not materially impact our unaudited condensed consolidated net earnings and cash flows.

 

Right-of-use (“ROU”) assets represent the Group’s rights to use underlying assets for the lease term and lease liabilities represent the Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, reduced by lease incentives received, plus any initial direct costs, using the discount rate for the lease at the commencement date. As the implicit rate in lease is not readily determinable for the Group’s operating leases, the Group generally use the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The Group’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Group will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Group accounts for lease and non-lease components separately. the Group has no finance leases for any of the periods presented.

 

Prior to the adoption of ASU No. 2016-02, leases were classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exist: (a) ownership is transferred to the lessee by the end of the lease term, (b) there is a bargain purchase option, (c) the lease term is at least 75% of the property’s estimated remaining economic life, or (d) the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an occurrence of an obligation at the inception of the lease. The Group has no capital leases for the six months ended June 30, 2022 and 2023.

 

(t) Warrants

 

The Group accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Group’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Group’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annual period end date while the warrants are outstanding.

 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. All warrants outstanding as of June 30, 2023 and December 31, 2022 do not meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815 and therefore, classified as equity.

 

(u) Share-based compensation

 

The Group accounts for share-based compensation in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). In accordance with ASC 718, the Group determines whether an award should be classified and accounted for as a liability award or an equity award. All the Group’s share-based awards were classified as equity awards and are recognized in the unaudited condensed consolidated financial statements based on their grant date fair values.

 

The Group has elected to recognize share-based compensation using the straight-line method for all share-based awards granted with graded vesting based on service conditions. The Group accounts for forfeitures as they occur in accordance with ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvement to Employee Share-based Payment Accounting. The Black-Scholes Model were applied in determining the estimated fair value of the options granted to employees and non-employees.

 

(v) Income taxes

 

The Group follows the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.

 

The Group accounted for uncertainties in income taxes in accordance with ASC 740. Interest and penalties related to unrecognized tax benefit recognized in accordance with ASC 740 are classified in the unaudited condensed consolidated statements of operations and comprehensive loss as income tax expenses.

 

For the six months ended June 30, 2022 and 2023, the Group did not have any significant unrecognized uncertain tax positions or any unrecognized liabilities, interest or penalties associated with unrecognized tax benefits. The Group does not believe that its uncertain tax benefits position will materially change over the next twelve months.

 

(w) Comprehensive loss

 

Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group’s comprehensive loss includes net loss and foreign currency translation differences, and is presented in the unaudited condensed consolidated statements of operations and comprehensive loss.

  

(x) Segment reporting

 

After the Group discontinued CDA business, the Group operates and manages its business as a single segment and the Group’s primary revenue are generated in the U.S. The Group has only one reportable segment for the six months ended June 30, 2023, in accordance with ASC 280, Segment Reporting. The Group’s Chief Executive Officer is the chief operating decision-maker that review the unaudited condensed consolidated financial results when making decisions about allocating resources and assessing the performance of the Group as a whole.

 

(y) Loss per share

 

Loss per share is calculated in accordance with ASC 260, Earnings per Share. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.

 

Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the share options, using the treasury share method. Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Group’s unaudited condensed consolidated statements of operations and comprehensive loss.

 

The rights, including the liquidation and dividend rights, of the holders of our Class A and Class B ordinary shares are identical, except with respect to voting. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to ten votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares under any circumstances. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis. For the six months ended June 30, 2022 and 2023, the net loss per share amounts are the same for Class A and Class B common ordinary shares because the holders of each class are entitled to equal per share dividends or distributions in liquidation.

 

The Group did not include share options, convertible debt and warrants in the computation of diluted earnings per share for the six months ended June 30, 2022 and 2023, because those were anti-dilutive for loss per share.

 

(z) Risks, Uncertainties and Concentrations

 

Concentration of credit risk

 

Financial instruments that potentially subject the Group to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivables. As of December 31, 2022 and June 30, 2023, the aggregate amounts of cash and cash equivalents of RMB14 and RMB62 (US$9), respectively, were held at major financial institutions located in the PRC and RMB1 and RMB268 (US$37), respectively, were deposited at banks located in U.S. and covered by the FDIC insurance program. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. There is a RMB 500,000 deposit insurance limit for a legal entity’s aggregated balance at each PRC bank.

 

As of December 31, 2022, no customer accounted for more than 10% of total accounts receivables. As of June 30, 2023, four customers accounted for 37%, 20%, 19% and 16% of total accounts receivables. The risk is mitigated by credit evaluations the Group performs on its customers.

 

Business, customer, supplier, political and economic risks

 

The Group’s e-commerce food-related business has a limited operating history. The recently acquired operations are subject to all of the risks inherent in the initial expenses, challenges, complications, and delays frequently encountered in connection with the formation of any new business.

 

The Group participates in a dynamic industry and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in industry standards; changes in certain strategic relationships or customer relationships; regulatory considerations; intellectual property considerations; and risks associated with the Group’s ability to attract and retain employees necessary to support its growth.

 

For the six months ended June 30, 2022, no customer accounted for more than 10% of the total revenues, respectively. For the six months ended June 30, 2023, the Group had one customer that accounted for 16% of total revenues.

 

For the six months ended June 30, 2022, no supplier accounted for more than for 10% of total cost of revenues. For the six months ended June 30, 2023, two suppliers that accounted for 22% and 22% of total cost of revenues, respectively.

 

As of December 31, 2022, no supplier accounted for more than 10% of total accounts payables As of June 30, 2023, three suppliers accounted for 25%, 14%and 12% of total accounts payables, respectively.

  

(aa) Recent accounting pronouncements

 

The Group is an emerging growth company (“EGC”) as defined by the Jumpstart Our Business Startups Act (“JOBS Act”). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Group. Early adoption is permitted. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the unaudited condensed consolidated financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, “‘Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). This ASU requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The amendments are effective for fiscal years beginning after December 15, 2023, and are applied prospectively to business combinations that occur after the effective date. The Group does not expect the adoption of ASU 2021-04 will have a material effect on the unaudited condensed consolidated financial statements.

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Group adopts as of the specified effective date. Unless otherwise discussed, the Group does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.

XML 19 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Acqusitions
6 Months Ended
Jun. 30, 2023
Acquisition [Abstract]  
ACQUSITIONS

4. ACQUSITIONS

 

Business Combinations

 

The Group accounted the following acquisitions as business combinations in accordance with ASC 805. Acquisition-related costs incurred for the acquisitions are not material.

 

GISN acquisition

 

On January 28, 2023, the Company, through its subsidiary Fresh2, entered into a Share Purchase Agreement to acquire GISN (HK) LIMITED, a Hong Kong corporation (“GISN”). GISN and its subsidiaries provide technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Group’s efficiency in its e-commerce operations. The acquisition closed on February 1, 2023. The Company issued 8,785,530 Class A ordinary shares with fair value of RMB25,938 (US$3,848) to purchase all the issued and outstanding equity interest of GISN.

 

The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:

 

   Amount 
   RMB 
     
Total consideration   25,938 
      
Assets acquired and liabilities assumed:     
Cash acquired   1,028 
Accounts receivable   100 
Accounts receivable-related parties   12,073 
Other current assets   123 
Right of use assets   

283

 
Property and equipment   1,573 
Intangible assets   11,233 
Advance from customer   (1,013)
Accrued expenses and other current liabilities   (13,705)
Lease liabilities   (239)
Deferred tax liability   (2,808)
Total net assets acquired   8,648 
Goodwill   17,290 

 

The intangible assets are mainly attributable to software acquired through the acquisition, which are amortized over 10 years.

 

The following unaudited pro forma summary presents consolidated information of the Group as of the business combination had occurred on January 1, 2022.

 

   Unaudited Pro Forma 
   For the six months
ended June 30,
 
   2022   2023 
   RMB   RMB 
Revenue   10,149    4,936 
           
Net losses   51,322    (71,405)

 

For the six months ended June 30, 2023, the revenue contributed by GISN was RMB677 (US$93), which was included in the Group’s consolidated statement of operation and comprehensive loss.

 

Fresh2 acquisition

 

On February 7, 2023, the Company, through its subsidiary Fresh2, entered into a Share Purchase Agreement (the “Ecommerce Agreement”) to acquire Fresh 2 Ecommerce Inc, a Delaware corporation (“Fresh2 Ecommerce”), from Mr. Haohan Xu, the Company’s Co-CEO and Co-Chairman of the board of directors. Fresh2 Ecommerce is a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants well as other retail customers in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as food companies, manufacturers, agents, importers, and wholesalers to restaurants and other retail customers. The acquisition was closed on February 8, 2023. The Company issued 5,440,420 Class A ordinary shares with fair value of RMB17,304 (US$2,549) to acquire all the issued and outstanding equity interests in Fresh2 Ecommerce.

 

The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:

 

   Amount 
   RMB 
     
Total consideration   17,304 
      
Assets acquired and liabilities assumed:     
Cash acquired   71 
Other current assets   938 
Accounts payables   (950)
Accrued expenses and other current liabilities   (72)
Total net assets acquired   (13)
Goodwill   17,317 

 

None of the goodwill is expected to be deductible for income tax purposes. For the six months ended June 30, 2023, Fresh2 Ecommerce contributed revenue of 199 and loss of 86 to the group from February 8, 2023 to June 30, 2023. Pro forma results reflecting this transaction were not presented because it is not significant to the Group’s consolidated financial results.

 

Asset acquisition

 

On March 31, 2023, the Group closed an asset purchase with Easy Hundred Inc. (“Easy Hundred”), a U.S.-based e-commerce startup company in the foodservice industry. Pursuant to the Asset Purchase Agreement (the “EZ Agreement”), the Group acquired certain fixed assets of Easy Hundred and Easy Hundred’s intellectual property relating to ez100, 2Supply and 100WAY systems with total consideration consisting of RMB5,013(US$730) in cash and 17,665,702 Class A ordinary shares of the Company. The fair value of the shares issued was RMB25,720 (US$3,745).

 

The following table summarizes the fair value of the identifiable assets:

 

   Amount 
   RMB 
Property and equipment- furniture, fixtures and equipment   160 
Property and equipment- motor vehicles   434 
Intangible assets- software*   30,139 
Total consideration   30,733 

 

*Intangible assets refer to intellectual property relating to ez100, 2Supply and 100WAY systems.
XML 20 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations
6 Months Ended
Jun. 30, 2023
Discontinued Operations [Abstract]  
DISCONTINUED OPERATION

5. DISCONTINUED OPERATION

 

In July, 2023, the Board approved the sale of its early cancer screening and detection business (the “CDA Business”), comprised of (i) AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”), a subsidiary based in Lishui, China, (ii) Anpac Technology USA CO., LTD. (“AnPac USA”), a subsidiary based in Pennsylvania and California, and (iii) Changhe Bio-Medical Technology (Yangzhou) Co., Ltd.(“Changhe”), a subsidiary based in Yangzhou, China. Accordingly, on July 28, 2023, the Group entered into Share purchase agreements with New-Horizon Bio-Medical Science Co., Ltd. (“New-Horizon”), a Hong Kong company focused on bio-medical technology, under which the Group agreed to sell 100% of the shares of AnPac Lishui and AnPac USA, which had experienced significant financial losses in its operations and are not expected to achieve a breakeven point in the immediate future, to New-Horizon in consideration of nil and nil, respectively. In addition, on July 28, 2023, the Group entered into a share purchase agreement with Ningkasai Technology (Shanghai) Co., Ltd. (“Ningkasai”), a PRC high-tech company specialized in nanotechnologies for life science applications, under which the Group agreed to sell 100% of the shares of Changhe, to Ningkasai for no consideration. The closing is expected to take place in November 2023.

 

The Group determined that the disposal of CDA Business met the criteria to be classified as a discontinued operation and, as a result, CDA business’s historical financial results are reflected in the Group’s unaudited condensed consolidated financial statements as a discontinued operation. The disposal of CDA Business represents a strategic shift that has a significant effect on the Group’s operations and financial results, which trigger discontinued operations accounting in accordance with ASC 205-20-45. The assets and liabilities related to the discontinued operations were retroactively classified as assets/liabilities held for sale, while results of operations related to the discontinued operations, including comparatives, were retroactively reported as income (loss) from discontinued operations for the six months ended June 30, 2022 and 2023, respectively.

 

In connection with the disposal of CDA business, the Group also sold its 70% equity interest in Changwei System Technology (Shanghai) Co., Ltd (“Changwei”) to Jiaxing Changxin Enterprise Management, LLP (“Changxin”) in consideration of US$350 (RMB2,538) and sold the remaining 29% equity interest in Changwei to Shanghai Yiyou Investment Management Co., LTD (“Yiyou”) in consideration of US$150 (RMB1,088). Yiyou further entered into an arrangement with Changxin and Ms. Ruoou Ying, pursuant to which the Group agreed to transfer 29% of Changwei’s shares to Changxin and 1% of the shares to Ms. Ruoou Ying (the “Changwei disposal”). The Group received the consideration in aggregated of RMB3,626 (US$500) from the Changwei disposal. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company. Loss from disposal of Changwei amounted to RMB16,724 (US$2,307) and was included in net loss from discontinued operations. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company.

 

The results of discontinued operations for the six months ended June 30, 2022 and 2023 were as follows:

 

   Six Months Ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Revenues:            
Revenues-third parties   3,972    2,937    405 
Revenues-related parties   1,241    91    13 
Total revenues   5,213    3,028    418 
Cost of revenues   (1,832)   (1,292)   (178)
Gross Profit   3,381    1,736    240 
Operating expenses:               
Selling and marketing expenses   (4,894)   (3,872)   (534)
General and administrative expenses   (15,629)   (8,593)   (1,185)
Research and development expenses   (4,330)   (3,438)   (474)
Impairment of intangible assets   (7,911)   
    
 
Impairment of goodwill   (12,758)   
    
 
Loss from operations   (42,141)   (14,167)   (1,953)
Non-operating income and expenses:               
Interest expense, net   (161)   (81)   (11)
Foreign exchange gain, net   7    9    1 
Share of net loss in equity method investments   (87)   (88)   (12)
Other income, net   472    3,106    428 
Loss from operations for discontinued operations   (41,910)   (11,221)   (1,547)
Loss from disposal of a subsidiary   
    (16,724)   (2,307)
Loss from discontinued operations before income taxes   (41,910)   (27,945)   (3,854)
Income tax benefit   2,130    
    
 
Net Loss from discontinued operations   (39,780)   (27,945)   (3,854)

 

Assets and liabilities of the discontinued operations:

 

   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
ASSETS            
Current assets:            
Cash and cash equivalents   1,854    319    44 
Prepayment   2,692    1,334    184 
Accounts receivable, net   2,235    3,318    458 
Amounts due from related parties, net   2,194    684    94 
Inventories, net   210    178    25 
Other current assets, net   3,448    3,944    543 
Total current assets held for sale   12,633    9,777    1,348 
                
Property and equipment, net   17,182    15,746    2,171 
Land use rights, net   1,111    1,097    151 
Intangible assets, net   185    271    37 
Goodwill               
Right of use assets   7,213    2,088    288 
Long-term investments, net   1,079    991    138 
Total noncurrent assets held for sale   26,770    20,193    2,785 
TOTAL ASSETS HELD FOR SALE   39,403    29,970    4,133 
                
LIABILITIES               
Current liabilities:               
Short-term debts   5,000    5,000    690 
Accounts payable   2,108    2,012    277 
Advance from customers   4,956    7,800    1,076 
Amounts due to related parties   2,280    1,079    149 
Lease liability-current   784    1,042    144 
Accrued expenses and other current liabilities   18,386    16,488    2,273 
Total current liabilities held for sale   33,514    33,421    4,609 
Deferred tax liabilities               
Lease liability-non-current   6,515    1,368    189 
Other long-term liabilities   1,080    1,066    147 
Total noncurrent liabilities held for sale   7,595    2,434    336 
TOTAL LIABILITIES HELD FOR SALE   41,109    35,855    4,945 
XML 21 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Receivable, Net
6 Months Ended
Jun. 30, 2023
Accounts Receivable, Net [Abstract]  
ACCOUNTS RECEIVABLE, NET

6. ACCOUNTS RECEIVABLE, NET

 

Accounts receivable as of December 31, 2022 and June 30, 2023 were as follows:

 

   December 31     
   2022   June 30 2023 
   RMB   RMB   US$ 
             
Accounts receivable   
    270    37 
Allowance for credit losses   
    
    
 
Balance at end of year   
    270    37 
XML 22 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Other Current Assets, Net
6 Months Ended
Jun. 30, 2023
Other Current Assets, Net [Abstract]  
OTHER CURRENT ASSETS, NET

7. OTHER CURRENT ASSETS, NET

 

Other current assets consist of the following:

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Deposits   
    154    21 
Receivable from private placement investors   
    260    36 
Loan to third-parties   422    444    61 
Total   422    858    118 
Allowance for credit losses   (422)   (444)   (61)
Other current assets, net   
    414    57 
XML 23 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment, Net
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

8. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consists of the following:

 

   December 31,     
   2022   June 30 2023 
   RMB   RMB   US$ 
Furniture, fixtures and equipment   
    3,255    448 
Motor vehicles   
    2,007    277 
Total   
    5,262    725 
Less: accumulated depreciation   
    (953)   (131)
Property and equipment, net   
    4,309    594 

 

Depreciation expense was nil and RMB449 (US$62) for the six months ended June 30, 2022 and June 30, 2023, respectively. No impairment charges were recognized on the property and equipment for the six months ended June 30, 2022 and 2023.

XML 24 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net
6 Months Ended
Jun. 30, 2023
Intangible Assets, Net [Abstract]  
INTANGIBLE ASSETS, NET

9. INTANGIBLE ASSETS, NET

 

Intangible assets, net consist of the following:

 

   December 31,     
   2022   June 30 2023 
   RMB   RMB   US$ 
Software   
    47,798    6,592 
Total   
    47,798    6,592 
Less: accumulated amortization   
    (2,629)   (363)
Intangible assets, net   
    45,169    6,229 

 

Amortization expense for six months ended June 30, 2022 and 2023 amounted to nil and RMB2,511 (US$346), respectively. The estimated aggregate amortization expense for each of the five succeeding years is as follows:

 

Twelve months ending June 30,  RMB 
2024   8,351 
2025   8,351 
2026   8,351 
2027   8,351 
2028   6,226 
Thereafter   5,539 
Total   45,169 
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Investments, Net
6 Months Ended
Jun. 30, 2023
Long-Term Investments, Net [Abstract]  
LONG-TERM INVESTMENTS, NET

10. LONG-TERM INVESTMENTS, NET

 

Long-term investments, net consisted of the following:

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Equity method investments               
Advanced Life Therapeutics Co., Ltd. (“Advanced Life”)   
    
    
 
Nassau Enterprises LLC (“Nassau”).   
    39,783    5,486 
Total   
    39,783    5,486 
Less: Impairment   
    
    
 
Long-term investments, net   
    39,783    5,486 

 

Equity method investments

 

Advanced Life

 

On May 15, 2021, the Company and other third parties established Advanced Life Therapeutics Co., Ltd. (“Advanced Life”), of which the Company owned a 40% equity interest in its registered capital. The Company has not made any capital contribution as yet because Advanced Life has not commenced its intended operations. The Group accounts for Advanced Life as long-term investment under the equity method, there’s no carrying value of this investment. Subsequently, the Board has approved the disposition of the 40% of equity interest in Advanced Life to a company controlled by Mr. Chris Yu at a nominal price on October 18, 2023.

 

Nassau

 

On May 24, 2023, the Company, through its subsidiary Foodbase Group Inc. (“Foodbase”), entered into a purchase agreement (the “Nassau Investment Agreement”) with Mr. Haohan Xu (“Mr. Xu”), the CEO of the Company, and Nassau Enterprises LLC, a Delaware limited liability company that was established to engage in real estate development (“Nassau”). Mr. Xu was the sole shareholder and CEO of Nassau prior to the Company’s investment. The Group’s investment in Nassau consisted of a capital injection of RMB39,882 (US$5,500) and a nominal payment to Mr. Xu to acquire 19.64% of the equity interests in Nassau. The transaction closed on May 24, 2023. After the closing, Mr. Xu holds 8,036 voting units in Nassau, representing 80.36% of the outstanding equity interests in Nassau. The Group can exercise significant influence on the management and operation of Nassau. The Group accounts for its investment in Nassau as long-term investment under the equity method. Nassau through its subsidiary intends to develop, market and sell real estate in Savannah Lakes Village (“SLV Project”) and to utilize an EB-5 program to finance the development of the SLV Project, which is expected to provide alternative financing for the Company’s growth.

 

The Group recorded its share of loss in this investment of RMB95 (US$13) for the six months ended June 30, 2023.

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Short-Term Debts
6 Months Ended
Jun. 30, 2023
Short-Term Debts [Abstract]  
SHORT-TERM DEBTS

11. SHORT-TERM DEBTS

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Convertible loan (“CL”) (i)   15    16    2 
Total   15    16    2 

 

(i)On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were originally due in one year and bear interest of 0% per annum if the conversion feature is not triggered. Pursuant to the agreement, the conversion price is lower of (i) US$15 or (ii) the lower of 82% of the closing bid price or 80% of VWAP of the Company’s ADSs during the ten consecutive trading days immediately preceding conversion, but not lower than a Floor Price of US$1 (the “floor price”). Due to significant drop of the ADS market price in 2022, the debenture holders and the Company renegotiated the Floor Price. On February 5, 2022, the Company entered into an amendment agreement, pursuant to which the Floor Price was reduced to US$0.10 per Class A Ordinary Share. The Company has elected to recognize the Convertible Debentures at fair value and therefore there was no further evaluation of embedded features for bifurcation. The Convertible Debentures were partially converted into 114,234 shares on December 10, 2021. The fair value of the Convertible Debentures loan immediately prior to conversion was assessed at RMB1,321. Substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares (refer to Note 14) on March 16, 2022. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).

 

For the six months ended June 30, 2022 and 2023, the Company recognized change in fair value of the Convertible Debenture of RMB139 and nil, respectively.

XML 27 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
6 Months Ended
Jun. 30, 2023
Lease [Abstract]  
LEASES

12. LEASES

 

The Group has several operating leases for offices. The Group’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

 

Effective on January 1, 2022, the Group adopted the new lease accounting standard using a modified retrospective transition method which allowed the Group not to recast comparative periods presented in its consolidated financial statements. In addition, the Group elected the package of practical expedients, which allowed the Group to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Group has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. The Group combines the lease and non-lease components in determining the ROU assets and related lease obligation. Adoption of this standard resulted in the recording of operating lease ROU assets and corresponding operating lease liabilities as disclosed below and had no impact on accumulated deficit as of January 1, 2022. ROU assets and related lease obligations are recognized at commencement date based on the present value of remaining lease payments over the lease term.

 

Supplemental balance sheet information related to operating leases was as follows:

 

   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
             
Right-of-use assets, net   
    223    31 
                
Operating lease liabilities - current   
    148    20 
Operating lease liabilities - non-current   
    37    5 
Total operating lease liabilities   
    185    25 

 

The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of June 30, 2023:

 

Weighted average remaining lease term (years)   1.51 
Weighted average discount rate   4.75%

 

The following is a schedule of maturities of lease liabilities are as follows:

 

Twelve months ending June 30,  RMB 
2024   150 
2025   37 
Total future minimum lease payments   187 
Less: imputed interest   (2)
Total   185 
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Expenses and Other Current Liabilities
6 Months Ended
Jun. 30, 2023
Accrued Expenses and Other Current Liabilities [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

13. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

 

   December 31     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Salary and welfare payable   1,740    9,312    1,283 
Accrued expenses (1)   5,762    9,057    1,249 
Payable for property and equipment   
    2,301    318 
Other payables   33    4,089    564 
Total   7,535    24,759    3,414 

 

(1):the accrued expenses mainly consist of accrued professional fees.
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity
6 Months Ended
Jun. 30, 2023
Shareholders' Equity [Abstract]  
SHAREHOLDERS' EQUITY

14. SHAREHOLDERS’ EQUITY

 

Ordinary Shares

 

On October 14, 2022, the Company amended and restated its memorandum and articles of association to increase the maximum number of authorized shares to 150,000,000 shares divided into 120,000,000 class A ordinary shares with a par value of US$0.01 each and 30,000,000 class B ordinary shares with a par value of US$0.01 each.

 

On February 14, 2023, the Company amended and restated its memorandum and articles of association to increase the maximum number of authorized shares from 150,000,000 shares to 2,430,000,000 shares divided into 2,400,000,000 Class A Ordinary Shares with a par value of US$0.01 each and 30,000,000 Class B Ordinary Shares with a par value of US$0.01 each.

 

As of December 31, 2022 and June 30, 2023, 79,536,589 and 176,070,465 Class A ordinary shares were issued and outstanding, respectively. As of December 31, 2022 and June 30, 2023, 3,573,100 and 3,573,100 Class B ordinary shares were issued and outstanding.

 

Completion of IPO

 

On January 30, 2020, the Company completed its IPO on the Nasdaq Share Exchange. In November 2022, the Company adopted an ordinary share / ADS ratio change from one (1) Class ‘A’ ordinary share being equal to one (1) ADS to 20 Class ‘A’ ordinary shares being equal to one (1) ADS).

 

Conversion of convertible loans

 

On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were partially converted into 114,234 Class ‘A’ ordinary shares on December 10, 2021. On March 16, 2022, substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).

 

On May 31, 2021, the Company issued a convertible note in the principal amount of RMB4,479 to Ascent Investor Relations Inc., (“Ascent”) for public relations services rendered. The convertible note was fully converted into 3,232,397 Class A ordinary shares with conversion prices ranging from US$0.16-0.33 per share by April 27, 2022. The fair value of the convertible note immediately prior to conversion was assessed at RMB5,502.

 

Shares issued for services

 

On June 1, 2022, the Company entered into a service agreement with a public relations firm. Pursuant to the service agreement, the Group was required to pay US$50 as compensation for the public relations services. On June 10, 2022, the Company issued 187,094 class A ordinary shares for the services. The fair value of the PR services was RMB359 (US$54) determined based on the Company’s ADS market price on June 10, 2022.

 

On August 31, 2022, the Company granted 140,000 class A ordinary shares to two employees as bonuses that vested immediately upon grant. On September 16, 2022, the Company issued the 140,000 class A ordinary shares. The fair value of the bonuses was RMB1,341 (US$195) determined based on the Company’s ADS market price on August 31, 2022.

 

On April 20, 2023, the Company entered into a service agreement with a finance service firm, Pursuant to the service agreement, the Company was required to pay 3,500,000 Class A ordinary shares for the service. On May 11, 2023, the Company issued 3,500,000 Class A ordinary shares to the finance service firm. The fair value of the services was RMB6,385 (US$919) determined based on the Company’s ADS market price on May 11, 2023.

 

Shares issued for reserve

 

As of December 31, 2022, the Group had 1,322,853 Class A ordinary shares held in an escrow account as reserve solely for potential convertible loans conversion. During the six months ended June 30, 2023, of 22,000,000 Class A ordinary shares issued in a private placement on June 9, 2023, 2,500,000 class A ordinary shares were subsequently recalled and cancelled on October 30, 2023 due to the inability to timely collect the funds from the investor. Such 2,500,000 class A ordinary shares were included as the shares held as a reserve and not included in the calculation of loss per share. As of June 30, 2023, 3,822,853 Class A ordinary shares were held in an escrow account as a reserve.

 

Private placements

 

On March 16, 2022, the Company entered into a share subscription agreement with a third-party investor, pursuant to which the Company issued 1,235,788 Class A ordinary shares at price of US$0.2563 per share to the investor (the “March 16, 2022 private placement”). In addition, the Company also issued pre-funded warrants to purchase an aggregate of 4,226,135 of Class A ordinary shares for US$0.2563 per share to the investor, equal to the exercise price minus US$0.00001 for the pre-funded warrants. Total gross proceeds of RMB9,395 (US$1,400) was received on May 19, 2022. 2,584,900 pre-funded warrants were exercised during the six months ended June 30, 2023; the remaining pre-funded warrants were exercised on July 13, 2023.

 

On March 29, 2022, the Company entered into a share subscription agreement with a third-party Chinese investor, pursuant to which the Company issued 654,622 Class A ordinary shares at price of US$0.35 to the investor and received gross proceeds of RMB1,500 (US$232) on March 30, 2022.

 

On May 27, 2022, the Company entered into investment agreements with nine third-party investors. The investors agreed to invest up to RMB20,094 (US$3,000) to purchase Class A ordinary shares, at a purchase price of the lower of (i) $0.30 per ADS (the equivalent of 1 Class A ordinary share) and (ii) 80% of the average ten-day trading closing price of the ADSs (the equivalent of 1 Class A ordinary share) for the ten consecutive day trading period ended on the date of investment agreement. On May 27, 2022 and May 30, 2022, the Company issued 6,229,235 and 6,263,048 Class A ordinary shares to the investors, respectively. In addition, warrants to purchase (i) an aggregate of 3,000,000 Class A ordinary shares for US$0.4 per share, (ii) an aggregate of 1,200,000 Class A ordinary shares for US$0.75 per share (ADS), and (iii) an aggregate of 750,000 Class A ordinary shares (ADS) for US$1.2 per share were issued to the investors. No warrants were excised during the year ended December 31, 2022. On September 2, 2022, three of the investors in the Company’s May 2022 private placements filed an action against the Company in the State of Delaware Court of Chancery captioned Chen Wenge, et al. v. Fresh2 Group Limited, C.A. No. 2022-0779-PAF. The Plaintiffs sued the Company for breaches of the investment agreements. The plaintiffs claimed that the entry into certain investment agreements and a merger agreement breached or would breach the terms of the plaintiffs’ (and several other investors’) securities purchase agreements, including a right of first refusal and a prohibition against certain acquisitions and changes of business. The Court issued a temporary restraining order concerning enforcement of the private placements on September 3, 2022, amended the temporary restraining order on September 9, 2022, and further amended the temporary restraining order on September 23, 2022 (“TRO”). In order to settle the litigation, the Company entered into a share repurchase agreement with the three plaintiffs, and all the other investors in the May 2022 private placements on October 15, 2022. The Company agreed to repurchase 12,492,283 Class A ordinary shares and warrants to purchase a total of 2,475,000 Class A ordinary shares from the nine investors for total consideration of RMB11,003(US$1,507). The Company fully settled the litigation on October 27, 2022. In connection with the settlement, Yuyang Cui and Jiawen Kang resigned from our board of directors of the Company and Yuyang Cui resigned as Co-CEO of the Company. The repurchased warrants were canceled and the repurchased Class A ordinary shares are treated a treasury shares as of December 31, 2022. The treasury shares were canceled on January 19, 2023.

 

On September 2, 2022, the Company entered into investment agreements with three third-party investors (the “September 2, 2022 private placement”). The investors agreed to purchase an aggregate of 5,000,000 Class A ordinary shares at price of US$0.1 per share and warrants to purchase an aggregate of 5,000,000 Class A ordinary shares at an exercise price of US$0.4 per share for RMB3,613. The warrants are exercisable within 2 years from the date of issuance. Total gross proceeds of RMB3,613 was received in September, 2022. No warrants were excised during the year ended December 31, 2022 and six months ended June 30, 2023.

 

On September 26, 2022, the Company entered into investment agreements with nine third-party investors, pursuant to which the Company issued 36,729,613 Class A ordinary Shares at price of US$0.10 per share to the investors and received gross proceeds of RMB26,410 (US$3,660) during the period October 2022 to November 2022.

 

In December 2022 and March 2023, the Company signed investment agreements with several third-party investors (the “March 2023 private placement”) to sell 30,885,707 Class A ordinary shares of the Company at a price of US$0.175 per share for a total purchase price of US$5,405. Proceeds of RMB36,608 (US$5,369) were received by June 30, 2023 and the remaining balance subsequently was received on August 10, 2023. For each Class A ordinary share purchased, the investors received two warrants with each warrant to purchase one Class A ordinary share at an exercise price of US$0.21 per share. The warrants are exercisable within 2 years from the date of issuance. No warrants were exercised during the six months ended June 30, 2023.

 

On April 6, 2023, the Company closed a registered direct offering (the “April 2023 private placement”), the Company sold to the institutional investors a total of 12,500,000 Class A ordinary shares priced at $0.2 per ordinary share, pre-funded warrants exercisable for 2,500,000 Class A ordinary shares and warrants exercisable for 15,000,000 Class A ordinary shares. The purchase price of each pre-funded warrant is equal to the offering price per Class A ordinary shares, minus $0.00005, and the exercise price of each pre-funded warrant is equal $0.00005 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The warrants are immediately exercisable and expire five (5) years from the original issuance date and have an exercise price of $0.2 per Class A ordinary shares. The Company also issued to Univest Securities, LLC, which acted as the sole placement agent for the offering, warrants exercisable for 750,000 Class A ordinary shares, with an exercise price of $0.24 per share. The net proceeds to the Company from the registered direct offering were RMB17,238 (US$2,510) after deducting the placement agent’s fees and other offering expenses. No pre-funded warrants were exercised during the six months ended June 30, 2023, and 5,000,000 warrants were exercised with proceeds of RMB6,911(US$1,000) during the six months ended June 30, 2023.

 

On June 2, 2023, the Company entered into an agreement with an investor, under which the investor agreed to purchase 22,000,000 Class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares at an aggregate purchase price of US$4,400 (the “June 2023 private placement”). The warrants are exercisable within 2 years from the date of issuance and have an exercise price of US$0.21 per share. On June 9, 2023, the Company issued 22,000,000 Class A ordinary shares to the investor, proceeds of RMB27,797 (US$3,900) were received by June 30, 2023. Due to inability to timely collect the remaining proceeds of RMB3,564(US$500) from the investor, the corresponding 2,500,000 shares was recalled and cancelled on October 30, 2023, subsequently. No warrants were exercised during the six months ended June 30, 2023.

 

Shares issued for acquisitions

 

In connection with the GISN acquisition on February 1, 2023, the Company issued 8,785,530 Class A shares to the original shareholders of GISN as consideration of 100% equity interest. The fair value of the shares issued amounted to RMB25,938(US$3,848).

 

In connection of the Fresh2 acquisition on February 8, 2023, the Company issued 5,440,420 Class A shares to the original shareholders of Fresh ecommerce as consideration of 100% equity interest. The fair value of the shares issued amounted to RMB17,304(US$2,549).

 

In connection of the assets acquisition from Easy Hundred on March 31, 2023, the Company issued 17,665,702 Class A shares to Easy Hundred as consideration. The fair value of the shares issued amounted to RMB25,720(US$3,745).

 

Warrants

 

As of June 30, 2023, there were 103,702,658 warrants outstanding. A summary of warrants activity for the six months ended June 30 2023 was as follows:

 

       Weighted
average
exercise
price per
share
   Weighted    
  

Number of

warrants

   US$ per
share
   average life
Years
 

Expiration

dates 

Balance of warrants outstanding and exercisable as of December 31, 2022   9,266,135    0.24   1.85 to unlimited  August 31, 2024 to unlimited
—warrants issued in connection with the March 2023 private placement   61,771,423    0.21   1.58 to 1.96  February 3, 2025 to June 16, 2025
—warrants issued in connection with the April 2023 private placement   18,250,000    0.00001-0.24   1.75 to Unlimited  March 31, 2025 to unlimited
—warrants issued in connection with the June 2023 private placement   22,000,000    0.21   1.95  June 9, 2025
Exercised   (7,584,900)   0.00001-0.2       
Balance of warrants outstanding and exercisable as of June 30, 2023   103,702,658    0.21   1.96 to unlimited  August 31, 2024 to unlimited
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation
6 Months Ended
Jun. 30, 2023
Share Based Compensation [Abstract]  
SHARE BASED COMPENSATION

15. SHARE BASED COMPENSATION

 

On October 31, 2019, the Board and the Company’s shareholders approved the 2019 Share Incentive Plan (“2019 Plan”) which authorized the compensation committee or such other committee to grant share options to purchase 1,105,300 Class A ordinary shares to directors, service providers, advisors, employees and consultants of the Group. On July 5, 2021, the Board and the Compensation Committee of the Board approved the Amended and Restated 2019 Plan increasing the number of Class A ordinary shares subject to the 2019 Plan to 1,885,300 shares. As of June 30, 2023, no shares remain available to be issued under the Amended and Restated 2019 Plan. On April 14, 2022, the Company’s Board approved and adopted the 2022 Share Incentive Plan (the “2022 Plan”) providing for the grant of options to purchase 2,800,000 Class A ordinary shares. On August 28, 2022, the Board and the Compensation Committee of the Board approved the Amended and Restated 2022 Plan increasing the number of Class A ordinary shares subject to the 2022 Plan to 4,700,000 shares. These options were granted to employees and professionals during 2022 and 2023 and will vest over four years. As of June 30, 2023, options to purchase 182,593 Class A ordinary shares remain available to be issued under the 2022 Plan.

 

On January 6, 2023, the Company’s Board approved and adopted the 2023 Share Incentive Plan (the “2023 Plan”) providing for the grant of restricted share unit (“RSU”) of 4,000,000 Class A ordinary shares. On March 10, 2023, the Board and the Compensation Committee of the Board approved an amended to the 2023 Plan increasing the number of Class A ordinary shares subject to the 2023 Plan to 13,000,000 shares. On August 23, 2023, the Board and the Compensation Committee of the Board further approved a further amendment to 2023 Plan increasing the number of Class A ordinary shares subject to the 2023 Plan to 41,000,000 shares These RSU are to be granted to employees and professionals. During the six months ended June 30, 2023, the Company issued 12,779,670 RSUs to that can be converted to Class A ordinary shares upon vesting to employees, directors and officers the Group under the 2023 Plan. The aggregate fair value of the RSUs granted was RMB32,310 (US$4,456). These RSUs vest over 1-4 years based on the related granted agreements. During six months ended June 30, 2023, 458,452 RSUs was forfeited and none vested. As of June 30, 2023, the Company had 12,321,218 RSUs outstanding. For the six months ended June 30, 2023, the Company recorded related share-based compensation expense of RMB2,872 (US$396).

 

Employees-options

 

The options granted to employees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards and contain only service vesting conditions. The following table summarized the Group’s employee share option activities:

 

               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
   Number of   Exercise   Grant date   Contractual   Intrinsic 
   Options   Price   Fair Value   Term   Value 
       US$ per   US$ per         
       option   option   Years   US$ 
Share options outstanding at December 31, 2022   2,334,906    1.69    5.08    8.05    452 
Granted   
    
    
    
    
 
Exercised   (13,900)   0.05    0.05    0.22    
 
Share options outstanding at June 30, 2023   2,321,006    1.70    2.32    7.54    306 
Vested and exercisable at June 30, 2023   2,199,006    1.41    2.08    7.54    306 

 

The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date for those awards that had exercise price below the estimated fair value of the relevant Class A ordinary shares.

 

For the six months ended June 30, 2022 and 2023, the total fair value of the equity awards vested were RMB2,962 and RMB894 (US$123) respectively. As of June 30, 2023, there was RMB2,525 (USD$348) in total unrecognized employee share-based compensation expense related to unvested options, that may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost may be recognized over a weighted-average period of 0.6 years.  

 

Nonemployees-options

 

The options granted to nonemployees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards with service and/or performance vesting conditions. The following table summarized the Group’s nonemployee share option activity:

 

               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
   Number of   Exercise   Grant date   Contractual   Intrinsic 
   Options   Price   Fair Value   Term   Value 
       US$ per   US$ per         
       option   option   Years   US$ 
Share options outstanding at December 31, 2022   2,651,700    0.86    0.85    9.27    532 
Granted   
    
    
    
    
 
Exercised   (650,000)   0.05    0.05    0.22    
 
Forfeited   (20,000)   
    
    
    
 
Share options outstanding at June 30, 2023   1,981,700    1.13    1.04    8.74    315 
Vested and exercisable at June 30, 2023   1,981,700    1.13    1.00    8.74    315 

 

The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant Class A ordinary shares.

 

The total fair value of the equity awards vested during the six months ended June 30, 2022 and 2023 were RMB1,566 and nil, respectively. There was no unrecognized nonemployee share-based compensation expenses as of June 30, 2023.

 

Fair value of options

 

The Group used the Black-Scholes simplified method for the valuation of new options issued during the six months ended June 30, 2022 and 2023. The assumptions used to value the share options granted to employees and nonemployee were as follows:

 

   For the six months ended
June 30,
 
   2022   2023 
Risk-free interest rate   0.34%   
%
Expected volatility range   100.2%   
%
Fair market value per ordinary share as at grant dates   US$0.29    
 

  

The following table sets forth the amount of share-based compensation expense included in each of the relevant financial statement line items:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Selling and marketing expenses   705    1,712    236 
Research and development expenses   1,263    818    113 
General and administrative expenses   2,560    1,236    170 
Total share-based compensation expenses   4,528    3,766    519 
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES

16. INCOME TAXES

 

BVI

 

The Company is incorporated in the BVI and conducts its primary business operations through the subsidiaries in the U.S. and PRC Under the current laws of the BVI, the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Company to its shareholders, no BVI withholding tax will be imposed.

 

Hong Kong

 

GISN (HK) Limited is a holding company registered in Hong Kong and had no operating profit and no taxable income for the six months ended June 30, 2023.

 

PRC

 

The Group’s subsidiaries in the PRC are subject to tax at the statutory rate of 25%, in accordance with the Enterprise Income Tax law (the “EIT Law”), which was effective since January 1, 2008. Hua You Sheng Future (Beijing) Technology Co., Ltd. is entitled to a preferential income tax treatment as they qualify as small and micro-sized enterprises. For the six months ended June 30, 2022 and 2023, if the annual taxable income of small and micro- profit enterprises does not exceed RMB 1,000, 12.5% shall be included in the taxable income and the enterprise income tax rate shall be 20%; if the annual taxable income exceeds RMB 1,000 but does not exceed RMB 3,000, 25% shall be included in the taxable income and the enterprise income tax shall be paid at the rate of 20%.

 

Dividends, interests, rent and royalties payable by the Group’s PRC subsidiaries, to non-PRC resident enterprises, and proceeds from any such non-resident enterprise investor’s disposition of assets (after deducting the net value of such assets) shall be subject to 10% withholding tax, unless the respective non-PRC resident enterprise’s jurisdiction of incorporation has a tax treaty or arrangements with PRC that provides for a reduced withholding tax rate or an exemption from withholding tax.

 

United States

 

The Group’s subsidiaries in the U.S. are subject to the U.S. federal corporate income tax and New York as well as Delaware state income tax at a rate of 21%, 6.5% and 8.7%, respectively, for the six months ended June 30, 2022 and 2023.

 

The Group’s Chinese subsidiaries tax returns filed with Chinese governments for the years after 2019 remain open for statutory examination by PRC tax authorities. The Group’s US subsidiaries tax returns filed with governments remain open for statutory examination by tax authorities in the future.

 

The Group’s loss before income taxes consisted of:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Non-US   (9,035)   (23,507)   (3,241)
US   
    (20,032)   (2,763)
Total   (9,035)   (43,539)   (6,004)

 

The current and deferred components of income tax benefit appearing in the unaudited condensed consolidated statements of comprehensive income are as follows:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Current tax expense   
    
    
 
Deferred tax benefit   
    79    11 
Total   
    79    11 

 

The reconciliation of tax computed by applying the federal statutory income tax rate of 21% for the six months ended June 30, 2022 and 2023 applicable to the U.S. operations to income tax benefit were as follows:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Loss before income taxes   (9,035)   (43,539)   (6,004)
Income tax benefit computed at the statutory income tax rate at 21%   (1,897)   9,142    1,261 
International rate differences   1,897    (4,726)   (652)
Change in valuation allowance       (4,337)   (598)
Income tax benefit       79    11 

 

Deferred Taxes

 

The significant components of deferred taxes were as follows:

 

   As of December 31, 
   December 31,   June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Deferred tax assets:            
Net loss carryforward   1,900    9,608    1,325 
Valuation allowance   (1,900)   (9,608)   (1,325)
Total deferred tax assets.   
    
    
 
                
Deferred tax liabilities:               
Long-lived assets arising from acquisitions   
    2,938    405 
Total deferred tax liabilities.   
    2,938    405 

 

The Group operates through several subsidiaries. Valuation allowance is considered for each of the entities.

 

Realization of the net deferred tax assets is dependent on factors including future reversals of existing taxable temporary differences and adequate future taxable income, exclusive of reversing deductible temporary differences and tax loss carry forwards. The Group evaluates the potential realization of deferred tax assets on an entity-by-entity basis. As of December 31, 2022 and June 30, 2023, the Company and all of its subsidiaries were in a cumulative loss position, valuation allowances were provided against deferred tax assets in entities where it was determined it was more likely than not that the benefits of the deferred tax assets will not be realized.

 

As of June 30, 2023, the Group had PRC net operating losses of RMB10,342 (US$ 1,426), which will expire from 2023 to 2027 if not utilized. As of June 30, 2023, the Group had Hongkong net operating losses of RMB 307 (US$42) that can be carried forward indefinitely for deduction in future periods. As of June 30, 2023, the Group had U.S. net operating losses of RMB33,198 (US$4,578) for U.S. federal and state income tax purposes. The Group files state tax returns in both New York and Delaware. U.S. federal net operating losses are limited to 80% and can be utilized indefinitely. State net operating losses can be carried forward for 20 years and will begin to expire from 2038 to 2042.

XML 32 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Balances
6 Months Ended
Jun. 30, 2023
Related Party Transactions and Balances [Abstract]  
RELATED PARTY TRANSACTIONS AND BALANCES

17. RELATED PARTY TRANSACTIONS AND BALANCES

 

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. The related parties that had transactions in the six months ended June 30, 2022 and 2023 or balances with the Group as of December 30, 2022 and June 30, 2023 consisted of:

 

Related Party   Nature of the party   Relationship with the Group
Haohan Xu   Individual   Chief Executive Officer
Apifiny Inc.   Investment management   Controlled by Haohan Xu
Roxe Holding Inc.   Investment management   Controlled by Haohan Xu
Dr. Chris Chang Yu*   Individual   Co-Founder and shareholder
CRS Holdings Inc.   Investor   Controlled by Dr. Chris Chang Yu
Jiaxing Zhijun Sihang Investment Partnership Enterprises (limited partnership) (“Jiaxing Zhijun”)   Private equity investment   Shareholder, due to diluted equity interest, no longer a related party for the six months ended June 30 2023

 

*Dr. Yu resigned from his position as the Chief Executive Officer (“CEO”) of the Company and Chairman of the Board on April 6, 2022 and was appointed as Co-Chairman and Co-CEO in May 2022. On May 17, 2023, Dr. Yu resigned as the Co-Chief Executive Officer of the Company.

 

Related party balances

 

   As of
December 31,
   As of June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Due from related parties:            
Apifiny Inc.   
    211    29 
Roxe Holding Inc.   
    363    50 
Dr. Chris Chang Yu   
    290    40 
Due from related parties, net   
    864    119 

 

   As of
December 31,
  

As of June 30,

 
   2022   2023   2023 
   RMB   RMB   US$ 
Due to related parties:            
CRS Holdings Inc.   287    592    82 
Jiaxing Zhijun   927    
    
 
Due to related parties   1,214    592    82 

 

   As of
December 31,
  

As of June 30,

 
   2022   2023   2023 
   RMB   RMB   US$ 
Accounts receivables-related parties:            
Apifiny Inc.   
    3,525    486 
Roxe Holding Inc.   
    7,925    1,093 
Accounts Receivables-related parties, net   
    11,450    1,579 

 

Accounts receivables-related parties represented receivables from Apifiny Inc. and Roxe Holding Inc. for research and development services provided by the Group’s subsidiaries before the GISN acquisition.

 

Related party transactions

 

For the six months ended June 30, 2022 and 2023, related party transactions consisted of the following:

 

   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Fixed assets purchased from Apifiny Inc.   
    970    134 
Consulting service received from Roxe Holding Inc.   
    464    64 
Rent expense incurred with Apifiny Inc.   32    624    86 

 

Acquisition, investment and divestitures

 

The Group completed one acquisition from a related party – Mr. Xu (details refer to Note 4) and completed divestiture transaction with a related party Dr. Chris Yu on July 28, 2023 (details refer to Note 5). On May 24, 2023, the Group completed equity investment in Nassau, controlled by a related party - Mr. Xu (details refer to Note 10).

XML 33 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

18. COMMITMENTS AND CONTINGENCIES

 

Litigation

 

In the ordinary course of the business, the Group is subject to periodic legal or administrative proceedings. As of December 31, 2022 and June 30, 2023, there was no contingent liability accrued relating to legal or administrative proceedings.

XML 34 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

19. SUBSEQUENT EVENTS

 

Recent Development

 

The Company announced that as of June 30, 2023, it no longer qualified as a Foreign Private Issuer, as defined in Rule 405 of Regulation C under the Securities Act of 1933 and Rule 3b-4 under the Securities Exchange Act of 1934. The Company will take all necessary actions to comply with the requirements for a domestic issuer under the federal securities laws, as of January 1, 2024.

 

On July 21, 2023, the Company appointed Mr. Yidong Hu as the Chief Strategy Officer of the Company.

 

On August 25, 2023, Mr. Edwards Jinqiu Tang resigned as the Co-Chief Financial Officer of the Company. Mr. Tang’s resignation did not result from any disagreement with the Company or its management.

 

Divestiture

 

On July 28, 2023, the Group entered into agreements to sell its CDA Business (details refer to Note 5).

 

Acquisition

 

On July 17, 2023, the Group entered into a definitive share purchase agreement with Immensus LLC, Zero2First Capital Limited, Future Capital Tech Pte. Ltd (Singapore), River Hill China Capital Ltd (collectively, the “Sellers”) and Roxe Holding Inc. (“Roxe”) under which Fresh2 Technology purchased 51% of the common share of Roxe (the “Roxe Shares”). As consideration for the purchase of the Roxe Shares, the Company issued an aggregate of 110,476,291 Class A Ordinary Shares of the Company to the Sellers, based on Roxe’s valuation of US$60,000 and the average trading price of the Company’s ADSs for the prior 90 trading days (each ADS represents 20 Class A Ordinary Shares). The closing took place simultaneously with the execution of the Share Purchase Agreement. Unaudited Pro-forma condensed combined financial information in connection with the above acquisition was included in the Company’s filling in a Form 6-K with the SEC on August 21, 2023. On July 27, 2023, Roxe entered into a share purchase agreement with SpeedIn INC (“SpeedIn”), a delivery service provider, and its shareholders, under which Roxe agreed to purchase 100% of the shares of SpeedIn from the Sellers with a nominal price. The closing took place simultaneously with the execution of the share purchase agreement. Due to badly performance, the Board have approved the disposition of SpeedIn to a company controlled by Mr. Haohan Xu on October 9, 2023.

 

On July 28, 2023, the Company, through its subsidiary, Foodbase Group Inc. agreed to acquire 100% of the equity interest in Windfall SLV Development LLC and SLV Windfall Management LLC, from XHome Group Inc, a company controlled by Mr. Haohan Xu, for a nominal price. Windfall SLV Development LLC and SLV Windfall Management LLC have not begun operations as yet.

 

On November 4, 2023 the Company and Fresh2 Technology entered into a definitive Share Purchase Agreement to purchase 38.61% of the common stock of Roxe.

 

Financing activities

 

On September 25, 2023, the Company entered into an agreement with an institutional investor to purchase up to US$2,000 of convertible notes, the convertible notes will be sold in two tranches (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date  and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment RMB1,697(US$234) from this offering, excluding related financing costs.

XML 35 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Accounting Policies, by Policy (Policies)
6 Months Ended
Jun. 30, 2023
Summary of Principal Accounting Policies [Abstract]  
Basis of presentation

(a) Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial reporting and pursuant to the applicable rules and regulations of the SEC pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2023 and 2022 are not necessarily indicative of the results that may be expected for the full year. The information included in this report should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Group’s annual financial statements for the fiscal year ended December 31, 2022 filed with the SEC on May 16, 2023.

Principles of consolidation

(b) Principles of consolidation

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Group. All inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power, has the power to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of the board of directors, or has the power to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders.

 

Use of estimates

(c) Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Areas where management uses subjective judgement include, but are not limited to allowance for doubtful accounts, share-based compensation, deferred tax and uncertain tax position, useful lives of intangible assets and property and equipment, impairment of long-lived assets, goodwill and long-term investments and the purchase price allocation with respect to business combinations. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences could be material to the unaudited condensed consolidated financial statements. 

Cash and cash equivalents

(d) Cash and cash equivalents

Cash and cash equivalents consist of cash on hand and demand deposits placed with banks which are unrestricted as to withdrawal or use and have original maturities less than three months. All highly liquid investments with a stated maturity of 90 days or less from the date of purchase are classified as cash equivalents.

Accounts receivable and allowance for credit losses

(e) Accounts receivable and allowance for credit losses

Accounts receivable represents the amounts that the Group has an unconditional right to consideration and is recorded net of allowance for credit losses.

In 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The Group has adopted this ASC Topic 326 and several associated ASUs on January 1, 2023 using a modified retrospective approach. The adoption has no material impact to the Company’s consolidated financial statements. The Group estimated allowance for credit losses to reserve for potentially uncollectible receivable amounts periodically, considering factors in assessing the collectability of its accounts receivable, such as historical distribution of the age of the amounts due, payment history, creditworthiness, forward-looking factor, historical collections data of the customers, to assess the credit risk characteristics. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Group also makes specific allowance in the period in which a loss is determined to be probable. Accounts receivable are considered impaired and written-off when it is probable that all contractual payments due will not be collected after all collection efforts have been exhausted.

Convenience translation

(f) Convenience translation

Amounts in US$ are presented for the convenience of the reader and are translated at the noon buying rate of US$1.00 to RMB7.2513 on June 30, 2023, representing the noon buying rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be converted, realized or settled into US$ at such rate or at any other rate.

Long-term investments

(g) Long-term investments

The Group’s long-term investments include equity method investments and equity investments without readily determinable fair values.

Investments in entities in which the Group can exercise significant influence but does not own a majority equity interest or control are accounted for using the equity method of accounting in accordance with ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Under the equity method, the Group initially records its investment at cost and the difference between the cost of the equity investee and the amount of the underlying equity in the net assets of the equity investee is accounted for as if the investee were a consolidated subsidiary. The share of earnings or losses of the investee are recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Equity method adjustments include the Group’s proportionate share of investee income or loss, adjustments to recognize certain differences between the Group’s carrying value and its equity in net assets of the investee at the date of investment, impairments, and other adjustments required by the equity method. The Group assesses its equity investment for other-than-temporary impairment by considering factors as well as all relevant and available information including, but not limited to, current economic and market conditions, the operating performance of the investees including current earnings trends, the general market conditions in the investee’s industry or geographic area, factors related to the investee’s ability to remain in business, such as the investee’s liquidity, debt ratios, and cash burn rate and other company-specific information.

 

Investments in equity securities without readily determinable fair values are measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. No impairment on its long-term investments was recognized for the six months ended June 30, 2022 and 2023.

Business combinations

(h) Business combinations

The cost of an acquisition is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued. The costs directly attributable to the acquisition are expensed as incurred. Identifiable assets, liabilities and contingent liabilities acquired or assumed are measured separately at their fair value as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total of the cost of the acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the fair value of the identifiable net assets of the acquiree, the difference is recognized directly in earnings.

The determination and allocation of fair values to the identifiable net assets acquired, liabilities assumed and noncontrolling interest is based on various assumptions and valuation methodologies requiring considerable judgment. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determines discount rates to be used based on the risk inherent in the acquiree’s current business model and industry comparisons. Although the Group believes that the assumptions applied in the determination are reasonable based on information available at the date of acquisition, actual results may differ from forecasted amounts and the differences could be material.

Asset Acquisition

(i) Asset Acquisition

We evaluate acquisitions pursuant to ASC 805, “Business Combinations,” to determine whether the acquisition should be classified as either an asset acquisition or a business combination. Acquisitions for which substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets are accounted for as an asset acquisition.

For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Common stock issued as consideration in an asset acquisition is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. However, as of the date of acquisition, if certain assets are carried at fair value under other applicable GAAP, the consideration is first allocated to those assets with the remainder allocated to the non-monetary identifiable assets based on relative fair value basis.

Goodwill

(j) Goodwill

Goodwill is the cost of acquired companies in excess of the fair value of identifiable net assets at acquisition date. Goodwill is not subject to amortization, but rather is evaluated for impairment at least annually. The Group evaluates its goodwill for impairment during the fourth quarter of its fiscal year or more frequently if indicators of potential impairment exist, in accordance with ASC 350, Intangibles - Goodwill and Other. Goodwill impairment is determined by comparing the estimated fair value of a reporting unit (generally defined as the businesses for which financial information is available and reviewed regularly by management) with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not deemed to be impaired. However, if the estimated fair value is below carrying value, further analysis is required to determine the amount of the impairment.

In the course of evaluating the potential impairment of goodwill, the Group may perform either a qualitative or a quantitative assessment. The Group’s qualitative assessment of potential impairment may result in the determination that a quantitative impairment analysis is not necessary. Under this elective process, the Group assesses qualitative factors to determine whether the existence of events or circumstances leads the Company to determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then performing a quantitative analysis is not required. However, if the Group concludes otherwise, then the Group performs a quantitative impairment analysis.

If the Group either chooses not to perform a qualitative assessment, or the Group chooses to perform a qualitative assessment but is unable to qualitatively conclude that no impairment has occurred, then the Group performs a quantitative evaluation. In the case of a quantitative assessment, the Group estimates the fair value of the reporting unit with which the goodwill that is subject to the quantitative analysis is associated and compares it to the carrying value. If the estimated fair value of a reporting unit is less than its carrying value, the excess is recorded as a goodwill impairment, which is limited to the total amount of goodwill allocated to that reporting unit.

 

For the six months ended June 30, 2022 and 2023, the Group performed a qualitative assessment for the reporting unit. Based on the requirements of ASC 350-20, the Group evaluated all relevant qualitative and quantitative factors, weighed all factors in their entirety and concluded that it was not more-likely-than-not that the fair value of the reporting unit was less than its carrying amount. Therefore, no goodwill impairment was recognized for the six months ended June 30, 2022 and 2023.

Discontinued operations

(k) Discontinued operations

A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity’s financial results and operations. Included in the unaudited condensed consolidated statements of income and comprehensive income, result from discontinued operations is reported separately from the income and expenses from continuing operations and prior periods are presented on a comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.

Fair value of financial instruments

(l) Fair value of financial instruments

The Group applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements.

ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. 

Level 2—Other inputs that are directly or indirectly observable in the marketplace. 

Level 3—Unobservable inputs which are supported by little or no market activity.

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

The Group’s financial instruments include cash and cash equivalents, accounts receivables, accounts payable, other receivables, other payables and short-term debt. The carrying values of these financial instruments approximate their fair values due to their short-term maturities.

The Group elected the fair value option to account for its convertible loans. The Group engaged an independent valuation firm to perform the valuation. The fair value of the convertible loans as of December 31, 2022 and June 30, 2023 was RMB15 and RMB16 (US$2) calculated using the binomial tree model. The convertible loans are classified as level 3 instruments as the valuation was determined based on unobservable inputs which are supported by little or no market activity and reflect the Group’s own assumptions in measuring fair value. Significant estimates used in developing the fair value of the convertible loans include time to maturity, risk-free interest rate, straight debt discount rate, probability to convert and expected timing of conversion. Refer to Note 11 for additional information.

As the inputs used in developing the fair value for level 3 instruments are unobservable, and require significant management estimate, a change in these inputs could result in a significant change in the fair value measurement.

 

The following is a reconciliation of the beginning and ending balances for convertible loans measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of December 31, 2022 and June 30, 2023:

   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
Opening balance   27,859    15    2 
Conversion of convertible loans   (27,739)   
    
 
Loss (gain) on change in fair value of convertible loan   (144)   
    
 
Other comprehensive income -foreign exchange translations   39    1    
 
Total   15    16    2 
Property and equipment

(m) Property and equipment

Property and equipment are stated at cost less accumulated depreciation and any recorded impairment. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, as follows:

Category  Estimated useful life
Furniture, fixtures and equipment  3-5 years
Motor vehicles  5 years
Intangible assets

(n) Intangible assets

The Company’s intangible assets mainly include acquired software from business acquisition and asset acquisition. In business combinations, identifiable intangible assets acquired are measured separately at their fair value as of the acquisition date. For asset acquisitions, the cost of the asset acquisition is allocated to identifiable assets acquired based on a relative fair value basis. Intangible assets with finite lives are carried at cost less accumulated amortization. All intangible assets with finite lives are amortized using the straight-line method over the estimated useful lives.

Intangible assets have estimated useful lives from the date of purchase as follows:

Category  Estimated useful life
Software  5-10 years
Impairment of Long-Lived Assets

(o) Impairment of Long-Lived Assets

The Company evaluates the recoverability of its long-lived assets, including property and equipment and the intangible assets and for impairment whenever events or changes in circumstances indicate that the carrying amount of its asset may not be fully recoverable. When these events occur, the Company measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the asset and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the asset, the Company recognizes an impairment loss based on the excess of the carrying amount of the asset over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the asset when the market prices are not readily available. The adjusted carrying amount of the asset is the new cost basis and is depreciated over the asset’s remaining useful life. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. No impairment of long-lived assets was recognized for the six months ended June 30, 2022 and 2023, respectively.

Treasury shares

(p) Treasury shares

The Company accounts for treasury share using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account on the unaudited condensed consolidated balance sheets. At retirement of the treasury shares, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is allocated between additional paid in capital (up to the amount credited to the additional paid in capital upon original issuance of the shares) and retained earnings.

 

Revenue recognition

(q) Revenue recognition

The Group applies the ASU 2014-09, Revenue from Contracts with Customers — Topic 606 for its revenue recognition for all periods presented. The majority of the Group’s revenue comes from product sales of Asia food and consumable through its software application (“APP”). Revenue is recognized when the Group satisfies the performance obligations in an amount of consideration to which the Group expects to be entitled to in exchange for those goods. The Group evaluates the presentation of revenue on a gross or net basis based on whether it controls the goods provided to customers and is the principal (i.e., “gross”), or the Group arranges for other parties to provide the goods to the customers and is an agent (i.e., “net”).

The Group sells food and consumable products through its own APP. The Group utilizes external delivery service providers to deliver goods to its customers. The customers pay for the goods in advance. The Group recognizes product sales made through APP on a gross basis because the Group is acting as a principal in these transactions as the Company (i) is responsible for fulfilling the promise to provide the specified goods, (ii) takes on inventory risk and (iii) has discretion in establishing price. Revenues are recognized when control is transferred, which typically happens upon delivery. The Group’s contracts with customer are primarily on a fixed-price basis. Discounts and allowances provided to customers are recognized as a reduction in net sales as control of the products is transferred to customers.

The Group generally allows customers to return non-food items within 30 days of receipt of proof that the products are unused and included in the original package. For food products, the Group does not accept returns. Customers may be qualified to receive a refund for food products received with unacceptable quality within 2 to 30 days from the date of delivery. The Group estimates returns of the products and refund, which are deducted from sales in the period in which the related revenue is recognized. The determination of the Group’s product returns and refund accruals is based on historical experience with the sales of such products. The Group estimates and adjusts these accruals at each balance sheet date in accordance with changes in these factors

Contract balances

Contract assets relate to the Group’s conditional right to consideration for completed performance obligations under the contract. Accounts receivable are recorded when the right to consideration becomes unconditional. The Group does not have contract assets for the periods presented. In instances where the timing of revenue recognition differs from the timing of invoicing, the Group has determined that its contracts generally do not include a significant financing component.

Contract liabilities represent considerations received from customers in advance of satisfying the Group’s performance obligations under the contract, which are presented in “advance from customers” in the unaudited condensed consolidated balance sheets. The Group classifies contract liabilities as current based on the timing of when we expect to recognize revenue, which typically occurs within one year. Revenue recognized that was included in contract liabilities at the beginning of the period was nil for the six months ended June 30, 2022 and 2023, respectively. As of December 31, 2022 and June 30, 2023, contract liabilities amounted to nil and RMB479 (US$66), respectively.

Practical expedients

The Group has applied the following practical expedients:

(i) The transaction price allocated to the performance obligations that are unsatisfied, or partially unsatisfied has not been disclosed, as substantially all of the Group’s contracts have a duration of one year or less.
(ii) The Group recognizes incremental costs to obtain a contract as expenses when incurred because the amortization period would be one year or less. These costs are recorded within sales and marketing expenses.
Research and development expenses

(r) Research and development expenses

Research and development expenses primarily are comprised of costs incurred in performing research and development activities, including related personnel and consultant’s compensation, benefits, share-based compensation and related materials and supplies costs. The Group expenses research and development expenses as they are incurred.

 

Leases

(s) Leases

The Group adopted ASU No. 2016-02—Leases (Topic 842) as of January 1, 2022, using a modified retrospective transition method permitted under ASU No. 2018-11. This transition approach provides a method for recording existing leases only at the date of adoption and does not require previously reported balances to be adjusted. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional lease assets and lease liabilities on the consolidated balance sheets. The standard did not materially impact our unaudited condensed consolidated net earnings and cash flows.

Right-of-use (“ROU”) assets represent the Group’s rights to use underlying assets for the lease term and lease liabilities represent the Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, reduced by lease incentives received, plus any initial direct costs, using the discount rate for the lease at the commencement date. As the implicit rate in lease is not readily determinable for the Group’s operating leases, the Group generally use the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The Group’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Group will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Group accounts for lease and non-lease components separately. the Group has no finance leases for any of the periods presented.

Prior to the adoption of ASU No. 2016-02, leases were classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exist: (a) ownership is transferred to the lessee by the end of the lease term, (b) there is a bargain purchase option, (c) the lease term is at least 75% of the property’s estimated remaining economic life, or (d) the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an occurrence of an obligation at the inception of the lease. The Group has no capital leases for the six months ended June 30, 2022 and 2023.

Warrants

(t) Warrants

The Group accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Group’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Group’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annual period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. All warrants outstanding as of June 30, 2023 and December 31, 2022 do not meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815 and therefore, classified as equity.

Share-based compensation

(u) Share-based compensation

The Group accounts for share-based compensation in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). In accordance with ASC 718, the Group determines whether an award should be classified and accounted for as a liability award or an equity award. All the Group’s share-based awards were classified as equity awards and are recognized in the unaudited condensed consolidated financial statements based on their grant date fair values.

The Group has elected to recognize share-based compensation using the straight-line method for all share-based awards granted with graded vesting based on service conditions. The Group accounts for forfeitures as they occur in accordance with ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvement to Employee Share-based Payment Accounting. The Black-Scholes Model were applied in determining the estimated fair value of the options granted to employees and non-employees.

Income taxes

(v) Income taxes

The Group follows the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.

 

The Group accounted for uncertainties in income taxes in accordance with ASC 740. Interest and penalties related to unrecognized tax benefit recognized in accordance with ASC 740 are classified in the unaudited condensed consolidated statements of operations and comprehensive loss as income tax expenses.

For the six months ended June 30, 2022 and 2023, the Group did not have any significant unrecognized uncertain tax positions or any unrecognized liabilities, interest or penalties associated with unrecognized tax benefits. The Group does not believe that its uncertain tax benefits position will materially change over the next twelve months.

Comprehensive loss

(w) Comprehensive loss

Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group’s comprehensive loss includes net loss and foreign currency translation differences, and is presented in the unaudited condensed consolidated statements of operations and comprehensive loss.

Segment reporting

(x) Segment reporting

After the Group discontinued CDA business, the Group operates and manages its business as a single segment and the Group’s primary revenue are generated in the U.S. The Group has only one reportable segment for the six months ended June 30, 2023, in accordance with ASC 280, Segment Reporting. The Group’s Chief Executive Officer is the chief operating decision-maker that review the unaudited condensed consolidated financial results when making decisions about allocating resources and assessing the performance of the Group as a whole.

Loss per share

(y) Loss per share

Loss per share is calculated in accordance with ASC 260, Earnings per Share. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.

Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the share options, using the treasury share method. Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Group’s unaudited condensed consolidated statements of operations and comprehensive loss.

The rights, including the liquidation and dividend rights, of the holders of our Class A and Class B ordinary shares are identical, except with respect to voting. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to ten votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares under any circumstances. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis. For the six months ended June 30, 2022 and 2023, the net loss per share amounts are the same for Class A and Class B common ordinary shares because the holders of each class are entitled to equal per share dividends or distributions in liquidation.

The Group did not include share options, convertible debt and warrants in the computation of diluted earnings per share for the six months ended June 30, 2022 and 2023, because those were anti-dilutive for loss per share.

Risks, Uncertainties and Concentrations

(z) Risks, Uncertainties and Concentrations

Concentration of credit risk

Financial instruments that potentially subject the Group to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivables. As of December 31, 2022 and June 30, 2023, the aggregate amounts of cash and cash equivalents of RMB14 and RMB62 (US$9), respectively, were held at major financial institutions located in the PRC and RMB1 and RMB268 (US$37), respectively, were deposited at banks located in U.S. and covered by the FDIC insurance program. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. There is a RMB 500,000 deposit insurance limit for a legal entity’s aggregated balance at each PRC bank.

 

As of December 31, 2022, no customer accounted for more than 10% of total accounts receivables. As of June 30, 2023, four customers accounted for 37%, 20%, 19% and 16% of total accounts receivables. The risk is mitigated by credit evaluations the Group performs on its customers.

Business, customer, supplier, political and economic risks

The Group’s e-commerce food-related business has a limited operating history. The recently acquired operations are subject to all of the risks inherent in the initial expenses, challenges, complications, and delays frequently encountered in connection with the formation of any new business.

The Group participates in a dynamic industry and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in industry standards; changes in certain strategic relationships or customer relationships; regulatory considerations; intellectual property considerations; and risks associated with the Group’s ability to attract and retain employees necessary to support its growth.

For the six months ended June 30, 2022, no customer accounted for more than 10% of the total revenues, respectively. For the six months ended June 30, 2023, the Group had one customer that accounted for 16% of total revenues.

For the six months ended June 30, 2022, no supplier accounted for more than for 10% of total cost of revenues. For the six months ended June 30, 2023, two suppliers that accounted for 22% and 22% of total cost of revenues, respectively.

As of December 31, 2022, no supplier accounted for more than 10% of total accounts payables As of June 30, 2023, three suppliers accounted for 25%, 14%and 12% of total accounts payables, respectively.

Recent accounting pronouncements

(aa) Recent accounting pronouncements

The Group is an emerging growth company (“EGC”) as defined by the Jumpstart Our Business Startups Act (“JOBS Act”). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.

In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Group. Early adoption is permitted. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the unaudited condensed consolidated financial statements.

In October 2021, the FASB issued ASU No. 2021-08, “‘Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). This ASU requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The amendments are effective for fiscal years beginning after December 15, 2023, and are applied prospectively to business combinations that occur after the effective date. The Group does not expect the adoption of ASU 2021-04 will have a material effect on the unaudited condensed consolidated financial statements.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Group adopts as of the specified effective date. Unless otherwise discussed, the Group does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.

XML 36 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Principal Activities (Tables)
6 Months Ended
Jun. 30, 2023
Organization and Principal Activities [Abstract]  
Schedule of Group’s Principal Subsidiaries As of June 30, 2023, the details of the Group’s principal subsidiaries are as follows:
Major subsidiaries  Percentage of
Ownership
  

Date of
Incorporation/

Acquisition

  Place of
Incorporation
  Major Operation
Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. *    100%  March 2010  the PRC  Cancer screening and detection tests
AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”) *

   100%  October 2012  the PRC  Cancer screening detection tests and device manufacturing
AnPac Bio-Medical Technology (Shanghai) Co., Ltd.*   100%  April 2014  the PRC  Cancer screening and detection tests
AnPac Technology USA Co., Ltd. (“AnPac US”) *

   100%  September 2015  the U.S.  Clinical trials for research on cancer screening and detection tests
Lishui AnPac Medical Laboratory Co., Ltd.*   100%  July 2016  the PRC  Cancer screening and detection tests
Shiji (Hainan) Medical Technology Ltd.*   100%  March 2013  the PRC  Cancer screening and detection research
Shanghai Muqing AnPac Health Technology Co., Ltd. (“AnPac Muqing”) (i)*   51%  March 2019  the PRC  Cancer screening and detection tests
Anpai (Shanghai) Healthcare Management and Consulting Co., Ltd.*   60%  August 15, 2021  the PRC  Cancer screening and detection tests
Fresh 2 Group Inc   100%  December 27, 2022  the U.S.  B2B e-commerce
Fresh 2 Technology Inc (“Fresh2”)   100%  October 4, 2022  the U.S.  B2B e-commerce
Fresh 2 Logistics Inc.   100%  February 22, 2023  the U.S.  B2B e-commerce
Fresh 2 HF Inc   100%  February 21, 2023  the U.S.  B2B e-commerce
Foodbase Group Inc   100%  January 19, 2023  the U.S.  B2B e-commerce
Fresh 2 EZ Inc   100%  March 3, 2023  the U.S.  B2B e-commerce
Fresh 2 information Inc (ii)   100%  April 12, 2023  the U.S.  B2B e-commerce
Fresh 2 Ecommerce (“Fresh2 Ecommerce”)   100%  February 8, 2023  the U.S.  B2B e-commerce
GISN (HK) Limited (“GISN”)   100%  February 1, 2023  Hongkong, PRC,  B2B e-commerce
Hua You Sheng Future (Beijing) Technology Co., Ltd.   100%  February 1, 2023  PRC  B2B e-commerce
Guanshi Technology (Beijing) Co., Ltd.   100%  February 1, 2023  PRC  Software development
* Subsidiaries that were sold subsequent to June 30, 2023.
(i) AnPac Muqing closed business in March 2023
(ii) On April 12, 2023, the Company, through its subsidiary, Fresh 2 EZ Inc to acquire 100% of equity interest in Fresh 2 information Inc from Roxe Holding Inc, a company controlled by Mr. Haohan Xu, with a nominal price. Fresh 2 information Inc has not begun operation yet.
XML 37 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Principal Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2023
Summary of Principal Accounting Policies [Abstract]  
Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis The following is a reconciliation of the beginning and ending balances for convertible loans measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of December 31, 2022 and June 30, 2023:
   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
Opening balance   27,859    15    2 
Conversion of convertible loans   (27,739)   
    
 
Loss (gain) on change in fair value of convertible loan   (144)   
    
 
Other comprehensive income -foreign exchange translations   39    1    
 
Total   15    16    2 
Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment Property and equipment are stated at cost less accumulated depreciation and any recorded impairment. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, as follows:
Category  Estimated useful life
Furniture, fixtures and equipment  3-5 years
Motor vehicles  5 years
Schedule of Intangible Assets Have Estimated Useful Lives Intangible assets have estimated useful lives from the date of purchase as follows:
Category  Estimated useful life
Software  5-10 years
XML 38 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Acqusitions (Tables)
6 Months Ended
Jun. 30, 2023
Acquisition [Abstract]  
Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:
   Amount 
   RMB 
     
Total consideration   25,938 
      
Assets acquired and liabilities assumed:     
Cash acquired   1,028 
Accounts receivable   100 
Accounts receivable-related parties   12,073 
Other current assets   123 
Right of use assets   

283

 
Property and equipment   1,573 
Intangible assets   11,233 
Advance from customer   (1,013)
Accrued expenses and other current liabilities   (13,705)
Lease liabilities   (239)
Deferred tax liability   (2,808)
Total net assets acquired   8,648 
Goodwill   17,290 
The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:
   Amount 
   RMB 
     
Total consideration   17,304 
      
Assets acquired and liabilities assumed:     
Cash acquired   71 
Other current assets   938 
Accounts payables   (950)
Accrued expenses and other current liabilities   (72)
Total net assets acquired   (13)
Goodwill   17,317 
Schedule of Pro Forma of Group Business Combination The following unaudited pro forma summary presents consolidated information of the Group as of the business combination had occurred on January 1, 2022.
   Unaudited Pro Forma 
   For the six months
ended June 30,
 
   2022   2023 
   RMB   RMB 
Revenue   10,149    4,936 
           
Net losses   51,322    (71,405)
Schedule of Fair Value of Identifiable Assets The following table summarizes the fair value of the identifiable assets:
   Amount 
   RMB 
Property and equipment- furniture, fixtures and equipment   160 
Property and equipment- motor vehicles   434 
Intangible assets- software*   30,139 
Total consideration   30,733 
*Intangible assets refer to intellectual property relating to ez100, 2Supply and 100WAY systems.
XML 39 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations (Tables)
6 Months Ended
Jun. 30, 2023
Discontinued Operations [Abstract]  
Schedule of Results of Discontinued Operations The results of discontinued operations for the six months ended June 30, 2022 and 2023 were as follows:
   Six Months Ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Revenues:            
Revenues-third parties   3,972    2,937    405 
Revenues-related parties   1,241    91    13 
Total revenues   5,213    3,028    418 
Cost of revenues   (1,832)   (1,292)   (178)
Gross Profit   3,381    1,736    240 
Operating expenses:               
Selling and marketing expenses   (4,894)   (3,872)   (534)
General and administrative expenses   (15,629)   (8,593)   (1,185)
Research and development expenses   (4,330)   (3,438)   (474)
Impairment of intangible assets   (7,911)   
    
 
Impairment of goodwill   (12,758)   
    
 
Loss from operations   (42,141)   (14,167)   (1,953)
Non-operating income and expenses:               
Interest expense, net   (161)   (81)   (11)
Foreign exchange gain, net   7    9    1 
Share of net loss in equity method investments   (87)   (88)   (12)
Other income, net   472    3,106    428 
Loss from operations for discontinued operations   (41,910)   (11,221)   (1,547)
Loss from disposal of a subsidiary   
    (16,724)   (2,307)
Loss from discontinued operations before income taxes   (41,910)   (27,945)   (3,854)
Income tax benefit   2,130    
    
 
Net Loss from discontinued operations   (39,780)   (27,945)   (3,854)

 

Schedule of Assets and Liabilities of the Discontinued Operations Assets and liabilities of the discontinued operations:
   December 31   June 30   June 30 
   2022   2023   2023 
   RMB   RMB   US$ 
ASSETS            
Current assets:            
Cash and cash equivalents   1,854    319    44 
Prepayment   2,692    1,334    184 
Accounts receivable, net   2,235    3,318    458 
Amounts due from related parties, net   2,194    684    94 
Inventories, net   210    178    25 
Other current assets, net   3,448    3,944    543 
Total current assets held for sale   12,633    9,777    1,348 
                
Property and equipment, net   17,182    15,746    2,171 
Land use rights, net   1,111    1,097    151 
Intangible assets, net   185    271    37 
Goodwill               
Right of use assets   7,213    2,088    288 
Long-term investments, net   1,079    991    138 
Total noncurrent assets held for sale   26,770    20,193    2,785 
TOTAL ASSETS HELD FOR SALE   39,403    29,970    4,133 
                
LIABILITIES               
Current liabilities:               
Short-term debts   5,000    5,000    690 
Accounts payable   2,108    2,012    277 
Advance from customers   4,956    7,800    1,076 
Amounts due to related parties   2,280    1,079    149 
Lease liability-current   784    1,042    144 
Accrued expenses and other current liabilities   18,386    16,488    2,273 
Total current liabilities held for sale   33,514    33,421    4,609 
Deferred tax liabilities               
Lease liability-non-current   6,515    1,368    189 
Other long-term liabilities   1,080    1,066    147 
Total noncurrent liabilities held for sale   7,595    2,434    336 
TOTAL LIABILITIES HELD FOR SALE   41,109    35,855    4,945 
XML 40 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Receivable, Net (Tables)
6 Months Ended
Jun. 30, 2023
Accounts Receivable, Net [Abstract]  
Schedule of Accounts Receivable Accounts receivable as of December 31, 2022 and June 30, 2023 were as follows:
   December 31     
   2022   June 30 2023 
   RMB   RMB   US$ 
             
Accounts receivable   
    270    37 
Allowance for credit losses   
    
    
 
Balance at end of year   
    270    37 
XML 41 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Other Current Assets, Net (Tables)
6 Months Ended
Jun. 30, 2023
Other Current Assets, Net [Abstract]  
Schedule of Other Current Assets Other current assets consist of the following:
   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Deposits   
    154    21 
Receivable from private placement investors   
    260    36 
Loan to third-parties   422    444    61 
Total   422    858    118 
Allowance for credit losses   (422)   (444)   (61)
Other current assets, net   
    414    57 
XML 42 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net Consists Property and equipment, net consists of the following:
   December 31,     
   2022   June 30 2023 
   RMB   RMB   US$ 
Furniture, fixtures and equipment   
    3,255    448 
Motor vehicles   
    2,007    277 
Total   
    5,262    725 
Less: accumulated depreciation   
    (953)   (131)
Property and equipment, net   
    4,309    594 
XML 43 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net (Tables)
6 Months Ended
Jun. 30, 2023
Intangible Assets, Net [Abstract]  
Schedule of Intangible Assets Net Intangible assets, net consist of the following:
   December 31,     
   2022   June 30 2023 
   RMB   RMB   US$ 
Software   
    47,798    6,592 
Total   
    47,798    6,592 
Less: accumulated amortization   
    (2,629)   (363)
Intangible assets, net   
    45,169    6,229 

 

Schedule of Estimated Aggregate Amortization Expense Amortization expense for six months ended June 30, 2022 and 2023 amounted to nil and RMB2,511 (US$346), respectively. The estimated aggregate amortization expense for each of the five succeeding years is as follows:
Twelve months ending June 30,  RMB 
2024   8,351 
2025   8,351 
2026   8,351 
2027   8,351 
2028   6,226 
Thereafter   5,539 
Total   45,169 
XML 44 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Investments, Net (Tables)
6 Months Ended
Jun. 30, 2023
Long-Term Investments, Net [Abstract]  
Schedule of Long-Term Investments Long-term investments, net consisted of the following:
   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Equity method investments               
Advanced Life Therapeutics Co., Ltd. (“Advanced Life”)   
    
    
 
Nassau Enterprises LLC (“Nassau”).   
    39,783    5,486 
Total   
    39,783    5,486 
Less: Impairment   
    
    
 
Long-term investments, net   
    39,783    5,486 
XML 45 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Short-Term Debts (Tables)
6 Months Ended
Jun. 30, 2023
Short-Term Debts [Abstract]  
Schedule of Short-Term Debts
   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Convertible loan (“CL”) (i)   15    16    2 
Total   15    16    2 
(i)On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were originally due in one year and bear interest of 0% per annum if the conversion feature is not triggered. Pursuant to the agreement, the conversion price is lower of (i) US$15 or (ii) the lower of 82% of the closing bid price or 80% of VWAP of the Company’s ADSs during the ten consecutive trading days immediately preceding conversion, but not lower than a Floor Price of US$1 (the “floor price”). Due to significant drop of the ADS market price in 2022, the debenture holders and the Company renegotiated the Floor Price. On February 5, 2022, the Company entered into an amendment agreement, pursuant to which the Floor Price was reduced to US$0.10 per Class A Ordinary Share. The Company has elected to recognize the Convertible Debentures at fair value and therefore there was no further evaluation of embedded features for bifurcation. The Convertible Debentures were partially converted into 114,234 shares on December 10, 2021. The fair value of the Convertible Debentures loan immediately prior to conversion was assessed at RMB1,321. Substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares (refer to Note 14) on March 16, 2022. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).
XML 46 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
6 Months Ended
Jun. 30, 2023
Lease [Abstract]  
Schedule of Operating Leases Supplemental balance sheet information related to operating leases was as follows:
   December 31,     
   2022   June 30, 2023 
   RMB   RMB   US$ 
             
Right-of-use assets, net   
    223    31 
                
Operating lease liabilities - current   
    148    20 
Operating lease liabilities - non-current   
    37    5 
Total operating lease liabilities   
    185    25 

 

Schedule of Weighted Average Remaining Lease Terms and Discount Rates The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of June 30, 2023:
Weighted average remaining lease term (years)   1.51 
Weighted average discount rate   4.75%
Schedule of Maturities of Lease Liabilities The following is a schedule of maturities of lease liabilities are as follows:
Twelve months ending June 30,  RMB 
2024   150 
2025   37 
Total future minimum lease payments   187 
Less: imputed interest   (2)
Total   185 
XML 47 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Expenses and Other Current Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Accrued Expenses and Other Current Liabilities [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities
   December 31     
   2022   June 30, 2023 
   RMB   RMB   US$ 
Salary and welfare payable   1,740    9,312    1,283 
Accrued expenses (1)   5,762    9,057    1,249 
Payable for property and equipment   
    2,301    318 
Other payables   33    4,089    564 
Total   7,535    24,759    3,414 
(1):the accrued expenses mainly consist of accrued professional fees.
XML 48 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity (Tables)
6 Months Ended
Jun. 30, 2023
Shareholders' Equity [Abstract]  
Sechedule of Warrants Activity As of June 30, 2023, there were 103,702,658 warrants outstanding. A summary of warrants activity for the six months ended June 30 2023 was as follows:
       Weighted
average
exercise
price per
share
   Weighted    
  

Number of

warrants

   US$ per
share
   average life
Years
 

Expiration

dates 

Balance of warrants outstanding and exercisable as of December 31, 2022   9,266,135    0.24   1.85 to unlimited  August 31, 2024 to unlimited
—warrants issued in connection with the March 2023 private placement   61,771,423    0.21   1.58 to 1.96  February 3, 2025 to June 16, 2025
—warrants issued in connection with the April 2023 private placement   18,250,000    0.00001-0.24   1.75 to Unlimited  March 31, 2025 to unlimited
—warrants issued in connection with the June 2023 private placement   22,000,000    0.21   1.95  June 9, 2025
Exercised   (7,584,900)   0.00001-0.2       
Balance of warrants outstanding and exercisable as of June 30, 2023   103,702,658    0.21   1.96 to unlimited  August 31, 2024 to unlimited
XML 49 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Tables)
6 Months Ended
Jun. 30, 2023
Share Based Compensation (Tables) [Line Items]  
Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued The Group used the Black-Scholes simplified method for the valuation of new options issued during the six months ended June 30, 2022 and 2023. The assumptions used to value the share options granted to employees and nonemployee were as follows:
   For the six months ended
June 30,
 
   2022   2023 
Risk-free interest rate   0.34%   
%
Expected volatility range   100.2%   
%
Fair market value per ordinary share as at grant dates   US$0.29    
 
Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense The following table sets forth the amount of share-based compensation expense included in each of the relevant financial statement line items:
   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Selling and marketing expenses   705    1,712    236 
Research and development expenses   1,263    818    113 
General and administrative expenses   2,560    1,236    170 
Total share-based compensation expenses   4,528    3,766    519 
Share-Based Payment Arrangement, Employee [Member]  
Share Based Compensation (Tables) [Line Items]  
Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument The options granted to employees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards and contain only service vesting conditions. The following table summarized the Group’s employee share option activities:
               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
   Number of   Exercise   Grant date   Contractual   Intrinsic 
   Options   Price   Fair Value   Term   Value 
       US$ per   US$ per         
       option   option   Years   US$ 
Share options outstanding at December 31, 2022   2,334,906    1.69    5.08    8.05    452 
Granted   
    
    
    
    
 
Exercised   (13,900)   0.05    0.05    0.22    
 
Share options outstanding at June 30, 2023   2,321,006    1.70    2.32    7.54    306 
Vested and exercisable at June 30, 2023   2,199,006    1.41    2.08    7.54    306 
Share-Based Payment Arrangement, Nonemployee [Member]  
Share Based Compensation (Tables) [Line Items]  
Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument The options granted to nonemployees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards with service and/or performance vesting conditions. The following table summarized the Group’s nonemployee share option activity:
               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
   Number of   Exercise   Grant date   Contractual   Intrinsic 
   Options   Price   Fair Value   Term   Value 
       US$ per   US$ per         
       option   option   Years   US$ 
Share options outstanding at December 31, 2022   2,651,700    0.86    0.85    9.27    532 
Granted   
    
    
    
    
 
Exercised   (650,000)   0.05    0.05    0.22    
 
Forfeited   (20,000)   
    
    
    
 
Share options outstanding at June 30, 2023   1,981,700    1.13    1.04    8.74    315 
Vested and exercisable at June 30, 2023   1,981,700    1.13    1.00    8.74    315 
XML 50 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Tables)
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of Loss Before Income Taxes The Group’s loss before income taxes consisted of:
   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Non-US   (9,035)   (23,507)   (3,241)
US   
    (20,032)   (2,763)
Total   (9,035)   (43,539)   (6,004)

 

Schedule of Current and Deferred Components of Income Tax Benefit The current and deferred components of income tax benefit appearing in the unaudited condensed consolidated statements of comprehensive income are as follows:
   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Current tax expense   
    
    
 
Deferred tax benefit   
    79    11 
Total   
    79    11 
Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate The reconciliation of tax computed by applying the federal statutory income tax rate of 21% for the six months ended June 30, 2022 and 2023 applicable to the U.S. operations to income tax benefit were as follows:
   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Loss before income taxes   (9,035)   (43,539)   (6,004)
Income tax benefit computed at the statutory income tax rate at 21%   (1,897)   9,142    1,261 
International rate differences   1,897    (4,726)   (652)
Change in valuation allowance       (4,337)   (598)
Income tax benefit       79    11 
Schedule of Significant Components of Deferred Taxes The significant components of deferred taxes were as follows:
   As of December 31, 
   December 31,   June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Deferred tax assets:            
Net loss carryforward   1,900    9,608    1,325 
Valuation allowance   (1,900)   (9,608)   (1,325)
Total deferred tax assets.   
    
    
 
                
Deferred tax liabilities:               
Long-lived assets arising from acquisitions   
    2,938    405 
Total deferred tax liabilities.   
    2,938    405 
XML 51 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Balances (Tables)
6 Months Ended
Jun. 30, 2023
Related Party Transactions and Balances [Abstract]  
Schedule of Related Parties Financial and Operational The related parties that had transactions in the six months ended June 30, 2022 and 2023 or balances with the Group as of December 30, 2022 and June 30, 2023 consisted of:
Related Party   Nature of the party   Relationship with the Group
Haohan Xu   Individual   Chief Executive Officer
Apifiny Inc.   Investment management   Controlled by Haohan Xu
Roxe Holding Inc.   Investment management   Controlled by Haohan Xu
Dr. Chris Chang Yu*   Individual   Co-Founder and shareholder
CRS Holdings Inc.   Investor   Controlled by Dr. Chris Chang Yu
Jiaxing Zhijun Sihang Investment Partnership Enterprises (limited partnership) (“Jiaxing Zhijun”)   Private equity investment   Shareholder, due to diluted equity interest, no longer a related party for the six months ended June 30 2023
*Dr. Yu resigned from his position as the Chief Executive Officer (“CEO”) of the Company and Chairman of the Board on April 6, 2022 and was appointed as Co-Chairman and Co-CEO in May 2022. On May 17, 2023, Dr. Yu resigned as the Co-Chief Executive Officer of the Company.
Schedule of Related Party Transactions Related party balances
   As of
December 31,
   As of June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Due from related parties:            
Apifiny Inc.   
    211    29 
Roxe Holding Inc.   
    363    50 
Dr. Chris Chang Yu   
    290    40 
Due from related parties, net   
    864    119 
   As of
December 31,
  

As of June 30,

 
   2022   2023   2023 
   RMB   RMB   US$ 
Due to related parties:            
CRS Holdings Inc.   287    592    82 
Jiaxing Zhijun   927    
    
 
Due to related parties   1,214    592    82 

 

Schedule of Accounts Receivables
   As of
December 31,
  

As of June 30,

 
   2022   2023   2023 
   RMB   RMB   US$ 
Accounts receivables-related parties:            
Apifiny Inc.   
    3,525    486 
Roxe Holding Inc.   
    7,925    1,093 
Accounts Receivables-related parties, net   
    11,450    1,579 
Schedule of Related Party Transactions For the six months ended June 30, 2022 and 2023, related party transactions consisted of the following:
   For the six months ended June 30, 
   2022   2023   2023 
   RMB   RMB   US$ 
Fixed assets purchased from Apifiny Inc.   
    970    134 
Consulting service received from Roxe Holding Inc.   
    464    64 
Rent expense incurred with Apifiny Inc.   32    624    86 
XML 52 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Principal Activities (Details)
1 Months Ended
Nov. 06, 2023
Jul. 17, 2023
Apr. 12, 2023
Jul. 27, 2023
Organization and Principal Activities (Details) [Line Items]        
Percentage of equity interest     100.00%  
Subsequent Event [Member]        
Organization and Principal Activities (Details) [Line Items]        
Percentage of share purchase agreement   51.00%    
Purchase percentage   51.00%    
Definitive share purchase agreement       100.00%
Forecast [Member]        
Organization and Principal Activities (Details) [Line Items]        
Definitive share purchase agreement 38.61%      
Fresh2 Group Limited [Member] | Subsequent Event [Member]        
Organization and Principal Activities (Details) [Line Items]        
Purchase percentage   100.00%    
XML 53 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Principal Activities (Details) - Schedule of Group’s Principal Subsidiaries
6 Months Ended
Jun. 30, 2023
Changwei System Technology (Shanghai) Co., Ltd. [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00% [1]
Date of Incorporation/ Acquisition March 2010 [1]
Place of Incorporation the PRC [1]
Major Operation Cancer screening and detection tests [1]
AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”) [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00% [1]
Date of Incorporation/ Acquisition October 2012 [1]
Place of Incorporation the PRC [1]
Major Operation Cancer screening detection tests and device manufacturing [1]
AnPac Bio-Medical Technology (Shanghai) Co., Ltd. [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00% [1]
Date of Incorporation/ Acquisition April 2014 [1]
Place of Incorporation the PRC [1]
Major Operation Cancer screening and detection tests [1]
AnPac Technology USA Co., Ltd. (“AnPac US”) [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00% [1]
Date of Incorporation/ Acquisition September 2015 [1]
Place of Incorporation the U.S. [1]
Major Operation Clinical trials for research on cancer screening and detection tests [1]
Lishui AnPac Medical Laboratory Co., Ltd. [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00% [1]
Date of Incorporation/ Acquisition July 2016 [1]
Place of Incorporation the PRC [1]
Major Operation Cancer screening and detection tests [1]
Shiji (Hainan) Medical Technology Ltd. [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00% [1]
Date of Incorporation/ Acquisition March 2013 [1]
Place of Incorporation the PRC [1]
Major Operation Cancer screening and detection research [1]
Shanghai Muqing AnPac Health Technology Co., Ltd. (“AnPac Muqing”) [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 51.00% [1],[2]
Date of Incorporation/ Acquisition March 2019 [1],[2]
Place of Incorporation the PRC [1],[2]
Major Operation Cancer screening and detection tests [1],[2]
Anpai (Shanghai) Healthcare Management and Consulting Co., Ltd. [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 60.00% [1]
Date of Incorporation/ Acquisition August 15, 2021 [1]
Place of Incorporation the PRC [1]
Major Operation Cancer screening and detection tests [1]
Fresh 2 Group Inc [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition December 27, 2022
Place of Incorporation the U.S.
Major Operation B2B e-commerce
Fresh 2 Technology Inc. (“Fresh2”) [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition October 4, 2022
Place of Incorporation the U.S.
Major Operation B2B e-commerce
Fresh 2 Logistics Inc [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition February 22, 2023
Place of Incorporation the U.S.
Major Operation B2B e-commerce
Fresh 2 HF Inc [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition February 21, 2023
Place of Incorporation the U.S.
Major Operation B2B e-commerce
Foodbase Group Inc [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition January 19, 2023
Place of Incorporation the U.S.
Major Operation B2B e-commerce
Fresh 2 EZ Inc [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition March 3, 2023
Place of Incorporation the U.S.
Major Operation B2B e-commerce
Fresh 2 information Inc [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00% [3]
Date of Incorporation/ Acquisition April 12, 2023 [3]
Place of Incorporation the U.S. [3]
Major Operation B2B e-commerce [3]
Fresh 2 Ecommerce (“Fresh2 Ecommerce”) [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition February 8, 2023
Place of Incorporation the U.S.
Major Operation B2B e-commerce
GSIN (HK) Limited (“GISN”) [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition February 1, 2023
Place of Incorporation Hongkong, PRC,
Major Operation B2B e-commerce
Hua You Sheng Future (Beijing) Technology Co., Ltd [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition February 1, 2023
Place of Incorporation PRC
Major Operation B2B e-commerce
Guanshi Technology (Beijing) Co., Ltd [Member]  
Schedule of Group’s Principal Subsidiaries [Abstract]  
Percentage of Ownership 100.00%
Date of Incorporation/ Acquisition February 1, 2023
Place of Incorporation PRC
Major Operation Software development
[1] Subsidiaries that were sold subsequent to June 30, 2023.
[2] AnPac Muqing closed business in March 2023
[3] On April 12, 2023, the Company, through its subsidiary, Fresh 2 EZ Inc to acquire 100% of equity interest in Fresh 2 information Inc from Roxe Holding Inc, a company controlled by Mr. Haohan Xu, with a nominal price. Fresh 2 information Inc has not begun operation yet.
XML 54 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Liquidity and Going Concern Uncertainties (Details)
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Sep. 25, 2023
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Liquidity and Going Concern Uncertainties (Details) [Line Items]            
Cash and cash equivalents ¥ 495       $ 68 ¥ 16
Working capital deficit 34,148 $ 4,710        
Loss from continuing operations (43,460) (5,993) ¥ (9,035)      
Net cash used in operating activities ¥ (35,609) $ (4,910) ¥ (17,705)      
Investor agreement, description (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at an exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at an exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment of RMB1,697(US$234) from this offering, excluding related financing costs. (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at an exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at an exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment of RMB1,697(US$234) from this offering, excluding related financing costs.        
Forecast [Member]            
Liquidity and Going Concern Uncertainties (Details) [Line Items]            
Convertible notes       $ 2,000    
XML 55 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Principal Accounting Policies (Details)
¥ in Thousands, $ in Thousands
6 Months Ended
Dec. 31, 2022
CNY (¥)
Jun. 30, 2023
CNY (¥)
Jun. 30, 2022
CNY (¥)
Jun. 30, 2023
USD ($)
Summary of Principal Accounting Policies [Line Items]        
Fair value of convertible loans ¥ 15 ¥ 16   $ 2
Contract liabilities    
Contract liabilities amounted 479   66
Cash and cash equivalents 14 62   9
Financial institutions deposited ¥ 1 268   $ 37
Deposit insurance limit (in Yuan Renminbi)   ¥ 500,000    
Accounts receivables 10.00%      
Customers accounted, description   As of June 30, 2023, four customers accounted for 37%, 20%, 19% and 16% of total accounts receivables. The risk is mitigated by credit evaluations the Group performs on its customers.    
Minimum [Member]        
Summary of Principal Accounting Policies [Line Items]        
Lease term   75.00%    
Maximum [Member]        
Summary of Principal Accounting Policies [Line Items]        
Lease term   90.00%    
Other Customer [Member]        
Summary of Principal Accounting Policies [Line Items]        
Percentage of revenue   16.00%    
Two Customers [Member]        
Summary of Principal Accounting Policies [Line Items]        
Percentage of revenue   22.00%    
Three Customers [Member]        
Summary of Principal Accounting Policies [Line Items]        
Percentage of revenue   22.00%    
One Suppliers [Member]        
Summary of Principal Accounting Policies [Line Items]        
Percentage of revenue     10.00%  
Two Suppliers [Member]        
Summary of Principal Accounting Policies [Line Items]        
Percentage of revenue     10.00%  
Percentage of total accounts payable   25.00%    
Three Suppliers [Member]        
Summary of Principal Accounting Policies [Line Items]        
Percentage of revenue     10.00%  
Percentage of total accounts payable   12.00%    
Four Suppliers [Member]        
Summary of Principal Accounting Policies [Line Items]        
Percentage of total accounts payable   14.00%    
XML 56 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Principal Accounting Policies (Details) - Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis
¥ in Thousands, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule of Convertible Loans Measured at Fair Value on A Recurring Basis [Abstract]      
Opening balance ¥ 15 $ 2 ¥ 27,859
Conversion of convertible loans (27,739)
Loss (gain) on change in fair value of convertible loan (144)
Other comprehensive income -foreign exchange translations 1 39
Total ¥ 16 $ 2 ¥ 15
XML 57 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Principal Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment
Jun. 30, 2023
Furniture, fixtures and equipment [Member] | Minimum [Member]  
Public Utility, Property, Plant and Equipment [Line Items]  
Estimated useful life 3 years
Furniture, fixtures and equipment [Member] | Maximum [Member]  
Public Utility, Property, Plant and Equipment [Line Items]  
Estimated useful life 5 years
Motor vehicles [Member]  
Public Utility, Property, Plant and Equipment [Line Items]  
Estimated useful life 5 years
XML 58 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives
Jun. 30, 2023
Sep. 30, 2008
Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives [Line Items]    
Software   10 years
Minimum [Member]    
Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives [Line Items]    
Software 5 years  
XML 59 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Acqusitions (Details)
¥ in Thousands, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2023
CNY (¥)
shares
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2022
CNY (¥)
Dec. 31, 2022
shares
Acqusitions (Details) [Line Items]        
Ordinary shares issued (in Shares) | shares 17,665,702 17,665,702    
Fair value ¥ 25,720 $ 3,745    
Amortized over year       10 years
Revenue contributed 677 93    
Revenue | ¥ 4,936   ¥ 10,149  
Loss | ¥ ¥ (71,405)   ¥ 51,322  
Total consideration | $   730    
Asset Acquisition [Member]        
Acqusitions (Details) [Line Items]        
Total consideration | $   $ 5,013    
Class A ordinary shares [Member]        
Acqusitions (Details) [Line Items]        
Ordinary shares issued (in Shares) | shares 176,070,465 176,070,465   79,536,589
Class A ordinary shares [Member] | GISN Acquisition [Member]        
Acqusitions (Details) [Line Items]        
Ordinary shares issued (in Shares) | shares 8,785,530 8,785,530    
Fair value ¥ 25,938 $ 3,848    
Class A ordinary shares [Member] | Fresh2 Acquisition [Member]        
Acqusitions (Details) [Line Items]        
Ordinary shares issued (in Shares) | shares 5,440,420 5,440,420    
Fair value ¥ 17,304 $ 2,549    
Pro Forma [Member] | Fresh2 Acquisition [Member]        
Acqusitions (Details) [Line Items]        
Revenue | $   199    
Loss | $   $ 86    
XML 60 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
GISN Acquisition [Member]  
Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities [Line Items]  
Total consideration $ 25,938
Assets acquired and liabilities assumed:  
Cash acquired 1,028
Accounts receivable 100
Accounts receivable-related parties 12,073
Other current assets 123
Right of use assets 283
Property and equipment 1,573
Intangible assets 11,233
Advance from customer (1,013)
Accrued expenses and other current liabilities (13,705)
Lease liabilities (239)
Deferred tax liability (2,808)
Total net assets acquired 8,648
Goodwill 17,290
Fresh2 Acquisition [Member]  
Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities [Line Items]  
Total consideration 17,304
Assets acquired and liabilities assumed:  
Cash acquired 71
Other current assets 938
Accounts payables (950)
Accrued expenses and other current liabilities (72)
Total net assets acquired (13)
Goodwill $ 17,317
XML 61 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Acqusitions (Details) - Schedule of Pro Forma of Group Business Combination - CNY (¥)
¥ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Schedule Of Pro Forma Of Group Business Combination Abstract    
Revenue ¥ 4,936 ¥ 10,149
Net losses ¥ (71,405) ¥ 51,322
XML 62 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets
¥ in Thousands
Jun. 30, 2023
CNY (¥)
Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets [Line Items]  
Property and equipment- furniture, fixtures and equipment ¥ 30,733
Furniture, fixtures and equipment [Member]  
Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets [Line Items]  
Property and equipment- furniture, fixtures and equipment 160
Motor vehicles [Member]  
Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets [Line Items]  
Property and equipment- furniture, fixtures and equipment 434
software [Member]  
Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets [Line Items]  
Property and equipment- furniture, fixtures and equipment ¥ 30,139 [1]
[1] Intangible assets refer to intellectual property relating to ez100, 2Supply and 100WAY systems.
XML 63 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Discontinued Operations [Line Items]  
Agreement percentage 100.00%
Consideration amount $ 730
Agreement rate 100.00%
Disposal description In connection with the disposal of CDA business, the Group also sold its 70% equity interest in Changwei System Technology (Shanghai) Co., Ltd (“Changwei”) to Jiaxing Changxin Enterprise Management, LLP (“Changxin”) in consideration of US$350 (RMB2,538) and sold the remaining 29% equity interest in Changwei to Shanghai Yiyou Investment Management Co., LTD (“Yiyou”) in consideration of US$150 (RMB1,088). Yiyou further entered into an arrangement with Changxin and Ms. Ruoou Ying, pursuant to which the Group agreed to transfer 29% of Changwei’s shares to Changxin and 1% of the shares to Ms. Ruoou Ying (the “Changwei disposal”). The Group received the consideration in aggregated of RMB3,626 (US$500) from the Changwei disposal. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company. Loss from disposal of Changwei amounted to RMB16,724 (US$2,307) and was included in net loss from discontinued operations. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company.
Minimum [Member]  
Discontinued Operations [Line Items]  
Consideration amount
Maximum [Member]  
Discontinued Operations [Line Items]  
Consideration amount
XML 64 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations (Details) - Schedule of Results of Discontinued Operations - Discontinued Operations [Member]
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Revenues:      
Revenues parties ¥ 3,028 $ 418 ¥ 5,213
Cost of revenues (1,292) (178) (1,832)
Gross Profit 1,736 240 3,381
Operating expenses:      
Selling and marketing expenses (3,872) (534) (4,894)
General and administrative expenses (8,593) (1,185) (15,629)
Research and development expenses (3,438) (474) (4,330)
Impairment of intangible assets (7,911)
Impairment of goodwill (12,758)
Loss from operations (14,167) (1,953) (42,141)
Non-operating income and expenses:      
Interest expense, net (81) (11) (161)
Foreign exchange gain, net 9 1 7
Share of net loss in equity method investments (88) (12) (87)
Other income, net 3,106 428 472
Loss from operations for discontinued operations (11,221) (1,547) (41,910)
Loss from disposal of a subsidiary (16,724) (2,307)
Loss from discontinued operations before income taxes (27,945) (3,854) (41,910)
Income tax benefit 2,130
Net Loss from discontinued operations (27,945) (3,854) (39,780)
Revenues-Third Parties      
Revenues:      
Revenues parties 2,937 405 3,972
Revenues-Related Parties      
Revenues:      
Revenues parties ¥ 91 $ 13 ¥ 1,241
XML 65 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations - Discontinued Operations [Member]
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Current assets:      
Cash and cash equivalents ¥ 319 $ 44 ¥ 1,854
Prepayment 1,334 184 2,692
Accounts receivable, net 3,318 458 2,235
Amounts due from related parties, net 684 94 2,194
Inventories, net 178 25 210
Other current assets, net 3,944 543 3,448
Total current assets held for sale 9,777 1,348 12,633
Property and equipment, net 15,746 2,171 17,182
Land use rights, net 1,097 151 1,111
Intangible assets, net 271 37 185
Right of use assets 2,088 288 7,213
Long-term investments, net 991 138 1,079
Total noncurrent assets held for sale 20,193 2,785 26,770
TOTAL ASSETS HELD FOR SALE 29,970 4,133 39,403
Current liabilities:      
Short-term debts 5,000 690 5,000
Accounts payable 2,012 277 2,108
Advance from customers 7,800 1,076 4,956
Amounts due to related parties 1,079 149 2,280
Lease liability-current 1,042 144 784
Accrued expenses and other current liabilities 16,488 2,273 18,386
Total current liabilities held for sale 33,421 4,609 33,514
Lease liability-non-current 1,368 189 6,515
Other long-term liabilities 1,066 147 1,080
Total noncurrent liabilities held for sale 2,434 336 7,595
TOTAL LIABILITIES HELD FOR SALE ¥ 35,855 $ 4,945 ¥ 41,109
XML 66 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Receivable, Net (Details) - Schedule of Accounts Receivable
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule of Accounts Receivable [Abstract]      
Accounts receivable ¥ 270 $ 37
Allowance for credit losses
Balance at end of year ¥ 270 $ 37
XML 67 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Other Current Assets, Net (Details) - Schedule of Other Current Assets
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Jun. 30, 2023
USD ($)
Schedule of Other Current Assets [Abstract]        
Deposits ¥ 154   $ 21
Receivable from private placement investors 260 $ 36  
Loan to third-parties 444   422 61
Total 858   422 118
Allowance for credit losses (444)   (422) (61)
Other current assets, net ¥ 414   $ 57
XML 68 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment, Net (Details)
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 62 ¥ 449
XML 69 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net Consists
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule Of Property And Equipment Net Consists Abstract      
Furniture, fixtures and equipment ¥ 3,255 $ 448
Motor vehicles 2,007 277
Total 5,262 725
Less: accumulated depreciation (953) (131)
Property and equipment, net ¥ 4,309 $ 594
XML 70 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net (Details)
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Intangible Assets, Net [Abstract]      
Amortization expense ¥ 2,511 $ 346
Estimated aggregate amortization expense year 5 years 5 years  
XML 71 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net (Details) - Schedule of Intangible Assets Net
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Finite-Lived Intangible Assets [Line Items]      
Total ¥ 47,798 $ 6,592
Less: accumulated amortization (2,629) (363)
Intangible assets, net 45,169 6,229
Software [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total ¥ 47,798 $ 6,592
XML 72 R64.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible Assets, Net (Details) - Schedule of Estimated Aggregate Amortization Expense
¥ in Thousands
Jun. 30, 2023
CNY (¥)
Schedule Of Estimated Aggregate Amortization Expense Abstract  
2024 ¥ 8,351
2025 8,351
2026 8,351
2027 8,351
2028 6,226
Thereafter 5,539
Total ¥ 45,169
XML 73 R65.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Investments, Net (Details)
6 Months Ended
May 15, 2021
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
May 24, 2023
CNY (¥)
May 24, 2023
USD ($)
Long-Term Investments, Net (Details) [Line Items]          
Capital amount       ¥ 39,882 $ 5,500
voting units description       Mr. Xu holds 8,036 voting units in Nassau Mr. Xu holds 8,036 voting units in Nassau
Full impairment loss   ¥ 95,000 $ 13    
Advanced Life Therapeutics Co., Ltd. (“Advanced Life”) [Member]          
Long-Term Investments, Net (Details) [Line Items]          
Registered capital, percentage 40.00%        
Equity interest 40.00%        
Nassau Enterprises LLC (“Nassau”) [Member]          
Long-Term Investments, Net (Details) [Line Items]          
Percentage of investment, owned   19.64% 19.64% 80.36% 80.36%
XML 74 R66.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Investments, Net (Details) - Schedule of Long-Term Investments
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule of Equity Method Investments [Line Items]      
Equity method investments ¥ 39,783 $ 5,486
Less: Impairment
Long-term investments, net 39,783 5,486
Advanced Life Therapeutics Co., Ltd. (“Advanced Life”) [Member]      
Schedule of Equity Method Investments [Line Items]      
Equity method investments
Nassau Enterprises LLC (“Nassau”) [Member]      
Schedule of Equity Method Investments [Line Items]      
Equity method investments ¥ 39,783 $ 5,486
XML 75 R67.htm IDEA: XBRL DOCUMENT v3.23.3
Short-Term Debts (Details)
$ / shares in Units, $ in Thousands
6 Months Ended
Mar. 31, 2023
CNY (¥)
Apr. 27, 2022
CNY (¥)
Mar. 16, 2022
CNY (¥)
shares
Dec. 10, 2021
CNY (¥)
shares
Jul. 22, 2021
CNY (¥)
Jul. 22, 2021
USD ($)
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Feb. 05, 2022
$ / shares
Jul. 22, 2021
USD ($)
Short-Term Debts (Details) [Line Items]                      
Aggregate principal amount         ¥ 20,788,000           $ 3,014
Discounted value         ¥ 18,898,000 $ 2,740          
Fixed interest rate         0.00%           0.00%
Conversion price ¥ 160         $ 15          
Consecutive trading days         10 10          
Conversion price | $           $ 1          
Converted shares       114,234              
Principal balance of debt converted | ¥       ¥ 1,321,000              
Number of shares issued upon conversion of loan     4,842,197                
Debt conversion   ¥ 5,502,000 ¥ 22,237,000       ¥ 16,000 $ 2      
Convertible debentures outstanding             ¥ 16,000 2      
Convertible debenture               ¥ 139,000    
Maximum [Member]                      
Short-Term Debts (Details) [Line Items]                      
Bid price percentage         82.00% 82.00%          
Minimum [Member]                      
Short-Term Debts (Details) [Line Items]                      
Bid price percentage         80.00% 80.00%          
Class A Ordinary Shares [Member]                      
Short-Term Debts (Details) [Line Items]                      
Conversion price per share | $ / shares                   $ 0.1  
XML 76 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Short-Term Debts (Details) - Schedule of Short-Term Debts
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule Of Short Term Debts Abstract      
Convertible loan (“CL”) [1] ¥ 16 $ 2 ¥ 15
Total ¥ 16 $ 2 ¥ 15
[1] On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were originally due in one year and bear interest of 0% per annum if the conversion feature is not triggered. Pursuant to the agreement, the conversion price is lower of (i) US$15 or (ii) the lower of 82% of the closing bid price or 80% of VWAP of the Company’s ADSs during the ten consecutive trading days immediately preceding conversion, but not lower than a Floor Price of US$1 (the “floor price”). Due to significant drop of the ADS market price in 2022, the debenture holders and the Company renegotiated the Floor Price. On February 5, 2022, the Company entered into an amendment agreement, pursuant to which the Floor Price was reduced to US$0.10 per Class A Ordinary Share. The Company has elected to recognize the Convertible Debentures at fair value and therefore there was no further evaluation of embedded features for bifurcation. The Convertible Debentures were partially converted into 114,234 shares on December 10, 2021. The fair value of the Convertible Debentures loan immediately prior to conversion was assessed at RMB1,321. Substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares (refer to Note 14) on March 16, 2022. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).
XML 77 R69.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details) - Schedule of Operating Leases
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule of Operating Leases [Abstract]      
Right-of-use assets, net ¥ 223 $ 31
Operating lease liabilities - current 148 20
Operating lease liabilities - non-current 37 5
Total operating lease liabilities ¥ 185 $ 25
XML 78 R70.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates
Jun. 30, 2023
Schedule of Weighted Average Remaining Lease Terms and Discount Rates [Abstract]  
Weighted average remaining lease term (years) 1 year 6 months 3 days
Weighted average discount rate 4.75%
XML 79 R71.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details) - Schedule of Maturities of Lease Liabilities
¥ in Thousands
Jun. 30, 2023
CNY (¥)
Schedule of Maturities of Lease Liabilities [Abstract]  
2024 ¥ 150
2025 37
Total future minimum lease payments 187
Less: imputed interest (2)
Total ¥ 185
XML 80 R72.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]      
Salary and welfare payable ¥ 9,312 $ 1,283 ¥ 1,740
Accrued expenses [1] 9,057 1,249 5,762
Payable for property and equipment 2,301 318
Other payables 4,089 564 33
Total ¥ 24,759 $ 3,414 ¥ 7,535
[1] the accrued expenses mainly consist of accrued professional fees.
XML 81 R73.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity (Details)
1 Months Ended 6 Months Ended 12 Months Ended
Jun. 09, 2023
shares
May 11, 2023
CNY (¥)
shares
May 11, 2023
USD ($)
shares
Mar. 31, 2023
CNY (¥)
shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Feb. 14, 2023
$ / shares
shares
Feb. 08, 2023
CNY (¥)
shares
Feb. 08, 2023
USD ($)
shares
Feb. 01, 2023
CNY (¥)
shares
Feb. 01, 2023
USD ($)
shares
Dec. 31, 2022
CNY (¥)
shares
Sep. 26, 2022
CNY (¥)
shares
Sep. 26, 2022
USD ($)
shares
Sep. 02, 2022
CNY (¥)
shares
Sep. 02, 2022
CNY (¥)
$ / shares
Jun. 10, 2022
CNY (¥)
shares
Jun. 10, 2022
USD ($)
shares
May 19, 2022
CNY (¥)
May 19, 2022
USD ($)
Apr. 27, 2022
CNY (¥)
Mar. 30, 2022
CNY (¥)
Mar. 30, 2022
USD ($)
Mar. 16, 2022
CNY (¥)
shares
Mar. 16, 2022
USD ($)
$ / shares
shares
Dec. 10, 2021
shares
Jul. 22, 2021
CNY (¥)
Jul. 22, 2021
USD ($)
Jul. 28, 2020
shares
Oct. 14, 2019
$ / shares
shares
Oct. 30, 2023
shares
Aug. 31, 2022
CNY (¥)
shares
May 27, 2022
CNY (¥)
May 27, 2022
USD ($)
$ / shares
shares
Mar. 16, 2022
CNY (¥)
Mar. 16, 2022
USD ($)
$ / shares
shares
Jun. 30, 2023
CNY (¥)
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
CNY (¥)
shares
Aug. 10, 2023
$ / shares
Jun. 01, 2023
USD ($)
Mar. 10, 2023
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Sep. 16, 2022
shares
Sep. 02, 2022
$ / shares
Aug. 31, 2022
USD ($)
May 30, 2022
shares
Mar. 29, 2022
$ / shares
shares
Shareholders' Equity (Details) [Line Items]                                                                                              
Number of shares authorized                                                         150,000,000                                    
Ordinary shares, shares issued                                                                         17,665,702                    
Principal amount       ¥ 4,479,000                                           ¥ 20,788,000 $ 3,014,000                                        
Discounted price                                                   ¥ 18,898,000 2,740,000                                        
Converted shares                                                                       12,779,670 12,779,670                    
Debt conversion                                       ¥ 5,502,000     ¥ 22,237,000                         ¥ 16,000 $ 2,000                    
Shares issued                                               30,885,707                     30,885,707                        
Conversion loan (in Yuan Renminbi)       ¥ 160                                             $ 15,000                                        
Service agreement pay (in Dollars) | $                                                                               $ 50,000              
Fair value   ¥ 6,385,000 $ 919,000                         ¥ 359,000 $ 54,000                                                            
Share issued                                                                                 13,000,000            
fair market value                                                             ¥ 1,341,000                           $ 195,000    
Price per share (in Dollars per share) | $ / shares                                                                 $ 0.3                            
Gross proceeds                       ¥ 26,410,000 $ 3,660,000 ¥ 3,613,000                                                                  
Investment amount                                                               ¥ 20,094,000 $ 3,000,000                            
Trading percentage                                                               80.00% 80.00%                            
Purchase of aggregate shares                     1,200,000                                                     1,200,000       1,200,000          
Price per share (in Dollars per share) | $ / shares                                                                                   $ 0.75   $ 0.1      
Total consideration | $                                                                                   $ 1,507,000          
Purchased shares                           5,000,000                                                                  
Warrants exercisable term                           2 years                                           2 years 2 years                    
Proceeds received                                                                       ¥ 36,608 $ 5,369                    
(in Dollars per share) | $ / shares                                                                             $ 1                
Shareholders' equity, description                                                                       On April 6, 2023, the Company closed a registered direct offering (the “April 2023 private placement”), the Company sold to the institutional investors a total of 12,500,000 Class A ordinary shares priced at $0.2 per ordinary share, pre-funded warrants exercisable for 2,500,000 Class A ordinary shares and warrants exercisable for 15,000,000 Class A ordinary shares. The purchase price of each pre-funded warrant is equal to the offering price per Class A ordinary shares, minus $0.00005, and the exercise price of each pre-funded warrant is equal $0.00005 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The warrants are immediately exercisable and expire five (5) years from the original issuance date and have an exercise price of $0.2 per Class A ordinary shares. The Company also issued to Univest Securities, LLC, which acted as the sole placement agent for the offering, warrants exercisable for 750,000 Class A ordinary shares, with an exercise price of $0.24 per share. The net proceeds to the Company from the registered direct offering were RMB17,238 (US$2,510) after deducting the placement agent’s fees and other offering expenses. No pre-funded warrants were exercised during the six months ended June 30, 2023, and 5,000,000 warrants were exercised with proceeds of RMB6,911(US$1,000) during the six months ended June 30, 2023. On April 6, 2023, the Company closed a registered direct offering (the “April 2023 private placement”), the Company sold to the institutional investors a total of 12,500,000 Class A ordinary shares priced at $0.2 per ordinary share, pre-funded warrants exercisable for 2,500,000 Class A ordinary shares and warrants exercisable for 15,000,000 Class A ordinary shares. The purchase price of each pre-funded warrant is equal to the offering price per Class A ordinary shares, minus $0.00005, and the exercise price of each pre-funded warrant is equal $0.00005 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The warrants are immediately exercisable and expire five (5) years from the original issuance date and have an exercise price of $0.2 per Class A ordinary shares. The Company also issued to Univest Securities, LLC, which acted as the sole placement agent for the offering, warrants exercisable for 750,000 Class A ordinary shares, with an exercise price of $0.24 per share. The net proceeds to the Company from the registered direct offering were RMB17,238 (US$2,510) after deducting the placement agent’s fees and other offering expenses. No pre-funded warrants were exercised during the six months ended June 30, 2023, and 5,000,000 warrants were exercised with proceeds of RMB6,911(US$1,000) during the six months ended June 30, 2023.                    
Shares, issued       17,665,702 17,665,702   5,440,420 5,440,420 8,785,530 8,785,530                                                                          
Equity interest, percentage             100.00% 100.00% 100.00% 100.00%                                                                          
Fair value shares amount       ¥ 25,720 $ 3,745   ¥ 17,304 $ 2,549 ¥ 25,938 $ 3,848                                                                          
Minimum [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Number of shares authorized           150,000,000                                                                                  
Prices, Per share (in Dollars per share) | $ / shares         $ 0.33                                                                                    
Maximum [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Number of shares authorized           2,430,000,000                                                                                  
Warrant [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Purchase of aggregate shares                     750,000                                                     750,000       750,000          
Price per share (in Dollars per share) | $ / shares                                                                                   $ 1.2          
Shares, outstanding       103,702,658 103,702,658                                                                                    
Private Placements [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Pre-funded warrants                                                                       2,584,900 2,584,900                    
Investing amount (in Yuan Renminbi) | ¥                           ¥ 3,613,000 ¥ 3,613,000                                                                
Shareholders' equity, description                                                                       On June 2, 2023, the Company entered into an agreement with an investor, under which the investor agreed to purchase 22,000,000 Class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares at an aggregate purchase price of US$4,400 (the “June 2023 private placement”). The warrants are exercisable within 2 years from the date of issuance and have an exercise price of US$0.21 per share. On June 9, 2023, the Company issued 22,000,000 Class A ordinary shares to the investor, proceeds of RMB27,797 (US$3,900) were received by June 30, 2023. Due to inability to timely collect the remaining proceeds of RMB3,564(US$500) from the investor, the corresponding 2,500,000 shares was recalled and cancelled on October 30, 2023, subsequently. No warrants were exercised during the six months ended June 30, 2023. On June 2, 2023, the Company entered into an agreement with an investor, under which the investor agreed to purchase 22,000,000 Class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares at an aggregate purchase price of US$4,400 (the “June 2023 private placement”). The warrants are exercisable within 2 years from the date of issuance and have an exercise price of US$0.21 per share. On June 9, 2023, the Company issued 22,000,000 Class A ordinary shares to the investor, proceeds of RMB27,797 (US$3,900) were received by June 30, 2023. Due to inability to timely collect the remaining proceeds of RMB3,564(US$500) from the investor, the corresponding 2,500,000 shares was recalled and cancelled on October 30, 2023, subsequently. No warrants were exercised during the six months ended June 30, 2023.                    
Class A Ordinary Shares [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Number of shares authorized                     2,400,000,000                                                   2,400,000,000 2,400,000,000       2,400,000,000          
Ordinary shares           2,400,000,000                                             120,000,000                                    
Par value (in Dollars per share) | $ / shares           $ 0.01                                             $ 0.01                                    
Ordinary shares, shares outstanding                     79,536,589                                                   176,070,465 79,536,589       79,536,589          
Ordinary shares, shares issued                     79,536,589                                                   176,070,465 79,536,589       79,536,589          
Converted shares                                             4,842,197 4,842,197 114,234                                            
Shares issued       3,232,397 3,232,397                                                                                    
Company issued                               187,094 187,094                                                            
Ordinary shares granted                                                             140,000                                
Share issued                       36,729,613 36,729,613                                                           140,000        
Service agreement   3,500,000 3,500,000                                                 3,500,000                                      
Company deposited                     1,322,853                                                                        
Stockholders equity                                                                       22,000,000 22,000,000                    
Ordinary shares issued 2,500,000                                                                     3,822,853 3,822,853                    
Price per share (in Dollars per share) | $ / shares                                                                                       $ 0.1      
Purchase of aggregate shares                     3,000,000                                                     3,000,000       3,000,000          
Price per share (in Dollars per share) | $ / shares                                                                                   $ 0.4          
Warrants purchase                                                                           2,475,000                  
Total consideration | ¥                     ¥ 11,003,000                                                     ¥ 11,003,000                  
Purchased shares                           5,000,000                                                                  
Exercise price (in Dollars per share) | $ / shares                             ¥ 0.4                                                                
Convertible debentures                                                                   ¥ 175 $ 5,405,000                        
Exercise price per share (in Dollars per share) | $ / shares                                                                             $ 0.21                
Class B Ordinary Shares [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Number of shares authorized                     30,000,000                                                   30,000,000 30,000,000       30,000,000          
Ordinary shares           30,000,000                                             30,000,000                                    
Par value (in Dollars per share) | $ / shares           $ 0.01                                             $ 0.01                                    
Ordinary shares, shares outstanding                     3,573,100                                                   3,573,100 3,573,100       3,573,100          
Ordinary shares, shares issued                     3,573,100                                                   3,573,100 3,573,100       3,573,100          
Forecast [Member] | Class A Ordinary Shares [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Ordinary shares issued                                                           2,500,000                                  
Investor [Member] | Class A Ordinary Shares [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Share issued                                               1,235,788                 6,229,235   1,235,788   4,226,135                 6,263,048 654,622
Price per share (in Dollars per share) | $ / shares                                               $ 0.2563                     $ 0.2563   $ 0.2563                   $ 0.35
Gross proceeds                                         ¥ 1,500,000 $ 232,000   $ 0.01000                                              
Total gross proceeds                                   ¥ 9,395,000 $ 1,400,000                                                        
Nine investors [Member] | Class A Ordinary Shares [Member]                                                                                              
Shareholders' Equity (Details) [Line Items]                                                                                              
Share issued                     12,492,283                                                     12,492,283       12,492,283          
XML 82 R74.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity (Details) - Sechedule of Warrants Activity - $ / shares
6 Months Ended
Dec. 31, 2022
Jun. 30, 2023
Class of Warrant or Right [Line Items]    
Number of warrants, Balance of warrants outstanding as of December 31, 2020 and 2021 (in Shares) 9,266,135  
Weighted average exercise price per share, warrants issued in connection with the March 16, 2022 private placement $ 0.24  
Weighted average life, warrants issued in connection with the September 2, 2022 private placement 1 year 10 months 6 days  
Expiration dates, warrants issued to 3rd party service providers  
Number of warrants, warrants issued in connection with the March 16, 2022 private placement (in Shares)   61,771,423
Weighted average exercise price per share, warrants issued in connection with the March 16, 2022 private placement   $ 0.21
Expiration dates, warrants issued in connection with the March 16, 2022 private placement   February 3, 2025 to June 16, 2025
Number of warrants, warrants issued in connection with the September 2, 2022 private placement (in Shares)   18,250,000
Weighted average life, warrants issued in connection with the September 2, 2022 private placement   1 year 9 months
Expiration dates, warrants issued in connection with the September 2, 2022 private placement   March 31, 2025 to unlimited
Number of warrants, warrants issued in connection with the June 2023 private placement (in Shares)   22,000,000
Weighted average exercise price per share, warrants issued in connection with the June 2023 private placement   $ 0.21
Weighted average life, warrants issued in connection with the June 2023 private placement   1 year 11 months 12 days
Expiration dates, warrants issued in connection with the June 2023 private placement   Jun. 09, 2025
Number of warrants, Exercised (in Shares)   (7,584,900)
Number of warrants, Balance of warrants outstanding and exercisable as of December 31, 2022 (in Shares)   103,702,658
Weighted average exercise price per share, Balance of warrants outstanding and exercisable as of December 31, 2022   $ 0.21
Weighted average life, Balance of warrants outstanding and exercisable as of December 31, 2022   1 year 11 months 15 days
Expiration dates, Balance of warrants outstanding and exercisable as of December 31, 2022   August 31, 2024 to unlimited
Minimum [Member]    
Class of Warrant or Right [Line Items]    
Weighted average life, warrants issued in connection with the March 16, 2022 private placement   1 year 6 months 29 days
Weighted average exercise price per share, warrants issued in connection with the September 2, 2022 private placement   $ 0.00001
Weighted average exercise price per share, Exercised   $ 0.00001
Maximum [Member]    
Class of Warrant or Right [Line Items]    
Weighted average life, warrants issued in connection with the March 16, 2022 private placement   1 year 11 months 15 days
Weighted average exercise price per share, warrants issued in connection with the September 2, 2022 private placement   $ 0.24
Weighted average exercise price per share, Exercised   $ 0.2
XML 83 R75.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Details)
1 Months Ended 6 Months Ended 12 Months Ended
Apr. 14, 2022
shares
Mar. 16, 2022
shares
Dec. 10, 2021
shares
Jan. 31, 2023
shares
Aug. 28, 2022
shares
Oct. 31, 2019
shares
Jun. 30, 2023
CNY (¥)
shares
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2022
CNY (¥)
Dec. 31, 2022
shares
Mar. 10, 2023
shares
Sep. 26, 2022
shares
Sep. 16, 2022
shares
Jul. 05, 2021
shares
Share Based Compensation [Line Items]                            
Share options purchase                   182,593        
Shares subject plan         4,700,000                  
Granted to employees year term                   4 years        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures       4,000,000                    
Shares issued                     13,000,000      
Rsu shares             41,000,000 41,000,000            
Conversion shares             12,779,670 12,779,670            
Restricted stock expense             ¥ 32,310 $ 4,456            
Forfeited shares             2,199,006 2,199,006            
Outstandingof shares             12,321,218 12,321,218            
Share-Based Payment Arrangement, Expense             ¥ 2,872 $ 396            
Minimum [Member]                            
Share Based Compensation [Line Items]                            
Related option agreements             1 year 1 year            
Maximum [Member]                            
Share Based Compensation [Line Items]                            
Related option agreements             4 years 4 years            
Class A Ordinary Shares [Member]                            
Share Based Compensation [Line Items]                            
Share options purchase 2,800,000         1,105,300                
Shares issued                           1,885,300
Shares issued                       36,729,613 140,000  
Conversion shares   4,842,197 114,234                      
Employees [Member]                            
Share Based Compensation [Line Items]                            
Total fair value of the equity awards vested             ¥ 894,000 $ 123,000 ¥ 2,962,000          
Total unrecognized employee share-based compensation expense             ¥ 2,525,000 $ 348,000            
Weighted-average period             7 months 6 days 7 months 6 days            
Non Employees [Member]                            
Share Based Compensation [Line Items]                            
Related option agreements             9 years 3 months 7 days 9 years 3 months 7 days            
Total fair value of the equity awards vested | ¥               ¥ 1,566,000          
RSU [Member]                            
Share Based Compensation [Line Items]                            
Forfeited shares             458,452 458,452            
XML 84 R76.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Details) - Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument [Abstract]  
Number of Options, outstanding ending balance (in Shares) | shares 2,334,906
Weighted Average Exercise Price, outstanding ending balance $ 1.69
Weighted Average Grant date Fair Value, outstanding ending balance $ 5,080.00
Weighted Average Remaining Contractual Term, outstanding ending balance 8 years 18 days
Aggregate Intrinsic Value, outstanding ending balance (in Dollars) | $ $ 452
Number of Options Granted (in Shares) | shares
Weighted Average Exercise Price Granted
Weighted Average Grant date Fair Value Granted
Weighted Average Remaining Contractual Term Granted
Aggregate Intrinsic Value Granted (in Dollars) | $
Number of Options Exercised (in Shares) | shares (13,900)
Weighted Average Exercise Price Exercised $ 0.05
Weighted Average Grant date Fair Value Exercised $ 50.00
Weighted Average Remaining Contractual Term Exercised 2 months 19 days
Aggregate Intrinsic Value Exercised (in Dollars) | $
Number of Options, outstanding ending balance (in Shares) | shares 2,321,006
Weighted Average Exercise Price, outstanding ending balance $ 1.7
Weighted Average Grant date Fair Value, outstanding ending balance $ 2,320
Weighted Average Remaining Contractual Term, outstanding ending balance 7 years 6 months 14 days
Aggregate Intrinsic Value, outstanding ending balance (in Dollars) | $ $ 306
Number of Options Vested and exercisable (in Shares) | shares 2,199,006
Weighted Average Exercise Price Vested and exercisable $ 1.41
Weighted Average Grant date Fair Value Vested and exercisable $ 2,080.00
Weighted Average Remaining Contractual Term Vested and exercisable 7 years 6 months 14 days
Aggregate Intrinsic Value Vested and exercisable (in Dollars) | $ $ 306
XML 85 R77.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument - Non Employees [Member]
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument [Line Items]  
Number of Options, Outstanding Beginning balance (in Shares) | shares 2,651,700
Weighted Average Exercise Price, Outstanding Beginning balance $ 0.86
Weighted Average Grant date Fair Value, Outstanding Beginning balance $ 0.85
Weighted Average Remaining Contractual Term, Outstanding Beginning balance 9 years 3 months 7 days
Aggregate Intrinsic Value, Outstanding Beginning balance (in Dollars) | $ $ 532
Number of Options, Granted (in Shares) | shares
Weighted Average Exercise Price, Granted
Weighted Average Grant date Fair Value, Granted
Weighted Average Remaining Contractual Term, Granted (in Shares) | shares
Aggregate Intrinsic Value, Granted (in Dollars) | $
Number of Options, Exercised (in Shares) | shares (650,000)
Weighted Average Exercise Price, Exercised $ 0.05
Weighted Average Grant date Fair Value, Exercised $ 0.05
Weighted Average Remaining Contractual Term, Exercised (in Shares) | shares 0.22
Aggregate Intrinsic Value, Exercised (in Dollars) | $
Number of Options, Forfeited (in Shares) | shares (20,000)
Weighted Average Exercise Price, Forfeited
Weighted Average Grant date Fair Value,
Forfeited (in Shares) | shares
Aggregate Intrinsic Value, (in Dollars) | $
Number of Options, Outstanding Beginning balance (in Shares) | shares 1,981,700
Weighted Average Exercise Price, Outstanding Beginning balance $ 1.13
Weighted Average Grant date Fair Value, Outstanding Beginning balance $ 1.04
Weighted Average Remaining Contractual Term, Outstanding Beginning balance 8 years 8 months 26 days
Aggregate Intrinsic Value, Outstanding Beginning balance (in Dollars) | $ $ 315
Number of Options, Vested and Exercisable (in Shares) | shares 1,981,700
Weighted Average Exercise Price, Vested and Exercisable $ 1.13
Weighted Average Grant date Fair Value, Vested and Exercisable $ 1
Weighted Average Remaining Contractual Term, Vested and Exercisable 8 years 8 months 26 days
Aggregate Intrinsic Value, Vested and Exercisable (in Dollars) | $ $ 315
XML 86 R78.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued - Minimum [Member] - $ / shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued [Line Items]    
Risk-free interest rate 0.34%
Expected volatility range 100.20%
Fair market value per ordinary share as at grant dates (in Dollars per share) $ 0.29
XML 87 R79.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Details) - Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Schedule of Share Based Compensation Expense Included in Each of the Relevant Financial Statement [Abstract]      
Selling and marketing expenses ¥ 1,712 $ 236 ¥ 705
Research and development expenses 818 113 1,263
General and administrative expenses 1,236 170 2,560
Total share-based compensation expenses ¥ 3,766 $ 519 ¥ 4,528
XML 88 R80.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details)
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Income Taxes (Details) [Line Items]      
Statutory income tax rate 21.00% 21.00% 21.00%
Taxable income (in Yuan Renminbi) ¥ 1,000   ¥ 1,000
Taxable income percentage 12.50% 12.50% 12.50%
Enterprise income tax rate percentage 20.00% 20.00%  
Taxable income does not exceeds (in Yuan Renminbi) ¥ 3,000    
Withholding tax percentage 10.00% 10.00%  
U.S. federal corporate income tax percentage     21.00%
Operating loss ¥ (43,156) $ (5,951) ¥ (8,630)
U.S. Federal [Member]      
Income Taxes (Details) [Line Items]      
Statutory income tax rate 80.00% 80.00%  
United States [Member]      
Income Taxes (Details) [Line Items]      
Income tax percentage 21.00% 21.00% 21.00%
New York [Member]      
Income Taxes (Details) [Line Items]      
Income tax percentage 6.50% 6.50% 6.50%
Deleware [Member]      
Income Taxes (Details) [Line Items]      
Income tax percentage 8.70% 8.70% 8.70%
Hong Kong [Member]      
Income Taxes (Details) [Line Items]      
Operating loss ¥ 307 $ 42  
PRC [Member]      
Income Taxes (Details) [Line Items]      
Taxable income percentage 25.00% 25.00%  
Non-PRC [Member]      
Income Taxes (Details) [Line Items]      
Adjusted tax loss before income taxes ¥ 33,198 $ 4,578  
Interest Income [Member]      
Income Taxes (Details) [Line Items]      
Enterprise income tax rate percentage 20.00% 20.00%  
Fresh 2 Technology Inc [Member]      
Income Taxes (Details) [Line Items]      
U.S. federal corporate income tax percentage 21.00% 21.00%  
PRC [Member]      
Income Taxes (Details) [Line Items]      
Statutory income tax rate 25.00% 25.00%  
Net operating losses ¥ 10,342 $ 1,426  
XML 89 R81.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - Schedule of Loss Before Income Taxes
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Income Taxes (Details) - Schedule of Loss Before Income Taxes [Line Items]      
Total ¥ (43,539) $ (6,004) ¥ (9,035)
Non-US [Member]      
Income Taxes (Details) - Schedule of Loss Before Income Taxes [Line Items]      
Total (23,507) (3,241) (9,035)
US [Member]      
Income Taxes (Details) - Schedule of Loss Before Income Taxes [Line Items]      
Total ¥ (20,032) $ (2,763)
XML 90 R82.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - Schedule of Current and Deferred Components of Income Tax Benefit
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Schedule of Current and Deferred Components of Income Tax Benefit [Abstract]      
Current tax expense
Deferred tax benefit 79 11
Total ¥ 79 $ 11
XML 91 R83.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate [Abstract]      
Loss before income taxes ¥ (43,539) $ (6,004) ¥ (9,035)
Income tax benefit computed at the statutory income tax rate at 21% 9,142 1,261 (1,897)
International rate differences (4,726) (652) ¥ 1,897
Change in valuation allowance (4,337) (598)  
Income tax benefit ¥ 79 $ 11  
XML 92 R84.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate (Parentheticals)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate [Abstract]    
Statutory income tax rate 21.00% 21.00%
XML 93 R85.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - Schedule of Significant Components of Deferred Taxes
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Schedule Of Significant Components Of Deferred Taxes Abstract      
Net loss carryforward ¥ 9,608 $ 1,325 ¥ 1,900
Valuation allowance (9,608) (1,325) (1,900)
Total deferred tax assets.
Long-lived assets arising from acquisitions 2,938 405
Total deferred tax liabilities. ¥ 2,938 $ 405
XML 94 R86.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational
6 Months Ended
Jun. 30, 2023
Haohan Xu [Member]  
Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Line Items]  
Nature of the party Individual
Relationship with the Group Chief Executive Officer
Apifiny Inc.[Member]  
Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Line Items]  
Nature of the party Investment management
Relationship with the Group Controlled by Haohan Xu
Roxe Holding Inc.[Member]  
Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Line Items]  
Nature of the party Investment management
Relationship with the Group Controlled by Haohan Xu
Dr. Chris Chang Yu [Member]  
Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Line Items]  
Nature of the party Individual [1]
Relationship with the Group Co-Founder and shareholder [1]
CRS Holdings Inc. [Member]  
Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Line Items]  
Nature of the party Investor
Relationship with the Group Controlled by Dr. Chris Chang Yu
Jiaxing Zhijun Sihang Investment Partnership Enterprises [Member]  
Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Line Items]  
Nature of the party Private equity investment
Relationship with the Group Shareholder, due to diluted equity interest, no longer a related party for the six months ended June 30 2023
[1] Dr. Yu resigned from his position as the Chief Executive Officer (“CEO”) of the Company and Chairman of the Board on April 6, 2022 and was appointed as Co-Chairman and Co-CEO in May 2022. On May 17, 2023, Dr. Yu resigned as the Co-Chief Executive Officer of the Company.
XML 95 R87.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]      
Due from related parties, net ¥ 864 $ 119
Due to related parties 592 82 1,214
Related Party [Member]      
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]      
Due from related parties, net 864 119
Related Party [Member] | Apifiny Inc.[Member]      
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]      
Due from related parties, net 211 29
Related Party [Member] | Roxe Holding Inc.[Member]      
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]      
Due from related parties, net 363 50
Related Party [Member] | Dr. Chris Chang Yu [Member]      
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]      
Due from related parties, net 290 40
Related Party [Member] | CRS Holdings Inc.[Member]      
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]      
Due to related parties 592 82 287
Related Party [Member] | Jiaxing Zhijun Investment Management Co., Ltd. (“Zhijun”) [Member]      
Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]      
Due to related parties ¥ 927
XML 96 R88.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Balances (Details) - Schedule of Accounts Receivables
¥ in Thousands, $ in Thousands
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Variable Interest Entity [Line Items]      
Accounts receivables-related parties ¥ 11,450 $ 1,579
Related Party [Member] | Apifiny Inc.[Member]      
Variable Interest Entity [Line Items]      
Accounts receivables-related parties 3,525 486
Related Party [Member] | Roxe Holding Inc.[Member]      
Variable Interest Entity [Line Items]      
Accounts receivables-related parties ¥ 7,925 $ 1,093
XML 97 R89.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions and Balances (Details) - Schedule of Related Party Transactions
¥ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
CNY (¥)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
CNY (¥)
Related Party Transaction [Line Items]      
Related party transactions ¥ 624 $ 86 ¥ 32
AnPac Beijing [Member]      
Related Party Transaction [Line Items]      
Related party transactions 970 134
Xudong Du [Member]      
Related Party Transaction [Line Items]      
Related party transactions ¥ 464 $ 64
XML 98 R90.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events (Details)
¥ in Thousands
1 Months Ended 6 Months Ended
Nov. 06, 2023
Sep. 25, 2023
USD ($)
Jul. 17, 2023
Jul. 27, 2023
Jun. 30, 2023
CNY (¥)
shares
Sep. 29, 2023
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
CNY (¥)
Subsequent Events (Details) [Line Items]                
Cash             $ 60,000,000  
Ordinary share and warrants, description         (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date  and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment RMB1,697(US$234) from this offering, excluding related financing costs.      
Class A Ordinary Shares [Member]                
Subsequent Events (Details) [Line Items]                
Aggregate shares (in Shares) | shares         110,476,291      
Value of share issued         ¥ 12,181   $ 1,680,000 ¥ 5,494
Subsequent Event [Member]                
Subsequent Events (Details) [Line Items]                
Purchase percentage     51.00%          
Definitive share purchase agreement       100.00%        
Issued and outstanding equity interests   $ 2,000,000            
Forecast [Member]                
Subsequent Events (Details) [Line Items]                
Definitive share purchase agreement 38.61%              
One Individual [Member] | Forecast [Member] | Class A Ordinary Shares [Member]                
Subsequent Events (Details) [Line Items]                
Value of share issued           $ 38.61    
XML 99 ea189176-6ka1_fresh2_htm.xml IDEA: XBRL DOCUMENT 0001786511 2023-01-01 2023-06-30 0001786511 2022-12-31 0001786511 2023-06-30 0001786511 us-gaap:RelatedPartyMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember 2023-06-30 0001786511 us-gaap:CommonClassAMember 2022-12-31 0001786511 us-gaap:CommonClassAMember 2023-06-30 0001786511 us-gaap:CommonClassBMember 2022-12-31 0001786511 us-gaap:CommonClassBMember 2023-06-30 0001786511 2022-01-01 2022-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001786511 us-gaap:TreasuryStockCommonMember 2021-12-31 0001786511 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001786511 us-gaap:RetainedEarningsMember 2021-12-31 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2021-12-31 0001786511 us-gaap:NoncontrollingInterestMember 2021-12-31 0001786511 2021-12-31 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001786511 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2022-01-01 2022-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2022-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001786511 us-gaap:RetainedEarningsMember 2022-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2022-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2022-06-30 0001786511 2022-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001786511 us-gaap:TreasuryStockCommonMember 2022-12-31 0001786511 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001786511 us-gaap:RetainedEarningsMember 2022-12-31 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2022-12-31 0001786511 us-gaap:NoncontrollingInterestMember 2022-12-31 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001786511 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2023-01-01 2023-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-06-30 0001786511 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001786511 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001786511 us-gaap:TreasuryStockCommonMember 2023-06-30 0001786511 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001786511 us-gaap:RetainedEarningsMember 2023-06-30 0001786511 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember 2023-06-30 0001786511 us-gaap:NoncontrollingInterestMember 2023-06-30 0001786511 us-gaap:SubsequentEventMember 2023-07-17 2023-07-17 0001786511 anpc:TotalFresh2GroupLimitedShareholdersEquityDeficitMember us-gaap:SubsequentEventMember 2023-07-17 2023-07-17 0001786511 srt:ScenarioForecastMember 2023-11-01 2023-11-06 0001786511 2023-04-12 2023-04-12 0001786511 anpc:ChangweiSystemTechnologyShanghaiCoLtdMember 2023-06-30 0001786511 anpc:ChangweiSystemTechnologyShanghaiCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyLishuiCoLtdAnPacLishuiMember 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyLishuiCoLtdAnPacLishuiMember 2023-01-01 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyShanghaiCoLtdMember 2023-06-30 0001786511 anpc:AnPacBioMedicalTechnologyShanghaiCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:AnPacTechnologyUSACoLtdAnPacUSMember 2023-06-30 0001786511 anpc:AnPacTechnologyUSACoLtdAnPacUSMember 2023-01-01 2023-06-30 0001786511 anpc:LishuiAnPacMedicalLaboratoryCoLtdMember 2023-06-30 0001786511 anpc:LishuiAnPacMedicalLaboratoryCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:ShijiHainanMedicalTechnologyLtdMember 2023-06-30 0001786511 anpc:ShijiHainanMedicalTechnologyLtdMember 2023-01-01 2023-06-30 0001786511 anpc:ShanghaiMuqingAnPacHealthTechnologyCoLtdAnPacMuqingMember 2023-06-30 0001786511 anpc:ShanghaiMuqingAnPacHealthTechnologyCoLtdAnPacMuqingMember 2023-01-01 2023-06-30 0001786511 anpc:AnpaiShanghaiHealthcareManagementAndConsultingCoLtdMember 2023-06-30 0001786511 anpc:AnpaiShanghaiHealthcareManagementAndConsultingCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2GroupIncMember 2023-06-30 0001786511 anpc:Fresh2GroupIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2TechnologyIncFresh2Member 2023-06-30 0001786511 anpc:Fresh2TechnologyIncFresh2Member 2023-01-01 2023-06-30 0001786511 anpc:Fresh2LogisticsIncMember 2023-06-30 0001786511 anpc:Fresh2LogisticsIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2HFIncMember 2023-06-30 0001786511 anpc:Fresh2HFIncMember 2023-01-01 2023-06-30 0001786511 anpc:FoodbaseGroupIncMember 2023-06-30 0001786511 anpc:FoodbaseGroupIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2EZIncMember 2023-06-30 0001786511 anpc:Fresh2EZIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2InformationIncMember 2023-06-30 0001786511 anpc:Fresh2InformationIncMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2EcommerceFresh2EcommerceMember 2023-06-30 0001786511 anpc:Fresh2EcommerceFresh2EcommerceMember 2023-01-01 2023-06-30 0001786511 anpc:GSINHKLimitedGISNMember 2023-06-30 0001786511 anpc:GSINHKLimitedGISNMember 2023-01-01 2023-06-30 0001786511 anpc:HuaYouShengFutureBeijingTechnologyCoLtdMember 2023-06-30 0001786511 anpc:HuaYouShengFutureBeijingTechnologyCoLtdMember 2023-01-01 2023-06-30 0001786511 anpc:GuanshiTechnologyBeijingCoLtdMember 2023-06-30 0001786511 anpc:GuanshiTechnologyBeijingCoLtdMember 2023-01-01 2023-06-30 0001786511 srt:ScenarioForecastMember 2023-09-25 0001786511 srt:MinimumMember 2023-01-01 2023-06-30 0001786511 srt:MaximumMember 2023-01-01 2023-06-30 0001786511 2022-12-31 2022-12-31 0001786511 anpc:OneSuppliersMember 2022-01-01 2022-06-30 0001786511 us-gaap:OtherCustomerMember 2023-01-01 2023-06-30 0001786511 anpc:TwoSuppliersMember 2022-01-01 2022-06-30 0001786511 anpc:TwoCustomersMember 2023-01-01 2023-06-30 0001786511 anpc:ThreeCustomersMember 2023-01-01 2023-06-30 0001786511 anpc:ThreeSuppliersMember 2022-01-01 2022-06-30 0001786511 anpc:TwoSuppliersMember 2023-01-01 2023-06-30 0001786511 anpc:FourSuppliersMember 2023-01-01 2023-06-30 0001786511 anpc:ThreeSuppliersMember 2023-01-01 2023-06-30 0001786511 2022-01-01 2022-12-31 0001786511 srt:MinimumMember anpc:FurnitureFixturesAndEquipmentMember 2023-06-30 0001786511 srt:MaximumMember anpc:FurnitureFixturesAndEquipmentMember 2023-06-30 0001786511 anpc:MotorVehiclesMember 2023-06-30 0001786511 srt:MinimumMember 2023-06-30 0001786511 2008-09-30 0001786511 anpc:GISNAcquisitionMember us-gaap:CommonClassAMember 2023-06-30 0001786511 anpc:GISNAcquisitionMember us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember us-gaap:CommonClassAMember 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember anpc:ProFormMember 2023-01-01 2023-06-30 0001786511 anpc:AssetAcquisitionMember 2023-01-01 2023-06-30 0001786511 anpc:GISNAcquisitionMember 2023-01-01 2023-06-30 0001786511 anpc:GISNAcquisitionMember 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember 2023-01-01 2023-06-30 0001786511 anpc:Fresh2AcquisitionMember 2023-06-30 0001786511 anpc:FurnitureFixturesAndEquipmentMember 2023-06-30 0001786511 anpc:MotorVehiclesMember 2023-06-30 0001786511 anpc:SoftwareMember 2023-06-30 0001786511 anpc:RevenuesThirdPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-06-30 0001786511 anpc:RevenuesThirdPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-06-30 0001786511 anpc:RevenuesRelatedPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-06-30 0001786511 anpc:RevenuesRelatedPartiesMember us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-06-30 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-06-30 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-06-30 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2022-12-31 0001786511 us-gaap:SegmentDiscontinuedOperationsMember 2023-06-30 0001786511 2022-07-01 2022-12-31 0001786511 us-gaap:SoftwareDevelopmentMember 2022-12-31 0001786511 us-gaap:SoftwareDevelopmentMember 2023-06-30 0001786511 anpc:AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember 2021-05-01 2021-05-15 0001786511 2023-05-24 0001786511 anpc:NassauEnterprisesLLCNassauMember 2023-06-30 0001786511 anpc:NassauEnterprisesLLCNassauMember 2023-05-24 0001786511 anpc:AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember 2022-12-31 0001786511 anpc:AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember 2023-06-30 0001786511 anpc:NassauEnterprisesLLCNassauMember 2022-12-31 0001786511 anpc:NassauEnterprisesLLCNassauMember 2023-06-30 0001786511 2021-07-22 0001786511 2021-07-22 2021-07-22 0001786511 srt:MaximumMember 2021-07-22 2021-07-22 0001786511 srt:MinimumMember 2021-07-22 2021-07-22 0001786511 us-gaap:CommonClassAMember 2022-02-05 0001786511 2021-12-10 0001786511 2021-12-10 2021-12-10 0001786511 2022-03-16 2022-03-16 0001786511 2019-10-14 0001786511 us-gaap:CommonClassAMember 2019-10-01 2019-10-14 0001786511 us-gaap:CommonClassBMember 2019-10-01 2019-10-14 0001786511 srt:MinimumMember 2023-02-14 0001786511 srt:MaximumMember 2023-02-14 0001786511 us-gaap:CommonClassAMember 2023-02-14 2023-02-14 0001786511 us-gaap:CommonClassBMember 2023-02-14 2023-02-14 0001786511 us-gaap:CommonClassAMember 2021-12-10 2021-12-10 0001786511 us-gaap:CommonClassAMember 2022-03-16 2022-03-16 0001786511 2023-03-31 2023-03-31 0001786511 us-gaap:CommonClassAMember 2023-03-31 0001786511 srt:MinimumMember 2023-03-31 2023-03-31 0001786511 2022-04-27 2022-04-27 0001786511 2023-06-01 0001786511 us-gaap:CommonClassAMember 2022-06-10 2022-06-10 0001786511 2022-06-10 2022-06-10 0001786511 us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001786511 us-gaap:CommonClassAMember 2022-09-16 0001786511 2022-08-31 0001786511 us-gaap:CommonClassAMember 2020-07-28 2020-07-28 0001786511 us-gaap:CommonClassAMember 2023-05-11 2023-05-11 0001786511 2023-05-11 2023-05-11 0001786511 us-gaap:CommonClassAMember 2022-12-31 2022-12-31 0001786511 us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001786511 us-gaap:CommonClassAMember 2023-06-01 2023-06-09 0001786511 srt:ScenarioForecastMember us-gaap:CommonClassAMember 2023-10-01 2023-10-30 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-16 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2023-06-30 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-16 2022-03-16 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-05-19 2022-05-19 0001786511 us-gaap:PrivatePlacementMember 2023-01-01 2023-06-30 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-29 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-03-30 2022-03-30 0001786511 2022-05-01 2022-05-27 0001786511 2022-05-27 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-05-27 0001786511 us-gaap:InvestorMember us-gaap:CommonClassAMember 2022-05-30 0001786511 us-gaap:WarrantMember 2022-12-31 0001786511 anpc:NineInvestorsMember us-gaap:CommonClassAMember 2022-12-31 0001786511 us-gaap:CommonClassAMember 2022-01-01 2022-12-31 0001786511 2022-09-02 2022-09-02 0001786511 2022-09-02 0001786511 us-gaap:CommonClassAMember 2022-09-02 2022-09-02 0001786511 us-gaap:PrivatePlacementMember 2022-09-02 0001786511 us-gaap:CommonClassAMember 2022-09-26 0001786511 us-gaap:CommonClassAMember 2022-09-02 0001786511 2022-09-26 2022-09-26 0001786511 2022-03-16 0001786511 us-gaap:CommonClassAMember 2022-03-01 2022-03-16 0001786511 2023-08-10 0001786511 us-gaap:CommonClassAMember 2023-08-10 0001786511 2023-02-01 2023-02-01 0001786511 2023-02-08 2023-02-08 0001786511 us-gaap:WarrantMember 2023-03-31 0001786511 2022-12-30 0001786511 us-gaap:CommonClassAMember 2019-10-01 2019-10-31 0001786511 us-gaap:CommonClassAMember 2021-07-05 0001786511 us-gaap:CommonClassAMember 2022-04-01 2022-04-14 0001786511 2022-08-01 2022-08-28 0001786511 2023-01-01 2023-01-31 0001786511 2023-03-10 0001786511 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001786511 anpc:EmployeesMember 2022-01-01 2022-06-30 0001786511 anpc:EmployeesMember 2023-01-01 2023-06-30 0001786511 anpc:NonEmployeesMember 2022-01-01 2022-06-30 0001786511 anpc:NonEmployeesMember 2023-01-01 2023-06-30 0001786511 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-06-30 0001786511 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-06-30 0001786511 anpc:NonEmployeesMember 2022-12-31 0001786511 anpc:NonEmployeesMember 2023-06-30 0001786511 srt:MinimumMember 2022-01-01 2022-06-30 0001786511 anpc:PRCMember 2023-01-01 2023-06-30 0001786511 us-gaap:InterestIncomeMember 2023-01-01 2023-06-30 0001786511 anpc:PRCMember 2023-01-01 2023-06-30 0001786511 country:US 2023-01-01 2023-06-30 0001786511 country:US 2022-01-01 2022-06-30 0001786511 stpr:NY 2023-01-01 2023-06-30 0001786511 stpr:NY 2022-01-01 2022-06-30 0001786511 stpr:DE 2023-01-01 2023-06-30 0001786511 stpr:DE 2022-01-01 2022-06-30 0001786511 anpc:Fresh2TechnologiesIncMember 2023-01-01 2023-06-30 0001786511 country:HK 2023-01-01 2023-06-30 0001786511 anpc:NonPRCMember 2023-01-01 2023-06-30 0001786511 us-gaap:InternalRevenueServiceIRSMember 2023-01-01 2023-06-30 0001786511 anpc:NonPRCMember 2022-01-01 2022-06-30 0001786511 country:US 2022-01-01 2022-06-30 0001786511 country:US 2023-01-01 2023-06-30 0001786511 anpc:HaohanXuMember 2023-01-01 2023-06-30 0001786511 anpc:ApifinyIncMember 2023-01-01 2023-06-30 0001786511 anpc:RoxeHoldingIncMember 2023-01-01 2023-06-30 0001786511 anpc:DrChrisChangYuMember 2023-01-01 2023-06-30 0001786511 anpc:CRSHoldingsIncMember 2023-01-01 2023-06-30 0001786511 anpc:JiaxingZhijunSihangInvestmentPartnershipEnterprisesMember 2023-01-01 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:ApifinyIncMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:ApifinyIncMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:RoxeHoldingIncMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:RoxeHoldingIncMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:DrChrisChangYuMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:DrChrisChangYuMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:CRSHoldingsIncMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:CRSHoldingsIncMember 2023-06-30 0001786511 us-gaap:RelatedPartyMember anpc:JiaxingZhijunInvestmentManagementCoLtdZhijunMember 2022-12-31 0001786511 us-gaap:RelatedPartyMember anpc:JiaxingZhijunInvestmentManagementCoLtdZhijunMember 2023-06-30 0001786511 anpc:AnPacBeijingMember 2022-01-01 2022-06-30 0001786511 anpc:AnPacBeijingMember 2023-01-01 2023-06-30 0001786511 anpc:XUdongDuMember 2022-01-01 2022-06-30 0001786511 anpc:XUdongDuMember 2023-01-01 2023-06-30 0001786511 us-gaap:SubsequentEventMember 2023-07-01 2023-07-27 0001786511 srt:ScenarioForecastMember anpc:OneIndividualMember us-gaap:CommonClassAMember 2023-09-29 0001786511 us-gaap:SubsequentEventMember 2023-09-25 2023-09-25 iso4217:CNY iso4217:USD iso4217:USD shares shares iso4217:CNY shares pure 6-K/A 2023 001-39137 Fresh2 Group Limited This Form 6-K/A is being filed as an amendment to the Form 6-K dated November 9, 2023 (the “Original Form 6-K”). The purpose of this Form 6-K/A is to amend Exhibits 99.1 and 99.2 of the Original Form 6-K. The amendments made in this document are as follows:   ● Numerical and Wording Revisions: We have made necessary corrections to certain numerical data and wording to ensure accuracy and clarity. These revisions do not materially alter the financial condition or results of operations previously reported.             1. We corrected disclosures regarding loss from disposal of Changwei on page F-18.             2. We corrected disclosures regarding revenues from related parties and third parties for the six months ended June 30, 2023 on page F-18.             3. We corrected disclosures regarding B. Liquidity and Capital Resources on page 5:               1) we changed the working capital deficit as of June 30, 2023 from RMB32,482 million to RMB32.5 million;                 2) we changed the value of convertible notes from US$2,000 million to US$2 million;                 3) we changed the two tranches of convertible notes sold from US$400 and US$1,600 to US$400,000 and US$1,600,000, respectively;                 4) we changed the first payment received from RMB1,697 (US$234) to RMB1,697,000 (US$234,000).               4. We corrected the disclosures regarding capital expenditures for the six months ended June 30, 2022 and 2023 on page 6. ●Additional Disclosures:   1. We added and corrected disclosures regarding the GISN acquisition on page F-16 and page F-32, specific changes were made to 1) correct the disclosure to note the GISN acquisition is not from a related party, 2) correct the fair value of the assets acquired and liabilities assumed table to include ROU which was missed previously and added the omitted disclosure about revenue contributed by GISN for the six months ended June 30, 2023. 2.We added Information pertaining to recent dispositions to provide a more comprehensive understanding of our financial activities. ●Accounting Policy Modifications: Changes have been made to reflect updates in accounting policy after the adoption of ASU 2017-04 in 2022 on page F-9. ●Revision of Product Warranty and Return Policy Description: We have updated the descriptions of our product warranty and return policy to better reflect current practices and ensure transparency on page F-12. Except as described herein, no other changes have been made to the Original Form 6-K. 16000 495000 68000 1050000 3948000 544000 270000 37000 11450000 1579000 864000 119000 135000 19000 414000 57000 12633000 9777000 1348000 13699000 27353000 3771000 4678000 645000 4309000 594000 45169000 6229000 36503000 5034000 223000 31000 39783000 5486000 26770000 20193000 2785000 40469000 178211000 24575000 15000 16000 2000 420000 56000 479000 66000 1214000 592000 82000 148000 20000 7535000 24759000 3414000 33514000 33421000 4609000 42278000 59835000 8249000 2938000 405000 37000 5000 903000 125000 7595000 2434000 336000 49873000 66147000 9120000 0.01 0.01 2400000000 2400000000 79536589 79536589 176070465 176070465 5494000 12181000 1680000 0.01 0.01 30000000 30000000 3573100 3573100 3573100 3573100 240000 240000 33000 11003000 564869000 715327000 98648000 -577539000 -648303000 -89405000 4263000 13079000 1804000 -13676000 92524000 12760000 4272000 19540000 2695000 -9404000 112064000 15455000 40469000 178211000 24575000 4936000 681000 4039000 557000 897000 124000 463000 6070000 837000 8167000 35680000 4920000 2303000 318000 -8630000 -43156000 -5951000 31000 309000 43000 -513000 -95000 -13000 139000 21000 3000 -9035000 -43539000 -6004000 -79000 -11000 -9035000 -43460000 -5993000 -39780000 -27945000 -3854000 -48815000 -71405000 -9847000 -740000 -641000 -88000 -48075000 -70764000 -9759000 -162000 8816000 1216000 -48977000 -62589000 -8631000 -740000 -641000 -88000 -48237000 -61948000 -8543000 -9035000 -43460000 -5993000 -39040000 -27304000 -3766000 -48075000 -70764000 -9759000 -0.38 -0.35 -0.05 -1.66 -0.22 -0.03 -2.04 -0.57 -0.08 23603709 124374140 124374140 16604402 1096000 2773100 185000 465334000 -475646000 4532000 -4499000 5817000 1318000 -48075000 -48075000 -740000 -48815000 14382693 961000 30028000 30989000 30989000 417702 27000 -27000 6000000 381000 -381000 187094 13000 -13000 27739000 27739000 27739000 4528000 4528000 4528000 162000 162000 162000 37591891 2478000 2773100 185000 527208000 -523721000 4370000 10520000 5077000 15597000 79536589 5494000 3573100 240000 -12492283 -11003000 564869000 -577539000 4263000 -13676000 4272000 -9404000 -70764000 -70764000 -641000 -71405000 62885707 4355000 77541000 81896000 81896000 663900 46000 182000 228000 228000 7584900 528000 6383000 6911000 6911000 31891652 2174000 66788000 68962000 68962000 3500000 243000 6142000 6385000 6385000 2500000 178000 -178000 -12492283 -837000 12492283 11003000 -10166000 3766000 3766000 3766000 15909000 15909000 -8816000 -8816000 -8816000 176070465 12181000 3573100 240000 715327000 -648303000 13079000 92524000 19540000 112064000 176070465 1680000 3573100 33000 98648000 -89405000 1804000 12760000 2695000 15455000 -48815000 -71405000 -9847000 -39780000 -27945000 -3854000 -9035000 -43460000 -5993000 2960000 408000 -95000 -13000 2872000 396000 68000 9000 139000 -79000 -11000 9034000 699000 96000 154000 21000 -962000 -133000 129000 18000 -658000 -742000 -102000 -569000 -78000 458000 63000 -155000 1384000 191000 -60000 -8000 -17705000 -35609000 -4910000 -13497000 -1669000 -230000 -31202000 -37278000 -5140000 2355000 325000 8980000 1238000 -1130000 -156000 38106000 5255000 -48311000 -6662000 -817000 2095000 289000 -817000 -46216000 -6373000 30989000 81643000 11259000 6911000 953000 228000 31000 982000 135000 160000 549000 76000 30829000 89215000 12302000 -1589000 -2799000 -386000 29240000 86416000 11916000 -362000 -2443000 -337000 -3141000 479000 66000 3152000 16000 2000 11000 495000 68000 27739000 8954000 253000 35000 6385000 881000 68962000 9510000 1851000 255000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. ORGANIZATION AND PRINCIPAL ACTIVITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., the “Company”) was incorporated in the British Virgin Islands (“the BVI”) in January 2010. The Company incorporated a new subsidiary, Fresh2 Technology Inc. (“Fresh2”) on October 4, 2022. On February 1, 2023, the Group acquired GISN (HK) LIMITED (“GISN”), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commerce operations. On February 8, 2023, the Group acquired Fresh 2 Ecommerce Inc. (“Fresh2 Ecommerce”), a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants and other retail customers in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as food companies, manufacturers, agents, importers, and wholesalers to restaurants and other retail customers. On March 31, 2023, the Group closed an asset purchase with Easy Hundred Inc. (“Easy Hundred”), a U.S.-based e-commerce startup company in the foodservice industry. On July 17, 2023, the Group entered into a definitive Share Purchase Agreement to purchase 51% of Roxe Holding Inc. (“Roxe”). On July 27, 2023, Roxe entered into a Share Purchase Agreement with SpeedIn INC (“SpeedIn”) to purchase 100% of the shares of SpeedIn. Due to its poor operating results, on October 9, 2023, Roxe sold SpeedIn to Immensus LLC, a company owned by our CEO. On November 4, 2023 the Company and Fresh2 Technology entered into a definitive Share Purchase Agreement to purchase 38.61% of the common stock of Roxe.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries (collectively, the “Group”) provides a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants and other retail customers in the U.S.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective on July 28, 2023, the Group disposed its multi-cancer screening and detection test business (the “CDA Business”) in the People’s Republic of China (the “PRC” or “China”). The Group determined that the disposal of the CDA Business met the criteria to be classified as a discontinued operation (see Note 4) and, as a result, the CDA business’s historical financial results are reflected in the Group’s unaudited condensed consolidated financial statements as a discontinued operation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, the details of the Group’s principal subsidiaries are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"> </span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-size: 9pt">Major subsidiaries</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Percentage of<br/> Ownership</span></td><td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt"><b>Date of<br/> Incorporation/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt"><b>Acquisition</b></span></p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 9pt">Place of<br/> Incorporation</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 9pt">Major Operation</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 30%; text-align: left"><span style="font-size: 9pt">Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. * </span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; width: 9%; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; width: 1%; text-align: left"><span style="font-size: 9pt">%</span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; width: 11%; text-align: center"><span style="font-size: 9pt">March 2010</span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; width: 11%; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; width: 33%; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”) *</span> <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></p></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">October 2012</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening detection tests and device manufacturing</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">AnPac Bio-Medical Technology (Shanghai) Co., Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">April 2014</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">AnPac Technology USA Co., Ltd. (“AnPac US”) *</span> <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></p></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">September 2015</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Clinical trials for research on cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Lishui AnPac Medical Laboratory Co., Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">July 2016</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Shiji (Hainan) Medical Technology Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">March 2013</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection research</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Shanghai Muqing AnPac Health Technology Co., Ltd. (“AnPac Muqing”) (i)*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">51</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">March 2019</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Anpai (Shanghai) Healthcare Management and Consulting Co., Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">60</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">August 15, 2021</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Group Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">December 27, 2022</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Technology Inc (“Fresh2”)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">October 4, 2022</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Logistics Inc.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 22, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 HF Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 21, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Foodbase Group Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">January 19, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 EZ Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">March 3, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 information Inc (ii)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">April 12, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Ecommerce (“Fresh2 Ecommerce”)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 8, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">GISN (HK) Limited (“GISN”)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 1, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Hongkong, PRC,</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Hua You Sheng Future (Beijing) Technology Co., Ltd.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 1, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Guanshi Technology (Beijing) Co., Ltd.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 1, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Software development</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">*</td> <td style="text-align: justify">Subsidiaries that were sold subsequent to June 30, 2023.</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AnPac Muqing closed business in March 2023</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2023, the Company, through its subsidiary, Fresh 2 EZ Inc to acquire 100% of equity interest in Fresh 2 information Inc from Roxe Holding Inc, a company controlled by Mr. Haohan Xu, with a nominal price. Fresh 2 information Inc has not begun operation yet.</span></td></tr> </table> 0.51 1 0.3861 As of June 30, 2023, the details of the Group’s principal subsidiaries are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-size: 9pt">Major subsidiaries</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Percentage of<br/> Ownership</span></td><td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 9pt"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt"><b>Date of<br/> Incorporation/</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 9pt"><b>Acquisition</b></span></p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 9pt">Place of<br/> Incorporation</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 9pt">Major Operation</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 30%; text-align: left"><span style="font-size: 9pt">Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. * </span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; width: 9%; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; width: 1%; text-align: left"><span style="font-size: 9pt">%</span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; width: 11%; text-align: center"><span style="font-size: 9pt">March 2010</span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; width: 11%; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td style="width: 1%"><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; width: 33%; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”) *</span> <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></p></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">October 2012</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening detection tests and device manufacturing</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">AnPac Bio-Medical Technology (Shanghai) Co., Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">April 2014</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">AnPac Technology USA Co., Ltd. (“AnPac US”) *</span> <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></p></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">September 2015</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Clinical trials for research on cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Lishui AnPac Medical Laboratory Co., Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">July 2016</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Shiji (Hainan) Medical Technology Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">March 2013</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection research</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Shanghai Muqing AnPac Health Technology Co., Ltd. (“AnPac Muqing”) (i)*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">51</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">March 2019</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Anpai (Shanghai) Healthcare Management and Consulting Co., Ltd.*</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">60</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">August 15, 2021</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Cancer screening and detection tests</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Group Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">December 27, 2022</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Technology Inc (“Fresh2”)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">October 4, 2022</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Logistics Inc.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 22, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 HF Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 21, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Foodbase Group Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">January 19, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 EZ Inc</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">March 3, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 information Inc (ii)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">April 12, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Fresh 2 Ecommerce (“Fresh2 Ecommerce”)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 8, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">the U.S.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">GISN (HK) Limited (“GISN”)</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 1, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Hongkong, PRC,</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Hua You Sheng Future (Beijing) Technology Co., Ltd.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 1, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">B2B e-commerce</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 9pt">Guanshi Technology (Beijing) Co., Ltd.</span></td><td><span style="font-size: 9pt"> </span></td> <td style="text-align: left"><span style="font-size: 9pt"> </span></td><td style="vertical-align: top; text-align: right"><span style="font-size: 9pt">100</span></td><td style="vertical-align: top; text-align: left"><span style="font-size: 9pt">%</span></td><td><span style="font-size: 9pt"> </span></td> <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 9pt">February 1, 2023</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">PRC</span></td><td><span style="font-size: 9pt"> </span></td> <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt">Software development</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">*</td> <td style="text-align: justify">Subsidiaries that were sold subsequent to June 30, 2023.</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AnPac Muqing closed business in March 2023</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2023, the Company, through its subsidiary, Fresh 2 EZ Inc to acquire 100% of equity interest in Fresh 2 information Inc from Roxe Holding Inc, a company controlled by Mr. Haohan Xu, with a nominal price. Fresh 2 information Inc has not begun operation yet.</span></td></tr> </table> 1 March 2010 the PRC Cancer screening and detection tests 1 October 2012 the PRC Cancer screening detection tests and device manufacturing 1 April 2014 the PRC Cancer screening and detection tests 1 September 2015 the U.S. Clinical trials for research on cancer screening and detection tests 1 July 2016 the PRC Cancer screening and detection tests 1 March 2013 the PRC Cancer screening and detection research 0.51 March 2019 the PRC Cancer screening and detection tests 0.60 August 15, 2021 the PRC Cancer screening and detection tests 1 December 27, 2022 the U.S. B2B e-commerce 1 October 4, 2022 the U.S. B2B e-commerce 1 February 22, 2023 the U.S. B2B e-commerce 1 February 21, 2023 the U.S. B2B e-commerce 1 January 19, 2023 the U.S. B2B e-commerce 1 March 3, 2023 the U.S. B2B e-commerce 1 April 12, 2023 the U.S. B2B e-commerce 1 February 8, 2023 the U.S. B2B e-commerce 1 February 1, 2023 Hongkong, PRC, B2B e-commerce 1 February 1, 2023 PRC B2B e-commerce 1 February 1, 2023 PRC Software development 1 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. LIQUIDITY AND GOING CONCERN UNCERTAINTIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s principal sources of liquidity have been cash generated from financing and operating activities. As of June 30, 2023, the Group had RMB495 (US$68) of cash and cash equivalents and a working capital deficit of RMB34,148 (US$4,710). For the six months ended June 30, 2023, the Group incurred a loss from continuing operations of RMB43,460(US$5,993). For the six months ended June 30, 2023, net cash used in continuing operating activities was RMB35,609 (US$4,910). The above-mentioned facts raise substantial doubt about the Group’s ability to continue as a going concern. In assessing its liquidity, management monitors and analyzes the Group’s cash on-hand, its ability to generate sufficient revenue sources in the future, and its operating and capital expenditure commitments. With respect to capital funding requirements, the Group budgeted capital spending based on ongoing assessments of needs to maintain adequate cash. The Group intends to finance its future working capital requirements and capital expenditures from financing activities until the Group’s operating activities generate positive cash flows, if ever. Management expects continued capital financing through debt or equity issuances to support its working capital requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2023, the Company entered into an agreement with an institutional investor to purchase up to US$2,000 of convertible notes, the convertible notes will be sold in two tranches (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at an exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at an exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment of RMB1,697(US$234) from this offering, excluding related financing costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group can make no assurances that required financings will be available for the amounts needed, or on terms commercially acceptable to the Group, if at all. If one or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material adverse effect on the Group and its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements have been prepared assuming that the Group will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty.</p> 495000 68000 34148000 4710000 -43460000 -5993000 -35609000 -4910000 2000000 (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at an exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at an exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment of RMB1,697(US$234) from this offering, excluding related financing costs. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. SUMMARY OF PRINCIPAL ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Basis of presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial reporting and pursuant to the applicable rules and regulations of the SEC pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2023 and 2022 are not necessarily indicative of the results that may be expected for the full year. The information included in this report should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Group’s annual financial statements for the fiscal year ended December 31, 2022 filed with the SEC on May 16, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Principles of consolidation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements include the financial statements of the Group. All inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power, has the power to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of the board of directors, or has the power to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Use of estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Areas where management uses subjective judgement include, but are not limited to allowance for doubtful accounts, share-based compensation, deferred tax and uncertain tax position, useful lives of intangible assets and property and equipment, impairment of long-lived assets, goodwill and long-term investments and the purchase price allocation with respect to business combinations. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences could be material to the unaudited condensed consolidated financial statements. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Cash and cash equivalents</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consist of cash on hand and demand deposits placed with banks which are unrestricted as to withdrawal or use and have original maturities less than three months. All highly liquid investments with a stated maturity of 90 days or less from the date of purchase are classified as cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Accounts receivable and allowance for credit losses</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable represents the amounts that the Group has an unconditional right to consideration and is recorded net of allowance for credit losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The Group has adopted this ASC Topic 326 and several associated ASUs on </span>January 1, 2023 using a modified retrospective approach. The adoption has no material impact to the Company’s consolidated financial statements. The Group estimated allowance for credit losses to reserve for potentially uncollectible receivable amounts periodically, considering factors in assessing the collectability of its accounts receivable, such as historical distribution of the age of the amounts due, payment history, creditworthiness, forward-looking factor, historical collections data of the customers, to assess the credit risk characteristics. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Group also makes specific allowance in the period in which a loss is determined to be probable. Accounts receivable are considered impaired and written-off when it is probable that all contractual payments due will not be collected after all collection efforts have been exhausted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(f) Convenience translation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts in US$ are presented for the convenience of the reader and are translated at the noon buying rate of US$1.00 to RMB7.2513 on June 30, 2023, representing the noon buying rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be converted, realized or settled into US$ at such rate or at any other rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(g) Long-term investments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s long-term investments include equity method investments and equity investments without readily determinable fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in entities in which the Group can exercise significant influence but does not own a majority equity interest or control are accounted for using the equity method of accounting in accordance with ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Under the equity method, the Group initially records its investment at cost and the difference between the cost of the equity investee and the amount of the underlying equity in the net assets of the equity investee is accounted for as if the investee were a consolidated subsidiary. The share of earnings or losses of the investee are recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Equity method adjustments include the Group’s proportionate share of investee income or loss, adjustments to recognize certain differences between the Group’s carrying value and its equity in net assets of the investee at the date of investment, impairments, and other adjustments required by the equity method. The Group assesses its equity investment for other-than-temporary impairment by considering factors as well as all relevant and available information including, but not limited to, current economic and market conditions, the operating performance of the investees including current earnings trends, the general market conditions in the investee’s industry or geographic area, factors related to the investee’s ability to remain in business, such as the investee’s liquidity, debt ratios, and cash burn rate and other company-specific information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in equity securities without readily determinable fair values are measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. No impairment on its long-term investments was recognized for the six months ended June 30, 2022 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(h) Business combinations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of an acquisition is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued. The costs directly attributable to the acquisition are expensed as incurred. Identifiable assets, liabilities and contingent liabilities acquired or assumed are measured separately at their fair value as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total of the cost of the acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the fair value of the identifiable net assets of the acquiree, the difference is recognized directly in earnings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The determination and allocation of fair values to the identifiable net assets acquired, liabilities assumed and noncontrolling interest is based on various assumptions and valuation methodologies requiring considerable judgment. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determines discount rates to be used based on the risk inherent in the acquiree’s current business model and industry comparisons. Although the Group believes that the assumptions applied in the determination are reasonable based on information available at the date of acquisition, actual results may differ from forecasted amounts and the differences could be material.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(i) Asset Acquisition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate acquisitions pursuant to ASC 805, “Business Combinations,” to determine whether the acquisition should be classified as either an asset acquisition or a business combination. Acquisitions for which substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets are accounted for as an asset acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Common stock issued as consideration in an asset acquisition is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. However, as of the date of acquisition, if certain assets are carried at fair value under other applicable GAAP, the consideration is first allocated to those assets with the remainder allocated to the non-monetary identifiable assets based on relative fair value basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(j) Goodwill</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is the cost of acquired companies in excess of the fair value of identifiable net assets at acquisition date. Goodwill is not subject to amortization, but rather is evaluated for impairment at least annually. The Group evaluates its goodwill for impairment during the fourth quarter of its fiscal year or more frequently if indicators of potential impairment exist, in accordance with ASC 350, Intangibles - Goodwill and Other. Goodwill impairment is determined by comparing the estimated fair value of a reporting unit (generally defined as the businesses for which financial information is available and reviewed regularly by management) with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not deemed to be impaired. However, if the estimated fair value is below carrying value, further analysis is required to determine the amount of the impairment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the course of evaluating the potential impairment of goodwill, the Group may perform either a qualitative or a quantitative assessment. The Group’s qualitative assessment of potential impairment may result in the determination that a quantitative impairment analysis is not necessary. Under this elective process, the Group assesses qualitative factors to determine whether the existence of events or circumstances leads the Company to determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then performing a quantitative analysis is not required. However, if the Group concludes otherwise, then the Group performs a quantitative impairment analysis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">If the Group either chooses not to perform a qualitative assessment, or the Group chooses to perform a qualitative assessment but is unable to qualitatively conclude that no impairment has occurred, then the Group performs a quantitative evaluation. In the case of a quantitative assessment, the Group estimates the fair value of the reporting unit with which the goodwill that is subject to the quantitative analysis is associated and compares it to the carrying value. If the estimated fair value of a reporting unit is less than its carrying value, the excess is recorded as a goodwill impairment, which is limited to the total amount of goodwill allocated to that reporting unit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and 2023, the Group performed a qualitative assessment for the reporting unit. Based on the requirements of ASC 350-20, the Group evaluated all relevant qualitative and quantitative factors, weighed all factors in their entirety and concluded that it was not more-likely-than-not that the fair value of the reporting unit was less than its carrying amount. Therefore, no goodwill impairment was recognized for the six months ended June 30, 2022 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(k) Discontinued operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity’s financial results and operations. Included in the unaudited condensed consolidated statements of income and comprehensive income, result from discontinued operations is reported separately from the income and expenses from continuing operations and prior periods are presented on a comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Fair value of financial instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2—Other inputs that are directly or indirectly observable in the marketplace. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3—Unobservable inputs which are supported by little or no market activity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s financial instruments include cash and cash equivalents, accounts receivables, accounts payable, other receivables, other payables and short-term debt. The carrying values of these financial instruments approximate their fair values due to their short-term maturities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group elected the fair value option to account for its convertible loans. The Group engaged an independent valuation firm to perform the valuation. The fair value of the convertible loans as of December 31, 2022 and June 30, 2023 was RMB15 and RMB16 (US$2) calculated using the binomial tree model. The convertible loans are classified as level 3 instruments as the valuation was determined based on unobservable inputs which are supported by little or no market activity and reflect the Group’s own assumptions in measuring fair value. Significant estimates used in developing the fair value of the convertible loans include time to maturity, risk-free interest rate, straight debt discount rate, probability to convert and expected timing of conversion. Refer to Note 11 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the inputs used in developing the fair value for level 3 instruments are unobservable, and require significant management estimate, a change in these inputs could result in a significant change in the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a reconciliation of the beginning and ending balances for convertible loans measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of December 31, 2022 and June 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Opening balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">27,859</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Conversion of convertible loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27,739</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss (gain) on change in fair value of convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(144</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive income -foreign exchange translations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(m) Property and equipment</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less accumulated depreciation and any recorded impairment. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold; text-align: justify">Category</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Estimated useful life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Furniture, fixtures and equipment</td><td> </td> <td style="text-align: center">3-5 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Motor vehicles</td><td> </td> <td style="text-align: center">5 years</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(n) Intangible assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s intangible assets mainly include acquired software from business acquisition and asset acquisition. In business combinations, identifiable intangible assets acquired are measured separately at their fair value as of the acquisition date. For asset acquisitions, the cost of the asset acquisition is allocated to identifiable assets acquired based on a relative fair value basis. Intangible assets with finite lives are carried at cost less accumulated amortization. All intangible assets with finite lives are amortized using the straight-line method over the estimated useful lives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets have estimated useful lives from the date of purchase as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold">Category</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Estimated useful life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="text-align: center">5-10 years</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Impairment of Long-Lived Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates the recoverability of its long-lived assets, including property and equipment and the intangible assets and for impairment whenever events or changes in circumstances indicate that the carrying amount of its asset may not be fully recoverable. When these events occur, the Company measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the asset and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the asset, the Company recognizes an impairment loss based on the excess of the carrying amount of the asset over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the asset when the market prices are not readily available. The adjusted carrying amount of the asset is the new cost basis and is depreciated over the asset’s remaining useful life. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. No impairment of long-lived assets was recognized for the six months ended June 30, 2022 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Treasury shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for treasury share using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account on the unaudited condensed consolidated balance sheets. At retirement of the treasury shares, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is allocated between additional paid in capital (up to the amount credited to the additional paid in capital upon original issuance of the shares) and retained earnings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) Revenue recognition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group applies the ASU 2014-09, Revenue from Contracts with Customers — Topic 606 for its revenue recognition for all periods presented. The majority of the Group’s revenue comes from product sales of Asia food and consumable through its software application (“APP”). Revenue is recognized when the Group satisfies the performance obligations in an amount of consideration to which the Group expects to be entitled to in exchange for those goods. The Group evaluates the presentation of revenue on a gross or net basis based on whether it controls the goods provided to customers and is the principal (i.e., “gross”), or the Group arranges for other parties to provide the goods to the customers and is an agent (i.e., “net”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group sells food and consumable products through its own APP. The Group utilizes external delivery service providers to deliver goods to its customers. The customers pay for the goods in advance. The Group recognizes product sales made through APP on a gross basis because the Group is acting as a principal in these transactions as the Company (i) is responsible for fulfilling the promise to provide the specified goods, (ii) takes on inventory risk and (iii) has discretion in establishing price. Revenues are recognized when control is transferred, which typically happens upon delivery. The Group’s contracts with customer are primarily on a fixed-price basis. Discounts and allowances provided to customers are recognized as a reduction in net sales as control of the products is transferred to customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group generally allows customers to return non-food items within 30 days of receipt of proof that the products are unused and included in the original package. For food products, the Group does not accept returns. Customers may be qualified to receive a refund for food products received with unacceptable quality within 2 to 30 days from the date of delivery. The Group estimates returns of the products and refund, which are deducted from sales in the period in which the related revenue is recognized. The determination of the Group’s product returns and refund accruals is based on historical experience with the sales of such products. The Group estimates and adjusts these accruals at each balance sheet date in accordance with changes in these factors</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract balances</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract assets relate to the Group’s conditional right to consideration for completed performance obligations under the contract. Accounts receivable are recorded when the right to consideration becomes unconditional. The Group does not have contract assets for the periods presented. In instances where the timing of revenue recognition differs from the timing of invoicing, the Group has determined that its contracts generally do not include a significant financing component.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract liabilities represent considerations received from customers in advance of satisfying the Group’s performance obligations under the contract, which are presented in “advance from customers” in the unaudited condensed consolidated balance sheets. The Group classifies contract liabilities as current based on the timing of when we expect to recognize revenue, which typically occurs within one year. Revenue recognized that was included in contract liabilities at the beginning of the period was <span style="-sec-ix-hidden: hidden-fact-195"><span style="-sec-ix-hidden: hidden-fact-196">nil</span></span> for the six months ended June 30, 2022 and 2023, respectively. As of December 31, 2022 and June 30, 2023, contract liabilities amounted to <span style="-sec-ix-hidden: hidden-fact-197">nil</span> and RMB479 (US$66), respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Practical expedients</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has applied the following practical expedients:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction price allocated to the performance obligations that are unsatisfied, or partially unsatisfied has not been disclosed, as substantially all of the Group’s contracts have a duration of one year or less.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group recognizes incremental costs to obtain a contract as expenses when incurred because the amortization period would be one year or less. These costs are recorded within sales and marketing expenses.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(r) Research and development expenses</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses primarily are comprised of costs incurred in performing research and development activities, including related personnel and consultant’s compensation, benefits, share-based compensation and related materials and supplies costs. The Group expenses research and development expenses as they are incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(s) Leases</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group adopted ASU No. 2016-02—Leases (Topic 842) as of January 1, 2022, using a modified retrospective transition method permitted under ASU No. 2018-11. This transition approach provides a method for recording existing leases only at the date of adoption and does not require previously reported balances to be adjusted. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional lease assets and lease liabilities on the consolidated balance sheets. The standard did not materially impact our unaudited condensed consolidated net earnings and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right-of-use (“ROU”) assets represent the Group’s rights to use underlying assets for the lease term and lease liabilities represent the Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, reduced by lease incentives received, plus any initial direct costs, using the discount rate for the lease at the commencement date. As the implicit rate in lease is not readily determinable for the Group’s operating leases, the Group generally use the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The Group’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Group will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Group accounts for lease and non-lease components separately. the Group has no finance leases for any of the periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the adoption of ASU No. 2016-02, leases were classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exist: (a) ownership is transferred to the lessee by the end of the lease term, (b) there is a bargain purchase option, (c) the lease term is at least 75% of the property’s estimated remaining economic life, or (d) the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an occurrence of an obligation at the inception of the lease. The Group has no capital leases for the six months ended June 30, 2022 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(t) Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Group’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Group’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annual period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. All warrants outstanding as of June 30, 2023 and December 31, 2022 do not meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815 and therefore, classified as equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(u) Share-based compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for share-based compensation in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). In accordance with ASC 718, the Group determines whether an award should be classified and accounted for as a liability award or an equity award. All the Group’s share-based awards were classified as equity awards and are recognized in the unaudited condensed consolidated financial statements based on their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has elected to recognize share-based compensation using the straight-line method for all share-based awards granted with graded vesting based on service conditions. The Group accounts for forfeitures as they occur in accordance with ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvement to Employee Share-based Payment Accounting. The Black-Scholes Model were applied in determining the estimated fair value of the options granted to employees and non-employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(v) Income taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group follows the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group accounted for uncertainties in income taxes in accordance with ASC 740. Interest and penalties related to unrecognized tax benefit recognized in accordance with ASC 740 are classified in the unaudited condensed consolidated statements of operations and comprehensive loss as income tax expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and 2023, the Group did not have any significant unrecognized uncertain tax positions or any unrecognized liabilities, interest or penalties associated with unrecognized tax benefits. The Group does not believe that its uncertain tax benefits position will materially change over the next twelve months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(w) Comprehensive loss</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group’s comprehensive loss includes net loss and foreign currency translation differences, and is presented in the unaudited condensed consolidated statements of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(x) Segment reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the Group discontinued CDA business, the Group operates and manages its business as a single segment and the Group’s primary revenue are generated in the U.S. The Group has only one reportable segment for the six months ended June 30, 2023, in accordance with ASC 280, Segment Reporting. The Group’s Chief Executive Officer is the chief operating decision-maker that review the unaudited condensed consolidated financial results when making decisions about allocating resources and assessing the performance of the Group as a whole.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(y) Loss per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share is calculated in accordance with ASC 260, Earnings per Share. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the share options, using the treasury share method. Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Group’s unaudited condensed consolidated statements of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rights, including the liquidation and dividend rights, of the holders of our Class A and Class B ordinary shares are identical, except with respect to voting. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to ten votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares under any circumstances. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis. For the six months ended June 30, 2022 and 2023, the net loss per share amounts are the same for Class A and Class B common ordinary shares because the holders of each class are entitled to equal per share dividends or distributions in liquidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group did not include share options, convertible debt and warrants in the computation of diluted earnings per share for the six months ended June 30, 2022 and 2023, because those were anti-dilutive for loss per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(z) Risks, Uncertainties and Concentrations </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of credit risk</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Group to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivables. As of December 31, 2022 and June 30, 2023, the aggregate amounts of cash and cash equivalents of RMB14 and RMB62 (US$9), respectively, were held at major financial institutions located in the PRC and RMB1 and RMB268 (US$37), respectively, were deposited at banks located in U.S. and covered by the FDIC insurance program. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. There is a RMB 500,000 deposit insurance limit for a legal entity’s aggregated balance at each PRC bank.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, no customer accounted for more than 10% of total accounts receivables. As of June 30, 2023, four customers accounted for 37%, 20%, 19% and 16% of total accounts receivables. The risk is mitigated by credit evaluations the Group performs on its customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Business, customer, supplier, political and economic risks</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s e-commerce food-related business has a limited operating history. The recently acquired operations are subject to all of the risks inherent in the initial expenses, challenges, complications, and delays frequently encountered in connection with the formation of any new business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group participates in a dynamic industry and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in industry standards; changes in certain strategic relationships or customer relationships; regulatory considerations; intellectual property considerations; and risks associated with the Group’s ability to attract and retain employees necessary to support its growth.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022, no customer accounted for more than 10% of the total revenues, respectively. For the six months ended June 30, 2023, the Group had one customer that accounted for 16% of total revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022, no supplier accounted for more than for 10% of total cost of revenues. For the six months ended June 30, 2023, two suppliers that accounted for 22% and 22% of total cost of revenues, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, no supplier accounted for more than 10% of total accounts payables As of June 30, 2023, three suppliers accounted for 25%, 14%and 12% of total accounts payables, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(aa) Recent accounting pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Group is an emerging growth company (“EGC”) as defined by the Jumpstart Our Business Startups Act (“JOBS Act”). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the <span>Group</span>. Early adoption is permitted. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the unaudited condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span>In October 2021, the FASB issued ASU No. 2021-08, “‘Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). This ASU requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The amendments are effective for fiscal years beginning after December 15, 2023, and are applied prospectively to business combinations that occur after the effective date. The Group does not expect the adoption of ASU 2021-04 will have a material effect on the unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the <span>Group</span> adopts as of the specified effective date. Unless otherwise discussed, the <span>Group</span> does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Basis of presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial reporting and pursuant to the applicable rules and regulations of the SEC pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2023 and 2022 are not necessarily indicative of the results that may be expected for the full year. The information included in this report should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Group’s annual financial statements for the fiscal year ended December 31, 2022 filed with the SEC on May 16, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Principles of consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements include the financial statements of the Group. All inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power, has the power to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of the board of directors, or has the power to govern the financial and operating policies of the investee under a statute or agreement among the shareholders or equity holders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Use of estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Areas where management uses subjective judgement include, but are not limited to allowance for doubtful accounts, share-based compensation, deferred tax and uncertain tax position, useful lives of intangible assets and property and equipment, impairment of long-lived assets, goodwill and long-term investments and the purchase price allocation with respect to business combinations. Changes in facts and circumstances may result in revised estimates. Actual results could differ from those estimates, and as such, differences could be material to the unaudited condensed consolidated financial statements. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Cash and cash equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents consist of cash on hand and demand deposits placed with banks which are unrestricted as to withdrawal or use and have original maturities less than three months. All highly liquid investments with a stated maturity of 90 days or less from the date of purchase are classified as cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Accounts receivable and allowance for credit losses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable represents the amounts that the Group has an unconditional right to consideration and is recorded net of allowance for credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The Group has adopted this ASC Topic 326 and several associated ASUs on </span>January 1, 2023 using a modified retrospective approach. The adoption has no material impact to the Company’s consolidated financial statements. The Group estimated allowance for credit losses to reserve for potentially uncollectible receivable amounts periodically, considering factors in assessing the collectability of its accounts receivable, such as historical distribution of the age of the amounts due, payment history, creditworthiness, forward-looking factor, historical collections data of the customers, to assess the credit risk characteristics. If there is strong evidence indicating that the accounts receivable is likely to be unrecoverable, the Group also makes specific allowance in the period in which a loss is determined to be probable. Accounts receivable are considered impaired and written-off when it is probable that all contractual payments due will not be collected after all collection efforts have been exhausted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(f) Convenience translation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts in US$ are presented for the convenience of the reader and are translated at the noon buying rate of US$1.00 to RMB7.2513 on June 30, 2023, representing the noon buying rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be converted, realized or settled into US$ at such rate or at any other rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(g) Long-term investments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s long-term investments include equity method investments and equity investments without readily determinable fair values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in entities in which the Group can exercise significant influence but does not own a majority equity interest or control are accounted for using the equity method of accounting in accordance with ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Under the equity method, the Group initially records its investment at cost and the difference between the cost of the equity investee and the amount of the underlying equity in the net assets of the equity investee is accounted for as if the investee were a consolidated subsidiary. The share of earnings or losses of the investee are recognized in the unaudited condensed consolidated statements of operations and comprehensive loss. Equity method adjustments include the Group’s proportionate share of investee income or loss, adjustments to recognize certain differences between the Group’s carrying value and its equity in net assets of the investee at the date of investment, impairments, and other adjustments required by the equity method. The Group assesses its equity investment for other-than-temporary impairment by considering factors as well as all relevant and available information including, but not limited to, current economic and market conditions, the operating performance of the investees including current earnings trends, the general market conditions in the investee’s industry or geographic area, factors related to the investee’s ability to remain in business, such as the investee’s liquidity, debt ratios, and cash burn rate and other company-specific information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in equity securities without readily determinable fair values are measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. No impairment on its long-term investments was recognized for the six months ended June 30, 2022 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(h) Business combinations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of an acquisition is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued. The costs directly attributable to the acquisition are expensed as incurred. Identifiable assets, liabilities and contingent liabilities acquired or assumed are measured separately at their fair value as of the acquisition date, irrespective of the extent of any noncontrolling interests. The excess of (i) the total of the cost of the acquisition, fair value of the noncontrolling interests and acquisition date fair value of any previously held equity interest in the acquiree over (ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the fair value of the identifiable net assets of the acquiree, the difference is recognized directly in earnings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The determination and allocation of fair values to the identifiable net assets acquired, liabilities assumed and noncontrolling interest is based on various assumptions and valuation methodologies requiring considerable judgment. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determines discount rates to be used based on the risk inherent in the acquiree’s current business model and industry comparisons. Although the Group believes that the assumptions applied in the determination are reasonable based on information available at the date of acquisition, actual results may differ from forecasted amounts and the differences could be material.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(i) Asset Acquisition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate acquisitions pursuant to ASC 805, “Business Combinations,” to determine whether the acquisition should be classified as either an asset acquisition or a business combination. Acquisitions for which substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets are accounted for as an asset acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Common stock issued as consideration in an asset acquisition is generally measured based on the acquisition date fair value of the equity interests issued. Direct transaction costs are recognized as part of the cost of an asset acquisition. The cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. However, as of the date of acquisition, if certain assets are carried at fair value under other applicable GAAP, the consideration is first allocated to those assets with the remainder allocated to the non-monetary identifiable assets based on relative fair value basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(j) Goodwill</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is the cost of acquired companies in excess of the fair value of identifiable net assets at acquisition date. Goodwill is not subject to amortization, but rather is evaluated for impairment at least annually. The Group evaluates its goodwill for impairment during the fourth quarter of its fiscal year or more frequently if indicators of potential impairment exist, in accordance with ASC 350, Intangibles - Goodwill and Other. Goodwill impairment is determined by comparing the estimated fair value of a reporting unit (generally defined as the businesses for which financial information is available and reviewed regularly by management) with its respective carrying value. If the estimated fair value exceeds the carrying value, goodwill at the reporting unit level is not deemed to be impaired. However, if the estimated fair value is below carrying value, further analysis is required to determine the amount of the impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the course of evaluating the potential impairment of goodwill, the Group may perform either a qualitative or a quantitative assessment. The Group’s qualitative assessment of potential impairment may result in the determination that a quantitative impairment analysis is not necessary. Under this elective process, the Group assesses qualitative factors to determine whether the existence of events or circumstances leads the Company to determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then performing a quantitative analysis is not required. However, if the Group concludes otherwise, then the Group performs a quantitative impairment analysis.</p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">If the Group either chooses not to perform a qualitative assessment, or the Group chooses to perform a qualitative assessment but is unable to qualitatively conclude that no impairment has occurred, then the Group performs a quantitative evaluation. In the case of a quantitative assessment, the Group estimates the fair value of the reporting unit with which the goodwill that is subject to the quantitative analysis is associated and compares it to the carrying value. If the estimated fair value of a reporting unit is less than its carrying value, the excess is recorded as a goodwill impairment, which is limited to the total amount of goodwill allocated to that reporting unit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and 2023, the Group performed a qualitative assessment for the reporting unit. Based on the requirements of ASC 350-20, the Group evaluated all relevant qualitative and quantitative factors, weighed all factors in their entirety and concluded that it was not more-likely-than-not that the fair value of the reporting unit was less than its carrying amount. Therefore, no goodwill impairment was recognized for the six months ended June 30, 2022 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(k) Discontinued operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A component of a reporting entity or a group of components of a reporting entity that are disposed or meet the criteria to be classified as held for sale, such as the management, having the authority to approve the action, commits to a plan to sell the disposal group, should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Discontinued operations are reported when a component of an entity comprising operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity is classified as held for disposal or has been disposed of, if the component either (1) represents a strategic shift or (2) have a major impact on an entity’s financial results and operations. Included in the unaudited condensed consolidated statements of income and comprehensive income, result from discontinued operations is reported separately from the income and expenses from continuing operations and prior periods are presented on a comparative basis. In order to present the financial effects of the continuing operations and discontinued operations, revenues and expenses arising from intra-group transactions are eliminated except for those revenues and expenses that are considered to continue after the disposal of the discontinued operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Fair value of financial instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2—Other inputs that are directly or indirectly observable in the marketplace. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3—Unobservable inputs which are supported by little or no market activity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s financial instruments include cash and cash equivalents, accounts receivables, accounts payable, other receivables, other payables and short-term debt. The carrying values of these financial instruments approximate their fair values due to their short-term maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group elected the fair value option to account for its convertible loans. The Group engaged an independent valuation firm to perform the valuation. The fair value of the convertible loans as of December 31, 2022 and June 30, 2023 was RMB15 and RMB16 (US$2) calculated using the binomial tree model. The convertible loans are classified as level 3 instruments as the valuation was determined based on unobservable inputs which are supported by little or no market activity and reflect the Group’s own assumptions in measuring fair value. Significant estimates used in developing the fair value of the convertible loans include time to maturity, risk-free interest rate, straight debt discount rate, probability to convert and expected timing of conversion. Refer to Note 11 for additional information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the inputs used in developing the fair value for level 3 instruments are unobservable, and require significant management estimate, a change in these inputs could result in a significant change in the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a reconciliation of the beginning and ending balances for convertible loans measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of December 31, 2022 and June 30, 2023:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Opening balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">27,859</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Conversion of convertible loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27,739</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss (gain) on change in fair value of convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(144</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive income -foreign exchange translations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 15000 16000 2000 The following is a reconciliation of the beginning and ending balances for convertible loans measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of December 31, 2022 and June 30, 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Opening balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">27,859</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Conversion of convertible loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27,739</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss (gain) on change in fair value of convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(144</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive income -foreign exchange translations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 27859000 15000 2000 -27739000 -144000 39000 1000 15000 16000 2000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(m) Property and equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less accumulated depreciation and any recorded impairment. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold; text-align: justify">Category</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Estimated useful life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Furniture, fixtures and equipment</td><td> </td> <td style="text-align: center">3-5 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Motor vehicles</td><td> </td> <td style="text-align: center">5 years</td></tr> </table> Property and equipment are stated at cost less accumulated depreciation and any recorded impairment. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets, as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold; text-align: justify">Category</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Estimated useful life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Furniture, fixtures and equipment</td><td> </td> <td style="text-align: center">3-5 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Motor vehicles</td><td> </td> <td style="text-align: center">5 years</td></tr> </table> P3Y P5Y P5Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(n) Intangible assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s intangible assets mainly include acquired software from business acquisition and asset acquisition. In business combinations, identifiable intangible assets acquired are measured separately at their fair value as of the acquisition date. For asset acquisitions, the cost of the asset acquisition is allocated to identifiable assets acquired based on a relative fair value basis. Intangible assets with finite lives are carried at cost less accumulated amortization. All intangible assets with finite lives are amortized using the straight-line method over the estimated useful lives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets have estimated useful lives from the date of purchase as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold">Category</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Estimated useful life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="text-align: center">5-10 years</td></tr> </table> Intangible assets have estimated useful lives from the date of purchase as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold">Category</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Estimated useful life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="text-align: center">5-10 years</td></tr> </table> P5Y P10Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Impairment of Long-Lived Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates the recoverability of its long-lived assets, including property and equipment and the intangible assets and for impairment whenever events or changes in circumstances indicate that the carrying amount of its asset may not be fully recoverable. When these events occur, the Company measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the asset and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the asset, the Company recognizes an impairment loss based on the excess of the carrying amount of the asset over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the asset when the market prices are not readily available. The adjusted carrying amount of the asset is the new cost basis and is depreciated over the asset’s remaining useful life. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. No impairment of long-lived assets was recognized for the six months ended June 30, 2022 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Treasury shares</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for treasury share using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account on the unaudited condensed consolidated balance sheets. At retirement of the treasury shares, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is allocated between additional paid in capital (up to the amount credited to the additional paid in capital upon original issuance of the shares) and retained earnings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) Revenue recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group applies the ASU 2014-09, Revenue from Contracts with Customers — Topic 606 for its revenue recognition for all periods presented. The majority of the Group’s revenue comes from product sales of Asia food and consumable through its software application (“APP”). Revenue is recognized when the Group satisfies the performance obligations in an amount of consideration to which the Group expects to be entitled to in exchange for those goods. The Group evaluates the presentation of revenue on a gross or net basis based on whether it controls the goods provided to customers and is the principal (i.e., “gross”), or the Group arranges for other parties to provide the goods to the customers and is an agent (i.e., “net”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group sells food and consumable products through its own APP. The Group utilizes external delivery service providers to deliver goods to its customers. The customers pay for the goods in advance. The Group recognizes product sales made through APP on a gross basis because the Group is acting as a principal in these transactions as the Company (i) is responsible for fulfilling the promise to provide the specified goods, (ii) takes on inventory risk and (iii) has discretion in establishing price. Revenues are recognized when control is transferred, which typically happens upon delivery. The Group’s contracts with customer are primarily on a fixed-price basis. Discounts and allowances provided to customers are recognized as a reduction in net sales as control of the products is transferred to customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group generally allows customers to return non-food items within 30 days of receipt of proof that the products are unused and included in the original package. For food products, the Group does not accept returns. Customers may be qualified to receive a refund for food products received with unacceptable quality within 2 to 30 days from the date of delivery. The Group estimates returns of the products and refund, which are deducted from sales in the period in which the related revenue is recognized. The determination of the Group’s product returns and refund accruals is based on historical experience with the sales of such products. The Group estimates and adjusts these accruals at each balance sheet date in accordance with changes in these factors</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract balances</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract assets relate to the Group’s conditional right to consideration for completed performance obligations under the contract. Accounts receivable are recorded when the right to consideration becomes unconditional. The Group does not have contract assets for the periods presented. In instances where the timing of revenue recognition differs from the timing of invoicing, the Group has determined that its contracts generally do not include a significant financing component.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract liabilities represent considerations received from customers in advance of satisfying the Group’s performance obligations under the contract, which are presented in “advance from customers” in the unaudited condensed consolidated balance sheets. The Group classifies contract liabilities as current based on the timing of when we expect to recognize revenue, which typically occurs within one year. Revenue recognized that was included in contract liabilities at the beginning of the period was <span style="-sec-ix-hidden: hidden-fact-195"><span style="-sec-ix-hidden: hidden-fact-196">nil</span></span> for the six months ended June 30, 2022 and 2023, respectively. As of December 31, 2022 and June 30, 2023, contract liabilities amounted to <span style="-sec-ix-hidden: hidden-fact-197">nil</span> and RMB479 (US$66), respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Practical expedients</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has applied the following practical expedients:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction price allocated to the performance obligations that are unsatisfied, or partially unsatisfied has not been disclosed, as substantially all of the Group’s contracts have a duration of one year or less.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group recognizes incremental costs to obtain a contract as expenses when incurred because the amortization period would be one year or less. These costs are recorded within sales and marketing expenses.</span></td></tr> </table> 479000 66000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(r) Research and development expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses primarily are comprised of costs incurred in performing research and development activities, including related personnel and consultant’s compensation, benefits, share-based compensation and related materials and supplies costs. The Group expenses research and development expenses as they are incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(s) Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group adopted ASU No. 2016-02—Leases (Topic 842) as of January 1, 2022, using a modified retrospective transition method permitted under ASU No. 2018-11. This transition approach provides a method for recording existing leases only at the date of adoption and does not require previously reported balances to be adjusted. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional lease assets and lease liabilities on the consolidated balance sheets. The standard did not materially impact our unaudited condensed consolidated net earnings and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right-of-use (“ROU”) assets represent the Group’s rights to use underlying assets for the lease term and lease liabilities represent the Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term, reduced by lease incentives received, plus any initial direct costs, using the discount rate for the lease at the commencement date. As the implicit rate in lease is not readily determinable for the Group’s operating leases, the Group generally use the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The Group’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Group will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Group accounts for lease and non-lease components separately. the Group has no finance leases for any of the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the adoption of ASU No. 2016-02, leases were classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exist: (a) ownership is transferred to the lessee by the end of the lease term, (b) there is a bargain purchase option, (c) the lease term is at least 75% of the property’s estimated remaining economic life, or (d) the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an occurrence of an obligation at the inception of the lease. The Group has no capital leases for the six months ended June 30, 2022 and 2023.</p> 0.75 0.90 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(t) Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Group’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Group’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent annual period end date while the warrants are outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. All warrants outstanding as of June 30, 2023 and December 31, 2022 do not meet the definition of a liability pursuant to ASC 480 and meet all of the requirements for equity classification under ASC 815 and therefore, classified as equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(u) Share-based compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for share-based compensation in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). In accordance with ASC 718, the Group determines whether an award should be classified and accounted for as a liability award or an equity award. All the Group’s share-based awards were classified as equity awards and are recognized in the unaudited condensed consolidated financial statements based on their grant date fair values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has elected to recognize share-based compensation using the straight-line method for all share-based awards granted with graded vesting based on service conditions. The Group accounts for forfeitures as they occur in accordance with ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvement to Employee Share-based Payment Accounting. The Black-Scholes Model were applied in determining the estimated fair value of the options granted to employees and non-employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(v) Income taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group follows the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group accounted for uncertainties in income taxes in accordance with ASC 740. Interest and penalties related to unrecognized tax benefit recognized in accordance with ASC 740 are classified in the unaudited condensed consolidated statements of operations and comprehensive loss as income tax expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and 2023, the Group did not have any significant unrecognized uncertain tax positions or any unrecognized liabilities, interest or penalties associated with unrecognized tax benefits. The Group does not believe that its uncertain tax benefits position will materially change over the next twelve months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(w) Comprehensive loss</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group’s comprehensive loss includes net loss and foreign currency translation differences, and is presented in the unaudited condensed consolidated statements of operations and comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(x) Segment reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the Group discontinued CDA business, the Group operates and manages its business as a single segment and the Group’s primary revenue are generated in the U.S. The Group has only one reportable segment for the six months ended June 30, 2023, in accordance with ASC 280, Segment Reporting. The Group’s Chief Executive Officer is the chief operating decision-maker that review the unaudited condensed consolidated financial results when making decisions about allocating resources and assessing the performance of the Group as a whole.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(y) Loss per share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share is calculated in accordance with ASC 260, Earnings per Share. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the share options, using the treasury share method. Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Group’s unaudited condensed consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rights, including the liquidation and dividend rights, of the holders of our Class A and Class B ordinary shares are identical, except with respect to voting. Each Class A ordinary share is entitled to one vote; and each Class B ordinary share is entitled to ten votes and is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares are not convertible into Class B ordinary shares under any circumstances. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis. For the six months ended June 30, 2022 and 2023, the net loss per share amounts are the same for Class A and Class B common ordinary shares because the holders of each class are entitled to equal per share dividends or distributions in liquidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group did not include share options, convertible debt and warrants in the computation of diluted earnings per share for the six months ended June 30, 2022 and 2023, because those were anti-dilutive for loss per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(z) Risks, Uncertainties and Concentrations </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of credit risk</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Group to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivables. As of December 31, 2022 and June 30, 2023, the aggregate amounts of cash and cash equivalents of RMB14 and RMB62 (US$9), respectively, were held at major financial institutions located in the PRC and RMB1 and RMB268 (US$37), respectively, were deposited at banks located in U.S. and covered by the FDIC insurance program. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. There is a RMB 500,000 deposit insurance limit for a legal entity’s aggregated balance at each PRC bank.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, no customer accounted for more than 10% of total accounts receivables. As of June 30, 2023, four customers accounted for 37%, 20%, 19% and 16% of total accounts receivables. The risk is mitigated by credit evaluations the Group performs on its customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Business, customer, supplier, political and economic risks</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s e-commerce food-related business has a limited operating history. The recently acquired operations are subject to all of the risks inherent in the initial expenses, challenges, complications, and delays frequently encountered in connection with the formation of any new business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group participates in a dynamic industry and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in industry standards; changes in certain strategic relationships or customer relationships; regulatory considerations; intellectual property considerations; and risks associated with the Group’s ability to attract and retain employees necessary to support its growth.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022, no customer accounted for more than 10% of the total revenues, respectively. For the six months ended June 30, 2023, the Group had one customer that accounted for 16% of total revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022, no supplier accounted for more than for 10% of total cost of revenues. For the six months ended June 30, 2023, two suppliers that accounted for 22% and 22% of total cost of revenues, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, no supplier accounted for more than 10% of total accounts payables As of June 30, 2023, three suppliers accounted for 25%, 14%and 12% of total accounts payables, respectively.</p> 14000 62000 9000 1000 268000 37000 500000000 0.10 As of June 30, 2023, four customers accounted for 37%, 20%, 19% and 16% of total accounts receivables. The risk is mitigated by credit evaluations the Group performs on its customers. 0.10 0.16 0.10 0.22 0.22 0.10 0.25 0.14 0.12 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(aa) Recent accounting pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Group is an emerging growth company (“EGC”) as defined by the Jumpstart Our Business Startups Act (“JOBS Act”). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the <span>Group</span>. Early adoption is permitted. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the unaudited condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span>In October 2021, the FASB issued ASU No. 2021-08, “‘Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). This ASU requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments improve comparability after the business combination by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. The amendments are effective for fiscal years beginning after December 15, 2023, and are applied prospectively to business combinations that occur after the effective date. The Group does not expect the adoption of ASU 2021-04 will have a material effect on the unaudited condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the <span>Group</span> adopts as of the specified effective date. Unless otherwise discussed, the <span>Group</span> does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4. ACQUSITIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Combinations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounted the following acquisitions as business combinations in accordance with ASC 805. Acquisition-related costs incurred for the acquisitions are not material.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">GISN acquisition </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 28, 2023, the Company, through its subsidiary Fresh2, entered into a Share Purchase Agreement to acquire GISN (HK) LIMITED, a Hong Kong corporation (“GISN”). GISN and its subsidiaries provide technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Group’s efficiency in its e-commerce operations. The acquisition closed on February 1, 2023. The Company issued 8,785,530 Class A ordinary shares with fair value of RMB25,938 (US$3,848) to purchase all the issued and outstanding equity interest of GISN.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Total consideration</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">25,938</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left">Assets acquired and liabilities assumed:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accounts receivable-related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,073</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">123</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">283</p></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,573</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,233</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advance from customer</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,013</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,705</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(239</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,808</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,648</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Goodwill</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">17,290</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The intangible assets are mainly attributable to software acquired through the acquisition, which are amortized over 10 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following unaudited pro forma summary presents consolidated information of the Group as of the business combination had occurred on January 1, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Unaudited Pro Forma</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months<br/> ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-weight: bold">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,149</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,936</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net losses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,322</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(71,405</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2023, the revenue contributed by GISN was RMB677 (US$93), which was included in the Group’s consolidated statement of operation and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fresh2 acquisition </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2023, the Company, through its subsidiary Fresh2, entered into a Share Purchase Agreement (the “Ecommerce Agreement”) to acquire Fresh 2 Ecommerce Inc, a Delaware corporation (“Fresh2 Ecommerce”), from Mr. Haohan Xu, the Company’s Co-CEO and Co-Chairman of the board of directors. Fresh2 Ecommerce is a business-to-business e-commerce platform focused on connecting Asian food suppliers and restaurants well as other retail customers in the U.S. Fresh2 Ecommerce provides an online direct selling platform for food suppliers such as food companies, manufacturers, agents, importers, and wholesalers to restaurants and other retail customers. The acquisition was closed on February 8, 2023. The Company issued 5,440,420 Class A ordinary shares with fair value of RMB17,304 (US$2,549) to acquire all the issued and outstanding equity interests in Fresh2 Ecommerce.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Total consideration</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">17,304</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left">Assets acquired and liabilities assumed:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accounts payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(950</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Goodwill</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">17,317</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the goodwill is expected to be deductible for income tax purposes. For the six months ended June 30, 2023, Fresh2 Ecommerce contributed revenue of 199 and loss of 86 to the group from February 8, 2023 to June 30, 2023. Pro forma results reflecting this transaction were not presented because it is not significant to the Group’s consolidated financial results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Asset acquisition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2023, the Group closed an asset purchase with Easy Hundred Inc. (“Easy Hundred”), a U.S.-based e-commerce startup company in the foodservice industry. Pursuant to the Asset Purchase Agreement (the “EZ Agreement”), the Group acquired certain fixed assets of Easy Hundred and Easy Hundred’s intellectual property relating to ez100, 2Supply and 100WAY systems with total consideration consisting of RMB5,013(US$730) in cash and 17,665,702 Class A ordinary shares of the Company. The fair value of the shares issued was RMB25,720 (US$3,745).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the fair value of the identifiable assets:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Property and equipment- furniture, fixtures and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">160</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Property and equipment- motor vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Intangible assets- software*</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">30,733</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Intangible assets refer to intellectual property relating to ez100, 2Supply and 100WAY systems.</td> </tr></table> 8785530 25938000 3848000 The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Total consideration</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">25,938</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left">Assets acquired and liabilities assumed:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accounts receivable-related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,073</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">123</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">283</p></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,573</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,233</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advance from customer</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,013</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,705</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(239</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,808</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,648</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Goodwill</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">17,290</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>The following table summarizes the fair value of the identifiable assets acquired and liabilities assumed for the combined entities at the acquisition date, which represents the net purchase price allocation at the date of the acquisition based on a valuation performed by an independent valuation firm engaged by the Group:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Total consideration</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">17,304</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; text-align: left">Assets acquired and liabilities assumed:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accounts payables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(950</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Goodwill</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">17,317</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 25938000 1028000 100000 12073000 123000 283000 1573000 11233000 -1013000 13705000 239000 2808000 8648000 17290000 P10Y The following unaudited pro forma summary presents consolidated information of the Group as of the business combination had occurred on January 1, 2022.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Unaudited Pro Forma</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months<br/> ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-weight: bold">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,149</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,936</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net losses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,322</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(71,405</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> </table> 10149000 4936000 51322000 -71405000 677000 93000 5440420 17304000 2549000 17304000 71000 938000 950000 72000 -13000 17317000 199000 86000 5013000 730000 17665702 25720000 3745000 The following table summarizes the fair value of the identifiable assets:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Property and equipment- furniture, fixtures and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">160</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Property and equipment- motor vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Intangible assets- software*</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">30,733</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Intangible assets refer to intellectual property relating to ez100, 2Supply and 100WAY systems.</td> </tr></table> 160000 434000 30139000 30733000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. DISCONTINUED OPERATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July, 2023, the Board approved the sale of its early cancer screening and detection business (the “CDA Business”), comprised of (i) AnPac Bio-Medical Technology (Lishui) Co., Ltd. (“AnPac Lishui”), a subsidiary based in Lishui, China, (ii) Anpac Technology USA CO., LTD. (“AnPac USA”), a subsidiary based in Pennsylvania and California, and (iii) Changhe Bio-Medical Technology (Yangzhou) Co., Ltd.(“Changhe”), a subsidiary based in Yangzhou, China. Accordingly, on July 28, 2023, the Group entered into Share purchase agreements with New-Horizon Bio-Medical Science Co., Ltd. (“New-Horizon”), a Hong Kong company focused on bio-medical technology, under which the Group agreed to sell 100% of the shares of AnPac Lishui and AnPac USA, which had experienced significant financial losses in its operations and are not expected to achieve a breakeven point in the immediate future, to New-Horizon in consideration of <span style="-sec-ix-hidden: hidden-fact-205">nil</span> and <span style="-sec-ix-hidden: hidden-fact-206">nil</span>, respectively. In addition, on July 28, 2023, the Group entered into a share purchase agreement with Ningkasai Technology (Shanghai) Co., Ltd. (“Ningkasai”), a PRC high-tech company specialized in nanotechnologies for life science applications, under which the Group agreed to sell 100% of the shares of Changhe, to Ningkasai for no consideration. The closing is expected to take place in November 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group determined that the disposal of CDA Business met the criteria to be classified as a discontinued operation and, as a result, CDA business’s historical financial results are reflected in the Group’s unaudited condensed consolidated financial statements as a discontinued operation. The disposal of CDA Business represents a strategic shift that has a significant effect on the Group’s operations and financial results, which trigger discontinued operations accounting in accordance with ASC 205-20-45. The assets and liabilities related to the discontinued operations were retroactively classified as assets/liabilities held for sale, while results of operations related to the discontinued operations, including comparatives, were retroactively reported as income (loss) from discontinued operations for the six months ended June 30, 2022 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the disposal of CDA business, the Group also sold its 70% equity interest in Changwei System Technology (Shanghai) Co., Ltd (“Changwei”) to Jiaxing Changxin Enterprise Management, LLP (“Changxin”) in consideration of US$350 (RMB2,538) and sold the remaining 29% equity interest in Changwei to Shanghai Yiyou Investment Management Co., LTD (“Yiyou”) in consideration of US$150 (RMB1,088). Yiyou further entered into an arrangement with Changxin and Ms. Ruoou Ying, pursuant to which the Group agreed to transfer 29% of Changwei’s shares to Changxin and 1% of the shares to Ms. Ruoou Ying (the “Changwei disposal”). The Group received the consideration in aggregated of RMB3,626 (US$500) from the Changwei disposal. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company. Loss from disposal of Changwei amounted to RMB16,724 (US$2,307) and was included in net loss from discontinued operations. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of discontinued operations for the six months ended June 30, 2022 and 2023 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Revenues:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 64%; text-align: left">Revenues-third parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,972</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">405</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Revenues-related parties</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total revenues</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">5,213</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,832</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,381</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,736</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">240</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Selling and marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,894</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,872</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(534</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">General and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,629</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,593</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,185</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,330</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,438</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(474</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Impairment of intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,911</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Impairment of goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,758</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Loss from operations</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(42,141</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(14,167</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,953</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-operating income and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Interest expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(161</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Foreign exchange gain, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Share of net loss in equity method investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(87</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(88</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,106</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">428</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Loss from operations for discontinued operations</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(41,910</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(11,221</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,547</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss from disposal of a subsidiary</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,724</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,307</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Loss from discontinued operations before income taxes</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(41,910</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(27,945</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(3,854</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income tax benefit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,130</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss from discontinued operations</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(39,780</td><td style="padding-bottom: 2pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(27,945</td><td style="padding-bottom: 2pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(3,854</td><td style="padding-bottom: 2pt; font-weight: bold; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities of the discontinued operations:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">ASSETS</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Current assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,854</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">319</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Prepayment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,692</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accounts receivable, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">458</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Amounts due from related parties, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,194</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Inventories, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other current assets, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,448</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total current assets held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,348</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,746</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,171</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Land use rights, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,097</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,213</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term investments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,079</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">991</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total noncurrent assets held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,770</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,193</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,785</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL ASSETS HELD FOR SALE</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,403</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,970</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,133</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">LIABILITIES</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Short-term debts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">690</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,012</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">277</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Advance from customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,956</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Amounts due to related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,280</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,079</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Lease liability-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,488</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,273</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total current liabilities held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,609</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Lease liability-non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,515</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other long-term liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,080</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">147</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total noncurrent liabilities held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,595</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,434</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">336</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES HELD FOR SALE</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,109</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,855</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,945</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 1 1 In connection with the disposal of CDA business, the Group also sold its 70% equity interest in Changwei System Technology (Shanghai) Co., Ltd (“Changwei”) to Jiaxing Changxin Enterprise Management, LLP (“Changxin”) in consideration of US$350 (RMB2,538) and sold the remaining 29% equity interest in Changwei to Shanghai Yiyou Investment Management Co., LTD (“Yiyou”) in consideration of US$150 (RMB1,088). Yiyou further entered into an arrangement with Changxin and Ms. Ruoou Ying, pursuant to which the Group agreed to transfer 29% of Changwei’s shares to Changxin and 1% of the shares to Ms. Ruoou Ying (the “Changwei disposal”). The Group received the consideration in aggregated of RMB3,626 (US$500) from the Changwei disposal. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company. Loss from disposal of Changwei amounted to RMB16,724 (US$2,307) and was included in net loss from discontinued operations. This transaction was a sale to related parties. Ms. Ruoou Ying held the position of Supervisor at Anpac Lishui, while Changxin was under the common control of Ms. Ruoou Ying and Mr. Chris Yu, the Co-Founder and Co-Chairman of the Company. The results of discontinued operations for the six months ended June 30, 2022 and 2023 were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Revenues:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 64%; text-align: left">Revenues-third parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,972</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">405</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Revenues-related parties</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total revenues</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">5,213</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,832</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,381</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,736</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">240</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0in; text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Selling and marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,894</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,872</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(534</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">General and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,629</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,593</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,185</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,330</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,438</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(474</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Impairment of intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,911</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Impairment of goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,758</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Loss from operations</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(42,141</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(14,167</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,953</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-operating income and expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Interest expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(161</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Foreign exchange gain, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Share of net loss in equity method investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(87</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(88</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,106</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">428</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Loss from operations for discontinued operations</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(41,910</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(11,221</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,547</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss from disposal of a subsidiary</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,724</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,307</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Loss from discontinued operations before income taxes</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(41,910</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(27,945</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(3,854</td><td style="font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income tax benefit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,130</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss from discontinued operations</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(39,780</td><td style="padding-bottom: 2pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(27,945</td><td style="padding-bottom: 2pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(3,854</td><td style="padding-bottom: 2pt; font-weight: bold; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 3972000 2937000 405000 1241000 91000 13000 5213000 3028000 418000 1832000 1292000 178000 3381000 1736000 240000 4894000 3872000 534000 15629000 8593000 1185000 4330000 3438000 474000 7911000 12758000 42141000 14167000 1953000 161000 81000 11000 7000 9000 1000 -87000 -88000 -12000 472000 3106000 428000 -41910000 -11221000 -1547000 -16724000 -2307000 -41910000 -27945000 -3854000 -2130000 -39780000 -27945000 -3854000 Assets and liabilities of the discontinued operations:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">ASSETS</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Current assets:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,854</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">319</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Prepayment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,692</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accounts receivable, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">458</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Amounts due from related parties, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,194</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Inventories, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other current assets, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,448</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,944</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total current assets held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,348</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,746</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,171</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Land use rights, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,097</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,213</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term investments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,079</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">991</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total noncurrent assets held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,770</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,193</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,785</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL ASSETS HELD FOR SALE</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,403</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,970</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,133</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">LIABILITIES</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Short-term debts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">690</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,012</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">277</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Advance from customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,956</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Amounts due to related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,280</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,079</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">149</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Lease liability-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,488</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,273</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total current liabilities held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,609</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Lease liability-non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,515</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other long-term liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,080</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,066</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">147</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total noncurrent liabilities held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,595</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,434</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">336</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES HELD FOR SALE</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,109</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,855</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,945</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 1854000 319000 44000 2692000 1334000 184000 2235000 3318000 458000 2194000 684000 94000 210000 178000 25000 3448000 3944000 543000 12633000 9777000 1348000 17182000 15746000 2171000 1111000 1097000 151000 185000 271000 37000 7213000 2088000 288000 1079000 991000 138000 26770000 20193000 2785000 39403000 29970000 4133000 5000000 5000000 690000 2108000 2012000 277000 4956000 7800000 1076000 2280000 1079000 149000 784000 1042000 144000 18386000 16488000 2273000 33514000 33421000 4609000 6515000 1368000 189000 1080000 1066000 147000 7595000 2434000 336000 41109000 35855000 4945000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. ACCOUNTS RECEIVABLE, NET</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable as of December 31, 2022 and June 30, 2023 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Balance at end of year</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">270</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">37</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Accounts receivable as of December 31, 2022 and June 30, 2023 were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Balance at end of year</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">270</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">37</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 270000 37000 270000 37000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. OTHER CURRENT ASSETS, NET </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other current assets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Deposits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">154</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Receivable from private placement investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Loan to third-parties</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">422</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">444</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">422</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(422</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(444</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Other current assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">414</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">57</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Other current assets consist of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Deposits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">154</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Receivable from private placement investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Loan to third-parties</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">422</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">444</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">422</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(422</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(444</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Other current assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">414</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">57</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 154000 21000 260000 36000 422000 444000 61000 422000 858000 118000 422000 444000 61000 414000 57000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. PROPERTY AND EQUIPMENT, NET</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment, net consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Furniture, fixtures and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,255</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicles</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">277</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">725</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(953</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(131</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,309</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">594</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was <span style="-sec-ix-hidden: hidden-fact-220">nil</span> and RMB449 (US$62) for the six months ended June 30, 2022 and June 30, 2023, respectively. No impairment charges were recognized on the property and equipment for the six months ended June 30, 2022 and 2023.</p> Property and equipment, net consists of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Furniture, fixtures and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,255</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicles</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">277</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">725</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(953</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(131</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,309</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">594</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 3255000 448000 2007000 277000 5262000 725000 953000 131000 4309000 594000 449000 62000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. INTANGIBLE ASSETS, NET</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intangible assets, net consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; padding-bottom: 1.5pt">Software</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">47,798</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,592</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,798</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,592</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,629</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">45,169</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,229</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense for six months ended June 30, 2022 and 2023 amounted to <span style="-sec-ix-hidden: hidden-fact-225">nil</span> and RMB2,511 (US$346), respectively. The estimated aggregate amortization expense for each of the five succeeding years is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Twelve months ending June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">RMB</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,351</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,226</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,539</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">45,169</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Intangible assets, net consist of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; padding-bottom: 1.5pt">Software</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">47,798</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">6,592</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,798</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,592</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,629</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">45,169</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,229</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 47798000 6592000 47798000 6592000 2629000 363000 45169000 6229000 Amortization expense for six months ended June 30, 2022 and 2023 amounted to <span style="-sec-ix-hidden: hidden-fact-225">nil</span> and RMB2,511 (US$346), respectively. The estimated aggregate amortization expense for each of the five succeeding years is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Twelve months ending June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">RMB</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,351</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,351</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,226</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,539</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">45,169</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 2511000 346000 P5Y 8351000 8351000 8351000 8351000 6226000 5539000 45169000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. LONG-TERM INVESTMENTS, NET</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Long-term investments, net consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Equity method investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advanced Life Therapeutics Co., Ltd. (“Advanced Life”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Nassau Enterprises LLC (“Nassau”).</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">39,783</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,486</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,486</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Less: Impairment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Long-term investments, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">39,783</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,486</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity method investments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Advanced Life</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 15, 2021, the Company and other third parties established Advanced Life Therapeutics Co., Ltd. (“Advanced Life”), of which the Company owned a 40% equity interest in its registered capital. The Company has not made any capital contribution as yet because Advanced Life has not commenced its intended operations. The Group accounts for Advanced Life as long-term investment under the equity method, there’s no carrying value of this investment. Subsequently, the Board has approved the disposition of the 40% of equity interest in Advanced Life to a company controlled by Mr. Chris Yu at a nominal price on October 18, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Nassau</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2023, the Company, through its subsidiary Foodbase Group Inc. (“Foodbase”), entered into a purchase agreement (the “Nassau Investment Agreement”) with Mr. Haohan Xu (“Mr. Xu”), the CEO of the Company, and Nassau Enterprises LLC, a Delaware limited liability company that was established to engage in real estate development (“Nassau”). Mr. Xu was the sole shareholder and CEO of Nassau prior to the Company’s investment. The Group’s investment in Nassau consisted of a capital injection of RMB39,882 (US$5,500) and a nominal payment to Mr. Xu to acquire 19.64% of the equity interests in Nassau. The transaction closed on May 24, 2023. After the closing, Mr. Xu holds 8,036 voting units in Nassau, representing 80.36% of the outstanding equity interests in Nassau. <span>The Group can exercise significant influence on the management and operation of </span>Nassau<span>. The Group accounts for its investment in </span>Nassau <span>as long-term investment under the equity method. </span>Nassau through its subsidiary intends to develop, market and sell real estate in Savannah Lakes Village (“SLV Project”) and to utilize an EB-5 program to finance the development of the SLV Project, which is expected to provide alternative financing for the Company’s growth.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group recorded its share of loss in this investment of RMB95 (US$13) for the six months ended June 30, 2023.</p> Long-term investments, net consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Equity method investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Advanced Life Therapeutics Co., Ltd. (“Advanced Life”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Nassau Enterprises LLC (“Nassau”).</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">39,783</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,486</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,486</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Less: Impairment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Long-term investments, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">39,783</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,486</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 39783000 5486000 39783000 5486000 39783000 5486000 0.40 0.40 39882 5500 0.1964 Mr. Xu holds 8,036 voting units in Nassau 0.8036 95000 13 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. SHORT-TERM DEBTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Convertible loan (“CL”) <sup>(i)</sup></td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">15</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">16</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were originally due in one year and bear interest of 0% per annum if the conversion feature is not triggered. Pursuant to the agreement, the conversion price is lower of (i) US$15 or (ii) the lower of 82% of the closing bid price or 80% of VWAP of the Company’s ADSs during the ten consecutive trading days immediately preceding conversion, but not lower than a Floor Price of US$1 (the “floor price”). Due to significant drop of the ADS market price in 2022, the debenture holders and the Company renegotiated the Floor Price. On February 5, 2022, the Company entered into an amendment agreement, pursuant to which the Floor Price was reduced to US$0.10 per Class A Ordinary Share. The Company has elected to recognize the Convertible Debentures at fair value and therefore there was no further evaluation of embedded features for bifurcation. The Convertible Debentures were partially converted into 114,234 shares on December 10, 2021. The fair value of the Convertible Debentures loan immediately prior to conversion was assessed at RMB1,321. Substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares (refer to Note 14) on March 16, 2022. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and 2023, the Company recognized change in fair value of the Convertible Debenture of RMB139 and <span style="-sec-ix-hidden: hidden-fact-235">nil</span>, respectively.</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Convertible loan (“CL”) <sup>(i)</sup></td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">15</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">16</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were originally due in one year and bear interest of 0% per annum if the conversion feature is not triggered. Pursuant to the agreement, the conversion price is lower of (i) US$15 or (ii) the lower of 82% of the closing bid price or 80% of VWAP of the Company’s ADSs during the ten consecutive trading days immediately preceding conversion, but not lower than a Floor Price of US$1 (the “floor price”). Due to significant drop of the ADS market price in 2022, the debenture holders and the Company renegotiated the Floor Price. On February 5, 2022, the Company entered into an amendment agreement, pursuant to which the Floor Price was reduced to US$0.10 per Class A Ordinary Share. The Company has elected to recognize the Convertible Debentures at fair value and therefore there was no further evaluation of embedded features for bifurcation. The Convertible Debentures were partially converted into 114,234 shares on December 10, 2021. The fair value of the Convertible Debentures loan immediately prior to conversion was assessed at RMB1,321. Substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares (refer to Note 14) on March 16, 2022. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).</td> </tr></table> 15000 16000 2000 15000 16000 2000 3014000 20788000 2740000 18898000 0 15000 0.82 0.80 10 1000 0.1 114234 1321000 4842197 22237000 16000 2000 139000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. LEASES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has several operating leases for offices. The Group’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective on January 1, 2022, the Group adopted the new lease accounting standard using a modified retrospective transition method which allowed the Group not to recast comparative periods presented in its consolidated financial statements. In addition, the Group elected the package of practical expedients, which allowed the Group to not reassess whether any existing contracts contain a lease, to not reassess historical lease classification as operating or finance leases, and to not reassess initial direct costs. The Group has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. The Group combines the lease and non-lease components in determining the ROU assets and related lease obligation. Adoption of this standard resulted in the recording of operating lease ROU assets and corresponding operating lease liabilities as disclosed below and had no impact on accumulated deficit as of January 1, 2022. ROU assets and related lease obligations are recognized at commencement date based on the present value of remaining lease payments over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental balance sheet information related to operating leases was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Right-of-use assets, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">223</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liabilities - current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities - non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">25</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of June 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Weighted average remaining lease term (years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a schedule of maturities of lease liabilities are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Twelve months ending June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">RMB</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">187</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Supplemental balance sheet information related to operating leases was as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Right-of-use assets, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">223</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liabilities - current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities - non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">25</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 223000 31000 148000 20000 37000 5000 185000 25000 The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of June 30, 2023:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Weighted average remaining lease term (years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.51</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table> P1Y6M3D 0.0475 The following is a schedule of maturities of lease liabilities are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Twelve months ending June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">RMB</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">187</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 150000 37000 187000 2000 185000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Salary and welfare payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,740</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9,312</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,283</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,249</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payable for property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,089</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">564</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7,535</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">24,759</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,414</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup>:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accrued expenses mainly consist of accrued professional fees.</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Salary and welfare payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,740</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9,312</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,283</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,249</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payable for property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,089</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">564</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7,535</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">24,759</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,414</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup>:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accrued expenses mainly consist of accrued professional fees.</span></td> </tr></table> 1740000 9312000 1283000 5762000 9057000 1249000 2301000 318000 33000 4089000 564000 7535000 24759000 3414000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. SHAREHOLDERS’ EQUITY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Ordinary Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 14, 2022, the Company amended and restated its memorandum and articles of association to increase the maximum number of authorized shares to 150,000,000 shares divided into 120,000,000 class A ordinary shares with a par value of US$0.01 each and 30,000,000 class B ordinary shares with a par value of US$0.01 each.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 14, 2023, the Company amended and restated its memorandum and articles of association to increase the maximum number of authorized shares from 150,000,000 shares to 2,430,000,000 shares divided into 2,400,000,000 Class A Ordinary Shares with a par value of US$0.01 each and 30,000,000 Class B Ordinary Shares with a par value of US$0.01 each.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and June 30, 2023, 79,536,589 and 176,070,465 Class A ordinary shares were issued and outstanding, respectively. As of December 31, 2022 and June 30, 2023, 3,573,100 and 3,573,100 Class B ordinary shares were issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Completion of IPO</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 30, 2020, the Company completed its IPO on the Nasdaq Share Exchange. In November 2022, the Company adopted an ordinary share / ADS ratio change from one (1) Class ‘A’ ordinary share being equal to one (1) ADS to 20 Class ‘A’ ordinary shares being equal to one (1) ADS).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Conversion of convertible loans </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 22, 2021, the Company issued convertible debentures (the “Convertible Debentures”) to certain investors in a registered direct offering in an aggregate principal amount of US$3,014 (RMB20,788) for the discounted price of US$2,740 (RMB18,898). The Convertible Debentures were partially converted into 114,234 Class ‘A’ ordinary shares on December 10, 2021. On March 16, 2022, substantially all of the remaining outstanding Convertible Debentures were converted into 4,842,197 Class A ordinary shares. The fair value of the Convertible Debentures on March 16, 2022 immediately prior to conversion was assessed at RMB22,237. As of June 30, 2023, the fair value of the outstanding balance of the Convertible Debentures was RMB16 (US$2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 31, 2021, the Company issued a convertible note in the principal amount of RMB4,479 to Ascent Investor Relations Inc., (“Ascent”) for public relations services rendered. The convertible note was fully converted into 3,232,397 Class A ordinary shares with conversion prices ranging from US$0.16-0.33 per share by April 27, 2022. The fair value of the convertible note immediately prior to conversion was assessed at RMB5,502.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shares issued for services </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2022, the Company entered into a service agreement with a public relations firm. Pursuant to the service agreement, the Group was required to pay US$50 as compensation for the public relations services. On June 10, 2022, the Company issued 187,094 class A ordinary shares for the services. The fair value of the PR services was RMB359 (US$54) determined based on the Company’s ADS market price on June 10, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2022, the Company granted 140,000 class A ordinary shares to two employees as bonuses that vested immediately upon grant. On September 16, 2022, the Company issued the 140,000 class A ordinary shares. The fair value of the bonuses was RMB1,341 (US$195) determined based on the Company’s ADS market price on August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2023, the Company entered into a service agreement with a finance service firm, Pursuant to the service agreement, the Company was required to pay 3,500,000 Class A ordinary shares for the service. On May 11, 2023, the Company issued 3,500,000 Class A ordinary shares to the finance service firm. The fair value of the services was RMB6,385 (US$919) determined based on the Company’s ADS market price on May 11, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shares issued for reserve</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Group had 1,322,853 Class A ordinary shares held in an escrow account as reserve solely for potential convertible loans conversion. During the six months ended June 30, 2023, of 22,000,000 Class A ordinary shares issued in a private placement on June 9, 2023, 2,500,000 class A ordinary shares were subsequently recalled and cancelled on October 30, 2023 due to the inability to timely collect the funds from the investor. Such 2,500,000 class A ordinary shares were included as the shares held as a reserve and not included in the calculation of loss per share. As of June 30, 2023, 3,822,853 Class A ordinary shares were held in an escrow account as a reserve.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Private placements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2022, the Company entered into a share subscription agreement with a third-party investor, pursuant to which the Company issued 1,235,788 Class A ordinary shares at price of US$0.2563 per share to the investor (the “March 16, 2022 private placement”). In addition, the Company also issued pre-funded warrants to purchase an aggregate of 4,226,135 of Class A ordinary shares for US$0.2563 per share to the investor, equal to the exercise price minus US$0.00001 for the pre-funded warrants. Total gross proceeds of RMB9,395 (US$1,400) was received on May 19, 2022. 2,584,900 pre-funded warrants were exercised during the six months ended June 30, 2023; the remaining pre-funded warrants were exercised on July 13, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2022, the Company entered into a share subscription agreement with a third-party Chinese investor, pursuant to which the Company issued 654,622 Class A ordinary shares at price of US$0.35 to the investor and received gross proceeds of RMB1,500 (US$232) on March 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2022, the Company entered into investment agreements with nine third-party investors. The investors agreed to invest up to RMB20,094 (US$3,000) to purchase Class A ordinary shares, at a purchase price of the lower of (i) $0.30 per ADS (the equivalent of 1 Class A ordinary share) and (ii) 80% of the average ten-day trading closing price of the ADSs (the equivalent of 1 Class A ordinary share) for the ten consecutive day trading period ended on the date of investment agreement. On May 27, 2022 and May 30, 2022, the Company issued 6,229,235 and 6,263,048 Class A ordinary shares to the investors, respectively. In addition, warrants to purchase (i) an aggregate of 3,000,000 Class A ordinary shares for US$0.4 per share, (ii) an aggregate of 1,200,000 Class A ordinary shares for US$0.75 per share (ADS), and (iii) an aggregate of 750,000 Class A ordinary shares (ADS) for US$1.2 per share were issued to the investors. No warrants were excised during the year ended December 31, 2022. On September 2, 2022, three of the investors in the Company’s May 2022 private placements filed an action against the Company in the State of Delaware Court of Chancery captioned Chen Wenge, et al. v. Fresh2 Group Limited, C.A. No. 2022-0779-PAF. The Plaintiffs sued the Company for breaches of the investment agreements. The plaintiffs claimed that the entry into certain investment agreements and a merger agreement breached or would breach the terms of the plaintiffs’ (and several other investors’) securities purchase agreements, including a right of first refusal and a prohibition against certain acquisitions and changes of business. The Court issued a temporary restraining order concerning enforcement of the private placements on September 3, 2022, amended the temporary restraining order on September 9, 2022, and further amended the temporary restraining order on September 23, 2022 (“TRO”). In order to settle the litigation, the Company entered into a share repurchase agreement with the three plaintiffs, and all the other investors in the May 2022 private placements on October 15, 2022. The Company agreed to repurchase 12,492,283 Class A ordinary shares and warrants to purchase a total of 2,475,000 Class A ordinary shares from the nine investors for total consideration of RMB11,003(US$1,507). The Company fully settled the litigation on October 27, 2022. In connection with the settlement, Yuyang Cui and Jiawen Kang resigned from our board of directors of the Company and Yuyang Cui resigned as Co-CEO of the Company. The repurchased warrants were canceled and the repurchased Class A ordinary shares are treated a treasury shares as of December 31, 2022. The treasury shares were canceled on January 19, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2022, the Company entered into investment agreements with three third-party investors (the “September 2, 2022 private placement”). The investors agreed to purchase an aggregate of 5,000,000 Class A ordinary shares at price of US$0.1 per share and warrants to purchase an aggregate of 5,000,000 Class A ordinary shares at an exercise price of US$0.4 per share for RMB3,613. The warrants are exercisable within 2 years from the date of issuance. Total gross proceeds of RMB3,613 was received in September, 2022. No warrants were excised during the year ended December 31, 2022 and six months ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2022, the Company entered into investment agreements with nine third-party investors, pursuant to which the Company issued 36,729,613 Class A ordinary Shares at price of US$0.10 per share to the investors and received gross proceeds of RMB26,410 (US$3,660) during the period October 2022 to November 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2022 and March 2023, the Company signed investment agreements with several third-party investors (the “March 2023 private placement”) to sell 30,885,707 Class A ordinary shares of the Company at a price of US$0.175 per share for a total purchase price of US$5,405. Proceeds of RMB36,608 (US$5,369) were received by June 30, 2023 and the remaining balance subsequently was received on August 10, 2023. For each Class A ordinary share purchased, the investors received two warrants with each warrant to purchase one Class A ordinary share at an exercise price of US$0.21 per share. The warrants are exercisable within 2 years from the date of issuance. No warrants were exercised during the six months ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2023, the Company closed a registered direct offering (the “April 2023 private placement”), the Company sold to the institutional investors a total of 12,500,000 Class A ordinary shares priced at $0.2 per ordinary share, pre-funded warrants exercisable for 2,500,000 Class A ordinary shares and warrants exercisable for 15,000,000 Class A ordinary shares. The purchase price of each pre-funded warrant is equal to the offering price per Class A ordinary shares, minus $0.00005, and the exercise price of each pre-funded warrant is equal $0.00005 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The warrants are immediately exercisable and expire five (5) years from the original issuance date and have an exercise price of $0.2 per Class A ordinary shares. The Company also issued to Univest Securities, LLC, which acted as the sole placement agent for the offering, warrants exercisable for 750,000 Class A ordinary shares, with an exercise price of $0.24 per share. The net proceeds to the Company from the registered direct offering were RMB17,238 (US$2,510) after deducting the placement agent’s fees and other offering expenses. No pre-funded warrants were exercised during the six months ended June 30, 2023, and 5,000,000 warrants were exercised with proceeds of RMB6,911(US$1,000) during the six months ended June 30, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 2, 2023, the Company entered into an agreement with an investor, under which the investor agreed to purchase 22,000,000 Class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares at an aggregate purchase price of US$4,400 (the “June 2023 private placement”). The warrants are exercisable within 2 years from the date of issuance and have an exercise price of US$0.21 per share. On June 9, 2023, the Company issued 22,000,000 Class A ordinary shares to the investor, proceeds of RMB27,797 (US$3,900) were received by June 30, 2023. Due to inability to timely collect the remaining proceeds of RMB3,564(US$500) from the investor, the corresponding 2,500,000 shares was recalled and cancelled on October 30, 2023, subsequently. No warrants were exercised during the six months ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shares issued for acquisitions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the GISN acquisition on February 1, 2023, the Company issued 8,785,530 Class A shares to the original shareholders of GISN as consideration of 100% equity interest. The fair value of the shares issued amounted to RMB25,938(US$3,848).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection of the Fresh2 acquisition on February 8, 2023, the Company issued 5,440,420 Class A shares to the original shareholders of Fresh ecommerce as consideration of 100% equity interest. The fair value of the shares issued amounted to RMB17,304(US$2,549).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection of the assets acquisition from Easy Hundred on March 31, 2023, the Company issued 17,665,702 Class A shares to Easy Hundred as consideration. The fair value of the shares issued amounted to RMB25,720(US$3,745).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, there were 103,702,658 warrants outstanding. A summary of warrants activity for the six months ended June 30 2023 was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-align: left; padding-left: 0.125in"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price per<br/> share</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted </td><td style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-align: left; padding-left: 0.125in"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>warrants</b></p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$ per<br/> share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">average life<br/> Years</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Expiration</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>dates </b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 38%; text-align: left; padding-bottom: 1.5pt">Balance of warrants outstanding and exercisable as of December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9,266,135</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.24</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; white-space: nowrap; width: 18%; text-align: center; padding-bottom: 1.5pt">1.85 to unlimited</td><td style="text-align: center; white-space: nowrap; width: 1%; padding-bottom: 1.5pt; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; width: 18%; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-hidden: hidden-fact-241">August 31, 2024 to unlimited</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">—warrants issued in connection with the March 2023 private placement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61,771,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.21</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">1.58 to 1.96</td><td style="text-align: center; white-space: nowrap; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">February 3, 2025 to June 16, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">—warrants issued in connection with the April 2023 private placement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00001-0.24</span></td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">1.75 to Unlimited</td><td style="text-align: center; white-space: nowrap; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">March 31, 2025 to unlimited</td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">—warrants issued in connection with the June 2023 private placement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.21</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">1.95</td><td style="text-align: center; white-space: nowrap; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">June 9, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,584,900</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00001-0.2</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Balance of warrants outstanding and exercisable as of June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,702,658</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt">1.96 to unlimited</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt">August 31, 2024 to unlimited</td></tr> </table> 150000000 120000000 0.01 30000000 0.01 150000000 2430000000 2400000000 0.01 30000000 0.01 79536589 176070465 3573100 3573100 3014000 20788000 2740000 18898000 114234 4842197 22237000 16000 2000 4479000 3232397 160 0.33 5502000 50000 187094 359000 54000 140000 140000 1341000 195000 3500000 3500000 6385000 919000 1322853 22000000 2500000 2500000 3822853 1235788 0.2563 4226135 0.2563 0.01000 9395000 1400000 2584900 654622 0.35 1500000 232000 20094000 3000000 0.3 0.80 6229235 6263048 3000000 0.4 1200000 0.75 750000 1.2 12492283 2475000 11003000 1507000 5000000 0.1 5000000 0.4 3613000 P2Y 3613000 36729613 0.1 26410000 3660000 30885707 175 5405000 36608 5369 1 0.21 P2Y On April 6, 2023, the Company closed a registered direct offering (the “April 2023 private placement”), the Company sold to the institutional investors a total of 12,500,000 Class A ordinary shares priced at $0.2 per ordinary share, pre-funded warrants exercisable for 2,500,000 Class A ordinary shares and warrants exercisable for 15,000,000 Class A ordinary shares. The purchase price of each pre-funded warrant is equal to the offering price per Class A ordinary shares, minus $0.00005, and the exercise price of each pre-funded warrant is equal $0.00005 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The warrants are immediately exercisable and expire five (5) years from the original issuance date and have an exercise price of $0.2 per Class A ordinary shares. The Company also issued to Univest Securities, LLC, which acted as the sole placement agent for the offering, warrants exercisable for 750,000 Class A ordinary shares, with an exercise price of $0.24 per share. The net proceeds to the Company from the registered direct offering were RMB17,238 (US$2,510) after deducting the placement agent’s fees and other offering expenses. No pre-funded warrants were exercised during the six months ended June 30, 2023, and 5,000,000 warrants were exercised with proceeds of RMB6,911(US$1,000) during the six months ended June 30, 2023. On June 2, 2023, the Company entered into an agreement with an investor, under which the investor agreed to purchase 22,000,000 Class A ordinary shares and warrants to purchase 22,000,000 Class A ordinary shares at an aggregate purchase price of US$4,400 (the “June 2023 private placement”). The warrants are exercisable within 2 years from the date of issuance and have an exercise price of US$0.21 per share. On June 9, 2023, the Company issued 22,000,000 Class A ordinary shares to the investor, proceeds of RMB27,797 (US$3,900) were received by June 30, 2023. Due to inability to timely collect the remaining proceeds of RMB3,564(US$500) from the investor, the corresponding 2,500,000 shares was recalled and cancelled on October 30, 2023, subsequently. No warrants were exercised during the six months ended June 30, 2023. 8785530 1 25938 3848 5440420 1 17304 2549 17665702 25720 3745 As of June 30, 2023, there were 103,702,658 warrants outstanding. A summary of warrants activity for the six months ended June 30 2023 was as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-align: left; padding-left: 0.125in"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted<br/> average<br/> exercise<br/> price per<br/> share</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Weighted </td><td style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-align: left; padding-left: 0.125in"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>warrants</b></p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$ per<br/> share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">average life<br/> Years</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Expiration</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>dates </b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 38%; text-align: left; padding-bottom: 1.5pt">Balance of warrants outstanding and exercisable as of December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9,266,135</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.24</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; white-space: nowrap; width: 18%; text-align: center; padding-bottom: 1.5pt">1.85 to unlimited</td><td style="text-align: center; white-space: nowrap; width: 1%; padding-bottom: 1.5pt; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; width: 18%; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-hidden: hidden-fact-241">August 31, 2024 to unlimited</span></td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">—warrants issued in connection with the March 2023 private placement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61,771,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.21</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">1.58 to 1.96</td><td style="text-align: center; white-space: nowrap; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">February 3, 2025 to June 16, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">—warrants issued in connection with the April 2023 private placement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00001-0.24</span></td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">1.75 to Unlimited</td><td style="text-align: center; white-space: nowrap; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">March 31, 2025 to unlimited</td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">—warrants issued in connection with the June 2023 private placement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.21</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">1.95</td><td style="text-align: center; white-space: nowrap; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center">June 9, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,584,900</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00001-0.2</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; "> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Balance of warrants outstanding and exercisable as of June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,702,658</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt">1.96 to unlimited</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; vertical-align: top"> </td> <td style="vertical-align: top; white-space: nowrap; text-align: center; padding-bottom: 1.5pt">August 31, 2024 to unlimited</td></tr> </table> 103702658 9266135 0.24 P1Y10M6D 61771423 0.21 P1Y6M29D P1Y11M15D February 3, 2025 to June 16, 2025 18250000 0.00001 0.24 P1Y9M March 31, 2025 to unlimited 22000000 0.21 P1Y11M12D 2025-06-09 -7584900 0.00001 0.2 103702658 0.21 P1Y11M15D August 31, 2024 to unlimited <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. SHARE BASED COMPENSATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 31, 2019, the Board and the Company’s shareholders approved the 2019 Share Incentive Plan (“2019 Plan”) which authorized the compensation committee or such other committee to grant share options to purchase 1,105,300 Class A ordinary shares to directors, service providers, advisors, employees and consultants of the Group. On July 5, 2021, the Board and the Compensation Committee of the Board approved the Amended and Restated 2019 Plan increasing the number of Class A ordinary shares subject to the 2019 Plan to 1,885,300 shares. As of June 30, 2023, no shares remain available to be issued under the Amended and Restated 2019 Plan. On April 14, 2022, the Company’s Board approved and adopted the 2022 Share Incentive Plan (the “2022 Plan”) providing for the grant of options to purchase 2,800,000 Class A ordinary shares. On August 28, 2022, the Board and the Compensation Committee of the Board approved the Amended and Restated 2022 Plan increasing the number of Class A ordinary shares subject to the 2022 Plan to 4,700,000 shares. These options were granted to employees and professionals during 2022 and 2023 and will vest over four years. As of June 30, 2023, options to purchase 182,593 Class A ordinary shares remain available to be issued under the 2022 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2023, the Company’s Board approved and adopted the 2023 Share Incentive Plan (the “2023 Plan”) providing for the grant of restricted share unit (“RSU”) of 4,000,000 Class A ordinary shares. On March 10, 2023, the Board and the Compensation Committee of the Board approved an amended to the 2023 Plan increasing the number of Class A ordinary shares subject to the 2023 Plan to 13,000,000 shares. On August 23, 2023, the Board and the Compensation Committee of the Board further approved a further amendment to 2023 Plan increasing the number of Class A ordinary shares subject to the 2023 Plan to 41,000,000 shares These RSU are to be granted to employees and professionals. During the six months ended June 30, 2023, the Company issued 12,779,670 RSUs to that can be converted to Class A ordinary shares upon vesting to employees, directors and officers the Group under the 2023 Plan. The aggregate fair value of the RSUs granted was RMB32,310 (US$4,456). These RSUs vest over 1-4 years based on the related granted agreements. During six months ended June 30, 2023, 458,452 RSUs was forfeited and none vested. As of June 30, 2023, the Company had 12,321,218 RSUs outstanding. For the six months ended June 30, 2023, the Company recorded related share-based compensation expense of RMB2,872 (US$396).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees-options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options granted to employees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards and contain only service vesting conditions. The following table summarized the Group’s employee share option activities:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant date</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Share options outstanding at December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,334,906</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.69</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5.08</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">8.05</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.25in; padding-left: 0.25in">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,900</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Share options outstanding at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,321,006</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2.32</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.54</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">306</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Vested and exercisable at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,199,006</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.41</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.54</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">306</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date for those awards that had exercise price below the estimated fair value of the relevant Class A ordinary shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For the six months ended June 30, 2022 and 2023, the total fair value of the equity awards vested were RMB2,962 and RMB894 (US$123) respectively. As of June 30, 2023, there was RMB2,525 (USD$348) in total unrecognized employee share-based compensation expense related to unvested options, that may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost may be recognized over a weighted-average period of 0.6 years.</span> <b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nonemployees-options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options granted to nonemployees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards with service and/or performance vesting conditions. The following table summarized the Group’s nonemployee share option activity:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant date</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share options outstanding at December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,651,700</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.86</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.85</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9.27</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">532</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(650,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share options outstanding at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,981,700</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.13</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.04</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.74</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">315</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,981,700</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.13</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.74</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">315</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant Class A ordinary shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total fair value of the equity awards vested during the six months ended June 30, 2022 and 2023 were RMB1,566 and <span style="-sec-ix-hidden: hidden-fact-261">nil</span>, respectively. There was no unrecognized nonemployee share-based compensation expenses as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair value of options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group used the Black-Scholes simplified method for the valuation of new options issued during the six months ended June 30, 2022 and 2023. The assumptions used to value the share options granted to employees and nonemployee were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.34</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">—</div></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">—</div></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair market value per ordinary share as at grant dates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$0.29</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">—</div></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the amount of share-based compensation expense included in each of the relevant financial statement line items:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Selling and marketing expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">705</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">236</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,236</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total share-based compensation expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,528</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">519</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 1105300 1885300 2800000 4700000 P4Y 182593 4000000 13000000 41000000 12779670 32310 4456 P1Y P4Y 458452 12321218 2872 396 The options granted to employees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards and contain only service vesting conditions. The following table summarized the Group’s employee share option activities:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant date</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.375in; padding-left: 0.25in"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Share options outstanding at December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,334,906</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1.69</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5.08</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">8.05</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">452</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.25in; padding-left: 0.25in">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,900</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Share options outstanding at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,321,006</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2.32</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.54</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">306</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Vested and exercisable at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,199,006</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.41</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.54</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">306</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 2334906 1.69 5080.00 P8Y18D 452000 13900 0.05 50.00 P0Y2M19D 2321006 1.7 2320 P7Y6M14D 306000 2199006 1.41 2080.00 P7Y6M14D 306000 2962000 894000 123000 2525000 348000 P0Y7M6D The options granted to nonemployees are measured based on the grant date fair value of the equity instrument. They are accounted for as equity awards with service and/or performance vesting conditions. The following table summarized the Group’s nonemployee share option activity:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Grant date</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$ per</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">option</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Share options outstanding at December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,651,700</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.86</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.85</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">9.27</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">532</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(650,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Share options outstanding at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,981,700</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.13</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.04</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.74</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">315</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,981,700</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.13</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.74</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">315</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 2651700 0.86 0.85 P9Y3M7D 532000 650000 0.05 0.05 0.22 -20000 1981700 1.13 1.04 P8Y8M26D 315000 1981700 1.13 1 P8Y8M26D 315000 1566000 The Group used the Black-Scholes simplified method for the valuation of new options issued during the six months ended June 30, 2022 and 2023. The assumptions used to value the share options granted to employees and nonemployee were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.34</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">—</div></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">—</div></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair market value per ordinary share as at grant dates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$0.29</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">—</div></td><td style="text-align: left"> </td></tr> </table> 0.0034 1.002 0.29 The following table sets forth the amount of share-based compensation expense included in each of the relevant financial statement line items:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Selling and marketing expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">705</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">236</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,236</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total share-based compensation expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,528</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">519</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 705000 1712000 236000 1263000 818000 113000 2560000 1236000 170000 4528000 3766000 519000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. INCOME TAXES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BVI</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is incorporated in the BVI and conducts its primary business operations through the subsidiaries in the U.S. and PRC Under the current laws of the BVI, the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Company to its shareholders, no BVI withholding tax will be imposed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hong Kong</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GISN (HK) Limited is a holding company registered in Hong Kong and had no operating profit and no taxable income for the six months ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRC</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s subsidiaries in the PRC are subject to tax at the statutory rate of 25%, in accordance with the Enterprise Income Tax law (the “EIT Law”), which was effective since January 1, 2008. Hua You Sheng Future (Beijing) Technology Co., Ltd. is entitled to a preferential income tax treatment as they qualify as small and micro-sized enterprises. For the six months ended June 30, 2022 and 2023, if the annual taxable income of small and micro- profit enterprises does not exceed RMB 1,000, 12.5% shall be included in the taxable income and the enterprise income tax rate shall be 20%; if the annual taxable income exceeds RMB 1,000 but does not exceed RMB 3,000, 25% shall be included in the taxable income and the enterprise income tax shall be paid at the rate of 20%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends, interests, rent and royalties payable by the Group’s PRC subsidiaries, to non-PRC resident enterprises, and proceeds from any such non-resident enterprise investor’s disposition of assets (after deducting the net value of such assets) shall be subject to 10% withholding tax, unless the respective non-PRC resident enterprise’s jurisdiction of incorporation has a tax treaty or arrangements with PRC that provides for a reduced withholding tax rate or an exemption from withholding tax.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">United States</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s subsidiaries in the U.S. are subject to the U.S. federal corporate income tax and New York as well as Delaware state income tax at a rate of 21%, 6.5% and 8.7%, respectively, for the six months ended June 30, 2022 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s Chinese subsidiaries tax returns filed with Chinese governments for the years after 2019 remain open for statutory examination by PRC tax authorities. The Group’s US subsidiaries tax returns filed with governments remain open for statutory examination by tax authorities in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group’s loss before income taxes consisted of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Non-US</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(9,035</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(23,507</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(3,241</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">US</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,032</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,763</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(9,035</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(43,539</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(6,004</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The current and deferred components of income tax benefit appearing in the unaudited condensed consolidated statements of comprehensive income are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Deferred tax benefit</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">79</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">11</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reconciliation of tax computed by applying the federal statutory income tax rate of 21% for the six months ended June 30, 2022 and 2023 applicable to the U.S. operations to income tax benefit were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before income taxes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(9,035</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(43,539</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(6,004</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income tax benefit computed at the statutory income tax rate at 21%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,897</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">International rate differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,726</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(652</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,337</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(598</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Income tax benefit</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred Taxes</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The significant components of deferred taxes were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Net loss carryforward</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9,608</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,900</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,608</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,325</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets.</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Long-lived assets arising from acquisitions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,938</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total deferred tax liabilities.</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,938</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">405</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group operates through several subsidiaries. Valuation allowance is considered for each of the entities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realization of the net deferred tax assets is dependent on factors including future reversals of existing taxable temporary differences and adequate future taxable income, exclusive of reversing deductible temporary differences and tax loss carry forwards. The Group evaluates the potential realization of deferred tax assets on an entity-by-entity basis. As of December 31, 2022 and June 30, 2023, the Company and all of its subsidiaries were in a cumulative loss position, valuation allowances were provided against deferred tax assets in entities where it was determined it was more likely than not that the benefits of the deferred tax assets will not be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, the Group had PRC net operating losses of RMB10,342 (US$ 1,426), which will expire from 2023 to 2027 if not utilized. As of June 30, 2023, the Group had Hongkong net operating losses of RMB 307 (US$42) that can be carried forward indefinitely for deduction in future periods. As of June 30, 2023, the Group had U.S. net operating losses of RMB33,198 (US$4,578) for U.S. federal and state income tax purposes. The Group files state tax returns in both New York and Delaware. U.S. federal net operating losses are limited to 80% and can be utilized indefinitely. State net operating losses can be carried forward for 20 years and will begin to expire from 2038 to 2042.</p> 0.25 1000000 0.125 0.125 0.20 1000000 3000000 0.25 0.20 0.10 0.21 0.21 0.065 0.065 0.087 0.087 The Group’s loss before income taxes consisted of:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Non-US</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(9,035</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(23,507</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(3,241</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">US</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,032</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,763</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(9,035</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(43,539</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(6,004</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> -9035000 -23507000 -3241000 -20032000 -2763000 -9035000 -43539000 -6004000 The current and deferred components of income tax benefit appearing in the unaudited condensed consolidated statements of comprehensive income are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Deferred tax benefit</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">79</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">11</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 79000 11000 79000 11000 The reconciliation of tax computed by applying the federal statutory income tax rate of 21% for the six months ended June 30, 2022 and 2023 applicable to the U.S. operations to income tax benefit were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before income taxes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(9,035</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(43,539</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(6,004</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income tax benefit computed at the statutory income tax rate at 21%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,897</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">International rate differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,726</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(652</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,337</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(598</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Income tax benefit</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 0.21 0.21 -9035000 -43539000 -6004000 0.21 0.21 0.21 -1897000 9142000 1261000 1897000 -4726000 -652000 -4337000 -598000 79000 11000 The significant components of deferred taxes were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Net loss carryforward</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9,608</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,900</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,608</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,325</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets.</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Long-lived assets arising from acquisitions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,938</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total deferred tax liabilities.</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,938</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">405</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 1900000 9608000 1325000 1900000 9608000 1325000 2938000 405000 2938000 405000 10342000 1426000 307000 42000 33198000 4578000 0.80 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. RELATED PARTY TRANSACTIONS AND BALANCES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. The related parties that had transactions in the six months ended June 30, 2022 and 2023 or balances with the Group as of December 30, 2022 and June 30, 2023 consisted of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature of the party</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relationship with the Group</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haohan Xu</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apifiny Inc.</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment management</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Haohan Xu</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roxe Holding Inc.</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment management</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Haohan Xu</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chris Chang Yu*</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder and shareholder</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRS Holdings Inc.</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Dr. Chris Chang Yu</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiaxing Zhijun Sihang Investment Partnership Enterprises (limited partnership) (“Jiaxing Zhijun”)</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private equity investment</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder, due to diluted equity interest, no longer a related party for the six months ended June 30 2023</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Yu resigned from his position as the Chief Executive Officer (“CEO”) of the Company and Chairman of the Board on April 6, 2022 and was appointed as Co-Chairman and Co-CEO in May 2022. On May 17, 2023, Dr. Yu resigned as the Co-Chief Executive Officer of the Company.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Related party balances</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Due from related parties:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Apifiny Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">211</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Roxe Holding Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dr. Chris Chang Yu</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Due from related parties, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Due to related parties:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">CRS Holdings Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">287</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">592</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">82</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Jiaxing Zhijun</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">927</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Due to related parties</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,214</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">592</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">82</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Accounts receivables-related parties:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Apifiny Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,525</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">486</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Roxe Holding Inc.</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,925</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,093</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Accounts Receivables-related parties, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,450</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,579</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivables-related parties represented receivables from Apifiny Inc. and Roxe Holding Inc. for research and development services provided by the Group’s subsidiaries before the GISN acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related party transactions</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and 2023, related party transactions consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed assets purchased from Apifiny Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">970</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consulting service received from Roxe Holding Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Rent expense incurred with Apifiny Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">624</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acquisition, investment and divestitures</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group completed one acquisition from a related party – Mr. Xu (details refer to Note 4) and completed divestiture transaction with a related party Dr. Chris Yu on July 28, 2023 (details refer to Note 5). On May 24, 2023, the Group completed equity investment in Nassau, controlled by a related party - Mr. Xu (details refer to Note 10).</p> The related parties that had transactions in the six months ended June 30, 2022 and 2023 or balances with the Group as of December 30, 2022 and June 30, 2023 consisted of:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature of the party</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relationship with the Group</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haohan Xu</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apifiny Inc.</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment management</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Haohan Xu</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roxe Holding Inc.</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment management</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Haohan Xu</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chris Chang Yu*</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder and shareholder</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRS Holdings Inc.</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled by Dr. Chris Chang Yu</span></td></tr> <tr style="vertical-align: top; "> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiaxing Zhijun Sihang Investment Partnership Enterprises (limited partnership) (“Jiaxing Zhijun”)</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private equity investment</span></td> <td> </td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder, due to diluted equity interest, no longer a related party for the six months ended June 30 2023</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Yu resigned from his position as the Chief Executive Officer (“CEO”) of the Company and Chairman of the Board on April 6, 2022 and was appointed as Co-Chairman and Co-CEO in May 2022. On May 17, 2023, Dr. Yu resigned as the Co-Chief Executive Officer of the Company.</span></td> </tr></table> Individual Chief Executive Officer Investment management Controlled by Haohan Xu Investment management Controlled by Haohan Xu Individual Co-Founder and shareholder Investor Controlled by Dr. Chris Chang Yu Private equity investment Shareholder, due to diluted equity interest, no longer a related party for the six months ended June 30 2023 Related party balances<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Due from related parties:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Apifiny Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">211</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Roxe Holding Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dr. Chris Chang Yu</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">290</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Due from related parties, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Due to related parties:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">CRS Holdings Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">287</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">592</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">82</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Jiaxing Zhijun</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">927</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Due to related parties</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,214</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">592</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">82</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 211000 29000 363000 50000 290000 40000 864000 119000 287000 592000 82000 927000 1214000 592000 82000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Accounts receivables-related parties:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Apifiny Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,525</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">486</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Roxe Holding Inc.</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,925</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,093</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Accounts Receivables-related parties, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,450</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,579</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 3525000 486000 7925000 1093000 11450000 1579000 For the six months ended June 30, 2022 and 2023, related party transactions consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">RMB</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed assets purchased from Apifiny Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">970</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consulting service received from Roxe Holding Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Rent expense incurred with Apifiny Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">624</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td></tr> </table> 970000 134000 464000 64000 32000 624000 86000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Litigation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of the business, the Group is subject to periodic legal or administrative proceedings. As of December 31, 2022 and June 30, 2023, there was no contingent liability accrued relating to legal or administrative proceedings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>19. SUBSEQUENT EVENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Development</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company announced that as of June 30, 2023, it no longer qualified as a Foreign Private Issuer, as defined in Rule 405 of Regulation C under the Securities Act of 1933 and Rule 3b-4 under the Securities Exchange Act of 1934. The Company will take all necessary actions to comply with the requirements for a domestic issuer under the federal securities laws, as of January 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2023, the Company appointed Mr. Yidong Hu as the Chief Strategy Officer of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2023, Mr. Edwards Jinqiu Tang resigned as the Co-Chief Financial Officer of the Company. Mr. Tang’s resignation did not result from any disagreement with the Company or its management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Divestiture</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 28, 2023, the Group entered into agreements to sell its CDA Business (details refer to Note 5).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Acquisition</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 17, 2023, the Group entered into a definitive share purchase agreement with Immensus LLC, Zero2First Capital Limited, Future Capital Tech Pte. Ltd (Singapore), River Hill China Capital Ltd (collectively, the “Sellers”) and Roxe Holding Inc. (“Roxe”) under which Fresh2 Technology purchased 51% of the common share of Roxe (the “Roxe Shares”). As consideration for the purchase of the Roxe Shares, the Company issued an aggregate of 110,476,291 Class A Ordinary Shares of the Company to the Sellers, based on Roxe’s valuation of US$60,000 and the average trading price of the Company’s ADSs for the prior 90 trading days (each ADS represents 20 Class A Ordinary Shares). The closing took place simultaneously with the execution of the Share Purchase Agreement. Unaudited Pro-forma condensed combined financial information in connection with the above acquisition was included in the Company’s filling in a Form 6-K with the SEC on August 21, 2023. On July 27, 2023, Roxe entered into a share purchase agreement with SpeedIn INC (“SpeedIn”), a delivery service provider, and its shareholders, under which Roxe agreed to purchase 100% of the shares of SpeedIn from the Sellers with a nominal price. The closing took place simultaneously with the execution of the share purchase agreement. Due to badly performance, the Board have approved the disposition of SpeedIn to a company controlled by Mr. Haohan Xu on October 9, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 28, 2023, the Company, through its subsidiary, Foodbase Group Inc. agreed to acquire 100% of the equity interest in Windfall SLV Development LLC and SLV Windfall Management LLC, from XHome Group Inc, a company controlled by Mr. Haohan Xu, for a nominal price. Windfall SLV Development LLC and SLV Windfall Management LLC have not begun operations as yet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 4, 2023 the Company and Fresh2 Technology entered into a definitive Share Purchase Agreement to purchase 38.61% of the common stock of Roxe.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Financing activities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2023, the Company entered into an agreement with an institutional investor to purchase up to US$2,000 of convertible notes, the convertible notes will be sold in two tranches (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date  and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment RMB1,697(US$234) from this offering, excluding related financing costs.</p> 0.51 110476291 60000000 1 38.61 2000000 (i) US$400 (original principal amount) of convertible notes, Series C warrants to purchase 258,065 ADSs (or 5,161,300 Class A ordinary shares) at exercise price equal to 125% of the lower of (a) $1.86 and (b) the lowest daily volume-weighted average price (“VWAP”) for the 10 trading days prior to the exercise date  and Series D warrants to purchase up to 283,688 ADSs (or 5,673,760 Class A ordinary shares) at exercise price equal to the lower of (x) $1.41 and (y) 75.83% of the lowest daily VWAP for the ten (10) trading days immediately prior to the exercise date, subject to adjustment, and (ii) US$1,600 (original principal amount) of convertible notes, 20,645,160 Series C warrants and 22,695,040 Series D warrants. The Company received the first payment RMB1,697(US$234) from this offering, excluding related financing costs. -0.05 -0.35 -0.38 -0.03 -0.22 -1.66 -0.08 -0.57 -2.04 124374140 124374140 23603709 true --12-31 Q2 2023-06-30 0001786511 EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

&UL4$L! A0#% @ 7:V!5T_TNM(*# (JP !D M ("!S3(" 'AL+W=O2*D$ "+%@ &0 @($./P( >&PO=V]R M:W-H965TY# @!X;"]W;W)K&UL M4$L! A0#% @ 7:V!5VFJ;+," P 70@ !D ("!&TD" M 'AL+W=O&PO=V]R:W-H965TI/ @!X;"]W;W)K&UL4$L! A0#% @ M7:V!5U^<:LDI P YPT !D ("!EE8" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7:V!5VWN/NIV @ M,P8 !D ("!H& " 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7:V!5WVJ]C:+! UQX !D M ("!YFL" 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 7:V!5^9A>CRG!P D#L !D ("!@'<" 'AL M+W=O?P( >&PO7BKL

3?UVH# 8 %D[ / " M >J# @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !=K8%7YN*DT* " % M-0 &@ @ $CB@( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " !=K8%7PH ,:SH" !H,P $P @ '[ LC ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 8@!B .4: !FCP( ! end XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 271 512 1 true 94 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.anpacbio.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.anpacbio.com/role/ConsolidatedBalanceSheet Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.anpacbio.com/role/ConsolidatedIncomeStatement Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) Sheet http://www.anpacbio.com/role/ConsolidatedIncomeStatement_Parentheticals Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Unaudited Condensed Consolidated Statements of Shareholders??? Equity/(Deficit) Sheet http://www.anpacbio.com/role/ShareholdersEquityType2or3 Unaudited Condensed Consolidated Statements of Shareholders??? Equity/(Deficit) Statements 6 false false R7.htm 006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.anpacbio.com/role/ConsolidatedCashFlow Unaudited Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Organization and Principal Activities Sheet http://www.anpacbio.com/role/OrganizationandPrincipalActivities Organization and Principal Activities Notes 8 false false R9.htm 008 - Disclosure - Liquidity and Going Concern Uncertainties Sheet http://www.anpacbio.com/role/LiquidityandGoingConcernUncertainties Liquidity and Going Concern Uncertainties Notes 9 false false R10.htm 009 - Disclosure - Summary of Principal Accounting Policies Sheet http://www.anpacbio.com/role/SummaryofPrincipalAccountingPolicies Summary of Principal Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Acqusitions Sheet http://www.anpacbio.com/role/Acqusitions Acqusitions Notes 11 false false R12.htm 011 - Disclosure - Discontinued Operations Sheet http://www.anpacbio.com/role/DiscontinuedOperations Discontinued Operations Notes 12 false false R13.htm 012 - Disclosure - Accounts Receivable, Net Sheet http://www.anpacbio.com/role/AccountsReceivableNet Accounts Receivable, Net Notes 13 false false R14.htm 013 - Disclosure - Other Current Assets, Net Sheet http://www.anpacbio.com/role/OtherCurrentAssetsNet Other Current Assets, Net Notes 14 false false R15.htm 014 - Disclosure - Property and Equipment, Net Sheet http://www.anpacbio.com/role/PropertyandEquipmentNet Property and Equipment, Net Notes 15 false false R16.htm 015 - Disclosure - Intangible Assets, Net Sheet http://www.anpacbio.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 16 false false R17.htm 016 - Disclosure - Long-Term Investments, Net Sheet http://www.anpacbio.com/role/LongTermInvestmentsNet Long-Term Investments, Net Notes 17 false false R18.htm 017 - Disclosure - Short-Term Debts Sheet http://www.anpacbio.com/role/ShortTermDebts Short-Term Debts Notes 18 false false R19.htm 018 - Disclosure - Leases Sheet http://www.anpacbio.com/role/Leases Leases Notes 19 false false R20.htm 019 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 20 false false R21.htm 020 - Disclosure - Shareholders' Equity Sheet http://www.anpacbio.com/role/ShareholdersEquity Shareholders' Equity Notes 21 false false R22.htm 021 - Disclosure - Share Based Compensation Sheet http://www.anpacbio.com/role/ShareBasedCompensation Share Based Compensation Notes 22 false false R23.htm 022 - Disclosure - Income Taxes Sheet http://www.anpacbio.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 023 - Disclosure - Related Party Transactions and Balances Sheet http://www.anpacbio.com/role/RelatedPartyTransactionsandBalances Related Party Transactions and Balances Notes 24 false false R25.htm 024 - Disclosure - Commitments and Contingencies Sheet http://www.anpacbio.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 25 false false R26.htm 025 - Disclosure - Subsequent Events Sheet http://www.anpacbio.com/role/SubsequentEvents Subsequent Events Notes 26 false false R27.htm 026 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.anpacbio.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.anpacbio.com/role/SummaryofPrincipalAccountingPolicies 27 false false R28.htm 027 - Disclosure - Organization and Principal Activities (Tables) Sheet http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesTables Organization and Principal Activities (Tables) Tables http://www.anpacbio.com/role/OrganizationandPrincipalActivities 28 false false R29.htm 028 - Disclosure - Summary of Principal Accounting Policies (Tables) Sheet http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables Summary of Principal Accounting Policies (Tables) Tables http://www.anpacbio.com/role/SummaryofPrincipalAccountingPolicies 29 false false R30.htm 029 - Disclosure - Acqusitions (Tables) Sheet http://www.anpacbio.com/role/AcqusitionsTables Acqusitions (Tables) Tables http://www.anpacbio.com/role/Acqusitions 30 false false R31.htm 030 - Disclosure - Discontinued Operations (Tables) Sheet http://www.anpacbio.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.anpacbio.com/role/DiscontinuedOperations 31 false false R32.htm 031 - Disclosure - Accounts Receivable, Net (Tables) Sheet http://www.anpacbio.com/role/AccountsReceivableNetTables Accounts Receivable, Net (Tables) Tables http://www.anpacbio.com/role/AccountsReceivableNet 32 false false R33.htm 032 - Disclosure - Other Current Assets, Net (Tables) Sheet http://www.anpacbio.com/role/OtherCurrentAssetsNetTables Other Current Assets, Net (Tables) Tables http://www.anpacbio.com/role/OtherCurrentAssetsNet 33 false false R34.htm 033 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.anpacbio.com/role/PropertyandEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.anpacbio.com/role/PropertyandEquipmentNet 34 false false R35.htm 034 - Disclosure - Intangible Assets, Net (Tables) Sheet http://www.anpacbio.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://www.anpacbio.com/role/IntangibleAssetsNet 35 false false R36.htm 035 - Disclosure - Long-Term Investments, Net (Tables) Sheet http://www.anpacbio.com/role/LongTermInvestmentsNetTables Long-Term Investments, Net (Tables) Tables http://www.anpacbio.com/role/LongTermInvestmentsNet 36 false false R37.htm 036 - Disclosure - Short-Term Debts (Tables) Sheet http://www.anpacbio.com/role/ShortTermDebtsTables Short-Term Debts (Tables) Tables http://www.anpacbio.com/role/ShortTermDebts 37 false false R38.htm 037 - Disclosure - Leases (Tables) Sheet http://www.anpacbio.com/role/LeasesTables Leases (Tables) Tables http://www.anpacbio.com/role/Leases 38 false false R39.htm 038 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilities 39 false false R40.htm 039 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.anpacbio.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.anpacbio.com/role/ShareholdersEquity 40 false false R41.htm 040 - Disclosure - Share Based Compensation (Tables) Sheet http://www.anpacbio.com/role/ShareBasedCompensationTables Share Based Compensation (Tables) Tables http://www.anpacbio.com/role/ShareBasedCompensation 41 false false R42.htm 041 - Disclosure - Income Taxes (Tables) Sheet http://www.anpacbio.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.anpacbio.com/role/IncomeTaxes 42 false false R43.htm 042 - Disclosure - Related Party Transactions and Balances (Tables) Sheet http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables Related Party Transactions and Balances (Tables) Tables http://www.anpacbio.com/role/RelatedPartyTransactionsandBalances 43 false false R44.htm 043 - Disclosure - Organization and Principal Activities (Details) Sheet http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails Organization and Principal Activities (Details) Details http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesTables 44 false false R45.htm 044 - Disclosure - Organization and Principal Activities (Details) - Schedule of Group???s Principal Subsidiaries Sheet http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable Organization and Principal Activities (Details) - Schedule of Group???s Principal Subsidiaries Details http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesTables 45 false false R46.htm 045 - Disclosure - Liquidity and Going Concern Uncertainties (Details) Sheet http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails Liquidity and Going Concern Uncertainties (Details) Details http://www.anpacbio.com/role/LiquidityandGoingConcernUncertainties 46 false false R47.htm 046 - Disclosure - Summary of Principal Accounting Policies (Details) Sheet http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails Summary of Principal Accounting Policies (Details) Details http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables 47 false false R48.htm 047 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis Sheet http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable Summary of Principal Accounting Policies (Details) - Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis Details http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables 48 false false R49.htm 048 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment Sheet http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable Summary of Principal Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment Details http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables 49 false false R50.htm 049 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives Sheet http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives Details http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables 50 false false R51.htm 050 - Disclosure - Acqusitions (Details) Sheet http://www.anpacbio.com/role/AcqusitionsDetails Acqusitions (Details) Details http://www.anpacbio.com/role/AcqusitionsTables 51 false false R52.htm 051 - Disclosure - Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities Sheet http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities Details http://www.anpacbio.com/role/AcqusitionsTables 52 false false R53.htm 052 - Disclosure - Acqusitions (Details) - Schedule of Pro Forma of Group Business Combination Sheet http://www.anpacbio.com/role/ScheduleofProFormaofGroupBusinessCombinationTable Acqusitions (Details) - Schedule of Pro Forma of Group Business Combination Details http://www.anpacbio.com/role/AcqusitionsTables 53 false false R54.htm 053 - Disclosure - Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets Sheet http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets Details http://www.anpacbio.com/role/AcqusitionsTables 54 false false R55.htm 054 - Disclosure - Discontinued Operations (Details) Sheet http://www.anpacbio.com/role/DiscontinuedOperationsDetails Discontinued Operations (Details) Details http://www.anpacbio.com/role/DiscontinuedOperationsTables 55 false false R56.htm 055 - Disclosure - Discontinued Operations (Details) - Schedule of Results of Discontinued Operations Sheet http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable Discontinued Operations (Details) - Schedule of Results of Discontinued Operations Details http://www.anpacbio.com/role/DiscontinuedOperationsTables 56 false false R57.htm 056 - Disclosure - Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations Sheet http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations Details http://www.anpacbio.com/role/DiscontinuedOperationsTables 57 false false R58.htm 057 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable Sheet http://www.anpacbio.com/role/ScheduleofAccountsReceivableTable Accounts Receivable, Net (Details) - Schedule of Accounts Receivable Details http://www.anpacbio.com/role/AccountsReceivableNetTables 58 false false R59.htm 058 - Disclosure - Other Current Assets, Net (Details) - Schedule of Other Current Assets Sheet http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable Other Current Assets, Net (Details) - Schedule of Other Current Assets Details http://www.anpacbio.com/role/OtherCurrentAssetsNetTables 59 false false R60.htm 059 - Disclosure - Property and Equipment, Net (Details) Sheet http://www.anpacbio.com/role/PropertyandEquipmentNetDetails Property and Equipment, Net (Details) Details http://www.anpacbio.com/role/PropertyandEquipmentNetTables 60 false false R61.htm 060 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net Consists Sheet http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net Consists Details http://www.anpacbio.com/role/PropertyandEquipmentNetTables 61 false false R62.htm 061 - Disclosure - Intangible Assets, Net (Details) Sheet http://www.anpacbio.com/role/IntangibleAssetsNetDetails Intangible Assets, Net (Details) Details http://www.anpacbio.com/role/IntangibleAssetsNetTables 62 false false R63.htm 062 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible Assets Net Sheet http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable Intangible Assets, Net (Details) - Schedule of Intangible Assets Net Details http://www.anpacbio.com/role/IntangibleAssetsNetTables 63 false false R64.htm 063 - Disclosure - Intangible Assets, Net (Details) - Schedule of Estimated Aggregate Amortization Expense Sheet http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable Intangible Assets, Net (Details) - Schedule of Estimated Aggregate Amortization Expense Details http://www.anpacbio.com/role/IntangibleAssetsNetTables 64 false false R65.htm 064 - Disclosure - Long-Term Investments, Net (Details) Sheet http://www.anpacbio.com/role/LongTermInvestmentsNetDetails Long-Term Investments, Net (Details) Details http://www.anpacbio.com/role/LongTermInvestmentsNetTables 65 false false R66.htm 065 - Disclosure - Long-Term Investments, Net (Details) - Schedule of Long-Term Investments Sheet http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable Long-Term Investments, Net (Details) - Schedule of Long-Term Investments Details http://www.anpacbio.com/role/LongTermInvestmentsNetTables 66 false false R67.htm 066 - Disclosure - Short-Term Debts (Details) Sheet http://www.anpacbio.com/role/ShortTermDebtsDetails Short-Term Debts (Details) Details http://www.anpacbio.com/role/ShortTermDebtsTables 67 false false R68.htm 067 - Disclosure - Short-Term Debts (Details) - Schedule of Short-Term Debts Sheet http://www.anpacbio.com/role/ScheduleofShortTermDebtsTable Short-Term Debts (Details) - Schedule of Short-Term Debts Details http://www.anpacbio.com/role/ShortTermDebtsTables 68 false false R69.htm 068 - Disclosure - Leases (Details) - Schedule of Operating Leases Sheet http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable Leases (Details) - Schedule of Operating Leases Details http://www.anpacbio.com/role/LeasesTables 69 false false R70.htm 069 - Disclosure - Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates Sheet http://www.anpacbio.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates Details http://www.anpacbio.com/role/LeasesTables 70 false false R71.htm 070 - Disclosure - Leases (Details) - Schedule of Maturities of Lease Liabilities Sheet http://www.anpacbio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable Leases (Details) - Schedule of Maturities of Lease Liabilities Details http://www.anpacbio.com/role/LeasesTables 71 false false R72.htm 071 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities Sheet http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities Details http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables 72 false false R73.htm 072 - Disclosure - Shareholders' Equity (Details) Sheet http://www.anpacbio.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://www.anpacbio.com/role/ShareholdersEquityTables 73 false false R74.htm 073 - Disclosure - Shareholders' Equity (Details) - Sechedule of Warrants Activity Sheet http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable Shareholders' Equity (Details) - Sechedule of Warrants Activity Details http://www.anpacbio.com/role/ShareholdersEquityTables 74 false false R75.htm 074 - Disclosure - Share Based Compensation (Details) Sheet http://www.anpacbio.com/role/ShareBasedCompensationDetails Share Based Compensation (Details) Details http://www.anpacbio.com/role/ShareBasedCompensationTables 75 false false R76.htm 075 - Disclosure - Share Based Compensation (Details) - Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument Sheet http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable Share Based Compensation (Details) - Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument Details http://www.anpacbio.com/role/ShareBasedCompensationTables 76 false false R77.htm 076 - Disclosure - Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument Sheet http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument Details http://www.anpacbio.com/role/ShareBasedCompensationTables 77 false false R78.htm 077 - Disclosure - Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued Sheet http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued Details http://www.anpacbio.com/role/ShareBasedCompensationTables 78 false false R79.htm 078 - Disclosure - Share Based Compensation (Details) - Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense Sheet http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable Share Based Compensation (Details) - Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense Details http://www.anpacbio.com/role/ShareBasedCompensationTables 79 false false R80.htm 079 - Disclosure - Income Taxes (Details) Sheet http://www.anpacbio.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.anpacbio.com/role/IncomeTaxesTables 80 false false R81.htm 080 - Disclosure - Income Taxes (Details) - Schedule of Loss Before Income Taxes Sheet http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable Income Taxes (Details) - Schedule of Loss Before Income Taxes Details http://www.anpacbio.com/role/IncomeTaxesTables 81 false false R82.htm 081 - Disclosure - Income Taxes (Details) - Schedule of Current and Deferred Components of Income Tax Benefit Sheet http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable Income Taxes (Details) - Schedule of Current and Deferred Components of Income Tax Benefit Details http://www.anpacbio.com/role/IncomeTaxesTables 82 false false R83.htm 082 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate Sheet http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate Details http://www.anpacbio.com/role/IncomeTaxesTables 83 false false R84.htm 083 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate (Parentheticals) Sheet http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable_Parentheticals Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate (Parentheticals) Details http://www.anpacbio.com/role/IncomeTaxesTables 84 false false R85.htm 084 - Disclosure - Income Taxes (Details) - Schedule of Significant Components of Deferred Taxes Sheet http://www.anpacbio.com/role/ScheduleofSignificantComponentsofDeferredTaxesTable Income Taxes (Details) - Schedule of Significant Components of Deferred Taxes Details http://www.anpacbio.com/role/IncomeTaxesTables 85 false false R86.htm 085 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational Sheet http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational Details http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables 86 false false R87.htm 086 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Party Balances Sheet http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable Related Party Transactions and Balances (Details) - Schedule of Related Party Balances Details http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables 87 false false R88.htm 087 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Accounts Receivables Sheet http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable Related Party Transactions and Balances (Details) - Schedule of Accounts Receivables Details http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables 88 false false R89.htm 088 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Party Transactions Sheet http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable Related Party Transactions and Balances (Details) - Schedule of Related Party Transactions Details http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables 89 false false R90.htm 089 - Disclosure - Subsequent Events (Details) Sheet http://www.anpacbio.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.anpacbio.com/role/SubsequentEvents 90 false false All Reports Book All Reports anpc-20230630.xsd anpc-20230630_cal.xml anpc-20230630_def.xml anpc-20230630_lab.xml anpc-20230630_pre.xml ea189176-6ka1_fresh2.htm ea189176ex99-1_fresh2.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 106 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea189176-6ka1_fresh2.htm ea189176ex99-1_fresh2.htm": { "nsprefix": "anpc", "nsuri": "http://www.anpacbio.com/20230630", "dts": { "schema": { "local": [ "anpc-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "anpc-20230630_cal.xml" ] }, "definitionLink": { "local": [ "anpc-20230630_def.xml" ] }, "labelLink": { "local": [ "anpc-20230630_lab.xml" ] }, "presentationLink": { "local": [ "anpc-20230630_pre.xml" ] }, "inline": { "local": [ "ea189176-6ka1_fresh2.htm", "ea189176ex99-1_fresh2.htm" ] } }, "keyStandard": 396, "keyCustom": 116, "axisStandard": 25, "axisCustom": 0, "memberStandard": 28, "memberCustom": 53, "hidden": { "total": 289, "http://fasb.org/us-gaap/2023": 236, "http://www.anpacbio.com/20230630": 48, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 271, "entityCount": 1, "segmentCount": 94, "elementCount": 792, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1257, "http://fasb.org/srt/2023": 2, "http://xbrl.sec.gov/dei/2023": 10 }, "report": { "R1": { "role": "http://www.anpacbio.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176-6ka1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176-6ka1_fresh2.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "anpc:LiquidityAndGoingConcernUncertaintiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R3": { "role": "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c6", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c6", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.anpacbio.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://www.anpacbio.com/role/ShareholdersEquityType2or3", "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Shareholders\u2019 Equity/(Deficit)", "shortName": "Unaudited Condensed Consolidated Statements of Shareholders\u2019 Equity/(Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c10", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c23", "name": "us-gaap:ProfitLoss", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R7": { "role": "http://www.anpacbio.com/role/ConsolidatedCashFlow", "longName": "006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R8": { "role": "http://www.anpacbio.com/role/OrganizationandPrincipalActivities", "longName": "007 - Disclosure - Organization and Principal Activities", "shortName": "Organization and Principal Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertainties", "longName": "008 - Disclosure - Liquidity and Going Concern Uncertainties", "shortName": "Liquidity and Going Concern Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "anpc:LiquidityAndGoingConcernUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "anpc:LiquidityAndGoingConcernUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPolicies", "longName": "009 - Disclosure - Summary of Principal Accounting Policies", "shortName": "Summary of Principal Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.anpacbio.com/role/Acqusitions", "longName": "010 - Disclosure - Acqusitions", "shortName": "Acqusitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.anpacbio.com/role/DiscontinuedOperations", "longName": "011 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.anpacbio.com/role/AccountsReceivableNet", "longName": "012 - Disclosure - Accounts Receivable, Net", "shortName": "Accounts Receivable, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.anpacbio.com/role/OtherCurrentAssetsNet", "longName": "013 - Disclosure - Other Current Assets, Net", "shortName": "Other Current Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.anpacbio.com/role/PropertyandEquipmentNet", "longName": "014 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.anpacbio.com/role/IntangibleAssetsNet", "longName": "015 - Disclosure - Intangible Assets, Net", "shortName": "Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.anpacbio.com/role/LongTermInvestmentsNet", "longName": "016 - Disclosure - Long-Term Investments, Net", "shortName": "Long-Term Investments, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.anpacbio.com/role/ShortTermDebts", "longName": "017 - Disclosure - Short-Term Debts", "shortName": "Short-Term Debts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.anpacbio.com/role/Leases", "longName": "018 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilities", "longName": "019 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.anpacbio.com/role/ShareholdersEquity", "longName": "020 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.anpacbio.com/role/ShareBasedCompensation", "longName": "021 - Disclosure - Share Based Compensation", "shortName": "Share Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.anpacbio.com/role/IncomeTaxes", "longName": "022 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.anpacbio.com/role/RelatedPartyTransactionsandBalances", "longName": "023 - Disclosure - Related Party Transactions and Balances", "shortName": "Related Party Transactions and Balances", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.anpacbio.com/role/CommitmentsandContingencies", "longName": "024 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.anpacbio.com/role/SubsequentEvents", "longName": "025 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.anpacbio.com/role/AccountingPoliciesByPolicy", "longName": "026 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesTables", "longName": "027 - Disclosure - Organization and Principal Activities (Tables)", "shortName": "Organization and Principal Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables", "longName": "028 - Disclosure - Summary of Principal Accounting Policies (Tables)", "shortName": "Summary of Principal Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.anpacbio.com/role/AcqusitionsTables", "longName": "029 - Disclosure - Acqusitions (Tables)", "shortName": "Acqusitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.anpacbio.com/role/DiscontinuedOperationsTables", "longName": "030 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.anpacbio.com/role/AccountsReceivableNetTables", "longName": "031 - Disclosure - Accounts Receivable, Net (Tables)", "shortName": "Accounts Receivable, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.anpacbio.com/role/OtherCurrentAssetsNetTables", "longName": "032 - Disclosure - Other Current Assets, Net (Tables)", "shortName": "Other Current Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.anpacbio.com/role/PropertyandEquipmentNetTables", "longName": "033 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.anpacbio.com/role/IntangibleAssetsNetTables", "longName": "034 - Disclosure - Intangible Assets, Net (Tables)", "shortName": "Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.anpacbio.com/role/LongTermInvestmentsNetTables", "longName": "035 - Disclosure - Long-Term Investments, Net (Tables)", "shortName": "Long-Term Investments, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.anpacbio.com/role/ShortTermDebtsTables", "longName": "036 - Disclosure - Short-Term Debts (Tables)", "shortName": "Short-Term Debts (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.anpacbio.com/role/LeasesTables", "longName": "037 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "longName": "038 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.anpacbio.com/role/ShareholdersEquityTables", "longName": "039 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.anpacbio.com/role/ShareBasedCompensationTables", "longName": "040 - Disclosure - Share Based Compensation (Tables)", "shortName": "Share Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c0", "name": "anpc:ScheduleOfShareBasedCompensationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "anpc:ScheduleOfShareBasedCompensationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.anpacbio.com/role/IncomeTaxesTables", "longName": "041 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables", "longName": "042 - Disclosure - Related Party Transactions and Balances (Tables)", "shortName": "Related Party Transactions and Balances (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c0", "name": "anpc:ScheduleOfRelatedPartyNamesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "anpc:ScheduleOfRelatedPartyNamesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "longName": "043 - Disclosure - Organization and Principal Activities (Details)", "shortName": "Organization and Principal Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c63", "name": "us-gaap:PublicUtilitiesApprovedReturnOnEquityPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "link:footnote", "td", "tr", "table", "ix:continuation", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c63", "name": "us-gaap:PublicUtilitiesApprovedReturnOnEquityPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "link:footnote", "td", "tr", "table", "ix:continuation", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable", "longName": "044 - Disclosure - Organization and Principal Activities (Details) - Schedule of Group\u2019s Principal Subsidiaries", "shortName": "Organization and Principal Activities (Details) - Schedule of Group\u2019s Principal Subsidiaries", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c64", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c64", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails", "longName": "045 - Disclosure - Liquidity and Going Concern Uncertainties (Details)", "shortName": "Liquidity and Going Concern Uncertainties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "anpc:LiquidityAndGoingConcernUncertaintiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "anpc:WorkingCapitalDeficit", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "anpc:LiquidityAndGoingConcernUncertaintiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R47": { "role": "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails", "longName": "046 - Disclosure - Summary of Principal Accounting Policies (Details)", "shortName": "Summary of Principal Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable", "longName": "047 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis", "shortName": "Summary of Principal Accounting Policies (Details) - Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable", "longName": "048 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment", "shortName": "Summary of Principal Accounting Policies (Details) - Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c116", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c116", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable", "longName": "049 - Disclosure - Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives", "shortName": "Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c120", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c120", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.anpacbio.com/role/AcqusitionsDetails", "longName": "050 - Disclosure - Acqusitions (Details)", "shortName": "Acqusitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueOfAssetsAcquired", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R52": { "role": "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable", "longName": "051 - Disclosure - Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities", "shortName": "Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c127", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c127", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.anpacbio.com/role/ScheduleofProFormaofGroupBusinessCombinationTable", "longName": "052 - Disclosure - Acqusitions (Details) - Schedule of Pro Forma of Group Business Combination", "shortName": "Acqusitions (Details) - Schedule of Pro Forma of Group Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable", "longName": "053 - Disclosure - Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets", "shortName": "Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.anpacbio.com/role/DiscontinuedOperationsDetails", "longName": "054 - Disclosure - Discontinued Operations (Details)", "shortName": "Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:VariableInterestEntityOwnershipPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:VariableInterestEntityOwnershipPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable", "longName": "055 - Disclosure - Discontinued Operations (Details) - Schedule of Results of Discontinued Operations", "shortName": "Discontinued Operations (Details) - Schedule of Results of Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c139", "name": "us-gaap:Revenues", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c139", "name": "us-gaap:Revenues", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "longName": "056 - Disclosure - Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations", "shortName": "Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c141", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c141", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.anpacbio.com/role/ScheduleofAccountsReceivableTable", "longName": "057 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable", "shortName": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable", "longName": "058 - Disclosure - Other Current Assets, Net (Details) - Schedule of Other Current Assets", "shortName": "Other Current Assets, Net (Details) - Schedule of Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:DepositAssets", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:DepositAssets", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.anpacbio.com/role/PropertyandEquipmentNetDetails", "longName": "059 - Disclosure - Property and Equipment, Net (Details)", "shortName": "Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable", "longName": "060 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net Consists", "shortName": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net Consists", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:FurnitureAndFixturesGross", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:FurnitureAndFixturesGross", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.anpacbio.com/role/IntangibleAssetsNetDetails", "longName": "061 - Disclosure - Intangible Assets, Net (Details)", "shortName": "Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable", "longName": "062 - Disclosure - Intangible Assets, Net (Details) - Schedule of Intangible Assets Net", "shortName": "Intangible Assets, Net (Details) - Schedule of Intangible Assets Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OtherFiniteLivedIntangibleAssetsGross", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OtherFiniteLivedIntangibleAssetsGross", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable", "longName": "063 - Disclosure - Intangible Assets, Net (Details) - Schedule of Estimated Aggregate Amortization Expense", "shortName": "Intangible Assets, Net (Details) - Schedule of Estimated Aggregate Amortization Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails", "longName": "064 - Disclosure - Long-Term Investments, Net (Details)", "shortName": "Long-Term Investments, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c146", "name": "us-gaap:OtherPartnersCapital", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c146", "name": "us-gaap:OtherPartnersCapital", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable", "longName": "065 - Disclosure - Long-Term Investments, Net (Details) - Schedule of Long-Term Investments", "shortName": "Long-Term Investments, Net (Details) - Schedule of Long-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.anpacbio.com/role/ShortTermDebtsDetails", "longName": "066 - Disclosure - Short-Term Debts (Details)", "shortName": "Short-Term Debts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c153", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "link:footnote", "td", "tr", "table", "ix:continuation", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c153", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "link:footnote", "td", "tr", "table", "ix:continuation", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.anpacbio.com/role/ScheduleofShortTermDebtsTable", "longName": "067 - Disclosure - Short-Term Debts (Details) - Schedule of Short-Term Debts", "shortName": "Short-Term Debts (Details) - Schedule of Short-Term Debts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c2", "name": "anpc:ConvertibleLoan", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "anpc:ConvertibleLoan", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable", "longName": "068 - Disclosure - Leases (Details) - Schedule of Operating Leases", "shortName": "Leases (Details) - Schedule of Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "anpc:OperatingLeaseLiabilities", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R70": { "role": "http://www.anpacbio.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable", "longName": "069 - Disclosure - Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates", "shortName": "Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.anpacbio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable", "longName": "070 - Disclosure - Leases (Details) - Schedule of Maturities of Lease Liabilities", "shortName": "Leases (Details) - Schedule of Maturities of Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable", "longName": "071 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.anpacbio.com/role/ShareholdersEquityDetails", "longName": "072 - Disclosure - Shareholders' Equity (Details)", "shortName": "Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c161", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c161", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable", "longName": "073 - Disclosure - Shareholders' Equity (Details) - Sechedule of Warrants Activity", "shortName": "Shareholders' Equity (Details) - Sechedule of Warrants Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c215", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c215", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "longName": "074 - Disclosure - Share Based Compensation (Details)", "shortName": "Share Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c115", "name": "us-gaap:IncrementalCommonSharesAttributableToWrittenPutOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c115", "name": "us-gaap:IncrementalCommonSharesAttributableToWrittenPutOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "longName": "075 - Disclosure - Share Based Compensation (Details) - Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument", "shortName": "Share Based Compensation (Details) - Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "longName": "076 - Disclosure - Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument", "shortName": "Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c229", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c229", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable", "longName": "077 - Disclosure - Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued", "shortName": "Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c231", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c231", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable", "longName": "078 - Disclosure - Share Based Compensation (Details) - Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense", "shortName": "Share Based Compensation (Details) - Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherSellingAndMarketingExpense", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherSellingAndMarketingExpense", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.anpacbio.com/role/IncomeTaxesDetails", "longName": "079 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DividendIncomeSecuritiesOperatingTaxable", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R81": { "role": "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable", "longName": "080 - Disclosure - Income Taxes (Details) - Schedule of Loss Before Income Taxes", "shortName": "Income Taxes (Details) - Schedule of Loss Before Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c243", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R82": { "role": "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable", "longName": "081 - Disclosure - Income Taxes (Details) - Schedule of Current and Deferred Components of Income Tax Benefit", "shortName": "Income Taxes (Details) - Schedule of Current and Deferred Components of Income Tax Benefit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredOtherTaxExpenseBenefit", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DeferredOtherTaxExpenseBenefit", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable", "longName": "082 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate", "shortName": "Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeLossAttributableToParent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeLossAttributableToParent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable_Parentheticals", "longName": "083 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate (Parentheticals)", "shortName": "Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": null }, "R85": { "role": "http://www.anpacbio.com/role/ScheduleofSignificantComponentsofDeferredTaxesTable", "longName": "084 - Disclosure - Income Taxes (Details) - Schedule of Significant Components of Deferred Taxes", "shortName": "Income Taxes (Details) - Schedule of Significant Components of Deferred Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable", "longName": "085 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational", "shortName": "Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c248", "name": "anpc:NatureOfTheParty", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c248", "name": "anpc:NatureOfTheParty", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable", "longName": "086 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Party Balances", "shortName": "Related Party Transactions and Balances (Details) - Schedule of Related Party Balances", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OtherReceivables", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OtherLiabilities", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "unique": true } }, "R88": { "role": "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "longName": "087 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Accounts Receivables", "shortName": "Related Party Transactions and Balances (Details) - Schedule of Accounts Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable", "longName": "088 - Disclosure - Related Party Transactions and Balances (Details) - Schedule of Related Party Transactions", "shortName": "Related Party Transactions and Balances (Details) - Schedule of Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "cny", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.anpacbio.com/role/SubsequentEventsDetails", "longName": "089 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:InvestmentsAndCash", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:InvestmentsAndCash", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea189176ex99-1_fresh2.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Investments and Cash", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r897", "r900" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of convertible loans", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r425", "r556", "r803", "r804" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r491", "r492", "r493", "r673", "r856", "r857", "r858", "r880", "r913" ] }, "us-gaap_OtherNonoperatingGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingGainsLosses", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses", "label": "Other Nonoperating Gains (Losses)", "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r183" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r870" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r124", "r126", "r423", "r574", "r803", "r804" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair market value per ordinary share as at grant dates (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r475" ] }, "us-gaap_InterestIncomeSecuritiesTaxable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeSecuritiesTaxable", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxable income does not exceeds (in Yuan Renminbi)", "label": "Interest Income, Securities, Operating, Taxable", "documentation": "Amount of operating interest income, including amortization and accretion of premiums and discounts, on securities subject to state, federal and other income tax." } } }, "auth_ref": [ "r231", "r253", "r254" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r837", "r900" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total consideration", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r165", "r698" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r57", "r275", "r787" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Options, outstanding ending balance (in Shares)", "periodEndLabel": "Number of Options, outstanding ending balance (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r461", "r462" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, outstanding ending balance", "periodEndLabel": "Weighted Average Exercise Price, outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r461", "r462" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility range", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r482" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r484" ] }, "us-gaap_InterestAndFeeIncomeLoansConsumerHomeEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndFeeIncomeLoansConsumerHomeEquity", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued and outstanding equity interests", "label": "Interest and Fee Income, Loans, Consumer, Home Equity", "documentation": "Interest and fee income from home equity lines-of-credit extended to individuals (borrowers). Such loans are generally secured by the borrower's equity in her or his home." } } }, "auth_ref": [ "r230" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r499" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r454", "r455", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r23", "r47", "r267", "r299", "r300", "r301", "r320", "r321", "r322", "r324", "r330", "r332", "r345", "r389", "r390", "r443", "r491", "r492", "r493", "r517", "r518", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r566", "r567", "r568", "r569", "r570", "r571", "r584", "r653", "r654", "r655", "r673", "r745" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r267", "r320", "r321", "r322", "r324", "r330", "r332", "r389", "r390", "r491", "r492", "r493", "r517", "r518", "r542", "r544", "r545", "r547", "r549", "r653", "r655", "r673", "r913" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Land use rights, net", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r279" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r288", "r378", "r391" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeMember", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income [Member]", "label": "Interest Income [Member]", "documentation": "Primary financial statement caption in which reported facts about interest income have been included." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherDebt", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Proceeds from Other Debt", "documentation": "Amount of cash inflow from debt classified as other." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss from discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r153", "r157", "r216" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r23", "r267", "r299", "r300", "r301", "r320", "r321", "r322", "r324", "r330", "r332", "r345", "r389", "r390", "r443", "r491", "r492", "r493", "r517", "r518", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r566", "r567", "r568", "r569", "r570", "r571", "r584", "r653", "r654", "r655", "r673", "r745" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss from discontinued operations attributable to noncontrolling interests", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r100", "r142", "r143", "r144", "r145", "r146", "r153", "r157", "r216" ] }, "us-gaap_AssetsHeldInTrustCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldInTrustCurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets held for sale", "label": "Asset, Held-in-Trust, Current", "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited." } } }, "auth_ref": [ "r851" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Results of Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r33", "r37", "r138", "r147", "r148", "r149", "r151", "r152", "r156", "r158", "r159", "r200" ] }, "country_HK": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "HK", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hong Kong [Member]", "label": "HONG KONG" } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityShares", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, issued", "label": "Option Indexed to Issuer's Equity, Shares", "documentation": "The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract." } } }, "auth_ref": [ "r118" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r85" ] }, "anpc_ShortTermDebtsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShortTermDebtsDetailsTable", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debts (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Table Sets Forth the Amount of Share-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r89" ] }, "us-gaap_AssetsHeldInTrustNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldInTrustNoncurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets held for sale", "label": "Asset, Held-in-Trust, Noncurrent", "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited." } } }, "auth_ref": [ "r851" ] }, "us-gaap_StockOptionExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionExercisePriceDecrease", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Stock Option, Exercise Price, Decrease", "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement." } } }, "auth_ref": [ "r442" ] }, "anpc_ShortTermDebtsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShortTermDebtsDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debts (Details) [Line Items]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets, net", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r291", "r816" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share issued", "verboseLabel": "Shares issued", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r23" ] }, "anpc_BidPricesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "BidPricesPercentage", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bid price percentage", "documentation": "Bid price percentage.", "label": "Bid Prices Percentage" } } }, "auth_ref": [] }, "anpc_DebtInstrumentNetOfDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DebtInstrumentNetOfDiscountPremium", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted value", "documentation": "The amount of the debt instrument net of discount (premium).", "label": "Debt Instrument Net Of Discount Premium" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r112", "r216", "r295", "r297", "r305", "r622", "r646" ] }, "us-gaap_ForwardContractIndexedToIssuersEquityShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForwardContractIndexedToIssuersEquityShares", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants", "label": "Forward Contract Indexed to Issuer's Equity, Shares", "documentation": "The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract." } } }, "auth_ref": [ "r117" ] }, "us-gaap_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentOther", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and equipment", "label": "Furniture and Fixtures, Gross", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ "r196" ] }, "anpc_ConvertibleDebenture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ConvertibleDebenture", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debenture", "documentation": "Convertible Debenture.", "label": "Convertible Debenture" } } }, "auth_ref": [] }, "anpc_ConvertibleDebenturesOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ConvertibleDebenturesOutstanding", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures outstanding", "documentation": "The amount of convertible debentures outstanding.", "label": "Convertible Debentures Outstanding" } } }, "auth_ref": [] }, "us-gaap_CommonStockConvertibleConversionPriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConvertibleConversionPriceIncrease", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prices, Per share (in Dollars per share)", "label": "Common Stock, Convertible, Conversion Price, Increase", "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r442" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Total comprehensive loss attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r14", "r103", "r112", "r295", "r297", "r306", "r623", "r647" ] }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pro Forma of Group Business Combination", "label": "Condensed Income Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r836", "r855" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r71", "r73", "r606" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Convertible Loans Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r25", "r119" ] }, "anpc_ShareholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareholdersEquityDetailsTable", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity (Details) [Table]" } } }, "auth_ref": [] }, "anpc_ServiceAgreementPay": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ServiceAgreementPay", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service agreement pay (in Dollars)", "documentation": "Service agreement pay.", "label": "Service Agreement Pay" } } }, "auth_ref": [] }, "anpc_ParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ParValue", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (in Dollars per share)", "label": "Par Value" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets Net", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r71", "r73" ] }, "anpc_ShareholdersEquityDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareholdersEquityDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Shareholders' Equity (Details) [Line Items]" } } }, "auth_ref": [] }, "anpc_DiscountedPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DiscountedPrice", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted price", "documentation": "Discounted price.", "label": "Discounted Price" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Allowance for credit losses", "label": "Allowance for Credit Loss, Receivable, Other, Current", "documentation": "Amount of allowance for credit loss on receivable, classified as other and current." } } }, "auth_ref": [ "r286" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r580", "r815" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable": { "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible loans", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "calculation": { "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Any Recorded Impairment", "label": "Public Utility Property, Plant, and Equipment [Table Text Block]", "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": [ "r135" ] }, "anpc_fairMarketValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "fairMarketValue", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "fair market value", "label": "fair Market Value" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Sechedule of Warrants Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r85" ] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable": { "parentTag": "us-gaap_EmployeeBenefitsAndShareBasedCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Other Research and Development Expense", "documentation": "Amount of other research and development expense." } } }, "auth_ref": [ "r871" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r100", "r443", "r856", "r857", "r858", "r913" ] }, "anpc_CompanyIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "CompanyIssued", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company issued", "label": "Company Issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r85" ] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ScheduleofShortTermDebtsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Short-term debts", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r161", "r220", "r816", "r898" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of warrants, Balance of warrants outstanding as of December 31, 2020 and 2021\t(in Shares)", "periodEndLabel": "Number of warrants, Balance of warrants outstanding and exercisable as of December 31, 2022 (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r26", "r27" ] }, "anpc_CompanyDeposited": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "CompanyDeposited", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company deposited", "label": "Company Deposited" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtPercentageBearingVariableInterestRate", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Short-Term Debt, Percentage Bearing Variable Interest Rate", "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r872" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/Acqusitions" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUSITIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r215", "r534" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "terseLabel": "Balance at June 30, 2023 (US$) (in Dollars)", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r100", "r101", "r111", "r267", "r268", "r300", "r320", "r321", "r322", "r324", "r330", "r389", "r390", "r443", "r491", "r492", "r493", "r517", "r518", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r566", "r567", "r571", "r584", "r654", "r655", "r671", "r700", "r717", "r746", "r747", "r770", "r827", "r853", "r861", "r881", "r913" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable-related party", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ShortTermBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Short-Term Debts [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-Term Debts", "label": "Schedule of Short-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r28" ] }, "anpc_TotalGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TotalGrossProceeds", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total gross proceeds", "documentation": "The amount of total gross proceeds.", "label": "Total Gross Proceeds" } } }, "auth_ref": [] }, "anpc_GrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "GrossProceeds", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "documentation": "The amount of gross proceeds.", "label": "Gross Proceeds" } } }, "auth_ref": [] }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable": { "parentTag": "us-gaap_EmployeeBenefitsAndShareBasedCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "Other General and Administrative Expense", "documentation": "Amount of general and administrative expense classified as other." } } }, "auth_ref": [ "r181", "r912" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options Exercised (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r29" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.anpacbio.com/role/PropertyandEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net Consists", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PublicUtilitiesPropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesPropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Public Utilities, Property, Plant and Equipment, Net", "documentation": "Period end amount of total net PPE." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss attributable to ordinary shareholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r53", "r295", "r297", "r307", "r624", "r648" ] }, "anpc_TradingPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TradingPricePercentage", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading percentage", "documentation": "The percentage (bottom number) is much more important than the amount of dollars (top number), because it tells you how much the value changed compared to the price you bought it at.", "label": "Trading Price Percentage" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r96", "r97", "r533", "r808", "r809" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit", "negatedTerseLabel": "Income tax benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r239", "r251", "r331", "r332", "r354", "r506", "r520", "r651" ] }, "anpc_PurchaseOfAggregateShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "PurchaseOfAggregateShares", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of aggregate shares", "documentation": "Total share amount of purchase of aggregate shares.", "label": "Purchase Of Aggregate Shares" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockExpense", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock expense", "label": "Restricted Stock or Unit Expense", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placements [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "anpc_LessImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LessImputedInterest", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "documentation": "Amount of Imputed interest.", "label": "Less Imputed Interest" } } }, "auth_ref": [] }, "anpc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDatesIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDatesIntrinsicValue", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Granted (in Dollars)", "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Dates Intrinsic Value" } } }, "auth_ref": [] }, "anpc_PayableForPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "PayableForPropertyAndEquipment", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Payable for property and equipment", "documentation": "Amount of accrual for capital expenditures incurred but not yet paid.", "label": "Payable For Property And Equipment" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r104", "r793" ] }, "anpc_ConnectionWithPrivatePlacement": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ConnectionWithPrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, warrants issued in connection with the March 16, 2022 private placement (in Shares)", "label": "Connection With Private Placement" } } }, "auth_ref": [] }, "anpc_ShareWarrantsIssuedInConnection": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareWarrantsIssuedInConnection", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price per share, warrants issued in connection with the March 16, 2022 private placement", "label": "Share Warrants Issued In Connection" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Investments", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r383" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "anpc_ExpirationDatesWarrantsIssuedInConnectioPrivatePlacement": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ExpirationDatesWarrantsIssuedInConnectioPrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration dates, warrants issued in connection with the March 16, 2022 private placement", "label": "Expiration Dates Warrants Issued In Connectio Private Placement" } } }, "auth_ref": [] }, "anpc_WeightedAverageLifeWarrantsConnectionWithPrivatePlacement": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageLifeWarrantsConnectionWithPrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average life, warrants issued in connection with the March 16, 2022 private placement", "label": "Weighted Average Life Warrants Connection With Private Placement" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r55" ] }, "anpc_NumberOfOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NumberOfOptionsExercised", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options, Exercised (in Shares)", "label": "Number Of Options Exercised" } } }, "auth_ref": [] }, "anpc_NumberOfWarrantsWarrantsIssuedConnectionWithPrivatePlacement": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NumberOfWarrantsWarrantsIssuedConnectionWithPrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, warrants issued in connection with the September 2, 2022 private placement (in Shares)", "label": "Number Of Warrants Warrants Issued Connection With Private Placement" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r127", "r128", "r724", "r725", "r728" ] }, "anpc_WeightedAverageExercisePricePerShareWarrantsIssuedInConnection": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageExercisePricePerShareWarrantsIssuedInConnection", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price per share, warrants issued in connection with the September 2, 2022 private placement", "label": "Weighted Average Exercise Price Per Share Warrants Issued In Connection" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Description", "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "anpc_WeightedAverageLifeWarrantsIssuedInConnectionWithPrivatePlacementterm": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageLifeWarrantsIssuedInConnectionWithPrivatePlacementterm", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average life, warrants issued in connection with the September 2, 2022 private placement", "label": "Weighted Average Life Warrants Issued In Connection With Private Placementterm" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/RelatedPartyTransactionsandBalances" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS AND BALANCES", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r585", "r586", "r587", "r589", "r592", "r668", "r669", "r670", "r726", "r727", "r728", "r749", "r751" ] }, "anpc_WarrantsIssuedInConnectionWithPrivatePlacement": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WarrantsIssuedInConnectionWithPrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration dates, warrants issued in connection with the September 2, 2022 private placement", "label": "Warrants Issued In Connection With Private Placement" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDescriptionAndTimingOfDisposal": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationDescriptionAndTimingOfDisposal", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal description", "label": "Disposal Group, Including Discontinued Operation, Description and Timing of Disposal", "documentation": "Description of the facts and circumstances leading to the completed or expected disposal, and the manner and timing of that disposal." } } }, "auth_ref": [ "r160", "r197", "r198", "r269", "r270" ] }, "anpc_NumberOfWarrantsWarrantsIssuedInConnectionWithTheJune2023PrivatePlacement": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NumberOfWarrantsWarrantsIssuedInConnectionWithTheJune2023PrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, warrants issued in connection with the June 2023 private placement (in Shares)", "documentation": "Number of warrants, warrants issued in connection with the June 2023 private placement.", "label": "Number Of Warrants Warrants Issued In Connection With The June2023 Private Placement" } } }, "auth_ref": [] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r397", "r399", "r802" ] }, "anpc_WeightedAverageExercisePricePerShareWarrantsIssuedInConnectionWithTheJune2023Priv": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageExercisePricePerShareWarrantsIssuedInConnectionWithTheJune2023Priv", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price per share, warrants issued in connection with the June 2023 private placement", "documentation": "Weighted average exercise price per share, warrants issued in connection with the June 2023.", "label": "Weighted Average Exercise Price Per Share Warrants Issued In Connection With The June2023 Priv" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled treasure shares (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "anpc_WeightedAverageLifeWarrantsIssuedInConnectionWithTheJune2023PrivatePlacement": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageLifeWarrantsIssuedInConnectionWithTheJune2023PrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average life, warrants issued in connection with the June 2023 private placement", "documentation": "Weighted average life, warrants issued in connection with the June 2023 private placement.", "label": "Weighted Average Life Warrants Issued In Connection With The June2023 Private Placement" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r724", "r725", "r728" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r281", "r555", "r790" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "anpc_ExpirationDatesWarrantsIssuedInConnectionWithTheJune2023PrivatePlacement": { "xbrltype": "dateItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ExpirationDatesWarrantsIssuedInConnectionWithTheJune2023PrivatePlacement", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration dates, warrants issued in connection with the June 2023 private placement", "documentation": "Expiration dates, warrants issued in connection with the June 2023 private placement.", "label": "Expiration Dates Warrants Issued In Connection With The June2023 Private Placement" } } }, "auth_ref": [] }, "anpc_NumberOfWarrantsExercisedinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NumberOfWarrantsExercisedinShares", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, Exercised (in Shares)", "documentation": "Number of warrants, Exercised.", "label": "Number Of Warrants Exercisedin Shares" } } }, "auth_ref": [] }, "anpc_WeightedAverageExercisePricePerShareExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageExercisePricePerShareExercised", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price per share, Exercised", "documentation": "Weighted average exercise price per share, exercised.", "label": "Weighted Average Exercise Price Per Share Exercised" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.anpacbio.com/role/ConsolidatedIncomeStatementAlt0": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to ordinary shareholders", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r176", "r188", "r229", "r272", "r294", "r296", "r301", "r314", "r323", "r325", "r326", "r327", "r328", "r331", "r332", "r339", "r348", "r362", "r366", "r368", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r551", "r557", "r644", "r719", "r743", "r744", "r799", "r826", "r866" ] }, "anpc_ExpirationDatesBalanceOfWarrantsOutstandingAndExercisable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ExpirationDatesBalanceOfWarrantsOutstandingAndExercisable", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration dates, Balance of warrants outstanding and exercisable as of December 31, 2022", "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.", "label": "Expiration Dates Balance Of Warrants Outstanding And Exercisable" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "anpc_WeightedAverageRemainingContractualTermOutstandingBeginningBalance": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageRemainingContractualTermOutstandingBeginningBalance", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, outstanding ending balance", "label": "Weighted Average Remaining Contractual Term Outstanding Beginning Balance" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromOtherEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherEquity", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received", "label": "Proceeds from Other Equity", "documentation": "Amount of cash inflow from the issuance of equity classified as other." } } }, "auth_ref": [ "r12" ] }, "anpc_WeightedAverageGrantDateFairValueGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageGrantDateFairValueGranted", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant date Fair Value Granted", "label": "Weighted Average Grant Date Fair Value Granted" } } }, "auth_ref": [] }, "anpc_WeightedAverageRemainingContractualTermGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageRemainingContractualTermGranted", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term Granted", "label": "Weighted Average Remaining Contractual Term Granted" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options Granted (in Shares)", "verboseLabel": "Weighted Average Remaining Contractual Term, Granted (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r465" ] }, "anpc_AggregateIntrinsicValueGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AggregateIntrinsicValueGranted", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Granted (in Dollars)", "label": "Aggregate Intrinsic Value Granted" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShareholdersEquityType2or3", "http://www.anpacbio.com/role/ShortTermDebtsDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r253", "r282", "r283", "r284", "r314", "r336", "r338", "r340", "r342", "r346", "r347", "r387", "r414", "r416", "r417", "r418", "r421", "r422", "r428", "r429", "r431", "r434", "r441", "r557", "r662", "r663", "r664", "r665", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r698", "r720", "r745", "r765", "r766", "r767", "r768", "r769", "r830", "r852", "r860" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "anpc_WeightedAverageRemainingContractualTermExercised": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageRemainingContractualTermExercised", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term Exercised", "label": "Weighted Average Remaining Contractual Term Exercised" } } }, "auth_ref": [] }, "anpc_WeightedAverageGrantDateFairValueExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageGrantDateFairValueExercised", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant date Fair Value Exercised", "label": "Weighted Average Grant Date Fair Value Exercised" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Significant Components of Deferred Taxes", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r211" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Current and Deferred Components of Income Tax Benefit", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r212" ] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total share-based compensation expenses", "label": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "anpc_AggregateIntrinsicValueExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AggregateIntrinsicValueExercised", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Exercised (in Dollars)", "label": "Aggregate Intrinsic Value Exercised" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r210" ] }, "anpc_WeightedAverageRemainingContractualTermOutstandingEndingBalance": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageRemainingContractualTermOutstandingEndingBalance", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, outstanding ending balance", "label": "Weighted Average Remaining Contractual Term Outstanding Ending Balance" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss Before Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r854" ] }, "anpc_WeightedAverageRemainingContractualTermVestedAndExercisable": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageRemainingContractualTermVestedAndExercisable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term Vested and exercisable", "label": "Weighted Average Remaining Contractual Term Vested And Exercisable" } } }, "auth_ref": [] }, "anpc_AggregateIntrinsicValueVestedAndExercisable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AggregateIntrinsicValueVestedAndExercisable", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Vested and exercisable (in Dollars)", "label": "Aggregate Intrinsic Value Vested And Exercisable" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other (Loss) Income", "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r247", "r293", "r299", "r842", "r843" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "anpc_ShareBasedCompensationDetailsScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationDetailsScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument [Table]" } } }, "auth_ref": [] }, "anpc_ShareBasedCompensationDetailsScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationDetailsScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation (Details) - Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r33", "r37", "r138", "r147", "r148", "r149", "r151", "r152", "r156", "r158", "r159", "r200" ] }, "anpc_WeightedAverageGrantDateFairValueOutstandingBeginningBalance": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageGrantDateFairValueOutstandingBeginningBalance", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant date Fair Value, Outstanding Beginning balance", "periodEndLabel": "Weighted Average Grant date Fair Value, Outstanding Beginning balance", "label": "Weighted Average Grant Date Fair Value Outstanding Beginning Balance" } } }, "auth_ref": [] }, "anpc_NumberOfOptionsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NumberOfOptionsGranted", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Granted (in Shares)", "label": "Number Of Options Granted" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "anpc_WeightedAverageGrantDateFairValueGranted1": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageGrantDateFairValueGranted1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant date Fair Value, Granted", "label": "Weighted Average Grant Date Fair Value Granted1" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "anpc_WeightedAverageExercisePriceGranted1": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageExercisePriceGranted1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Granted", "label": "Weighted Average Exercise Price Granted1" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "US [Member]", "verboseLabel": "United States [Member]", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposit insurance limit (in Yuan Renminbi)", "label": "Time Deposits, at or Above FDIC Insurance Limit", "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit." } } }, "auth_ref": [ "r20" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Employee [Member]", "label": "Share-Based Payment Arrangement, Employee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r455", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r99" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusAxis", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r454", "r455", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consecutive trading days", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "anpc_OtherComprehensiveLossIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OtherComprehensiveLossIncomeNetOfTaxAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income, net of tax:", "label": "Other Comprehensive Loss Income Net Of Tax Abstract" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusDomain", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r454", "r455", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r89" ] }, "anpc_AmountsAttributableToOrdinaryShareholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AmountsAttributableToOrdinaryShareholdersAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts attributable to ordinary shareholders:", "label": "Amounts Attributable To Ordinary Shareholders Abstract" } } }, "auth_ref": [] }, "srt_FederalFundsPurchasedAverageRatePaid": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "FederalFundsPurchasedAverageRatePaid", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of share purchase agreement", "label": "Federal Funds Purchased, Average Rate Paid", "documentation": "Average rate paid on federal funds purchased." } } }, "auth_ref": [ "r253", "r255" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r69", "r72" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Nonemployee [Member]", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r454", "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "anpc_LossPerClassAAndBOrdinarySharesBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LossPerClassAAndBOrdinarySharesBasicAndDilutedAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per Class A and B ordinary shares - basic and diluted", "label": "Loss Per Class AAnd BOrdinary Shares Basic And Diluted Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities", "label": "Schedule of Other Assets and Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, classified as other." } } }, "auth_ref": [] }, "anpc_WeightedAverageSharesOutstandingUsedInCalculatingBasicAndDilutedLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageSharesOutstandingUsedInCalculatingBasicAndDilutedLossPerShareAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding used in calculating basic and diluted loss per share", "label": "Weighted Average Shares Outstanding Used In Calculating Basic And Diluted Loss Per Share Abstract" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted shares", "verboseLabel": "Conversion shares", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r59", "r60", "r61" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Principal Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r191", "r606" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r277", "r395", "r620", "r802", "r816", "r862", "r863" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r191", "r607" ] }, "us-gaap_OtherFiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherFiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Other Finite-Lived Intangible Assets, Gross", "documentation": "Amount before accumulated amortization of finite-lived intangible assets classified as other." } } }, "auth_ref": [ "r191" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price", "verboseLabel": "Conversion loan (in Yuan Renminbi)", "label": "Conversion of Stock, Amount Issued", "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r59", "r60", "r61" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r44" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r165" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt conversion", "label": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r59", "r61" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets obtained in exchange for lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r579", "r815" ] }, "us-gaap_NetAssetValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetAssetValuePerShare", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in Dollars per share)", "label": "Net Asset Value Per Share", "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure." } } }, "auth_ref": [ "r4", "r5", "r34", "r676", "r683", "r684", "r700", "r717", "r765", "r828" ] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal balance of debt converted", "label": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r59", "r61" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations [Abstract]" } } }, "auth_ref": [] }, "stpr_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "DE", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deleware [Member]", "label": "DELAWARE" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued upon conversion of loan", "label": "Debt Conversion, Converted Instrument, Shares Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r59", "r61" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency translation differences", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r9", "r171", "r560", "r562", "r565" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r64", "r65", "r120", "r121", "r372", "r773" ] }, "anpc_AssetsAcquiredAndLiabilitiesAssumedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AssetsAcquiredAndLiabilitiesAssumedAbstract", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Assets acquired and liabilities assumed:", "label": "Assets Acquired And Liabilities Assumed Abstract" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r50", "r223", "r314", "r387", "r414", "r416", "r417", "r418", "r421", "r422", "r557", "r637", "r700" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r64", "r65", "r120", "r121", "r372", "r659", "r773" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r62", "r63" ] }, "anpc_RevenuesThirdPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RevenuesThirdPartiesMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues-Third Parties", "label": "Revenues Third Parties Member" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/PropertyandEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT, NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r193", "r244", "r248", "r249" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r16" ] }, "anpc_Fresh2TechnologyIncFresh2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2TechnologyIncFresh2Member", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 Technology Inc. (\u201cFresh2\u201d) [Member]", "label": "Fresh2 Technology Inc Fresh2 Member" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r185" ] }, "anpc_GISNAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "GISNAcquisitionMember", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "GISN Acquisition [Member]", "label": "GISNAcquisition Member" } } }, "auth_ref": [] }, "anpc_FurnitureFixturesAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "FurnitureFixturesAndEquipmentMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable", "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and equipment [Member]", "label": "Furniture Fixtures And Equipment Member" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of revenues", "negatedTerseLabel": "Cost of revenues", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r179", "r314", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r557", "r866" ] }, "anpc_GSINHKLimitedGISNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "GSINHKLimitedGISNMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "GSIN (HK) Limited (\u201cGISN\u201d) [Member]", "label": "GSINHKLimited GISNMember" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.anpacbio.com/role/ConsolidatedIncomeStatementAlt0": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow", "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from continuing operations", "terseLabel": "Net loss from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r102", "r178", "r188", "r325", "r326", "r327", "r328", "r339", "r342" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "anpc_HaohanXuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "HaohanXuMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Haohan Xu [Member]", "label": "Haohan Xu Member" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r196" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations basic (in Dollars per share and Yuan Renminbi per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r172", "r225", "r228", "r308", "r323", "r325", "r326", "r327", "r328", "r336", "r340", "r341", "r551", "r625", "r902" ] }, "anpc_GuanshiTechnologyBeijingCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "GuanshiTechnologyBeijingCoLtdMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Guanshi Technology (Beijing) Co., Ltd [Member]", "label": "Guanshi Technology Beijing Co Ltd Member" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r320", "r321", "r322", "r345", "r605", "r660", "r684", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r701", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r712", "r713", "r714", "r715", "r716", "r718", "r722", "r723", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r745", "r821" ] }, "anpc_HuaYouShengFutureBeijingTechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "HuaYouShengFutureBeijingTechnologyCoLtdMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Hua You Sheng Future (Beijing) Technology Co., Ltd [Member]", "label": "Hua You Sheng Future Beijing Technology Co Ltd Member" } } }, "auth_ref": [] }, "anpc_JiaxingZhijunInvestmentManagementCoLtdZhijunMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "JiaxingZhijunInvestmentManagementCoLtdZhijunMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Jiaxing Zhijun Investment Management Co., Ltd. (\u201cZhijun\u201d) [Member]", "label": "Jiaxing Zhijun Investment Management Co Ltd Zhijun Member" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations diluted", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r172", "r308", "r323", "r325", "r326", "r327", "r328", "r336", "r340", "r341", "r342", "r551", "r625", "r902" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r16" ] }, "anpc_JiaxingZhijunSihangInvestmentPartnershipEnterprisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "JiaxingZhijunSihangInvestmentPartnershipEnterprisesMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Jiaxing Zhijun Sihang Investment Partnership Enterprises [Member]", "label": "Jiaxing Zhijun Sihang Investment Partnership Enterprises Member" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatementAlt0": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss from discontinued operations", "verboseLabel": "Loss from operations for discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r157", "r272", "r528", "r642" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r16" ] }, "anpc_LishuiAnPacMedicalLaboratoryCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LishuiAnPacMedicalLaboratoryCoLtdMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lishui AnPac Medical Laboratory Co., Ltd. [Member]", "label": "Lishui An Pac Medical Laboratory Co Ltd Member" } } }, "auth_ref": [] }, "anpc_MotorVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "MotorVehiclesMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable", "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Motor vehicles [Member]", "label": "Motor Vehicles Member" } } }, "auth_ref": [] }, "anpc_NineInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NineInvestorsMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nine investors [Member]", "label": "Nine Investors Member" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow", "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from discontinued operations, net of taxes", "verboseLabel": "Less: net loss from discontinued operations", "netLabel": "Loss from discontinued operations before income taxes", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r153", "r175", "r901" ] }, "anpc_NassauEnterprisesLLCNassauMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NassauEnterprisesLLCNassauMember", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails", "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Nassau Enterprises LLC (\u201cNassau\u201d) [Member]", "verboseLabel": "Nassau [Member]", "label": "Nassau Enterprises LLCNassau Member" } } }, "auth_ref": [] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Software [Member]", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "stpr_NY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "NY", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New York [Member]", "label": "NEW YORK" } } }, "auth_ref": [] }, "anpc_NonEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NonEmployeesMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non Employees [Member]", "label": "Non Employees Member" } } }, "auth_ref": [] }, "anpc_OneIndividualMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OneIndividualMember", "presentation": [ "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Individual [Member]", "label": "One Individual Member" } } }, "auth_ref": [] }, "anpc_NonPRCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NonPRCMember", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-US [Member]", "verboseLabel": "Non-PRC [Member]", "label": "Non PRCMember" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepayment", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r16" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations basic (in Dollars per share and Yuan Renminbi per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Enterprise income tax rate percentage", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent", "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments." } } }, "auth_ref": [] }, "us-gaap_IncomeLossAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossAttributableToParent", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss before income taxes", "label": "Income (Loss) Attributable to Parent, before Tax", "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": [ "r180", "r301" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "negatedTerseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r136", "r500", "r895" ] }, "anpc_OneSuppliersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OneSuppliersMember", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Suppliers [Member]", "label": "One Suppliers Member" } } }, "auth_ref": [] }, "anpc_LeasesTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LeasesTablesLineItems", "presentation": [ "http://www.anpacbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease [Abstract]", "label": "Leases Tables Line Items" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations diluted", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "anpc_ProFormMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ProFormMember", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro Forma [Member]", "label": "Pro Form Member" } } }, "auth_ref": [] }, "anpc_PRCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "PRCMember", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PRC [Member]", "label": "PRCMember" } } }, "auth_ref": [] }, "anpc_RevenuesRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RevenuesRelatedPartiesMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues-Related Parties", "label": "Revenues Related Parties Member" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable-related party", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r16" ] }, "us-gaap_OtherPartnersCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPartnersCapital", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital amount", "label": "Other Partners' Capital", "documentation": "Amount of other partners' capital." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r407", "r728" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r572", "r594" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND EQUITY (DEFICIT)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r170", "r224", "r638", "r816", "r853", "r861", "r881" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "verboseLabel": "Revenues parties", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r303", "r314", "r349", "r350", "r361", "r364", "r365", "r369", "r370", "r372", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r557", "r626", "r866" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r406", "r407", "r728" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Property, Plant and Equipment, Other, Accumulated Depreciation", "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit computed at the statutory income tax rate at 21%", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r507" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r489" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/OtherCurrentAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r320", "r321", "r322", "r345", "r605", "r660", "r684", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r701", "r702", "r703", "r704", "r705", "r707", "r708", "r709", "r710", "r712", "r713", "r714", "r715", "r716", "r718", "r722", "r723", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r745", "r821" ] }, "us-gaap_IncrementalCommonSharesAttributableToWrittenPutOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToWrittenPutOptions", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share options purchase", "label": "Incremental Common Shares Attributable to Dilutive Effect of Written Put Options", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of outstanding written put options using the reverse treasury stock method." } } }, "auth_ref": [ "r337", "r342", "r795", "r796" ] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations [Member]", "label": "Discontinued Operations [Member]", "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r13", "r139", "r140", "r141" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r6", "r186" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Advance from customers", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r601", "r849" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r882" ] }, "us-gaap_FairValueOfAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfAssetsAcquired", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Fair Value of Assets Acquired", "documentation": "The fair value of assets acquired in noncash investing or financing activities." } } }, "auth_ref": [ "r59", "r60", "r61" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r57", "r186", "r311" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r73", "r602", "r603", "r604", "r606", "r794" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://www.anpacbio.com/role/OtherCurrentAssetsNet" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER CURRENT ASSETS, NET", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r308", "r325", "r326", "r327", "r328", "r329", "r336", "r340", "r341", "r342", "r343", "r550", "r551", "r625", "r649", "r797" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r394", "r400", "r802" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSignificantComponentsofDeferredTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss carryforward", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r92" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "negatedLabel": "Loss from operations", "terseLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r348", "r362", "r366", "r368", "r799" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperations" ], "lang": { "en-us": { "role": { "terseLabel": "DISCONTINUED OPERATION", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r137", "r193" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r11", "r299", "r304", "r506", "r525", "r527", "r566", "r569", "r571", "r621", "r645" ] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebts" ], "lang": { "en-us": { "role": { "terseLabel": "SHORT-TERM DEBTS", "label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r203" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/IntangibleAssetsNet" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS, NET", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r401" ] }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityOwnershipPercentage", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement percentage", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)." } } }, "auth_ref": [ "r108" ] }, "anpc_WarrantsPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WarrantsPurchase", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants purchase", "documentation": "The amount of warrants purchase.", "label": "Warrants Purchase" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts due to related parties", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r40" ] }, "anpc_ConvertibleDebentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ConvertibleDebentures", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures", "label": "Convertible Debentures" } } }, "auth_ref": [] }, "anpc_SharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SharesIssued1", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares Issued1" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r818", "r819", "r822", "r823", "r824", "r825" ] }, "anpc_ShareBasedCompensationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationDetailsTable", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation (Details) [Table]" } } }, "auth_ref": [] }, "anpc_GrantedToEmployeesYearTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "GrantedToEmployeesYearTerm", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted to employees year term", "documentation": "Granted to employees year term.", "label": "Granted To Employees Year Term" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable", "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "verboseLabel": "Property and equipment- furniture, fixtures and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r98", "r99" ] }, "us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders equity", "label": "Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares", "documentation": "Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement." } } }, "auth_ref": [ "r208" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r98", "r99" ] }, "anpc_IncomeTaxesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsTable", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss basic (in Dollars per share and Yuan Renminbi per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r308", "r325", "r326", "r327", "r328", "r329", "r334", "r336", "r340", "r341", "r342", "r343", "r550", "r551", "r625", "r649", "r797" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r278", "r404" ] }, "anpc_IncomeTaxesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r51", "r52", "r171", "r287", "r635", "r657", "r658" ] }, "anpc_WithholdingTaxRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WithholdingTaxRatePercentage", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding tax percentage", "documentation": "The percentage of withholding tax rate.", "label": "Withholding Tax Rate Percentage" } } }, "auth_ref": [] }, "anpc_EffectveCorporateIncomeTaxRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "EffectveCorporateIncomeTaxRatePercentage", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal corporate income tax percentage", "documentation": "The percentage of corporate income tax rate.", "label": "Effectve Corporate Income Tax Rate Percentage" } } }, "auth_ref": [] }, "anpc_IncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxRate", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax percentage", "documentation": "Income tax rate.", "label": "Income Tax Rate" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "verboseLabel": "Related Party [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r316", "r317", "r588", "r589", "r590", "r591", "r691", "r692", "r693", "r694", "r695", "r716", "r718", "r752" ] }, "anpc_AdjustedTaxLossBeforeIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AdjustedTaxLossBeforeIncomeTaxes", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted tax loss before income taxes", "documentation": "Adjusted tax loss before income taxes.", "label": "Adjusted Tax Loss Before Income Taxes" } } }, "auth_ref": [] }, "anpc_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r572", "r594" ] }, "anpc_AggregateShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AggregateShares", "presentation": [ "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate shares (in Shares)", "documentation": "Aggregate shares.", "label": "Aggregate Shares" } } }, "auth_ref": [] }, "anpc_SubsequentEventsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SubsequentEventsDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "auth_ref": [] }, "anpc_AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AdvancedLifeTherapeuticsCoLtdAdvancedLifeMember", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails", "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced Life Therapeutics Co., Ltd. (\u201cAdvanced Life\u201d) [Member]", "label": "Advanced Life Therapeutics Co Ltd Advanced Life Member" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r99" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash acquired from acquisition", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r54" ] }, "anpc_AnPacBeijingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AnPacBeijingMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "AnPac Beijing [Member]", "label": "An Pac Beijing Member" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r572", "r594" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r99" ] }, "anpc_AnPacBioMedicalTechnologyShanghaiCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AnPacBioMedicalTechnologyShanghaiCoLtdMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "AnPac Bio-Medical Technology (Shanghai) Co., Ltd. [Member]", "label": "An Pac Bio Medical Technology Shanghai Co Ltd Member" } } }, "auth_ref": [] }, "anpc_AnPacBioMedicalTechnologyLishuiCoLtdAnPacLishuiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AnPacBioMedicalTechnologyLishuiCoLtdAnPacLishuiMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "AnPac Bio-Medical Technology (Lishui) Co., Ltd. (\u201cAnPac Lishui\u201d) [Member]", "label": "An Pac Bio Medical Technology Lishui Co Ltd An Pac Lishui Member" } } }, "auth_ref": [] }, "anpc_AssetAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AssetAcquisitionMember", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Member]", "label": "Asset Acquisition Member" } } }, "auth_ref": [] }, "anpc_AnPacTechnologyUSACoLtdAnPacUSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AnPacTechnologyUSACoLtdAnPacUSMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "AnPac Technology USA Co., Ltd. (\u201cAnPac US\u201d) [Member]", "label": "An Pac Technology USACo Ltd An Pac USMember" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of investment, owned", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r384" ] }, "anpc_AnpaiShanghaiHealthcareManagementAndConsultingCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AnpaiShanghaiHealthcareManagementAndConsultingCoLtdMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Anpai (Shanghai) Healthcare Management and Consulting Co., Ltd. [Member]", "label": "Anpai Shanghai Healthcare Management And Consulting Co Ltd Member" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r99" ] }, "anpc_ApifinyIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ApifinyIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Apifiny Inc.[Member]", "label": "Apifiny Inc Member" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts payables", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r99" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities \u2013 continuing operations", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r848" ] }, "anpc_ShareBasedCompensationTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationTablesTable", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation (Tables) [Table]" } } }, "auth_ref": [] }, "anpc_ScheduleOfShareBasedCompensationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfShareBasedCompensationAssumptionsTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued", "documentation": "Tabular disclosure of assumptions used to value share-based compensation arrangements.", "label": "Schedule Of Share Based Compensation Assumptions Table Text Block" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r167", "r207", "r636", "r656", "r658", "r666", "r699", "r816" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r578" ] }, "anpc_ShareBasedCompensationTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationTablesLineItems", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation (Tables) [Line Items]" } } }, "auth_ref": [] }, "anpc_ScheduleOfRelatedPartyNamesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfRelatedPartyNamesTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Parties Financial and Operational", "label": "Schedule Of Related Party Names Table Text Block" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r273", "r292", "r314", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r536", "r540", "r557", "r816", "r866", "r867", "r887" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities \u2013 continuing operations", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r848" ] }, "anpc_ScheduleOfRelatedPartyBalancesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfRelatedPartyBalancesTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions", "label": "Schedule Of Related Party Balances Table Text Block" } } }, "auth_ref": [] }, "anpc_DateOfIncorporation": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DateOfIncorporation", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Date of Incorporation/ Acquisition", "documentation": "Description of date of incorporation.", "label": "Date Of Incorporation" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38", "r816" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r185" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "anpc_PlaceOfIncorporationAcquisition": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "PlaceOfIncorporationAcquisition", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Place of Incorporation", "documentation": "Description of place of incorporation/ acquisition.", "label": "Place Of Incorporation Acquisition" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstandingof shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "anpc_LossgainOnChangeInFairValueOfConvertibleLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LossgainOnChangeInFairValueOfConvertibleLoan", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable": { "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss (gain) on change in fair value of convertible loan", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Lossgain On Change In Fair Value Of Convertible Loan" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares subject plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)", "documentation": "Number of increase (decrease) of non-vested options." } } }, "auth_ref": [] }, "anpc_MajorOperation": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "MajorOperation", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Major Operation", "documentation": "Description of major operation.", "label": "Major Operation" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant date Fair Value, outstanding ending balance", "periodEndLabel": "Weighted Average Grant date Fair Value, outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Accounts Payable, Other, Current", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right of use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r850" ] }, "anpc_OtherComprehensiveIncomeforeignExchangeTranslations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OtherComprehensiveIncomeforeignExchangeTranslations", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable": { "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income -foreign exchange translations", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Other Comprehensive Incomeforeign Exchange Translations" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r285", "r374", "r375", "r789" ] }, "anpc_SummaryofPrincipalAccountingPoliciesDetailsScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SummaryofPrincipalAccountingPoliciesDetailsScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable" ], "lang": { "en-us": { "role": { "label": "Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives [Table]" } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivities" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND PRINCIPAL ACTIVITIES", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r240", "r252" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails", "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r452", "r835", "r859" ] }, "anpc_SummaryofPrincipalAccountingPoliciesDetailsScheduleofIntangibleAssetsHaveEstimatedUsefulLivesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SummaryofPrincipalAccountingPoliciesDetailsScheduleofIntangibleAssetsHaveEstimatedUsefulLivesLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable" ], "lang": { "en-us": { "role": { "label": "Summary of Principal Accounting Policies (Details) - Schedule of Intangible Assets Have Estimated Useful Lives [Line Items]" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r829" ] }, "anpc_AcqusitionsDetailsScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AcqusitionsDetailsScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities [Table]" } } }, "auth_ref": [] }, "anpc_AcqusitionsDetailsScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AcqusitionsDetailsScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Acqusitions (Details) - Schedule of Summarizes the Fair Value of the Identifiable Assets Acquired and Liabilities [Line Items]" } } }, "auth_ref": [] }, "anpc_businessCombinationAccountsReceivablerelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "businessCombinationAccountsReceivablerelatedParties", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable-related parties", "documentation": "It represents accounts receivable related parties.", "label": "business Combination Accounts Receivablerelated Parties" } } }, "auth_ref": [] }, "anpc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets", "documentation": "Amount of right of use assets at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Assets" } } }, "auth_ref": [] }, "anpc_BusinessCombinationAdvancesFromCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "BusinessCombinationAdvancesFromCustomer", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Advance from customer", "documentation": "It represents advance from customers.", "label": "Business Combination Advances From Customer" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r450", "r588", "r589", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r691", "r692", "r693", "r694", "r695", "r716", "r718", "r752", "r886" ] }, "us-gaap_TradeReceivablesHeldForSaleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeReceivablesHeldForSaleAmount", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Balance at end of year", "label": "Accounts Receivable, Held-for-Sale", "documentation": "Amount, before valuation allowance, of accounts receivable held for sale." } } }, "auth_ref": [ "r374" ] }, "anpc_TotalNetAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TotalNetAssetsAcquired", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total net assets acquired", "documentation": "Total net assets acquired.", "label": "Total Net Assets Acquired" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r7", "r138", "r155", "r199" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r10", "r138", "r155", "r199" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow", "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities \u2013 continuing operations", "terseLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r186", "r187", "r188" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory income tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r315", "r507", "r523" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r21" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails", "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable", "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable", "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable_Parentheticals", "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r333", "r452", "r831", "r832", "r859" ] }, "anpc_AcqusitionsDetailsScheduleofFairValueofIdentifiableAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AcqusitionsDetailsScheduleofFairValueofIdentifiableAssetsLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable" ], "lang": { "en-us": { "role": { "label": "Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets [Line Items]" } } }, "auth_ref": [] }, "anpc_AcqusitionsDetailsScheduleofFairValueofIdentifiableAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AcqusitionsDetailsScheduleofFairValueofIdentifiableAssetsTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable" ], "lang": { "en-us": { "role": { "label": "Acqusitions (Details) - Schedule of Fair Value of Identifiable Assets [Table]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r310" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails", "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable", "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable", "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable_Parentheticals", "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r333", "r452", "r831", "r859" ] }, "anpc_DiscontinuedOperationsDetailsScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DiscontinuedOperationsDetailsScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations [Table]" } } }, "auth_ref": [] }, "anpc_DiscontinuedOperationsDetailsScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DiscontinuedOperationsDetailsScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations (Details) - Schedule of Assets and Liabilities of the Discontinued Operations [Line Items]" } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash used in operating activities \u2013discontinued operations", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r154", "r186" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible loans", "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature", "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature." } } }, "auth_ref": [ "r23", "r207", "r516" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r310" ] }, "anpc_AccountsReceivablesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AccountsReceivablesNet", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "documentation": "The amount of accounts receivable, net.", "label": "Accounts Receivables Net" } } }, "auth_ref": [] }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash (used in) provided by investing activities \u2013discontinued operations", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r154", "r186" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r829" ] }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash used in financing activities \u2013discontinued operations", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r186" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r186", "r187", "r188" ] }, "anpc_OperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OperatingLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liabilities" } } }, "auth_ref": [] }, "anpc_LoanToThirdparties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LoanToThirdparties", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loan to third-parties", "documentation": "Loan to third-parties.", "label": "Loan To Thirdparties" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42" ] }, "anpc_ReceivableFromPrivatePlacementInvestors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ReceivableFromPrivatePlacementInvestors", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable from private placement investors", "documentation": "Receivable from private placement investors.", "label": "Receivable From Private Placement Investors" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued expenses and other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r99" ] }, "us-gaap_RevenueRecognitionAllowances": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionAllowances", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue Recognition, Allowances [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue recognition for sales allowances." } } }, "auth_ref": [] }, "anpc_Impairmentoflongterminvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Impairmentoflongterminvestment", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Impairment", "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.", "label": "Impairmentoflongterminvestment" } } }, "auth_ref": [] }, "us-gaap_PublicUtilitiesApprovedReturnOnEquityPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesApprovedReturnOnEquityPercentage", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of equity interest", "label": "Public Utilities, Approved Return on Equity, Percentage", "documentation": "Percentage of public utility's approved return on equity." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r662" ] }, "anpc_MotorVehicles": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "MotorVehicles", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentOther", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Motor vehicles", "documentation": "The self-propelled land vehicle, commonly wheeled, that does not operate on rails (such as trains or trams) and is used for the transportation of people or cargo.", "label": "Motor Vehicles" } } }, "auth_ref": [] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts due from related parties, net", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r218", "r279", "r630", "r828" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxable income percentage", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r872", "r875" ] }, "anpc_ConvertibleLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ConvertibleLoan", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofShortTermDebtsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan (\u201cCL\u201d)", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Loan" } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service agreement", "label": "Share-Based Goods and Nonemployee Services Transaction, Shares Approved for Issuance", "documentation": "The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction." } } }, "auth_ref": [ "r238" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r355", "r356", "r357", "r358", "r359", "r360", "r370", "r800" ] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAbstract", "lang": { "en-us": { "role": { "label": "Share Based Compensation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding Beginning balance", "verboseLabel": "Related option agreements", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r477" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average life, Balance of warrants outstanding and exercisable as of December 31, 2022", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r86" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF PRINCIPAL ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r189", "r312" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r66", "r67", "r68", "r241", "r242", "r245", "r246" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r876" ] }, "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOrLossOnSaleOfStockInSubsidiary", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from disposal of a subsidiary", "label": "Gain (Loss) on Disposition of Stock in Subsidiary", "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries." } } }, "auth_ref": [ "r844", "r845", "r850", "r896" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r876" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Vested and Exercisable", "verboseLabel": "Warrants exercisable term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r478" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average life, warrants issued in connection with the September 2, 2022 private placement", "verboseLabel": "Weighted Average Remaining Contractual Term, Outstanding Beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r209" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsOutstanding", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, outstanding", "label": "Capital Units, Outstanding", "documentation": "Number of capital units or capital shares outstanding. This element is relevant to issuers of face-amount certificates and registered investment companies." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r17", "r352" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r192" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r192" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r192" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r192" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r192" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofEstimatedAggregateAmortizationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "SHARE BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r453", "r456", "r487", "r488", "r490", "r811" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r24", "r113", "r114", "r115", "r116", "r319" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.anpacbio.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r575" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment of goodwill", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r17", "r396", "r398", "r400", "r802" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r465" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of the equity awards vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r476" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/DiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total consideration", "verboseLabel": "Consideration amount", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r812", "r877", "r878", "r879" ] }, "us-gaap_DividendIncomeSecuritiesOperatingTaxable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendIncomeSecuritiesOperatingTaxable", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxable income (in Yuan Renminbi)", "label": "Dividend Income, Securities, Operating, Taxable", "documentation": "Amount of operating dividend income on securities subject to state, federal and other income tax." } } }, "auth_ref": [ "r231" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r466" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities", "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r7", "r138", "r155", "r199" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShareholdersEquityType2or3", "http://www.anpacbio.com/role/ShortTermDebtsDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Ordinary Shares", "verboseLabel": "Class A", "netLabel": "Class A ordinary shares [Member]", "label": "Class A Ordinary Shares [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r913" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r201" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountsReceivableNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r48" ] }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireLongtermInvestments", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Long-term investment", "label": "Payments to Acquire Long-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": [ "r846" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Fresh2 Group Limited shareholders\u2019 equity (deficit)", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r165", "r168", "r169", "r190", "r700", "r717", "r746", "r747", "r816", "r828", "r853", "r861", "r881", "r913" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSU [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/PropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r17", "r76" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Aggregate Amortization Expense", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "anpc_ScheduleOfResultsOfDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfResultsOfDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Results Of Discontinued Operations Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfAssetsAndLiabilitiesOfTheDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfAssetsAndLiabilitiesOfTheDiscontinuedOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities Of The Discontinued Operations Abstract" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r588", "r589", "r886" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense, net", "negatedTerseLabel": "Interest expense, net", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r125", "r232", "r302", "r351", "r573", "r729", "r826", "r911" ] }, "anpc_ScheduleOfAccountsReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfAccountsReceivableAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accounts Receivable [Abstract]" } } }, "auth_ref": [] }, "anpc_ScheduleOfOtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfOtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "anpc_ScheduleOfPropertyAndEquipmentNetConsistsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfPropertyAndEquipmentNetConsistsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Net Consists Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfIntangibleAssetsNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Net Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfEstimatedAggregateAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfEstimatedAggregateAmortizationExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Estimated Aggregate Amortization Expense Abstract" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r166" ] }, "anpc_OperatingExpensesAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OperatingExpensesAbstract0", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses Abstract0" } } }, "auth_ref": [] }, "anpc_ScheduleOfLongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfLongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Long Term Investments Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfShortTermDebtsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfShortTermDebtsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Short Term Debts Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfGroupSPrincipalSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfGroupSPrincipalSubsidiariesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Group SPrincipal Subsidiaries Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfOperatingLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfOperatingLeasesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Operating Leases [Abstract]" } } }, "auth_ref": [] }, "anpc_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rates [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation differences", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r8" ] }, "anpc_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Lease Liabilities [Abstract]" } } }, "auth_ref": [] }, "anpc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": [] }, "anpc_SecheduleOfWarrantsActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SecheduleOfWarrantsActivityAbstract", "lang": { "en-us": { "role": { "label": "Sechedule Of Warrants Activity Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfOptionsGrantedToEmployeesAreMeasuredBasedOnTheGrantDateFairValueOfTheEquityInstrumentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfOptionsGrantedToEmployeesAreMeasuredBasedOnTheGrantDateFairValueOfTheEquityInstrumentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Options Granted to Employees are Measured Based on the Grant Date Fair Value of the Equity Instrument [Abstract]" } } }, "auth_ref": [] }, "anpc_NonOperatingIncomeAndExpensesAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NonOperatingIncomeAndExpensesAbstract0", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-operating income and expenses:", "label": "Non Operating Income And Expenses Abstract0" } } }, "auth_ref": [] }, "anpc_ScheduleOfOptionsGrantedToNonemployeesAreMeasuredBasedOnTheGrantDateFairValueOfTheEquityInstrumentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfOptionsGrantedToNonemployeesAreMeasuredBasedOnTheGrantDateFairValueOfTheEquityInstrumentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Options Granted To Nonemployees Are Measured Based On The Grant Date Fair Value Of The Equity Instrument Abstract" } } }, "auth_ref": [] }, "anpc_LiquidityAndGoingConcernUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LiquidityAndGoingConcernUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern Uncertainties [Abstract]" } } }, "auth_ref": [] }, "anpc_CurrentAssetsAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "CurrentAssetsAbstract0", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Current Assets Abstract0" } } }, "auth_ref": [] }, "anpc_ScheduleOfBlackScholesSimplifiedMethodForTheValuationOfNewOptionsIssuedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfBlackScholesSimplifiedMethodForTheValuationOfNewOptionsIssuedAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued [Abstract]" } } }, "auth_ref": [] }, "anpc_ScheduleOfTableSetsForthTheAmountOfShareBasedCompensationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfTableSetsForthTheAmountOfShareBasedCompensationExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Share Based Compensation Expense Included in Each of the Relevant Financial Statement [Abstract]" } } }, "auth_ref": [] }, "anpc_ScheduleOfLossBeforeIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfLossBeforeIncomeTaxesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Loss Before Income Taxes Abstract" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial instruments", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "anpc_ScheduleOfCurrentAndDeferredComponentsOfIncomeTaxBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfCurrentAndDeferredComponentsOfIncomeTaxBenefitAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Current And Deferred Components Of Income Tax Benefit Abstract" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance from customers", "verboseLabel": "Contract liabilities amounted", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r444", "r445", "r448" ] }, "anpc_ScheduleOfReconciliationOfTaxComputedByApplyingTheStatutoryIncomeTaxRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfReconciliationOfTaxComputedByApplyingTheStatutoryIncomeTaxRateAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Reconciliation Of Tax Computed By Applying The Statutory Income Tax Rate Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfSignificantComponentsOfDeferredTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfSignificantComponentsOfDeferredTaxesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Significant Components Of Deferred Taxes Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfRelatedPartiesFinancialAndOperationalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfRelatedPartiesFinancialAndOperationalAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Related Parties Financial And Operational Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfRelatedPartyBalancesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfRelatedPartyBalancesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Related Party Balances Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfAccountsReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfAccountsReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Accounts Receivables Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfRelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfRelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyLLCPreferredUnitIssued", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued", "label": "Limited Liability Company (LLC) Preferred Unit, Issued", "documentation": "Number of preferred units issued of limited liability company (LLC)." } } }, "auth_ref": [ "r207" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r577" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of convertible debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r17", "r78", "r79" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable": { "parentTag": "anpc_OperatingLeaseLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability-current", "verboseLabel": "Operating lease liabilities - current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r577" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "negatedTerseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r181", "r723" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from continuing operations before income taxes", "terseLabel": "Total", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r173", "r227", "r348", "r362", "r366", "r368", "r626", "r641", "r799" ] }, "anpc_CurrentLiabilitiesAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "CurrentLiabilitiesAbstract0", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Current Liabilities Abstract0" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r486", "r498" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share Based Compensation Expense Included in Each of the Relevant Financial Statement [Abstract]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets, net", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r841" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable": { "parentTag": "anpc_OperatingLeaseLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability-non-current", "verboseLabel": "Operating lease liabilities - non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r577" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r16" ] }, "anpc_NonOperatingIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NonOperatingIncomeAndExpensesAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Non-operating income and expenses:", "label": "Non Operating Income And Expenses Abstract" } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r189" ] }, "us-gaap_PlanOfReorganizationDescriptionOfEquitySecuritiesIssuedOrToBeIssued": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanOfReorganizationDescriptionOfEquitySecuritiesIssuedOrToBeIssued", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity, description", "label": "Plan of Reorganization, Description of Equity Securities Issued or to be Issued", "documentation": "Description of the terms of equity securities to be issued or to be issued to prepetition creditors in accordance with the plan of reorganization, including the amount and impact, if any, on diluted earnings per share." } } }, "auth_ref": [ "r129" ] }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "Other Current Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts due to related parties", "verboseLabel": "Due to related parties", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r131", "r628", "r692", "r693", "r828", "r910" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Options Granted to Nonemployees are Measured Based on the Grant Date Fair Value of the Equity Instrument", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r30", "r31", "r87" ] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total noncurrent assets held for sale", "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Other, Current", "documentation": "Amount of other assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r194" ] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total current assets held for sale", "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r194", "r816" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails", "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable", "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable", "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable", "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShortTermDebtsDetails", "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r410", "r411", "r412", "r413", "r449", "r451", "r482", "r483", "r484", "r596", "r600", "r652", "r688", "r689", "r753", "r755", "r757", "r758", "r760", "r784", "r785", "r801", "r805", "r810", "r817", "r820", "r864", "r868", "r890", "r891", "r892", "r893", "r894" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts due from related parties, net", "verboseLabel": "Due from related parties, net", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r286", "r706" ] }, "us-gaap_CapitalUnitsTotalCostToInvestors": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsTotalCostToInvestors", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investing amount (in Yuan Renminbi)", "label": "Capital Units, Cost to Investors", "documentation": "Cost to investors of each class of capital shares or other capital units." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r143", "r144", "r145", "r146", "r153", "r157", "r506", "r520", "r526" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant date Fair Value Vested and exercisable", "verboseLabel": "Weighted Average Exercise Price, Vested and Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r478" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails", "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable", "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShortTermDebtsDetails", "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r410", "r411", "r412", "r413", "r451", "r600", "r652", "r688", "r689", "r753", "r755", "r757", "r758", "r760", "r784", "r785", "r801", "r805", "r810", "r817", "r868", "r889", "r890", "r891", "r892", "r893", "r894" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails", "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable", "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable", "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShortTermDebtsDetails", "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r410", "r411", "r412", "r413", "r449", "r451", "r482", "r483", "r484", "r596", "r600", "r652", "r688", "r689", "r753", "r755", "r757", "r758", "r760", "r784", "r785", "r801", "r805", "r810", "r817", "r820", "r864", "r868", "r890", "r891", "r892", "r893", "r894" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, net", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r276" ] }, "us-gaap_LongTermInvestmentsAndReceivablesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestmentsAndReceivablesNet", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, net", "label": "Long-Term Investments and Receivables, Net", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r840" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails", "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable", "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsHaveEstimatedUsefulLivesTable", "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable", "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShortTermDebtsDetails", "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r410", "r411", "r412", "r413", "r451", "r600", "r652", "r688", "r689", "r753", "r755", "r757", "r758", "r760", "r784", "r785", "r801", "r805", "r810", "r817", "r868", "r889", "r890", "r891", "r892", "r893", "r894" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Vested and Exercisable (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r478" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, outstanding ending balance (in Dollars)", "periodEndLabel": "Aggregate Intrinsic Value, outstanding ending balance (in Dollars)", "terseLabel": "Aggregate Intrinsic Value, Outstanding Beginning balance (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r477" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Options, Outstanding Beginning balance (in Shares)", "periodEndLabel": "Number of Options, Outstanding Beginning balance (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r477" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r272", "r314", "r384", "r385", "r386", "r387", "r557" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning balance", "periodEndLabel": "Weighted Average Exercise Price, Outstanding Beginning balance", "terseLabel": "Weighted Average Exercise Price Vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r477" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "TOTAL ASSETS HELD FOR SALE", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r7", "r138", "r155", "r199", "r271", "r272" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoEmployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options Vested and exercisable (in Shares)", "verboseLabel": "Forfeited shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r478" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r372", "r807", "r869", "r903", "r907" ] }, "us-gaap_AssetsSoldUnderAgreementsToRepurchaseInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsSoldUnderAgreementsToRepurchaseInterestRate", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement rate", "label": "Assets Sold under Agreements to Repurchase, Interest Rate", "documentation": "Interest rate on the amount to be repaid to the counterparty to the repurchase agreement when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under the repurchase agreement exceeds 10 percent of total assets." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r314", "r384", "r385", "r386", "r387", "r557" ] }, "us-gaap_OtherLongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermInvestments", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, net", "label": "Other Long-Term Investments", "documentation": "Amount of long-term investments classified as other." } } }, "auth_ref": [ "r629", "r838" ] }, "us-gaap_LongTermInvestmentsAndReceivablesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestmentsAndReceivablesNetAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Investments, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r315", "r501", "r508", "r509", "r513", "r519", "r524", "r529", "r530", "r667" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Convenience translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r558" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShareholdersEquityType2or3", "http://www.anpacbio.com/role/ShortTermDebtsDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r253", "r282", "r283", "r284", "r314", "r336", "r338", "r340", "r342", "r346", "r347", "r387", "r414", "r416", "r417", "r418", "r421", "r422", "r428", "r429", "r431", "r434", "r441", "r557", "r662", "r663", "r664", "r665", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r698", "r720", "r745", "r765", "r766", "r767", "r768", "r769", "r830", "r852", "r860" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r298", "r502", "r503", "r509", "r510", "r512", "r514", "r661" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r41", "r314", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r537", "r540", "r541", "r557", "r696", "r798", "r828", "r866", "r887", "r888" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities held for sale", "terseLabel": "Current liabilities held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r138", "r155", "r195", "r199", "r271", "r272" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES HELD FOR SALE", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r7", "r138", "r155", "r199", "r271", "r272" ] }, "anpc_ScheduleOfIntangibleAssetsHaveEstimatedUsefulLivesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfIntangibleAssetsHaveEstimatedUsefulLivesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Have Estimated Useful Lives Abstract" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationEquityMethodInvestmentRetainedAfterDisposalOwnershipInterestAfterDisposal": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationEquityMethodInvestmentRetainedAfterDisposalOwnershipInterestAfterDisposal", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest, percentage", "label": "Discontinued Operation, Equity Method Investment Retained after Disposal, Ownership Interest after Disposal", "documentation": "Percent, after disposal, of ownership interest of a discontinued operation in which an equity method investment is retained." } } }, "auth_ref": [ "r150" ] }, "anpc_ScheduleOfConvertibleLoansMeasuredAtFairValueOnARecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfConvertibleLoansMeasuredAtFairValueOnARecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Convertible Loans Measured at Fair Value on A Recurring Basis [Abstract]" } } }, "auth_ref": [] }, "anpc_ScheduleOfFairValueOfIdentifiableAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfFairValueOfIdentifiableAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Identifiable Assets Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfProFormaOfGroupBusinessCombinationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfProFormaOfGroupBusinessCombinationAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Pro Forma Of Group Business Combination Abstract" } } }, "auth_ref": [] }, "anpc_ScheduleOfSummarizesTheFairValueOfTheIdentifiableAssetsAcquiredAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfSummarizesTheFairValueOfTheIdentifiableAssetsAcquiredAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Summarizes The Fair Value Of The Identifiable Assets Acquired And Liabilities Abstract" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent liabilities held for sale", "terseLabel": "Noncurrent liabilities held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r10", "r138", "r155", "r199", "r271", "r272" ] }, "anpc_ScheduleOfPropertyAndEquipmentAreStatedAtCostLessAccumulatedDepreciationAndAnyRecordedImpairmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfPropertyAndEquipmentAreStatedAtCostLessAccumulatedDepreciationAndAnyRecordedImpairmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Are Stated At Cost Less Accumulated Depreciation And Any Recorded Impairment Abstract" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling and marketing expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r181" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling and marketing expenses", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentImpairment": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentImpairment", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Impairment [Policy Text Block]", "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment." } } }, "auth_ref": [ "r77" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "anpc_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WorkingCapitalDeficit", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital deficit", "documentation": "The amount of working capital is the money available to meet your current, short-term obligations. To make sure your working capital works for you, you'll need to calculate your current levels, project your future needs and consider ways to make sure you always have enough cash.", "label": "Working Capital Deficit" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r18", "r627", "r639", "r816" ] }, "anpc_RoxeHoldingIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RoxeHoldingIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Roxe Holding Inc.[Member]", "label": "Roxe Holding Inc Member" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation", "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise", "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement." } } }, "auth_ref": [] }, "anpc_LeaseTerms": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LeaseTerms", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lease Terms" } } }, "auth_ref": [] }, "us-gaap_OtherSellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable": { "parentTag": "us-gaap_EmployeeBenefitsAndShareBasedCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofTableSetsForththeAmountofShareBasedCompensationExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Selling and marketing expenses", "label": "Other Selling and Marketing Expense", "documentation": "Amount of selling and marketing expense classified as other." } } }, "auth_ref": [ "r181" ] }, "anpc_ThreeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ThreeCustomersMember", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Customers [Member]", "label": "Three Customers Member" } } }, "auth_ref": [] }, "anpc_SummaryofPrincipalAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SummaryofPrincipalAccountingPoliciesDetailsTable", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Principal Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "anpc_ShijiHainanMedicalTechnologyLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShijiHainanMedicalTechnologyLtdMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shiji (Hainan) Medical Technology Ltd. [Member]", "label": "Shiji Hainan Medical Technology Ltd Member" } } }, "auth_ref": [] }, "anpc_AccountsReceivables": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AccountsReceivables", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivables", "label": "Accounts Receivables" } } }, "auth_ref": [] }, "anpc_ShanghaiMuqingAnPacHealthTechnologyCoLtdAnPacMuqingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShanghaiMuqingAnPacHealthTechnologyCoLtdAnPacMuqingMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shanghai Muqing AnPac Health Technology Co., Ltd. (\u201cAnPac Muqing\u201d) [Member]", "label": "Shanghai Muqing An Pac Health Technology Co Ltd An Pac Muqing Member" } } }, "auth_ref": [] }, "anpc_SoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SoftwareMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofFairValueofIdentifiableAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "software [Member]", "label": "Software Member" } } }, "auth_ref": [] }, "anpc_CustomersAccounted": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "CustomersAccounted", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customers accounted, description", "label": "Customers Accounted" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": [] }, "anpc_PercentageOfRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "PercentageOfRevenue", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of revenue", "documentation": "The percentage of total revenue.", "label": "Percentage Of Revenue" } } }, "auth_ref": [] }, "anpc_ThreeSuppliersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ThreeSuppliersMember", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Suppliers [Member]", "label": "Three Suppliers Member" } } }, "auth_ref": [] }, "anpc_TwoCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TwoCustomersMember", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Customers [Member]", "label": "Two Customers Member" } } }, "auth_ref": [] }, "anpc_TotalAccountsPayablePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TotalAccountsPayablePercent", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of total accounts payable", "documentation": "The total percentage of accounts receivable.", "label": "Total Accounts Payable Percent" } } }, "auth_ref": [] }, "anpc_TotalFresh2GroupLimitedShareholdersEquityDeficitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TotalFresh2GroupLimitedShareholdersEquityDeficitMember", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Total Fresh2 Group Limited Shareholders\u2019 Equity (Deficit)", "verboseLabel": "Fresh2 Group Limited [Member]", "label": "Total Fresh2 Group Limited Shareholders Equity Deficit Member" } } }, "auth_ref": [] }, "anpc_AcqusitionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AcqusitionsDetailsTable", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "label": "Acqusitions (Details) [Table]" } } }, "auth_ref": [] }, "anpc_TwoSuppliersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TwoSuppliersMember", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Suppliers [Member]", "label": "Two Suppliers Member" } } }, "auth_ref": [] }, "anpc_OrganizationAndPrincipalActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OrganizationAndPrincipalActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Organization and Principal Activities [Abstract]" } } }, "auth_ref": [] }, "anpc_AcqusitionsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AcqusitionsDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "label": "Acqusitions (Details) [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow", "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r272", "r294", "r296", "r309", "r314", "r323", "r331", "r332", "r348", "r362", "r366", "r368", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r535", "r538", "r539", "r551", "r557", "r626", "r643", "r672", "r719", "r743", "r744", "r799", "r813", "r814", "r827", "r843", "r866" ] }, "anpc_XUdongDuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "XUdongDuMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Xudong Du [Member]", "label": "XUdong Du Member" } } }, "auth_ref": [] }, "anpc_AmortizationOverYear": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AmortizationOverYear", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized over year", "documentation": "The amortization over year.", "label": "Amortization Over Year" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "terseLabel": "Balance at June 30, 2023 (US$) (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "anpc_SummaryOfPrincipalAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "SummaryOfPrincipalAccountingPoliciesLineItems", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Principal Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "anpc_EstimatedAggregateAmortizationExpenseYears": { "xbrltype": "durationItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "EstimatedAggregateAmortizationExpenseYears", "presentation": [ "http://www.anpacbio.com/role/IntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated aggregate amortization expense year", "documentation": "The duration estimated aggregate amortization expense years.", "label": "Estimated Aggregate Amortization Expense Years" } } }, "auth_ref": [] }, "anpc_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price per share", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r204", "r424" ] }, "anpc_DiscontinuedOperationsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DiscontinuedOperationsDetailsTable", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": [ "http://www.anpacbio.com/role/RelatedPartyTransactionsandBalancesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivables", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r105", "r106", "r107", "r109", "r110" ] }, "anpc_LongTermInvestmentsNetDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LongTermInvestmentsNetDetailsTable", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments, Net (Details) [Table]" } } }, "auth_ref": [] }, "anpc_LongTermInvestmentsNetDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LongTermInvestmentsNetDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments, Net (Details) [Line Items]" } } }, "auth_ref": [] }, "anpc_RegisteredCapitalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RegisteredCapitalPercentage", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registered capital, percentage", "documentation": "Percentage of registered capital.", "label": "Registered Capital Percentage" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for service", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for service (in Shares)", "verboseLabel": "Ordinary shares issued", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "anpc_EquityPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "EquityPercentage", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest", "documentation": "Equity Percentage.", "label": "Equity Percentage" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccruedExpensesandOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r536", "r537", "r540", "r541", "r597", "r598", "r599" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r289", "r788", "r816" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in private placement, cancelled subsequently (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r23", "r81", "r164", "r165", "r207" ] }, "anpc_VotingUnitsDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "VotingUnitsDescription", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "voting units description", "documentation": "Description of voting units.", "label": "Voting Units Description" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Variable Interest Entities [Table]", "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r105", "r106", "r107", "r109", "r110", "r536", "r537", "r540", "r541", "r597", "r598", "r599" ] }, "anpc_FullImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "FullImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Full impairment loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Full Impairment Loss" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased shares", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r23", "r164", "r165", "r207", "r665", "r745", "r768" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions and Balances [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r202", "r408", "r409", "r774", "r865" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercising of options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r12", "r32" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r83" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury shares", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r49", "r83", "r84" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of Ownership", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r650", "r721", "r761", "r762", "r763" ] }, "us-gaap_AccountsAndNontradeReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsAndNontradeReceivableTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountsReceivableNet" ], "lang": { "en-us": { "role": { "terseLabel": "ACCOUNTS RECEIVABLE, NET", "label": "Accounts and Nontrade Receivable [Text Block]", "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable." } } }, "auth_ref": [ "r373", "r388" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r849" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareholdersEquityDetails", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Ordinary Shares", "verboseLabel": "Class B", "netLabel": "Class B Ordinary Shares [Member]", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r913" ] }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InternalRevenueServiceIRSMember", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal [Member]", "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares issued", "verboseLabel": "Ordinary shares issued (in Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r165" ] }, "us-gaap_PropertyPlantAndEquipmentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentOther", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentNetConsistsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Property, Plant and Equipment, Other, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r18" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSignificantComponentsofDeferredTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived assets arising from acquisitions", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r93", "r874" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares", "verboseLabel": "Value of share issued", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r165", "r634", "r816" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment to related parties", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r56" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r833", "r849" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ScheduleofProFormaofGroupBusinessCombinationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r531", "r532" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares authorized", "verboseLabel": "Number of shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r165", "r698" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r23", "r165", "r698", "r717", "r913", "r914" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ScheduleofProFormaofGroupBusinessCombinationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net losses", "verboseLabel": "Loss", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r531", "r532" ] }, "us-gaap_TaxCreditCarryforwardValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardValuationAllowance", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSignificantComponentsofDeferredTaxesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Tax Credit Carryforward, Valuation Allowance", "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r91" ] }, "us-gaap_DepositAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositAssets", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Deposit Assets", "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement." } } }, "auth_ref": [ "r839" ] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leases", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": [ "r344", "r583" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax benefits", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r17", "r214", "r250", "r521", "r522", "r854" ] }, "anpc_LiquidityandGoingConcernUncertaintiesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LiquidityandGoingConcernUncertaintiesDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern Uncertainties (Details) [Line Items]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Class A and Class B ordinary shares - diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r335", "r342" ] }, "anpc_WeightedAverageGrantDateFairValueExercised1": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageGrantDateFairValueExercised1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant date Fair Value, Exercised", "label": "Weighted Average Grant Date Fair Value Exercised1" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ScheduleofOperatingLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets", "verboseLabel": "Right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r576" ] }, "anpc_WeightedAverageExercisePriceExercised1": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageExercisePriceExercised1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercised", "label": "Weighted Average Exercise Price Exercised1" } } }, "auth_ref": [] }, "anpc_AggregateIntrinsicValueExercisedinDollars": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AggregateIntrinsicValueExercisedinDollars", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercised (in Dollars)", "label": "Aggregate Intrinsic Value Exercisedin Dollars" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.anpacbio.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSignificantComponentsofDeferredTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total deferred tax liabilities.", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r162", "r163", "r221", "r511" ] }, "anpc_NumberOfOptionsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NumberOfOptionsForfeited", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Forfeited (in Shares)", "documentation": "Number of Options, Forfeited.", "label": "Number Of Options Forfeited" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Class A and Class B ordinary shares - basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r334", "r342" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "anpc_WeightedAverageGrantDateFairValue1": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageGrantDateFairValue1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant date Fair Value,", "label": "Weighted Average Grant Date Fair Value1" } } }, "auth_ref": [] }, "anpc_WeightedAverageExercisePriceForfeitedinShares1": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageExercisePriceForfeitedinShares1", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Forfeited", "label": "Weighted Average Exercise Price Forfeitedin Shares1" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/IntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r17", "r70", "r74" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "anpc_AggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, (in Dollars)", "label": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "anpc_NumberOfOptionsVestedAndExercisableinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NumberOfOptionsVestedAndExercisableinShares", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Vested and Exercisable (in Shares)", "label": "Number Of Options Vested And Exercisablein Shares" } } }, "auth_ref": [] }, "anpc_AggregateIntrinsicValueOutstandingBeginningBalance1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AggregateIntrinsicValueOutstandingBeginningBalance1", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding Beginning balance (in Dollars)", "label": "Aggregate Intrinsic Value Outstanding Beginning Balance1" } } }, "auth_ref": [] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r816" ] }, "anpc_WeightedAverageGrantDateFairValueVestedAndExercisables": { "xbrltype": "perShareItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "WeightedAverageGrantDateFairValueVestedAndExercisables", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant date Fair Value, Vested and Exercisable", "documentation": "Weighted average grant date fair value, vested and exercisable.", "label": "Weighted Average Grant Date Fair Value Vested And Exercisables" } } }, "auth_ref": [] }, "anpc_ShareBasedCompensationDetailsScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationDetailsScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued [Table]" } } }, "auth_ref": [] }, "anpc_ShareBasedCompensationDetailsScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ShareBasedCompensationDetailsScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofBlackScholesSimplifiedMethodfortheValuationofNewOptionsIssuedTable" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation (Details) - Schedule of Black-Scholes Simplified Method for the Valuation of New Options Issued [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes", "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r35", "r222", "r899" ] }, "anpc_IncomeTaxesDetailsScheduleofLossBeforeIncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofLossBeforeIncomeTaxesTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of Loss Before Income Taxes [Table]" } } }, "auth_ref": [] }, "anpc_IncomeTaxesDetailsScheduleofLossBeforeIncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofLossBeforeIncomeTaxesLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofLossBeforeIncomeTaxesTable" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of Loss Before Income Taxes [Line Items]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r43", "r274", "r314", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r537", "r540", "r541", "r557", "r816", "r866", "r887", "r888" ] }, "anpc_IncomeTaxesDetailsScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of Current and Deferred Components of Income Tax Benefit [Table]" } } }, "auth_ref": [] }, "anpc_IncomeTaxesDetailsScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Current and Deferred Components of Income Tax Benefit [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax expense", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r214", "r515", "r522", "r854" ] }, "anpc_IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate [Table]" } } }, "auth_ref": [] }, "anpc_IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate [Abstract]" } } }, "auth_ref": [] }, "anpc_EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateDifferentialAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "EffectiveIncomeTaxRateReconciliationPreferentialIncomeTaxRateDifferentialAmount", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "International rate differences", "documentation": "Amount of the difference between the statutory rate and the preferential rate impacting the reconciliation of the statutory tax rate to the effective tax rate.", "label": "Effective Income Tax Rate Reconciliation Preferential Income Tax Rate Differential Amount" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue contributed", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r349", "r350", "r361", "r364", "r365", "r369", "r370", "r372", "r446", "r447", "r605" ] }, "anpc_IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateParentheticalsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateParentheticalsTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable_Parentheticals" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate (Parentheticals) [Table]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r504", "r505", "r632" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and allowance for credit losses", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r235", "r236", "r237", "r376", "r377", "r379" ] }, "anpc_IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateParentheticalsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IncomeTaxesDetailsScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateParentheticalsLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofReconciliationofTaxComputedbyApplyingtheStatutoryIncomeTaxRateTable_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Tax Computed by Applying the Statutory Income Tax Rate [Abstract]", "label": "Income Taxes Details Scheduleof Reconciliationof Tax Computedby Applyingthe Statutory Income Tax Rate Parentheticals Line Items" } } }, "auth_ref": [] }, "anpc_RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartiesFinancialandOperationalTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartiesFinancialandOperationalTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Table]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price per share, warrants issued in connection with the March 16, 2022 private placement", "periodEndLabel": "Weighted average exercise price per share, Balance of warrants outstanding and exercisable as of December 31, 2022", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r88" ] }, "anpc_RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartiesFinancialandOperationalLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartiesFinancialandOperationalLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions and Balances (Details) - Schedule of Related Parties Financial and Operational [Line Items]" } } }, "auth_ref": [] }, "anpc_NatureOfTheParty": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "NatureOfTheParty", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of the party", "documentation": "Description of nature of the party.", "label": "Nature Of The Party" } } }, "auth_ref": [] }, "us-gaap_DeferredOtherTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOtherTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofCurrentandDeferredComponentsofIncomeTaxBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax benefit", "label": "Deferred Other Tax Expense (Benefit)", "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods." } } }, "auth_ref": [ "r94", "r213", "r854" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://www.anpacbio.com/role/ShortTermDebtsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted shares", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r36", "r81", "r164", "r206", "r437" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "anpc_RelationshipWithTheGroup": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RelationshipWithTheGroup", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship with the Group", "documentation": "Description of relationship with the group.", "label": "Relationship With The Group" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "presentation": [ "http://www.anpacbio.com/role/SecheduleofWarrantsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration dates, warrants issued to 3rd party service providers", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms", "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price." } } }, "auth_ref": [ "r90" ] }, "anpc_RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartyBalancesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartyBalancesLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Line Items]" } } }, "auth_ref": [] }, "anpc_RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartyBalancesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "RelatedPartyTransactionsandBalancesDetailsScheduleofRelatedPartyBalancesTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions and Balances (Details) - Schedule of Related Party Balances [Table]" } } }, "auth_ref": [] }, "anpc_LiquidityandGoingConcernUncertaintiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LiquidityandGoingConcernUncertaintiesDetailsTable", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern Uncertainties (Details) [Table]" } } }, "auth_ref": [] }, "anpc_OrganizationandPrincipalActivitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OrganizationandPrincipalActivitiesDetailsTable", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Principal Activities (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r45", "r132", "r633", "r697" ] }, "anpc_OrganizationandPrincipalActivitiesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "OrganizationandPrincipalActivitiesDetailsLineItems", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Principal Activities (Details) [Line Items]" } } }, "auth_ref": [] }, "anpc_PurchasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "PurchasePercentage", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase percentage", "documentation": "Purchase percentage.", "label": "Purchase Percentage" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails", "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable", "http://www.anpacbio.com/role/ScheduleofLongTermInvestmentsTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable", "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r450", "r588", "r589", "r691", "r692", "r693", "r694", "r695", "r716", "r718", "r752" ] }, "us-gaap_InterestBearingDepositsInBanks": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestBearingDepositsInBanks", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial institutions deposited", "label": "Interest-Bearing Deposits in Banks and Other Financial Institutions", "documentation": "For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet." } } }, "auth_ref": [ "r130", "r133" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r533", "r808", "r809" ] }, "us-gaap_OtherCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCustomerMember", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Customer [Member]", "label": "Other Customer [Member]", "documentation": "Customer classified as other." } } }, "auth_ref": [ "r834", "r903", "r904", "r905", "r906", "r908" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNet", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment amount", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r182", "r184" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss, net", "verboseLabel": "Foreign exchange gain, net", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r559", "r561", "r563", "r564", "r742" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercising of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r847" ] }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Group\u2019s Principal Subsidiaries [Abstract]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r15", "r122", "r385" ] }, "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Group\u2019s Principal Subsidiaries", "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]", "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSignificantComponentsofDeferredTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total deferred tax assets.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r873" ] }, "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]", "documentation": "This table describes the key aspects of a subsidiary (partnership, corporation, or other entity) of the Limited Liability Company (LLC) or Limited Partnership (LP)." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r384", "r385", "r386" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Business combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r95" ] }, "us-gaap_PublicUtilityPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilityPropertyPlantAndEquipmentTable", "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable" ], "lang": { "en-us": { "role": { "label": "Public Utility, Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r135" ] }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOptionChangesInFairValueGainLoss1", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of convertible debt", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings." } } }, "auth_ref": [ "r123" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS.", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r219", "r280", "r314", "r348", "r363", "r367", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r536", "r540", "r557", "r631", "r711", "r816", "r828", "r866", "r867", "r887" ] }, "us-gaap_AssetsFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueAdjustment", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Assets, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.anpacbio.com/role/OrganizationandPrincipalActivitiesDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definitive share purchase agreement", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNet" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM INVESTMENTS, NET", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r217", "r233", "r234", "r256", "r380", "r381", "r553", "r554" ] }, "us-gaap_EquityFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityFairValueAdjustment", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value shares amount", "label": "Equity, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestorMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investor [Member]", "label": "Investor [Member]", "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value." } } }, "auth_ref": [ "r884", "r885" ] }, "us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilityPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable" ], "lang": { "en-us": { "role": { "label": "Public Utility, Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails", "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r457", "r458", "r459", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r606" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable": { "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofConvertibleLoansMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Opening balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3", "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r552" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r818", "r819", "r820", "r822", "r823", "r824", "r825", "r856", "r857", "r880", "r909", "r913" ] }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "presentation": [ "http://www.anpacbio.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary share and warrants, description", "label": "Warrant or Right, Reason for Issuance, Description", "documentation": "Description of reason for issuing warrant or right." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable", "http://www.anpacbio.com/role/ScheduleofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAnyRecordedImpairmentTable" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r402", "r403", "r404", "r405", "r606", "r607" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_CreditLossAdditionalImprovementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossAdditionalImprovementsAbstract", "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.anpacbio.com/role/ScheduleofIntangibleAssetsNetTable" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r71", "r73" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Risks, Uncertainties and Concentrations", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r134", "r243" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r372", "r807", "r869", "r903", "r907" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r453", "r460", "r479", "r480", "r481", "r482", "r485", "r494", "r495", "r496", "r497" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Salary and welfare payable", "label": "Accrued Salaries, Current", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42", "r792" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Profit", "terseLabel": "Gross Profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r177", "r314", "r348", "r362", "r366", "r368", "r387", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r557", "r799", "r866" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rsu shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": [ "r86" ] }, "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesAndDeferredRevenueNoncurrent", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Other Liabilities and Deferred Revenue, Noncurrent", "documentation": "Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet", "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r290", "r392", "r393", "r791" ] }, "us-gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockRedemptionPricePerShare", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(in Dollars per share)", "label": "Preferred Stock, Redemption Price Per Share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": [ "r80", "r81", "r82" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares in private placements, net of offering costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r23", "r164", "r165", "r207", "r673", "r745", "r766", "r827" ] }, "anpc_CRSHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "CRSHoldingsIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "CRS Holdings Inc. [Member]", "verboseLabel": "CRS Holdings Inc.[Member]", "label": "CRSHoldings Inc Member" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsShares", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares", "label": "Common Stock Dividends, Shares", "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r23" ] }, "anpc_DrChrisChangYuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DrChrisChangYuMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofRelatedPartiesFinancialandOperationalTable", "http://www.anpacbio.com/role/ScheduleofRelatedPartyBalancesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dr. Chris Chang Yu [Member]", "label": "Dr Chris Chang Yu Member" } } }, "auth_ref": [] }, "us-gaap_InvestmentCompanyExpenseLimitationAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyExpenseLimitationAgreementDescription", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertaintiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investor agreement, description", "label": "Investment Company, Expense Limitation Agreement, Description", "documentation": "Description of expense limitation agreement. Includes, but is not limited to, term of carryover expense and expense in excess of expense limitation." } } }, "auth_ref": [ "r670" ] }, "anpc_ChangweiSystemTechnologyShanghaiCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ChangweiSystemTechnologyShanghaiCoLtdMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Changwei System Technology (Shanghai) Co., Ltd. [Member]", "label": "Changwei System Technology Shanghai Co Ltd Member" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]" } } }, "auth_ref": [] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.anpacbio.com/role/LongTermInvestmentsNetDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r384", "r385", "r386" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for acquisition", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r23", "r47", "r207" ] }, "anpc_StockIssuedDuringPeriodValueOfSharesIssuedInPrivatePlacementCancelledSubsequently": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "StockIssuedDuringPeriodValueOfSharesIssuedInPrivatePlacementCancelledSubsequently", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in private placement, cancelled subsequently", "documentation": "Shares issued in private placement, cancelled subsequently.", "label": "Stock Issued During Period Value Of Shares Issued In Private Placement Cancelled Subsequently" } } }, "auth_ref": [] }, "anpc_FoodbaseGroupIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "FoodbaseGroupIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foodbase Group Inc [Member]", "label": "Foodbase Group Inc Member" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for exercise of share option", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r23", "r47", "r207" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.anpacbio.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r581", "r815" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares reserved for convertible loan", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r23", "r47", "r207" ] }, "anpc_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "EmployeesMember", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees [Member]", "label": "Employees Member" } } }, "auth_ref": [] }, "anpc_TransferClassBSharesToClassAShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TransferClassBSharesToClassAShares", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled treasure shares", "label": "Transfer Class BShares To Class AShares" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r7", "r138", "r155", "r199" ] }, "anpc_DispositionOfChangwei": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "DispositionOfChangwei", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Disposition of Changwei", "documentation": "Disposition of Changwei.", "label": "Disposition Of Changwei" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment of intangible assets", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r17", "r75" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity (deficit):", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability-non-current", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r7", "r138", "r155", "r195", "r199" ] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Long term -prepayment", "label": "Prepaid Expense, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r839" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares in private placements, net of offering costs (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r23", "r164", "r165", "r207", "r662", "r745", "r766" ] }, "anpc_ConversionOfConvertibleLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ConversionOfConvertibleLoans", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible loans", "documentation": "The amount of conversion of convertible loans.", "label": "Conversion Of Convertible Loans" } } }, "auth_ref": [] }, "anpc_FourSuppliersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "FourSuppliersMember", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Four Suppliers [Member]", "label": "Four Suppliers Member" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAccountsReceivablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivables-related parties", "label": "Accounts and Other Receivables, Net, Current", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r205", "r313", "r427", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r438", "r439", "r440", "r443", "r548", "r748", "r750", "r771" ] }, "anpc_IssuancesOfSharesForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IssuancesOfSharesForServices", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuances of shares for services", "documentation": "Issuances of shares for services.", "label": "Issuances Of Shares For Services" } } }, "auth_ref": [] }, "anpc_ReceivableFromIssuanceSharesForPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ReceivableFromIssuanceSharesForPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable from issuance shares for private placement", "documentation": "Receivable from issuance shares for private placement.", "label": "Receivable From Issuance Shares For Private Placement" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofAssetsandLiabilitiesoftheDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Liabilities, Other than Long-Term Debt, Noncurrent", "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities." } } }, "auth_ref": [] }, "anpc_Fresh2AcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2AcquisitionMember", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsDetails", "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh2 Acquisition [Member]", "label": "Fresh2 Acquisition Member" } } }, "auth_ref": [] }, "anpc_AdditionsToIntangibleAssetsThroughAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AdditionsToIntangibleAssetsThroughAccruedExpensesAndOtherCurrentLiabilities", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Additions to intangible assets through accrued expenses and other current liabilities", "documentation": "Additions to intangible assets through accrued expenses and other current liabilities.", "label": "Additions To Intangible Assets Through Accrued Expenses And Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r582" ] }, "anpc_IssuancesOfSharesForAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "IssuancesOfSharesForAcquisitions", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuances of shares for acquisitions", "documentation": "Issuances of shares for acquisitions.", "label": "Issuances Of Shares For Acquisitions" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofSummarizestheFairValueoftheIdentifiableAssetsAcquiredandLiabilitiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease liabilities", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": [ "r99" ] }, "anpc_Fresh2EZIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2EZIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 EZ Inc [Member]", "label": "Fresh2 EZInc Member" } } }, "auth_ref": [] }, "anpc_LeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LeasesLineItems", "presentation": [ "http://www.anpacbio.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "Lease [Abstract]" } } }, "auth_ref": [] }, "anpc_LiquidityAndGoingConcernUncertaintiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LiquidityAndGoingConcernUncertaintiesTextBlock", "presentation": [ "http://www.anpacbio.com/role/LiquidityandGoingConcernUncertainties" ], "lang": { "en-us": { "role": { "terseLabel": "LIQUIDITY AND GOING CONCERN UNCERTAINTIES", "documentation": "Disclosure of going concern uncertainty should be \u201csubstantial doubt about whether a governmental entity will continue to exist as the same legally separate entity, regardless of its financial condition.\u201d", "label": "Liquidity And Going Concern Uncertainties Text Block" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for exercise of warrants", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r582" ] }, "anpc_LeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LeasesTable", "presentation": [ "http://www.anpacbio.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "Leases [Table]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for exercise of warrants (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "anpc_Fresh2GroupIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2GroupIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 Group Inc [Member]", "label": "Fresh2 Group Inc Member" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized employee share-based compensation expense", "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits." } } }, "auth_ref": [ "r17" ] }, "anpc_AssetAcquisitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "AssetAcquisitionPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition", "label": "Asset Acquisition Policy Text Block" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r257", "r266", "r370", "r371", "r685", "r686", "r687", "r754", "r756", "r759", "r764", "r772", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r786", "r806", "r820", "r869", "r903" ] }, "anpc_Fresh2EcommerceFresh2EcommerceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2EcommerceFresh2EcommerceMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 Ecommerce (\u201cFresh2 Ecommerce\u201d) [Member]", "label": "Fresh2 Ecommerce Fresh2 Ecommerce Member" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for acquisition (in Shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r164", "r165", "r207" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOptionsGrantedtoNonemployeesareMeasuredBasedontheGrantDateFairValueoftheEquityInstrumentTable", "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares for exercise of share option (in Shares)", "verboseLabel": "Weighted Average Remaining Contractual Term, Exercised (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r23", "r164", "r165", "r207", "r466" ] }, "anpc_TreasurySharesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "TreasurySharesPolicyTextBlock", "presentation": [ "http://www.anpacbio.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "documentation": "The entire disclosure of treasury shares.", "label": "Treasury Shares Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r582" ] }, "anpc_Fresh2HFIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2HFIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 HF Inc [Member]", "label": "Fresh2 HFInc Member" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.anpacbio.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance shares reserved for convertible loan (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r23", "r46", "r81", "r207", "r426" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.anpacbio.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r593", "r595" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r883" ] }, "anpc_ScheduleOfIdentifiableAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfIdentifiableAssetsTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/AcqusitionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Identifiable Assets", "documentation": "Schedule of Identifiable Assets.", "label": "Schedule Of Identifiable Assets Table Text Block" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.anpacbio.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "http://www.anpacbio.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.anpacbio.com/role/ConsolidatedCashFlow", "http://www.anpacbio.com/role/ConsolidatedIncomeStatement", "http://www.anpacbio.com/role/ScheduleofResultsofDiscontinuedOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share of net loss in equity method investments", "negatedLabel": "Share of net loss in equity method investments", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r17", "r174", "r226", "r353", "r382", "r640" ] }, "anpc_ScheduleOfIntangibleAssetsHaveEstimatedUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfIntangibleAssetsHaveEstimatedUsefulLivesTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/SummaryofPrincipalAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets Have Estimated Useful Lives", "label": "Schedule Of Intangible Assets Have Estimated Useful Lives Table Text Block" } } }, "auth_ref": [] }, "anpc_Fresh2InformationIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2InformationIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 information Inc [Member]", "label": "Fresh2 Information Inc Member" } } }, "auth_ref": [] }, "anpc_ScheduleOfDiscontinuedOperationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfDiscontinuedOperationsTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/DiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities of the Discontinued Operations", "documentation": "Schedule of Discontinued Operations Table Text Block", "label": "Schedule Of Discontinued Operations Table Text Block" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "presentation": [ "http://www.anpacbio.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "anpc_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock", "presentation": [ "http://www.anpacbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rates", "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rates Table Text Block" } } }, "auth_ref": [] }, "anpc_LeasesTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "LeasesTablesTable", "presentation": [ "http://www.anpacbio.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Leases (Tables) [Table]" } } }, "auth_ref": [] }, "anpc_Fresh2LogisticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2LogisticsIncMember", "presentation": [ "http://www.anpacbio.com/role/ScheduleofGroupsPrincipalSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 Logistics Inc [Member]", "label": "Fresh2 Logistics Inc Member" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r370", "r371", "r685", "r686", "r687", "r754", "r756", "r759", "r764", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r786", "r806", "r820", "r869", "r903" ] }, "anpc_Fresh2TechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.anpacbio.com/20230630", "localname": "Fresh2TechnologiesIncMember", "presentation": [ "http://www.anpacbio.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fresh 2 Technology Inc [Member]", "label": "Fresh2 Technologies Inc Member" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "59", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-59" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a-c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)-(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)(2),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-11" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481309/942-210-45-4" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "20", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481834/980-20-45-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.Z.5.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7,9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482309/360-10-15-4" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r232": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r233": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r234": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r235": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r236": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r237": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r238": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//326/tableOfContent" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-51" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "35", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-35" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-36" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r832": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-9C" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7B" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 107 0001213900-23-092268-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-092268-xbrl.zip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

!TN2LMCY6]H #:V MPSMAX.9PM )%]+ND&1SZS!;G<;13T]KLXCN2QD]YV^C= W6"B-W]O+O"R:[\ M+PA)'!J T4(P!AD<*H>B+ Z],5*WBA#0LG/$ 8YCF^)0E#7[!E;$--LV@" M L^DD'#'8J8$-&\P!4ORO\H2H^0 M#6O47-/F(X]<1**KJ]/L9QJLZ5QDY+SH M)@):2^KL7KPG;D+3'.^+IQL/6(\)05AUK?K9AF*2@7,HE8S+S=;Q*,A88H*,4*),=VS;O UXTS'%2,\2@;$8=.IW:.2$4PPZ#Q]_V(^& MX*TK#4,/M5!N=4G#; #)(MJ1@ZS)8\AX06,>$>+=,910J7\SAD>T=LH>!K#4 MMXOENWU90U=T^-!*(94&:!8::%4:Z9<;"_3IGU5=U+1YEF25/OG(7_P\164F MZ8]6!,[%.<[% .*7=#H&=+Z,!"S>:.%.>*/(BNK/.$$?:<#Q=V*@JKW3Y%]/ MY-!TT4#%B+=S=W\@7!.3Q8S9?6-]0^RHM:3H.BS#7@4C,G5MGEP;0 MSA+L0@QC-*SW'=7A=V4*A3'AD489*>*#4VNA"WT$E3?8C,;;1*G&9F$DDCMWA%]9_%)J 0[AW?H1Y: MQW,QD!%8#L:,K(UQ$M(09WQ38SIO@33>%%0UF"^,G5T4!KVXTGWD(Y@O0BIJ MXJFD0CJ6&$/XN1>/E.B$,N.C-B>[C#/\:9-">D%G3$Y-ED!4Q @[2PW+Y:61R]LFABYLPF&_3 M;@=IZ<%EP&S1)(U;SI,XBIV #X:_23!:'0^!LM7G%'T+:!@V(CVMI9@]UI%/ M?QK-DG@=4N\S6;QC?@6]CT/W8X8P'WD2G3\S\\6+R"WU7)*>IA+:V>]%M>2+ MRB25T4M2HMC9%F1X+[12?58!DOWEP'^L'-]]%:5^R!*93 MYO#P,$'B^#R-Z=M!1!QW!R]"DI&9K)#_.ZC!P _F=;CPEIZ;?G)&(I=ZZ09G MP2)-L!N+H:""JLWZ]0'M R6NJ404C>H@ Y)VL_C@Q>OZ0':EIY:.)2:B1I2H MH3(2V. YG0M%$9:]C**$IX4<4%%[,N]88_B<1$,6=!(CY\'?X)X;:^J>-_\H M$ X'N:K3T/[]25ASL\?Y6=*FZ'GSUN/9IJ4IY!+IP&8TMW6CY(Y9W^"O?G:W,-;YG$"7(P]04Q7!VL3LP@\ M0;U[=%T,31Q$HL?[V_2]9S4@6*FH,UEMR,M>M+JD* MC@&U>%*X'.HX/:S)OY. P%I$+F0 ;&0!P TB0'J &UH$ M=3I''Y[@A62TSZ-'OL3[*@A0@%.5AIYD+@2A)5B%YEB#" $8L G9\' $+M@O MCY,!F F%PEIX^9.AT?7?7&72U[J * 4S6H)<2-?U'AFPJ_BPXI2B'YJT*A@& M$\F">J+,$>0)H8I/E,.D6N#N8")B9I7)A;RVQN?Z7O=YGL9!TY6>S'GAT0%Q MD_M=8_7I7N@Z)"R283KB<3;:@J:"^I9O@"SB\'RS]<,=(1&3ZFOB1 DEB_2- MFS<'(>FO\? @0FV^?&BB9MRB M%!.7'CW,C/,4FIDRX\H]E>)GO2//('()DHLBYS%>RV@P5-NLO/$*:2O6HVC; M-F7Q;9<)E*XK?4W FS =%$ 6-=R;A!V9>:^!^!>JD@>2"I4)UWWC#3)WI'3V MZBG>)D$($S!?CG"!,0:EUT!?-?X^E??4,=H2-Z4D_U'9:2IF0U^RK7I!Y+EH M>M'*/KX<2;9/:[3!WWVW]#9[! AN"?7"Q5L:1J/)XF_!\&BY@O&Z,^\<12HC M+53'Y'L!8CZ"1D/CDV%(R>C,YX>P59M$R:EI8I'*%QM#9R.KIF<+G;OS_!%] MDA[<[EKRR['0C @.7Q(@,=]T6-RQQ)=WC+MH"I[^C]A309+R,,:6&+59V0/+B4K]*ES_I?D/71GQ=*95!@ M#K*Q/.BL]P6Z2EKD5JF2&D>9U$T8$-!**;-&DPWU?49BQ_,C?,2OQ(.!VCI: MC@%9DS=JR\@+AA>-D\H/N/6Y_:9D;_84YF0[C"P"7\BN=[ MN_.BCR>[$Q*XZXU#/ZH.>M(9Q=4%#DTF.Z=!C4@4FAY -YO YU')01> SRKC MGM DI 8.[T&C=8Z5[H%IYUZ=A-:XIS86"YQ_5D9G8;)0:=R62>N?,-A;_:() M4;)>/\W/+#?W4=0BA_8^@HVCG1+\P..4WF+$$Z.LN,(C-!F'EQF5^6@C%?OI M1Z7'_EKS19\0I; U9,/>SJPQX"IL/0 6,S]'*(8 #,.<,]6C)8'VP9A*GSK MC=D,X(_P,(R00Z.M^SZV/S@:,Q:,F:[^") =I8OFN552JH46Q)_:RS,>H="T MTGB0RNN**9R#_L;$ A4O=%00K6:FA/HJM=AH)?=&W&]9[2@"FIY&0PY:TZF. M#6^FT/!FA,(X1$<UA][>H2TL=[S$]N[K,!8SA?.H5XD"F]5$6^AG8 M(H%H"=T;6=AQZ'[,QD*=)>QB667W34JS*/W']EN@OP&MC\#Q54AH'AMP$F/( M7U>YNA>HVI8@C\%7!:N8,D%7YS5$%:%N2WZC5O-J( MT>82RBBRCW:,+$8KPO#HSZ#$:(7",&PU;A^S]"@6ZH:H4LFMC60T_=2?;T>6 M=6:R@Z-3C9%=9B1+Q;EH"?]"*;N69%$U:\UDW:/]KJ0@VWE3"$GK:*[>/KNH M5X+1C':5]8Z79Z=SW\Z/0B:@8\3'7D^3[_4T0OD>"4?VIP:S>VJ33J*3K*92 M#9<^!DUT@R82%A7RTA8M'U$1C?P<3+R(QF1C1Q-CR"(:(]$KCA=<.OEP%\VD MRV@4]G&T7BQ8+YWQL[9W'"L=ZTY\Q_W(_LI^&MU[C 7>TB.+:Q*OP\4RI(S$ M? ;^V" M$FX1$\JLY3MF'8_%R5+&=^PU4_!VR("R *H84/ N_+WWH<^6\9G'.78IEF \ M\L#R1,18)@[=/;]&4%G=&4H?BU@;8C_NN-<()=Q42A3ZDUF*::6>TCV)>8IB MO&8TG6W")(C#I9A&_#@'$3D$LTP.:=$O]I[0)\\E$F[XZ2+L3_/E'7'#5>!] M9LQ(*7X:1G$DB5?U/H30V!FG)^S'B\!@) A5]5=8*#@.&,!"%LF*TL'A)T!0 M2MN;O(^9>N.+WKLDV- ^@4U[WU)=3!3IXT H.)-[5P09K ;!^G%!KWF]RV_S_G[!XMJA'TG,APQG]@[PM=D%;7B[?,![L)/4P.,9*G#O2$08.=8,\!EY M(GZXY<*(R.5V@!9B#$-SNH/BG7$ 8U:_)0'SQWP&=[;8,-I&Z5"+)X+(["Z0 M+_]<=Q(=J5-WL;\3!G_IQ1%#0+Q')&>Q&^Z+YKT&^16:25L)A%R%471"EB$E MEP'[9_+@/).H5]).:9U&;$L(31+1D"24]%C>M(I&&Z1Z>HSATE@7J#C3I3]' M]VDKIJ3L[>Z;:-<]&K,D7H?4BW<((P^/+ OM(608.++G\ZHKO?W]VW"'-$W+^NPJ?C&/ M4=_WWN.#[_'!]_C@V\\/SX_O_ISF#Q3Y<04VBCN V>M1AGSKJ1(;Z<6WP#M] MF<+F<0>P%\_C+F(C)7RGX#C2E*RY+GHB!P>+88'QRML";80>*B"+.VFMDN9L MQ?WD+YJ!Z_E>GBW.L.7[2&*R>-S-MEM_Q]QHMCM^6R5,V'9[NO!JA<(=!77# M^J$$YYI"X6%4HH^'&(S?"H'#T.7X PJ=DF<+PD<+I?='7Q?C*/;V?8_.[]'Y M/3J_$(_0W&R;Q3'U'I.8']&'\-:AF0[%>1$2 ANG8X1P4:H2'_<-D6-8V9O$ M*9_%%V3!4SG%.\1*5@#!S5H' JL2!<99T)3LE"[GRR5QX[V_F$.J8GM+N7O* M3H#G^)5?._.6^W_(BE.5S'IHF+;: =@PY\'YI5K_#*743M>\DOLR*$(>/(,C MBD@<[2O&>;[S)]YS?AA-IH/0"(-(PRLO+0XJY)0;1I"]R,TR-,ABGZ#!-6IZ M0.9+X;]#!Y:-<+#8$=B2(!GR*I>=EJ[74XU8_IY9E&L2>Z[C1^,*8%9Q&TLX M4X851AX.)*9CB':*,!I/#@^JM X0!Q7R^YC_,]68:,OQ/68''0.DQP"IW0"I MB@,\;(0, J,7&!=3N)A!>:I:=32\PW#OK0)V-EPGB,L)'B7_N67[#B0?A3A]+=,J2\O1]T26L+(%NM%WLQL9(, MU$)$E0O2B'-<.3#DO+@,$#VFIPK56L=8,*8JTQH2@@BR8(0E,U1>>!\%A.S^SG$4DC;9S;T@IGL',T++V!7 MB<<'/Q_"\8YOG&M;6GWW0)T@8J3CU;1L^7RZM,CW4,!(+S8] !JFP6@TU-2C MS\@H#!MN'D[B]O%E;!9:Z2XDV11"BZ$V2);[# US.,MW2"O9<9K?2$"B="9J MAV6W/9&"Q"MP"K=142M0\&Y%W=RRVK((DF%XS8M^=L*U$_R2:+0OJGUBL=6. MDF[87X3UK0+7#:0P9EMFH@<\ JQ!T,9']OI^ZE&TN5L<(;T+G\G/H;](^];H M4%;XH16GW8S XHU#QV=24&?T=$V]*,VA^U5''0@_G!"-Q1N'#FFDH$[O[G-N M1GIR+/QP0C06;UPE!5.;QO_VG&<&Y[>U]T<2W'N<-L+:,\2328(3YZC;[_.DQJP<%.Q,C]9LK.G%"R7SYL"8I^DI<:GQDZ>7, M@K??I!?H^,?#MO@^F!!\\.(U@_66ALE6/9PC^MC62YBMD(R0@(I7N]5 [*X@ M2RDU8.C XAZ'02.M JC&YP< B\%BJ#6(:%<92LQ4+BI0(=(Z0_HW'CB&1.V$ M1,5'"S ":O@0>@R"'H.@QR H1A"T W)TLBO_RW#*5 3X"]6M0AX,(@CH^G70 MA'I]O=HB_3*^*>M6&-Z@ZM/AKCP#%6K,&U4U^D6_?>@^>(#5];SD]PZ31PZH M;.&7_,9A\K !U5/U);]KF#QF0 VI;$;B#S'X:R=P5FDHX32\BA?9/YL^8J@M M.W:>F%!*;:ID+R-%Q!10$Z7"GC'PI_5YJ8U$:+&3?**P2[PG[GB UVO5EY_F M6U-[E%1.2\31ZGC)_HWE7SS/1+G^+2: E2>FF9N.18M*\G5X83*1HO<.]?@" MQ:RK\R#VXIWDQ:BW4'5!,_1Y#P4@0@">\!FH]V94H0Z6/:_)T_(!4*8@0,/H MX].-27C14-:/[S+'=YGCN\SQ7>;+?9?!4YS'1Y?CH\OQT>7XZ#*"V-[QT66J MCR['D.@X0Z)%I&46+.H1O1L2Y]/?@%FD!M-FE81!:$&1D"HI^'93NLMW7+^@ MFV15K*A;)SACI76PJ=6, =PPG X.B*I/&I=39;LX,*=%X6.8;C3>IL') W: M'6-VQYC=,68WEIA=YJT%MXY[0KP_F&>AXY(V/YN(!2_=->R12,'\\FX1!JLS MG=2UVB>3Z=91W^H KFD)J=N$NFLG(M$%VT+Y=X91.7+PHSP4K5:>/H756#V4 MPS2G*R?P/F=%O<'BEGJ!ZVT=?\8;@Z>Q]3Q'P[1)MC( B0\E.?@&RQI&SI0A MJ1>L:BZ)%+\4UZ.:\VNOW'0I9LWE.4DBMHDHFKE_)E[D(;D[,BC6A[F82799 M^TD)B!;<$T'D?Z2$H/@XW?"LO[1U2'$7OVK4PW%U.@&#NSMJC+/H\$"R#<7A M^0+'6YEKQ.[Y5& OH\<)5<<)59:"-6.>4'6?/$;DSX0A=O[$_N>!?8)@S,F@ M3%AU=1)0I6T3%,M0C#@YG$'"GBVV6X?0=K '2[EU@@2WUEHY9-%(@^ /O,HK M:]B+D!+7B6+US!/%>Z>VL(70JI*A4[]QZO1 B%,_A+'C7U 2K;]-&]M=>1LO M)HO[M4/).O09O.B<6>?Q[HQ1RO6$K)%$A@R7MACW5G;(]^$A4_+A>*:U8XN2 MP"6&82\ML?/>;=%K6%F*_ SGHR8ODF 1%1'TQ>R)_6Q%LMF6W@) PRF!L3@5 MJ5\(5IV0L)=2BGH![)99K$Q8&#@EM2?X;++TE](!SXSFFO.1LYB/SF)F33:; MD%(GR-H#G.P.OW+K[/B/9GR.X1Y+ZKEDOF1?;\+@/@[=CSG>T'H0#U$K&ZC>Q; M0 G1)O:HAMY=>0R_!<.0$>!MZ 6KTS!P"0W>\?]EFP_J3\W:5X\.A :A6V\G MLY5-4XQTH*D_.>NO.ECQ>W_N[:]= ]H-.N#M"WQ2,19GM5<5(&_P^*9R?%,Y MOJD< XS6 XR%M7?J1.M9L.#_X9;=D^/S@E.&O:QX 1YC;TF851"31J&W#Y^O.V M]?7BBWHK&I:Q:)!%/:JHO>B0Q?OFW-K;I_I$LS,=+7T:.N%/0V_#<,$;=MR$ M =EL_7!'R#VA3QZ?3',H3SO9W2?;K>\1BI$BV0\9RW. 3,])XS&O!SM0.IWI M(E6@A).1V0\92T%3V./61V+JS$&KM^J'&'R>*(#<6*WZ&9OH*%8.Z0:/KYT_ M0GJ:1'&X(30">N$2+(J7]H%_6\CHA,".&V=#YLL*,+"G+?G:%I^VY/)74+Z% M)*#7;RLLD$>M#@98>]3JP0.,AJ(UD$+PPVB@$DD4Q[/K4QSL MZ;"\FK6Z:Z$@52DI!O[U'0 J+*-(HU!!\9K=Y M#8Q[=^CA(2 +N).1E8-\"DT8(/CL13% 1!:<%^D'1F>C,R#\T&IK:&@>""FC M-&!*CP4784)-."#ZSF(M&##YA53I?$TVB7*D[8T+$Q2E!$P$P5+&4Z3;5]:S16>"N[4-5U1UC)/]>.\^P1*VL-TJB5G<,K0(*+7Y&'N/+ M(&*K\+?'"\>C&/FC,B@6LV",GW\[*8?4L;4^SY394&=D22CEE5Y/)$@(,ZE< ME!D66J!MY;KT9J@>@:%#8J6DJI@R(_B#%Z^+RZI :HAOCHCVS#RXN@R.'&"C_!)]JW )LR_+C)V)UT:\N_!VY "VBR> MT]EC^$0NSBY/F1V44#Z2/@MLYVDN^MU3_UHWTK20H>=#[6#547P;OR9?WY M>I4_-)=I$*CC0I%_;_9RT%Q1O8!!]NW@=0H*9"W=9)(-0PS2.,[1T$[!ZA! MH($9QVD9QVD9QVD9HYV6L<^!*%JYG/I.%,V7:2L^C"HK*1S;.?$:ZK"%6%A/ M865(*#I0 ,"ZTNL4RDK@4$ AK [S35C@JDW"#YLU0/VX@3="8Q9%),8UXH0@ M)J2QQ"3">B:L0T-16!(@EFLLVV2QC2$:&@N.(^!*JXTG5G57/[;@I/"_O;R_ M*8'22'(3?VFO,7_[>=\' "0;QDC+S.8TF%%7]JW=/'U%&DLWCC18O(:5SG!Q M\:(CI6+(O)-.:*&@ M?;;H?)EJNB@_L="\D<.QE_ZBR9P64B&46\TV(8WS@0SS)T)_)8[B52OZ\+R9C-_F_QX#P#'PH3#"QEOVJ>%2/: M*C38!'JIB'+#PQ$F9&"\5#0@COY$:I&O.U$3FG,W)#XT]AV0?U6XTSB-&G14 MR-B$"$DQI1!YB[RW;EIMFY4W((>HI& GHGJ_)HQ$P6*V6*3X.SZ'SC:?,(/Z9,?^L@TCQT_G M>D;[FTB,88,7H'W7A\'<+*C6RC'UY"6%9;!>NAI)3!;%9F_BJI 5($7JV'1* M0X#E;:;@VL@<^TP=^TR-N<_4L5_ L5_ M/H%O'>HQ[5X48-VSG1]O)M_"@B- MUMX6;:2K.EQ[;[26+!P#UH JL:.W.7[9T'9@6U]8S<4CN@_]Q3OFQM+]O)#H M(;PCVWQ6=2&[?!0]AIQHP;?8+VT,XJ+'*ZSW@LJFVO=4FCS#B/3@;?@HJ66Q M + XP>%E]]G:LJ0!LE?M(6.HV-LM#1GBZ>0EWFMARXE[0^)R\,WH/!3KWC(^ M<0[M%Y\]1NF+#["<=\/K<2>R%_I\EI>VF?&DS+!J^'# QOI(LJT(M(_14WY;7]:!0%LX[<"L MVK]Z_*W8(ATD!$U?2V.8YU'L;=A]N)BMF.&S8G\JXY!/ON-9$FIUS1K+V=13 M^AS2)I9J/M50FNPJ#%:\8=5ANF%=F>FW_6I;4O*N)6L)IK:4:5YQZ_+J3TT* MRPSVU&3 @4/W,@5R]'XBT@UCWKMKLDA\,E]RJR'>79-X'2X.*#9_2@AOB OT MIM0+/)HN4WN(4A?O(H+:C]C@HX%DX,#&,W4 L%3E!27V!5>[R(CP0M8.$N31 M3(5WUI[2AF,?3M78;/'$8R"+*V])'M:$.EN2Q)X;G897\:+\CSJE.)IKVK $ MU;7.(7=8EU08E6@W3A0YR3D/1VZI%Y'HZNHT^YD&@SH7F0A'NHD!W)\ZA7I' M5E[$P\&+4V?KQ8XO>PB44+_M>VL]P PMR59:P);G9QY8*B":!&]\9"FGUI#& MS3V#SG$H?.*T)?BM0V/^AIIS$SAH(P1A+S%6GQ_MM%)X%C)AC-BPP$]#4(<[ MF?-D0%*%EQ9]-?8^Y+T5WS%21:67'B5E)OET:A>'C *P91Y9#7OB^Y>;K>-1 MCEVSF$-6M]_\S&*9IR&917M7*\ 8*BYYOPYIS'?&9XQ$YH\K62=3T6)ZD(K[YH+EZ@1E"D8X! O;>2O0/E@E]50IK#*VGX(G0*$VKS9RY M])!GS>^^ ;>D6H%-B8E==%-Y'=%7DB?>XI9Z+HDT'WI%WTU$#0JWW/D8TM\T MR!@<\_SGAS5O]AOZ"UXP2=PD]I[( W72&B5G%T&?$G,\K+UU];4NM(C=_4QC M6%+E$K*(\KYY!3H<3V#^MD&:$ =;":;4 0ONA!ZT<:HK!CN1#;B6'OP!SU^3 ME*!#4*OW9PJ16;-9W7FC^>Z[;5JDGN.#8HSH83 9]AJ1MW,(J^F9+1E+U%MY MO)"8_32SF##.:CL\B\D*9N>T@WP*XUS-U>T!=BY2O#"L4!ME8<+E8R?PR9Q, M7:(J#(I%X>T0I[,%[)1\075:%LR$"=BDZ%9-+P:,-V>8)W$4.P$WFI7\P\Y% M)F"7*E*C8 %<*$4*V)CTDY#^EFT7-!Y)%XY4HW*7DAW0+,'5N %'3B/)>@TZ M=>2N=2YCE-8I750( UE/S](59QC7E M7#T8WH GZDFX8S%1#YHWJD.QM9L;% F%]RX)'.J%4%T+A.LB'AEHY=9"'.#: MS:Q:.P/P+HBVQ/66'EF M1B0KVVSNT";W!V:04BI@I'T(P4'DBO8P09[C0)Z M<0)OVO6Q'$+?$NLNB8!-53E61!PK(HX5$1+]E3Q&WL)SZ.[>X6U8T/27%,X$ M]9><9IT96$8\.D#AW3SFRY*ICJ+/% .<)[:E%N7U%;8I4 ^\'$RZL#!M9\B M]^SJ0U@&*OJ=/:ZK#PYE0.,YO?-6ZQA!08EIX0DB4_ M55E0.SF$U.=. 2:6!2CGDU7M!\4JE"%3+[).5B>>UJR5AKA&%@1A+L*7%R$EKA-I<$ QJ%M;V$)MA](K0CV< M6Z<'3M^46^H].3&Y]1TWC=2@R+\$B,UF_NK1A6I>OYA::%'#8_V^M?I] :P3 M;!Z<3),')S4>@+Z"'\O]CXTIT!I3@/=0R%HMAA1%4]06MV#)=.=TE55$G1C@ M\>:LH3=/=,PA13H-S07?C9:D\IWBO)!EVKU4%C5+XG5(O<_@XVG;(%E,K=?) MJE4B&F*#I^RF]IZ\!0D6408:CTMU0-;*BWJRJ$$P\,F^*9[L0+]W_$0MN7S_ MRU8+\;0SR@][Q)IRVSA:TC(>>(74*/:9 E_4"-?=B@.$65G%'C:?VZD!;X(ZJY.$G;TQCL79(V"D=H&V MO 6&H6EWY6V\F ]!6Q.,_CZ7O G29>!2XD30?2[U8$^/IUJ4[6Z-8129N"?TB<&9 MK2A)7S-OG9V2A2GZ;AJFO'S;W:TO#-I>I-I6=&])^UV4OYB,32C:K4J;"S.M M-(LB$D<7CI>%G&:+/Y)LMA6P!I+#F9JV::%8P::6$(,AFU)43YCZ6G#)($'D M9$2B_(F. S_9'7Z%'<'4U/SDT,4-N^C2N6[9!@^&:/269R*!FX"(B$Y-4#!Y M5DA:6WRDAZ3AA!B;<<6),;,>2OP&J.MHBM>2:91KAWXDL?H#1_V;J1P1\88+ MJ@+'. Z'[&T8+J)9P \8V6S]<$=(;KY$I82U_+%QNZ7A$UE[[,O3Z,YWDD)"B24%UX%:C;VD8147W?:4[L/K%9.P2T6X+F@(/5GD(F=K4 M)ZS@LVE15[3O@L3P\1*FD[@G?1H&,64FY&6P(,]D\1"F&JO &<5VT($\&0X: MD;7@+E0.1S4/.LT:"=QP0VX(=+!2!&$:(?E6&A4,:8E:F"BT;&1.>A-I#HN2 M?#J1T%#K[@M:M\0R3+)?$^JNF=L\7\Y6*TI63DQ$2DR6#BO]>BJV3Q<1"JJW M! -Z-N I&)U"A#9&96"FI7ODU"K2F<&*KU(L\Z+JJ) +I;/0^&@27IEDOP5= MP?L6'1[6TQ#M(%GB#4@3N0Z4B%9PJB7WP#C\<4>VN40(7'6,D$<[P(DI+04* M%LP#+\=(@>=/?L_,B/"BS+$_(RC90)W@)G;BNLE7< ZZ,B,+@O*LORCU;T_# M*&;>4%%4"*TDN\!-C&_=Y"OX!ERSD:+[V/TR_UA_F<^$+'K/\".+6; X?]X2 M-^8>,/]1+GR\']0'PAO!L-]Y(I3Y W>$TX\IE,)S3AR?C[Z!3M8WV<@]:_B*<6*7XLBGZYF*F7A<0V M,8Q):+X.,A6URK 3D&Y])Y@O[PC;GA-XG],K](Q$+O52P9@O\R<"XC+_*O:* M)^0Y?0A/"$K2(01&4SN6$$PHY .X$TIF+ WX'J< <%J1"A4*%LQK+7$QJA?E M%<5![ 5<7K;,C#VD*5^3>!TN#@]/=WPO ;-VES&A[+MM&#G^_%/ D%U[V\N M_93]9N5?@5F/C.RTQ :;7$L&T..M&X4<12GFH\:#E3@Z:VRY8.")D4-;925W.(,E3$)65DG@2(ER1ZG$:XG$:HH*2L#8-\3AP M27%,S7'@DN6!2ZER/\\;\.B,_:E_8X5VNE[[_D6AL6/8L9#9F*$P,"&LX#,[ MCYS&Q!5M7$5N>Y2J'6<[-EWXX68[WI$HIAY/?4^12M^V[^[?H;"C'9:%U)PA MWJ#*C.T@=B>/S3HON#3= R_5.31UFL4,D\G%,@MLDS@LC@#EO MB,2814+K*;PO,X #=@>W,!(VH&]+68BJ7>1?!G]$!%$)O=DH9"M:M&7H9M6N M1:-TK.+3(5"V:H7B'/=A6 T]<"YOK)5V+7X(]^;@K\2AO-1-256T?#Y\(0:B MSF@C$\YD.>--Y#*58AQ=!IDT#9WCH(?<2[IBL/B',R&O?!=BR(C-CN(#\+?> M=%Q>$SRH"L@#4HUKI5!>8]$&G7B^.,< D:6=\P.!!EIEH+^X"8*X"R6E"[:1\/*F.%*4RBM! S#M$J8%'^_".F2\(DA5:-Q9,I:%>NC)N[! M<96QFD:U=7[Z[V0AI@^.-:D(]"4*C"J]NV=\VFS.5P2U]E7PXS0@!6B^1)G" MXZG*9%2CKA-YS..$!(P%,1]1)B8-TX^N$ZV!I4L;_$N4>>J Q@[2,-^9PC M*1;939GNK.AH>OAWWMWT)HQ_)?$=<<-5X'UFM,@$.J3YC_CO06NJ@9%_@6^O M0[-?>;KK4%U LB$B#\XSB4JM/[0?@IO+-,C>^A+<]KU9XDIS1?6N&[)O$55Q MH]N&*EGWC\S2#?=OG&$:'/:YL7GKT'A7FO@9G>S*_X)0^:05H/# MZM1$21$L@T&I!10 L%X+J"_#,IXI%P?"\ :\,E#"'8N5@="\4:QYAM2%PRF_ MEZ'M%!M# '((7=,U8=GM^:,@J0J,4B^%!N<5JN83T[(*8/08$<*#:3=3@IE87>?+4-[ !6V;!M MT?7L,E-N(?19=<,DB.GN]W?W+1R)B/O75?CT)O_EC"'Y7PZ\*"UE(>5;R;3A MA"[O&/1Y+8JW]/>;7Q7HR'\S(R+_4^GBSE>PD\2E3,']1H%E,5WW[+PO =D* M4R @WZA"/Q"3P_SS?\ .,UMJ"H>9[Q@IWA,3&CC^'7DB05)D?EW>W:-TL^J" M9J_/A8KM5;W&.NB&T&'O]NY4H['>X;IIPH M96SL:=Q*!:2>>MDXS4R>\6Z7.@BK:=I*3\B-:Z5!)9PGA?/EDC 9>2)[%7/' M\.09VH'K^5[V9AA?$ ;;\?D>$K;6KO++P R$P,C&&=3)3@:E/E:"WIGWY"U( ML,CE=S] .Q^H&ZP8!LW\\=[\5P9KY5";<%F=D-VN$M89G\=K0@_#R*G(=V&S*JIJD%-459>;/0F MH"9MNEO2F=D$Z<5S$P9A87&^99N+KL(H F]?TPIJ_,=%C6*=[>>,&56 R]#E M\*#Y(X P$1-+2!R%AF?:RBRST\F"8<:!G)!E2$D)624EUKG(V-T;15(HM.\: ML'C_/GF,R)\)4ZCG3]S/ZE/!+UFK0:SVV0]=BQ@.H1 OJU[0W[K X%7]JJ0^ MS)QHW;^M^G[A4'>H+EV5M1$YI#@<4T$ *YVVJJ3!B69CSB,:JB.E"8IV"R:$ M4J_52]*(+F0!5P(B77L,)2 BF=M37TX5C-FU4G P]1_M;+!?_V'$ M"?CY['OU63VF2(:J#,IDM%0GN7">:07@<"Q0*9Q!#( 60[)#/CMX@Z7'.D'" M6W=M'+)HGT'P!U&[%5JW/"P80[])X>"='R0%)Z<85G:"?) SU+BC)@#KI6R= MDEF97"2@$)9*:\("UV42?MC48OVX :_ RM;@14B)ZT2Q>FZLHHU<6]A6O4N7 M4U:WCNOT0(H;5A4G2F*R&(:])/Q.<[/E.M>HTC#32^F,[_3LS5"8(0!@MZF\ M_%ZL3K5KT@6:!ZDE,0_(9;#@>:N)XVL41HB^&_-HI![O ?NG*"&M,.J7;A/J MKAFBFMDT@L\LYF%HO_2)=@U[_V8/W:L5)2MF&8B&.LF>^&O?V$M'TJ9J8[L* M5;J&":A\4$!ZUMA1.H6?'B( ,!'Q;B.1BO]E_KQE,IUF?PZIYY+Y,KN*TOL* M)W$<$=%IG-,A.-;=?,O3V)G6F4"T** MC#DGX".0HV1#Z,_L!^=_)EZ\ U?(ZI GIZDUB-J=KMXO:O/!X2H@GM,[/ASV MCCA1&#!W^3**$IX_']Z$ MQ$P>+X-E2#?IU:&;#+D@WN_%>J5E&B1LZ$=67E1S,\5=ZE[\42XH(5H@RY;Q(0 [C-5 M1HK',4"D/UUH>$5N*O?9OE4\6VW2GB:4,@@77N0Z_J_$H>?!XJR]&4(WF:6+ MVC&3=,DNITFW-ZM+_QE#:L$1N_"=52^B5U>R492A2^?:WD'KABOKGY'(I5XZ ME1:&Q.4%)Z"HQ80 =M@.-\(I@T0=_Y*9>L__(6UNF>K=6%_12N##['IL$$/% MG3*](+/1I! J7+SB).@N(8:"7V-,]\-5<<%^ N-(U-><@D:7TJ.S(+@?Y8N1 MO+"T+Z\Z 2W?0A*%.E\S57_A^>0FZ7C85M7RI<4FH6B:)% HXFT-G_SS#0? M ^!&UL[+U]<^0VDB?\]]VGP#-S-]&.:-E2>^RQ/;M[47IKUZY: MI9&J[?%N;$Q0)$J%,8NL(5EJU7SZ!P#?20 $0!"@>AVQ.VY)!#*!_"&1F4@D M_N7_O>Q"\ R3%,71O_[N[,O3WP$8^7& HJ=__=W'AY/%P\5R^;O_]V\ _.]_ M^?].3L![&,'$RV 'H_@(M[M'WP$UHD7I9LXV8$WV>X+< *V6;;_X:NO/GWZ M]*6/OTE]E, T/B0^3,DOP,D)[K#L\B*!I,,?P(.7@4OH@]-WX/3LAV^^^>'L M'?BXO@#O3M]]G3?YW_\2HNC71R^% /,=I?_ZNP:EE\Z"O3?&9]'C-5_K*:-TLSN,8+"VI- M8Z-E/9%_ M_=TA/7GRO/W?[F%(>+SSDNQ(U[[G$]0O7E#:G[H4' MW_U;T0+0)J#1!OP7:?7?_Y+3:PJ!_+Q(VI+P$K]D"?]S8!C%%U_Y,59,^^RD M-:)-$N^49)C%\N/'PM!!TB)-899>')($1IEA[+3[SE>14;QD<>:%-P+0M#C@ MP&1-.@%^_@WP:(L&-!P@@RF3)A;ZPVHN10WY3R+X!B1M2ILGYM5Z<0,6#P]7 MZX /IAUS9T@(Q!@35Q(AYMX6EI M8 ;WLHW# #M!5_\XH.QH'"P] BYVD#X;PAWD&C.Q?0?>)_%A#V[0#A'W(MUZ M"2SZ^,/OOWMW]J<_ TC[ F\"N$$^RKYP"R>>+-LX8LZ$]B[3[V\9^>&!A+7N MXH1Z+EF6H,=#YCV&#F M8G8>H!T#'S'0M6?RJW\SBX(]3% <8(V>9':P<,H P[D7DJ"J8P_I-6_#N^Y(&7@7\_1!!\??HV/_EY\_'A M_WP!WJ (7.*>O"3]XC?M(#'#)CST111,;HL/DC,/= 5OGLF2K(L/%K>7X.HO M'Y?K7\";RZOKY<5RW0*O8\]?*%Y..( _(9I' -B=2=.[)-X@T_9VLV?; :$& M;0Y:Z!<@_\1M+(@A@:;PNT.9P/\8VGDZ++ ,1\YTSG\^3SNA!Z7%L]J3; RJ M^_UX!V]PSX87$8N":<]C<#4QF."L*O(G0,0!XKQ-'*6.X2"041,6O#&:#$RQ M4C649IRU\L13_NHF_-3X7C&DW3B,L-RCZE,0XJ]>-;#/= V&NIMKS,X%MG]1 M=,#=KRKTG<--G,#\N[7W M.KERSQX@3;T5YR7&9PEUH)^$W)J6V#9L*Q#*IR MOZ+64#'@D=(#B!($&:'H5.U8P&5S64TM$ =FWL1#8FU>-/C\&VP,SO$(:W:8 M-^L*VKZM.\R3GKYT'7>0%ZX:7(T;R>:T%4_IW,*,VF__0Z5UJFOYY4[S!$YN MHV,'IZLU=<[*+O'B-DS4G_VFZ#N#,*XVAU9CF[YHU3GVFE2F\50_BH]'.UE, MJ-VWB\R9%@<#JP9XC3,3D,6@-&5:N3..4<$45Q,8_1%K0X-^VF!C;P99,J:YLV[ &1Z .*FX26L&>\1$T&HNA"FF=X3/(F#'WL)P<$8J MX$81L:]"/TN(61*D8\Y*'\B$I*M#1JZ>$J ;AEB__XERC(:SS+J<<$!59HV0 M])"\C>/,09Z$6FD>S,$9CNC*)7.Q.!'DY3'G^55-\ZE]UX3)AR#Y390"U<.X M&W6H/_]G(VX%%'<-\IP3HF+C"/^83GF;A$G+-()"$7A$G'"48OXIJ+_M7SEV M>;%$)#_FY1+NT$?8;7@[OO#2+?:WGU$ @_/CQQ0&RZ@ZK%SX&7K.K[U-'X<> MR8Q]ZV\]@@/N#&!E%U>GW5[5'Z"77,[^/!PV=>/%&P!5Q^T?.]&V MTQG&L\R+W@V"P_6V.$?YGVION/*TG:G#6:N^,6KNU2BR<: =XPQSJ"RC9YC. M90>7968V,)9D6!;:J.SNE>_@BJ"26 PJ$SWY G&V&&8-_#$@?S4P'@?9">!Y MC2(O\F>BOV69F0V,)1D>@O:^Z)94>=R47>KH\/E@7Q%7$NM!9:XG7R/.UL.L ML3\6YZ\%R>-0.P:AA 3Y?Q*C>_9"$IZ[Q[M$@OP,!N0/BRAH_Z+QY1T]HUA& M?@*]%%["_+_5,>[5B[_%8H/W7@:O-AOH&\\UL,N\@]PRNR,4+#=4]$(J?.3_ M^H+83G05>E&0_P/6M)V>XKD!=>L V;[<=,-$HUB=TX*>Y@1V\*A[%,^\JF*\ M947.%A_A$XHB:K)M0,ZDZ\"I$0P96S\3W7^1.I$?S3@K>"Z$ \2_9P'A-QCH MWF?QHKW_MU7RY$7HG]0'P%3N$KP#HKT7UF;7XA$3]KIE,%=OIMU^?4N6F MVIV5PMB*3''T5+,#"M"J"U#W ?ZK[.6_G5@%FN(D.-29)0W I4GVM]6G"";I M%NUETR%PH\:6BG^JM]-^?W:*:/;H\F!3?L.HI6X3&=QY)[)G#T97G=P@K)@" ME!TQ@M['>/.^(&PET4?ROYF'(F6-HM:C'0"H,\:[#%?V0;4*[044W8!6/TSE M8E^]:(FWTC#J,Z9;K]_WXP,)<3W=Q2'RN9 ;7\.=3\BPE2Y*ON)SP8'=PV&W M(YG+V)YJ[F1E+Z#LQO66)B_/5GEX\72H%XFFX"7OZ02'$*XV&+7/&*_H,80W ML1>E'[#;>DA@L,BN/93\Y(4'N(H6]Y"44L=,G'LI4E-YADA9U(5F..:AM>B< MP+71/:#]@Y( \1$("4!I &RH+4!%!E Z+#C;UJ!F852I5H,"T-2Y5>\%09(1 M^3/*MA^C^#&%R3.Y-K&,]@?BVI!)0B&BIF:;D[*$VY$='#*LONWP;+L&BI51 MB6[/N$RYMPK#YJYC;];U7SFX1A'*X UZ)BW^.$%LB? M(%-=A?($-W5%UI,":QS0YSV2:\X11733Q$9NBH(B=25_UQ4FV,@],PPB)=+6K_"K<#=PV[G1RNW9BHZPFR!4 MGA/=2">=N5L,>+KI4=@G]>NF0O^>T]1>AI* "R%.(EB^_0B\XGN7T4BQ""K? M6#!0 UJIJ?#,V\T\*I9M9 X;O-ONQ=>@O9_-P>P=D!I+D[#&K%W4YBXA^:?8 MO<,3EBVB@)SC[HG==WY UQ=]$J,XT:0:1.>]WI^?'YE_LO>#.(CR'!]T9?,F\[_X6$)4RBS(+ MZI*6>.>=-RVZ=8S*R@Z,*Z$/\(G\97NN1)/./ M?WTX[/N$1S3#-*T?S RRQ LV9EN8@-([S\_\!3K-T9&,M)"[!S%RTZ(8 M\.Z@FTYA,8-%TH2>*A-T9%^5\9F14&4L5,WK.LFPT!AZ;&!.S*2A-P)'5UPI&U)2JRZJ0N")'.2SC7-=BA)=#Z7%!I<<9#5NY+ MW0_G=1&!(63).PC=.=%69&(:5J'G0I&).9JS(I,3G#R<1BDRDK>VALDN+TV: MNYZDHDOI/$RHSI1(VTPI4&%,E Y(^@"-3N:DVW3DW@JQJ<[1B*CQPS9.,D+L M/$Z2^!.*GJ8*I8DH674S!8SP7 +2(H?<)7QDNP!N])V$^-J/'HF'KOWR6Z_; MZ<%C_^(-@PG9O7 >T)"$A+-'RSF\L X:\R69D249D"7I]KVW,3.M_.!XUYDO M<]%NR%5Q[9@-IQ=+#H\<-S(1FRKI,&_J7E6KB8L5K1%,AM;I1;O#QH&>%&;X MK2UZ*F).A.DJ]8,V(2WYV\A3<'HV,2B5NF2?<-SCM,G/$#UM,Q@LGC&-)W@/ M=QZ*2E)$>14W .A!"*G1JZMP1A!RHY/T&9906V7GH.@=5-WG>@Q0 K1<7$D" M4!KS.UD;CR"&#APY^2,/>3]XV2$I4AZZ:TX3_E)=VC\MD6%+ LYU-^2G',&- MGEP7F!LA7@8VI>=,_US%.U*_'V-\X?O)P0NG[:GW;R,X.99) MN:28\>ATFR^C!PQV&HW&_.KG#A;T&AU/"5D!U6"*M4";"I$F*J$A@Y]*XK\1J2RZF^%?20Q?ZOVS@,L"3R1]=O MXXR3;FG@.JZ0F-UT7S$SW$,++X%%HS]X^SC],\C;SN243$Z<[>NW@].@>U1+ M)^L MV:T.69KA)8V]U-O#[M%X_I,5EJ=Z9V;PW2$;H^,]"$;_2(PVW!^F1PZ7SSW\ MB0^;OP1QW1_PJ*-["7U(VWY]]A9@@9U2E8[_9GJ50P#>)6TU.2_? M:BOP9KH.YZR&YG8KG,DL<+;,ZOC"*XXO"N4"P9YT0YYO REA^&VMCU":'O(G MRO'ZCR"MY ,^H6P+L L$/F#EL 5GWQ:*"'?S[&6XH]#SZ;IS[:G.22A$Q4$(2F+=ICB^9!^_U;/('OD.; IO@/YA[.HL\B5 M3!,9[/&-S4:D2B[O.EC'5[M]&!\AUIQ)^41.0,&XBM9;2#^[Q(9=_4C5!O^Z MZS-IYS1.R8NKS,@)QR257YF7N2T8 %D,*A8 T9[5PVRY&L7*DYCS]'- .&F] MUK:A?RS"TC4_[@_G7:":F?HYM;2M!\R+(1<.W M+<\"YO]Y+!P0=EQP1O;0>!P:B0(*A3!50&FJ6+5H,.+ M#ZD?D.4DA!&700T MQI'(PYVOFA=R/8&Q9W\#$(UP*+!;YJ67C0!M)5K1G\TJEH'S1&M[4&+&_6'; M6\C0"(41TS&@_ V3DTE,/U.3'7KML_G(8?,VIE?F8=!ALN\963FIG(1QAWZ( ME0'*[D1Y2"%HAQ1FOB%9A?;PF<9DXG/IVE@;I=36- *EOX%T8O$Y])9^HGR2 MNFDO>^C3V![Y56.;73P])? ),[V,L@1%*?(GV[>P6N#\#9L3BDV[YN;43+ZB8]R1@_E<8Q%3'/@*%8Y.A8%MZ_H=LY1Y]SC&)HW*Q Q0"V04ZU>TGL\XY,O#Y$:\4H M:-KXX*E7@XON13.IFQ6C"%B_/CV:Y9&)")([B>U+#2904MU4&#V]DUC>',O$ M",=C#OWE$/$_&A"GVA=2+L@PHRQ_;/@>I;^>'\]AY&]W7O+K!%<3!\E9O:DX MQ U'E;6: =(.5,UZUQA=/ (L*=/6X[\R4S'NCN-YZ/F_XA_Q*-('M-N':(-@ M\ %FVSBXCI/U%A*H4P96FUOXJ; -EK3@A>9=1C,T'113-<*XQ,5$2N>D( 1J M2B G!39Q0B\;5M1((TRONM&84YS!5>\IT<:X8VA.0.IYOQU6UL0A>8!9BNEF M6TQYL2/UW%<;MEE>%)#57%$CB5G1[T99EEA$W ((15=@&?GA(#<:;'=P@^F(< MFZYA0TB>KF%;?[ "LC1GPN=B4M+DA*:< K^Y),JRO:Y/<94%W[26U.9(_V(' MUAOQ#JZ]EZ* 3G:2_#.$=QY279<8PO!@D9Q4_0]QPD%0T [0=:#:D\=["PW;^ M\(JJB)M DYJ9<8Z=&O(&+=(/8=(8I><TR]FGAH#7^3H#$%/I?/L7/7^$F.0CQ/VKL]3HR[0[P#FV[ MA#F8*3\!Y!L7P7C>3!-Y,\>@7!6RVYNWZ(]*&KRD;LUSISQ MGG2K@6CNX,4C:[5-7]WA'LZ1,V_W-7JTJ?RX;DJ9_WJ)O_#NU_1DR8EO_W?'J;0IE MGW=E MUHS<'NT;(CP&1B"!8%'GKJPA$>F"+I8J$_0&W/X()F3X7+*( O_P&/ M!ER#;H].O,$.$V+WH/@8T*\!_MP5"(0B:?L'K %JGL MTA1F4YVW=3JW_TYO MBS[/='QXN%H_N(X/L^70>FNW/Y@19Q)Y;X7U,:GXNS1L!8.%7 S8DAYM\X/+ M"S-" ?5QP1J??@['A9=NR2D#_@]Y4N#9"^FY0W;A)3HVG/]53B MBX2_GD'[!N[C;76D6ZK3,HZ:G0W(WN$KCW4%#DRW4>'C>$,S8-VUJ) MR04'1?1;>O_,I4(2RJ:)$O[0]!72/?0AQMMC"--;F$T###8-V\!@FT*>?S(/^;-$ MT4X6[PQ(TR6@&&KYN%,HX38!%X5&^FQP8$ _!'XK4C$#//#EU-,(_5%JOWJ< M=_4C#(-EM$X.Z42F'I>,HY!FGQ.I@!;8XG;T>FSJA6Z?'Q@27#_"Q1FS;@F5 MCQ']2?&6=K^5O:V"S0!'\"X?4^5.;95[SQ[%",.@'7.XQ0Q:B!TUR%C7 SQ. M.'"XB:,G@#O=@9-]/YKDR,D;$AH_J-09[RC@Q'N(_=T[/%T9*>;TCP/:D\DQ M;V$*2;DP.40,<4.1>9.\M%CY_2R"3C*2;"-J8/3:1LDRRO"<(>SQY#L7[O#J MA5RF1]'3^S@./J$P-(PM*9*VHPLR3'%]G;+I?"Q<%;&V/2'):="/4TV$JB9R MK&NG 824?W9Y)"*2>E^R6MXO5E$>N>EU [T4WI.*6ZO-QS1'DFE'6$C+NH4C M9(=W-YI\1>ZM'M)2<3CVBF7DUW*0!T<]P5J4B5@.\<4*7]+/3N+-22V.MA[_ M+"2B7=>=&.5K;),OZ5MV]&JGX27-HF!](3.8$'@I)]1+0?6WLS N!:)J8H4W MU-&)6HW@QV3.K8B2_8"X@!O>^RS5!P/AKEG$N\3N[M#H=8I?]((NIWHA+[N% MN#D\2(2]W,>]3INB%0U$MQ+J#?(>48C(D2 IYY3%_J_;. SP7!)O-CM.E-@I M3=9B^K3& QVE3BP6$;$FC%!0+2N&/TA-EXG4O2%8^QEEVPML%L4[F)2(/$X# M&2F2MI6.#%,\, 7/] $XFE?D%VT=ATE4Q-JI "XW#4ZRO&2Y8X5.RK;-70)X M- \/!I^WL$9EB-W&&9QV"V%1L!Y383 AD;N9Q=U$0L=IO@)I-9'#&^T(G+2C M>A-O(0/$''A)8HYXOA'YME)(QY,B(#&G"+N,'I(8N^GUK!Q@E]TFJE8@; F' M[!8GH"^@ST9$I_IG:I=P W$_057.N.'2F,_Z&*)FVW(XDIRAXGBB+'+S$F)B /O__NW=F?_DSO)61'\": &^2C[(L?W-H-:N?T$B?S M^OM,'-'N)RG?U.W>_I%8FP&>>9D$*/*28_[:F_-M@R61[E[1&Y6CTZP^)RP' MD?Z1Y"0:(/A[JVGO7G>I19U&-#N^\9)709S(#VO<=3*CFFFX1^?,)@.A3U*;OP,#C>*H/.JAC.!%T^.'%@QAV]XFU;;2%@>ET75%R<,'!X45S1/>-D#AAJRTZ(G\:@71PB"/AA M'AVTI5#,/MW!\^9?S,A,'"&+,4<$O6Y7ARS-O(A<%IYZ.3=)S6)--QA27-AQ MW7)FJYLA3R&LNG.@7RHI"!!Y3\@+[SP4+*,+;X\R+VP0-(PO"8+VRR<-\L3- MFBT; E*'Y 3K+#]OZUIGR>*G_)!7:OQC[L?6/=(C5XS@?0*W M,$K1,\QS?&[BE&3VK#9K[\6TCE.D[N2BB0J'$G",\P*$S7X HATY5X5Z6.A< M65&>+LV[+!]0A'V_[+B,L!!A:EH=]KJW'9#O,L"_MGU"3G)QIR%)*T+%YZ[! MQ!-/$RW,(9I*[?A:[P3WZQFR3+XL M2CQ.]289GX[+:SA=9GCACBKY%A8-?G!\@VM0;,P$6^9P5;4LU=C8>JAZS M@A WZE7XU&RJ,^/"Y%#DD665],3WA%MVQ/?9"V^,E5-'$*[Q"/+\ MO@\PV\;!=$4 Y6BZ>/)$@B]1VB?)!\#0HSH$[V]EWN>.]M$L(>BZ;K""S-N% M@V4GR%1HY_M<=!%\(@$P(\)CJ1%-Z7V6LM-/^KCV4$+3PU9[HJLNJ$9.EU'U M^U)[G9DV4^0)V]&IS=&8EYOR=6#:AV_T[.0^8TY;>($Q][=F4+:>(8;>/<7&>/1MFTN4YC>R M#C HO+0X:NM!YB>Y<55=QS>,%5-<6:_38(9O;J5EO.G2"F!!HQ,0E[WD/AE1 M>YGWXOKBK6%@M8I!&)QE)[N9 M)8"]4[J(,DJA6&190EZ/&2DN-HZ)F4*ZL/XB5(3 MC+/GX.C&]!AX07P9U0N\!@%2Y2]JD:A2*F85"#&'2K[?;4@L6B=3O5R"/^KE M<_QQ!OD?;3P0C**6UF" M;X@F^Z+I&A<>Q@].C$=ML5;X4IZGD;6C.-F(_ .,1130GT*J^1;!WP]YZ'&B M=-B)F'02XS$^C($C4;_H$61U)WC#WVP@^;7;2@73@J\7CIIFZD==RNKRX]!Z M'LN-HZM=8W@6)ANV]QAJ++\.>]@0K#K7QT;/L_(-,[:I]8V>N?O-#,S=;UZ% MN?O-L+G[C;ZY6]2-;Z.FO&[9K+JD9/.J]VK7\%7F;Z#J?E<1Q:W[JD5?#JU? M;2E7F-.;,5,9-&('WV'8ROY50Q7NQ@2;YI..(2=\W>B0P\=V5=EDGMQ4P=]EL]*^?;&5@YW[X**^?;82OG6WTKA^#E#CN< MH9>F"^Q%GK=VKO3<2Y&/?WV)PD-6$Y22N6;7=NT=/29%206D!AOM#BSH98/S MCLU#JL0_DF[I7X.\8T?)WP8@4*%RQ$R:,H;R2L('[,_5*@^S1$E/46U0E;KK M%.-!#KEUI\MVK7-M"F)F^4$*[5\.7@3N8;1#T2-BE2:U]!SQ2P+!;Y(YI9A@)$)-Q33W%G?;@P/0''M,1R& M5[J:AK:K*>9YQ&965O J:U'3M6IX;;!IV#[]9W(AB)A2MW?TGN Q$*1-J'( MGQ%]U[7;9X'5B1%54G%Q!L[A90A9;D,DDN(2H:4Y3D-GRW_2B[K^:091US^] MBJCKGYJ"%0U$*^KZ,T1/6Q(%>\9[UA/L%;K]F$):DC3T224^_(M.]*R(M=%V M2C'920C;C=A.,00.)$M2P,MI,8HK@P,F!V@QW(I@/[R;'RI6FY[+:.^4T*O6 MRF0RTM]N.RSE#RJL-CW6IC#KU&@[N,NAQ" O>M8X\\C_S3_YF%'%>RU<-'=[ M];G3K7? H=1T*Y%237KW Q$>I\6"3.GWKP7ME%H<0 M7<"9)!;"HDW]]F=,.YLE9(=!(:MN^=,V(MHN7"X.L2QBP('CILZE 3PSU?%\ MD"V!$6G%+,:VY:QH/4Y9N=%58*NP],$]W'F(!*T!20LAX9:#%X(U3'9O0=7; MC)P=EZ(_G6:#OJ#E]5),;K6YJ$OM/4 ??TDJX%O;3?U K'#1S601R#(SFUB!),,F%L)KV05, M+@R5Z9T@();_^CI.'K!8D&]U*^C3GH^9RV90P<)-\R9.\Q*U!"^KS-F3HWL M(5P=CD#*(SX3 X7#GCI&YW1FIH<#:3W+!^V\7"XFG_+O?L_0HIQ4@MWBGXJ/ M-Y137$.O\R3?%=MW8\ M,2(=%YXQC:;VP](&YU73F)3A@:[41R^% :F9 Z/4*PI)E<&.U:89 G&P<%0Y M='$L-L$XA"^^T&YHQ:>R'Z?&ZX1 4UU3.K,\22"/5G"SZ*'E]&9T)EQSI7G8 M\,E+$L_YLT72,I9UQNHI,8V[(C7''O":!.=RAMO@:23N7L4!ERH$N]-C_G"6 M@GSA_^. 4C2%S2!-=F81JB9O"LCTZF8S!"%7V++:L#B(U]P-:IGU3U$D[SPFLX[QJ M6OZ3E(*7Z,;NM*2Q\ M376E.3^Z,:C6 =4]),-$(7EYI*Y7A6T!I[B>A$7KL?\I1L%[PJ(F15ZN2$IB M]6O Y&$=_&\?D\-.4TX//![+7^H-8P0+DGM2;E,Z8,*=QCX2%JD^!_ MA[ X&%[LXB1#_Z2_-[S8I$A:?U%=@BF>>=)H2BLC>(TVKM,15>3;*C H.Q\C M?#:F86S:&V,3<7 Y@$T"<75?5"Z)G.9%0F[R+A1)5)_N-4U9?$VTI(1^0?AQ0"C_3E./5$ M%PNMAR1UYDK;;;N$&Y@D9",OGG O>CV'$=P@T[;L$#7[.ZN0'^ZFFK]!PFOP$N;_;=B)1=K?1-Z2 F$GKWI(,L<+7I)0 M35Z$I>&K4,5'K;L0>8\H=!\+4!=_Y[T#E6G2?Z"C0V7A^_1)P#OO2%X#G!R9 M77HN=N9!KGA;?.LL6MOK?WNRQH-]-X =K>QXDUNBB5[ MG!QN8NIST(9"#KG1GF>:\D1?#/2+1NGLX"@E>C$XAV?'F":DV::=Q4 <;-]/ M#C"XJ7>9Z7=O:4Y 9"WI 5!:*9QT.@3_\_KMW9V=_EGB:V 'JC0"JN1+& MS[-F\EWO#8?OI'))&,W><<]"^C9YBZS!<1,3"? M?!$!E[R[(66+F>>+2 ! (E]D:'YT42M)R]D>+<_+'/9H:6Z']N@WQ2;]12N= M S$@+[]CSV3#5D;7T(:M-NFF-NSO]3;L[V>P87__*C;L[X1% MOL,-6\3 ?#9L 9<<>%4M9KYA2P! 8L,>FA]=U&(Z/H0!?76TO!Z[VG2OOQE& MJB11%^<]MFCMU=-5$W,:DP*=JG04T:/^?U*LH"-Z8-0R$I MUZ#K,B0%M:+8!U&&[#(SKO'&DR@/9V@9<^QD*.GM.0>G@3PJRF8=MQ97+!NY1#S^K".'HZP?WNYG, (A07 M#S;MT9H]V>\Z")O*\S"%H(LVM[,'&AN%HO+Z##65 #<5)U.;95)SD[%0O M4')V:KEN (.#H3B)\QA)/;G\($DQ#'UM=[790#];;:Y>?)JM>8]]B%5$$$;^ M_^H?!^Q5A.2>U3W$%)&?P8#\81$%[5\TOEQ&?G@@+W?F]W:]\'T2'_;TV64+ M*G,& W(0QW$_:LYRRADCQBDL6 ,)<1L_AO(F<0&+>6UMS!)\3$D1WFJ]FGO8H\.>SSD5KWD47G$ MJ&PL.'^TK7K0*1_X2=?Q$KM:T1,Q)^F&FZZW27QXVA97MXI2 RGV3N@9TT5^N8U[KY"# M,I/T+$883?/.O1A;4"#ESE!%H[0#LYP*QK+>G4/;4)\ 7-6J,"T,S7NXZ[PB M[9$>UU_$NUT+MAITB+AEC'L_W^0J(X!.V6@*1S\/CA8/I\O-NJ6D''LJ0 ML)KNAW"4(^ZM7L0I]FKNX3.,C*.DW;=)LTX>'2T>N*&8E+JX2?Z54TPPY=$Z M9^X-R)PAU)[6]6!J09<5U@.XW,E]';-[.B(*_P##, ^@?O"27R$)#$Q3P$U MR%2<77[%\9GAA=;S!M1JV)5-*F/"\4. @R)L5084#UT?2>]A!!,O))4+@AV* M$ G 9^@93@.G(6KV,37 $0=81:N\:&FKW4S0)2G6)L1D9L*@(Z*X(TAPQ]HC MU 3U^4AJU+/H]S"%> 0DA^ 2[U=AO"=QO6DT@IB6 Z-?R! W()RWH3 +ZE9S MP9B40%M'$H.3,)W-/:@*!IEC*0(E$7T>,CK5+[F502S B59\M_?)]A01ACI, M<,L2Y%^5('E+*O.[+A;$E$V[)%!_;!,ITL&URN"%M3J')OKUS/3IJ)*,%JH< M"ZH;.UF'*K6-\Z^;E8U=+T;IBL:#E8S=K$XN4^Q5*IC^USO_8P(Q>: ]WNT3 MN,7=8B,\)W0=)Q ]17D(WC_29_Q($A]]"H+^%-+DVO<>BLCS)8N$WNIK/H)V M"[/5!C-L>/W;X-B!V6YA6+Q2"#F%XD#*/X*L[A4$:+.!Y-=N8[\68=IZ+<"2 M4$;XNH1$2FC =!5=O9# V@&E6V)*KS837!L=IN=F(Q[D2UCTG=[4\U "GLG) M43?M-,#-7;M7TG)N!5JD)L5@#>Z[!.X]%$SE> V0F\H.&3!!A$QQK\7CCXXS MJ.LA*T-QS5;&F(T_'%"G\4V.*P9)^Y%]&;:&W@](JB^='BZJ"%7N#8'.%)A\ M2Z5/XAZ&1%AW7F*E*OL@ XXB3JI\RH/S),D;@CUN>72]U>I#0A6[C/G2O1;2 M)T>N*46X@0W(-FDY<)Z$# E*MA9?S$PW,@0G!E9WL&:+]3=2\?*LO_]%'4$Y0F[<"SDV>.Y&)BIK9?F^?7[HC$]/H1E2]HKQK4T]:ND+@,:="O_A;M_OS0XHB2((X M-&A(JV/D?S%>>E"%M ,[3X4_7KPO+T>0?Y-??VQ<.'(9X]:1NQ"60Y,SPDSL MT;J)HR=2E"^OC4#_-C4V623MFXDR;/&><:HJ&:+J6\>%#!7$*H0>;Q+TS<3[ M,EZ:DB3TRFT^3G#$(23E9O<5L<3;>/,&Y'Y:,[KBNO2 A!C;26(# ]?>9IN] M?8"[1Y@8AU&/@(O"O7TVN$F@.4KN6C$X)QCA2::-#.:XC-]]?H;)8ZPSQ>PL MSL8<@__*/_YOMTI_S'2/23W)K^I=A-@36$RR !D$7"S /AL\TY1\ A9@E00H M\I(C>'!^#Y,OH_;5,.8(72Q%-BO,VW?Y;#M^DVC$_)Y.<@Z4J<_NF0#+<8GE MHL #0^6]MGD_FZ"<0:@\Z>_D%4A_TE_9C+\SL\N<3[W+G,]CESF7V&7.9[K+ MG$MAXWP^N\RYS"YS/IM=1GE^W>XRYS*[3 _+,]QEE.?];+3.H_4P)E1YS?[M M59SB\L [B^6H.7=X8,BE#X?NP,P5O9D$$7PZ#HK+_EY9=@K+XE0])1.%'9E$K&_0[$9X2=%'G:'/#AX"3?(;]Q-_^#;G2< EIW5;\N[\%-T_84C)]X #JH2J".FT[S_)(AOC626%0!CBMWMP><\)#NJ MPI5%DV7(@K#NWFMLZK?D':*Z#%)B\[)'"UF>R10P8! M)\CIL<$+&MZ_7]PN_W.Q7JYNP>+V$MS=+V\OEG>+&["X6"]_6JZ75P^N?7N^ MU%JH88]9&RL/_A8&AQ#W^'!X3%& O.2XVA1JKWK7A9AO7G1<)<4?2-I(A,6S M1?M+F/H)HL]EK^%+=H[)_6H8;M/PZ""2.+5F"UHD3Y]N984]EH*[!$4^ MVF,;KN+"^9/;D\*P5;AV,A'H!F<_H"A.,,UR!UA]*BC=08R_*/.>X/D1,V#^ MQI0*91?Z78$_7M)L]2%9!E5[EZ$X#7$W\:LZ)\H; S6#+\FCKAOBX2?[.-]G MI)QA5CN[GBZ# PXVR)<$%:UOOP(+QNT1%ZZJ0 25M\(;K&:4A#Z9U>FO,1U2 M"!CJPU:,4H89GM(@K7K(< H&27L15+VY%9298Q%M?R+Q^7E\OU+]2#?+]:WKX'%ZO;BZO[6_"1_&>]6-YV M'4G;"-(3;(4PC8G2]SS14X0VR">7N_-**O14($0^'WOC74DYHBZL73G6>-[> MQP\?%O>_@-5U*[9QL?J((8F!>K>Z65ZTL>G"RU,2>>RBA+TTU M7BC[0--Q8+"*[B$I (*IGGLI2C]&\2-Y 9,<6RVC_2'#?\;CQZV\*2,AD[!H M/2=GBE%(1$$:SW8#^FXW*(D"+P.$*?!37BXR AZHV "4#Z>AY2F1V5QEDPEF MQ-%(Q5/!"+D\^C/*MCWZ:9N!*I9#Z[=N,":QRQS?D)<)OIYJ59IDT=VJ-#@* M7CQ^#TER$7CT0O*^JN.T[BD1QEQ=IB?8P>IJZX(^A[?0=+!R2DYM)TY-.!;N MPX]D[TM)"?!.,>20[(3SV-VFPZ")92@[^;HN>9RF3]C#6D5Y">ME5#&ZVC1, M%V*YR#GD*AW:# MDM\FKX]_]9)/ AHPG8V,VFCR3?0'*OO75% J/&S_=9VGP1'8D''B/*=PIJT:;Y(SH)K60O>"&MS=6IH_>L^PFL*2U#-,U_0"@-*)TV@B=HW>L>Q* M:."Z8Y#W#$C7H(9LWCF@O3M,UC8%C\KV,#*W^A?TKU&$,DCZ#3KT)].K4B2M MQS4DF.+!.-YDG["IX#H6J"#)5E!!=N3Z("O+OV(3^Q%%U%2Z1*D?QB2(,95M M*TG4Q7FI'&N\:X$7?_GXL"3YX*Z.Z_7$VL2Y?K5&PMT)\:IT2B M[=N@@Z7$A/43%#T^)?;UA\-NYR7HGS %N*O64>6&_F898,,-;9#7V/K+VM#4 MGVI0GXL/I0,HM@.E/-L:!R;4S+C?/2X>TRSQ_$S*0FU^;S6>U2#,JP[[X=Q9 M+)0QC94EU^5<+TOQ8T1_@D'9U]D[*8&QVMGU$A@<<"3H3'R"R:W$R!N&9F"Z MW]W7FO*T>+#.XV#^\OQ:0IY?CY%GH:R+'0HK[8:^QG\[[&I"4G)6Z<^FK:K* M',]:S7=TK[FCAW4GY/$5TLL/3L\0-&1:P4MUBG3O6C%,9A)E?HJP;14TC2@) MANC[&WG<[-D+)W@A8V)FK9O'TXY'YGT8IVD.=K WX"":GO 1J4=&N6L^8%>_ MQSGK%@\]KGKOW^;"!Y6YEAN.OU: M=:4U&-1\*-E9;&:L@"LS3G>NM,.3DZV9U[)QO'(K;OSCNY_5#F%U6Q@5"37) MU3UZVF:KS<>4^0(K9]^8E %[>5F3CX47_B6?D=.#0\IXN]7VWF,#3=4F-?EL MS\0GLO7NMAV>;:KWS/4WH6W)X@K);FM#X\5C%/-M!.P.:0 M1(C4F7L+-NB%_"/E8/$W)$XBJIEL(74JTYP=HB:7]C/J)QH)9VMH9'A^=JX0 M VU3+;_N1"NFT_/LR$7P3.XSI]=XCBX.:1;O)(N(R_9E]^Q:DBON*RKT4T M@_WW_%LG)S ZXA*Y"]Q)T$_N?!_'P2<4AN^3.#6M:]M]NTC5;'' @4OYC4O3 M@BF%I@[J#T0O/ZF1Y72JFDEV:CL\T:0MD4WF,IWLM+=\>\SK1KSZ&3!_U$Q! M^J/S%*0_SC\%Z8\]2?*&82RE[!M->7[C7)[?S%^>WTC(\QM+*65R*E>I0[L( M4&'-5$K9C-/)^EI?>8+4092$L^"W'FG]YWIK5WE>Q&XWX91 MAW^J#3HMDA;3273XD[M7#J[C9.=5I>Q!:92#AE7N*OEQ#! (8+5GS4"0J%$3 M.,733&?Y'C[#Z&#ZOJ(,18>93P*V>"9O_M=9I!1*B)$521D:M%:B4'];_U;3 MKOK6N5WU[?SMJF\E[*IO#=T\9>'E%F;U0X 6=4:;KJO3P4'.> ]8P0R$^,^- MC*^9J0^F7&652'\*G)ZM2;'(.A\C?YO'L>OT(M(Z=.H67^A%X<>5]1CJSG(@ M3)XS":NV?8F7<8'791EY=9&R2G'(3)*!J[AGJA'4,X<1U+.91U#/>@+M,3_" M[[A$Z3Y.O9!Z<6GU%C I6Q"3DNX'&-0/VTU?W6(T.]:S;\=RS'L+:?EPL2(O M!7R\N@2KNZM[^E2B2]O$%%*:^Z&1R1N!_EHU*G'2B02S[#P0BKESV)^Z9J MAU2"YG8+*'/YX#\!D3< L&CQ@SO[=U@(=95C\4#UTD%NXZCJ-]=$)"54"Q"2 M75DO@B''E^"]][@"3%%.FR8D][%C'SUJTJN0I# CNIL+O3O7(5)0,/] QP Q M!V:_($04("AJOHP:-O:&?8_EE& M]5/:AC$E0]$!L"38$CU;03-B@\(\)>:\!]*JH>.$;@49MQ(C)6=$%WIUK)HD MW;)M> SOU6;MO2RR+$&/AXP&&^-[N(\3NF'C!IEI@)KCRT5>KC'N!<=<+<37 M3FO<=UH=(=XXM)KKPNP,ZUF7+9>807_4&8U4EU9=$37>).(N9:I#B57/CQISBB>^DK-@>+H'K_V"/OW''GF+E]W4 MLLC97,C7;.HXA?;7ME ]1+G#W/$$5:CU/84X8.Z_HK]0(&P7LIBE\,@.!07 M&CN%NQR"0B":7ER@5Z5$[Q$IN/=0&:HJ*Z[G71<*QS V9"@Z>41JD"V%HE9= M"#D!D8)LVX])R0 MZSCSP@X@P1;W"39Q G ?T#4R]2#0!*G&1!F[6_@G*0.)U> M\<,;AOZFUX*(.)G 5N$M(RRY"#N:8%RI=-8LME:3".)FM8V93>TJK(W-_A;/ MPR2;,)N&0T>AYH)WU$,@2,HK)J1(8,>\<^L?]*7$\10Z@[2B/KLO.$X&*3,\ MN4T!UF5;MKR4<]0:!8ZFVAR81MU(6EE,1NFEFUXCJVHSK.4CG-K*0&0. M1'L#O(FCIS5,=LOH&:89V5#)0W2B".EHY25%TO;V*,,4-S$B>CK!!'8 U8W= MY]^H2+:I7:1G0G]+57-GZ:;N-#"27X'IU#QX6-U=.M>T( M&/3QJSY/QJ)]WVE&^[YS'NW[;O[1ON]ZQAQO&/KZJ%DN:IJ+.2P*UEU)!A,\ M\VRY.%_>+-?+JP?7<32!;%H6&&=LNMY:L=LQNE7*=V&V=Y/TPF)E(/.E42%N M#NDO(F%TD=C_[D)9749F?@#087??^8XB7X\ M+C0C5:S9&A?6;RR;*2+ZS>Z=!/,;#$BD_F1Q-_''>42?(:!>,+\[2"?5F%B< ML(HN77XV\SSJ'0_]54\NK/M^@K^8;O&:YF[.IR@R ^#O2^3#ZIXJ/9:.6\E? M#9/*M64]$>3,[&7\:1^SR. &8C$$:^]E>I=O@)B#!$8Q1[Q:044CD'DO//2Z M *^4*%M8'!Z];KZB LSIQM'W4=SI:QY#MLVS\2SS8AG02V&%W.-)%$!*?!TGE_'A,=LXGI3EI9I$W)R4S#NM*Y5[V$J@U%$ MR;X?+>"&YSBO?[RZ!Q>8DG(P\;E-FU#A]ZT-?ZFR?0FIV-)%Y"?=QBK)):H^T^W:2$=/D@'OP M0K]Q>A3.E$+[4*4[$,T7LJN-DA3.NTOPOS-X%WH^K<^>7ZN(DPX0>$^_2/9E M-_E6DBMNP?2R=5Z/9I^W!_NR@^(>#>[!9:*>HACK1V<4)DHN2 MH,@QD0(3HYGU8MI]'KBWJKR()--DY-,3AZDT S->R9TSLE$%L'-=] &E/@SQ M[,#X,%'0:8B:P]OJ+'Y$]YR5%+05&8Q"\/B01RC"HZ1G2"_E72J/\ MAI''I^,@P,YEAH.TZONW8%-\WBY3Y#;[:%"&34B)QZ[U>&'-Z*[N[/Q9=D_ON\!@B_V-6I/!P=8_YDA@J ME%W$>!3X>WW5S33$WMJB%.=&^YBD6\MG>A->AJ*#W4N"+5Z1J-OUXO;]\OSF M:C:')PI2;;_.(3<'NKJPCHQ?([Q=PAOT#(,N44O'*O(=9B!A#ZZF=-D1^P2)EX#=O&W?.Q^]^JPVY#]2.R6$V,-NXL-EN\L -SF9.8H;C'+B^QN80(] M\N&K,B28B-"'=7^F1F"[\7;",B*5/Q91\,%+?H49"8>0(^'L^ #]0Y+7;8J" M"YAD'HK(13L4/=D[WYV(31<>X52#X>6GKV[?GZRO[C^ Y>U/5P]KDOO9/4YV M=* \+?;:I] 3SKFV2YK3_0"S;1PT.)QJ%0V2LQ_L&V))(K9-7[4A[\" 1@>N M4W5D)=O$J-1<*,;L:.(9IV.E-[&&^K#Z1-8 ,QS0Y*W CC9K/H'D\*%Y2=%4 M.80R(Q^ICFHU>/U\BR9101T2#F);+#Y&P,:ACF&+JZ]7&&,==>.+\?K6%,DI M+#+671D>)R/>67,#F2')]:MMA!J&&94P;YJ8Q:>I\ MPY(5*CL/TQS(\B=K8JS2DHR$6LB%:"DCN-O&HN'"HL][2*C^"H3DZ7"T>&L^/N2AL+"6U5C'CX8%J6[JM3NG_+",_WDV;O"A+U;X=+,>8 M3(&FLB>0B\MMOK::E%M&LL*,Z+Z*UW]Z\7NIW8K5SO7;E]_/_^W+[WM[$F\8 MFD5Q:I/F9XB>MAGN%V]YWA.\ASL/1268B*E#(M'T%8%#E-U[&11>9.+ P" Y MN^@QQ[B$0BI)@((&J(CD&@I0,O12:$D(4$JNC.J)H%2!WO#LC[@7U5*Q@\R< M3;H92Y!W<:2HRB1G052+P"L605(M@I N AK4>D/*PZ9?N U.Z**"OWE+SII^ M\5@1M>;RN8,8'N8+9ZF2GQV.&4S*XC@H53;N'F9WH43W,%2Y6Z@^?? MU#B4N70U8Z *;EOI3(3!H#N+E",PSB40S^)-5,\"; ZD_AO889=D=]@5[MB^ M:/Q:=.D8;)J,XY?=3QNWKZBX]Z0J7N1JIKCWBWHB$@3=6V/3]G*Z3V'WWL%> M1$'W ?HZ(;@H@CSUHY:&F'/Y^*69(? ?R;S_>'4)KOYZ=W7[V$R?%[/ J0>>-Z+.L M>V95:&=9*W(2JL[R)8:OKY>:NV;S<;II7: 6)2;K6:S3+>>B%S6R\HC'V33/TC'MTFA\\&AZ<"RT:\Z:K;+?8BWKT4AA< MQ#MB^=*"(@M"Z8F^]GA^K#\I@NZ+3UX2K/;DPW1UR-(,FSXH>N*E25W$$'3$4<1A)WS88[/NQR3IY(^ MQ ':()\VN82IGR Z#.Q0TU3X*;:]J5AU<1M^NN'PRG>\[%&2%[D/R-V$_A:6 MQ>#K) #D+>0C2&'RC'Q( C[/B%AF3ITG"T#M+>4IQ:-Y4;LP+W[&UD7WF7*I M:.1 %PZN<0O8X>#X]D#-*>P4)[[IA -]CI*ND84(3ZO=NS%<8Q.HDW*P]< MZ\@=C9<*T^.F7/=R>VV>71+KC+NFM."NW;G=:H::7&H;O*]./8\%25T^<,):*4'-O8]@HP@:)J%8P6@HY5W=E> MK@IC\H[8DG;^&_'R)(@#J!4Z!"S>9=,;.LF_<7""6R!KY^ MI7Z"!LHDG095L:A>FS%@GS'8LN!5L*C:W3U,LV_-\Q"L-G>AJ,DP:,@+X0G, M^&G$-/N648(NU]DHSB=Q55[#KWXMRUZ;&DX+)4;9F>AVN_@RLR MKC_!GHO)_(2*G#$?H.[1]J&:$G?CS?>J*T?U4_1EK&1CMV?,T<6;@@ER\5(R M.=IT_6L7(WB%%V\TAJEFY9_G-PZ:FP"(&W<3Z,7TF@G@T8JQE]#/@[=?G^71 M6\LZ3@,"KV[]1#D&95V"(Z XFR/>!ZROMV]VC07YST,,2-XO:99VKN$,-F-[+'8KU37> M4JD\;8:LE]$8S;+4^V6T/7A/E&%^A^PVCN!N'\9'2$KH)1!\@!Z!40 H"P#O M,R2@1%L HE3!M8<2\),7'FB7Y(_%6]/+*,V2@_M+TL;0R'O1G%QK\#GDS,G>MF\86S/_3NVCM/-0P C*\^(/N=-N_ M 5VLR_=Y5#BZ@PF*@_=)G,[FXK. 0Q?&V 3C& P2=S>G&5SOM \(Q>9!V;= MN,LK6SC#_%A&%\;X#5W&)3*B@MD02ZD23Z+XN&U%;Y#S&1:\,#%WYO@@D\N8+-1S7SOH M^-I=Q#OW* :ER?,;Q!-D &<\QV0$VH:ZG*/;JP@[OM7$P)YK\$F*6-5U[0!1 M(U*S>'I*X!,&]Q)WC*(4^Y19 M05X5CB0F8TS.Q9C]O-RR7Z4YK,:\JTP+:R/4M(K[.4ZOT2[6 K)1TUA=5B8R M_OIVT:AT/U%W;HL&"#@;9R,SB8&-!]04C,R ML7)K'%%>Y0>5DYZ2MVG,5?7Q&+9T1CY3S3@$E1&GX_U9UGV7<>S9SD\P)9R3 ME,@]]/$_US'Y52-!,C^GG=EQN33;U@K_V!Z9]*EZWF$O&=CQ+2Q7^#5Y+JHD MJ@ETOX7#>)4ALD[HK^-D Q'!'[V,Y?HUWO\A8#N=+!0YFLDYA2:G'8SU/&*G MPQT7OF'O4>Y?JW&^%.QJ$*E@YV>XAPV-6RKWK!V1?]O$]!4+T[^A>@8<-?/8 M)HLY-%A4N^LXIG^G%4]5.#40;IW1]F$*%ZK!!>[,:MX[X<3JM*<I_U,)D" M<\I16X'[W0OASB2"*X5+U3D;%> :.9S%M\\>USDV= M5M&SYL4!R>-X3E/+A_!L+F3/3@8NC;DJ6L>61J]2'6/,AAS=E@M=]'\FA0JI MCF93;[KD2"\I\^W\;FX(!2=5;:XU)4:*-',OA6@A2M";2UCQV1H5.&=!S#G( MA@6J?#]H#-Q,WWXM6$S;?J\45BVQ8GF/M3,JU<#+6_%]$R4[8RB8E,RDMU>]V;5S)5F2WW[?FWI[CUY2N>]MR=IW'-M MQ;Y=Y=WIQ&KJQG8/D7ELR(=KZG3#.3TRP),)+V+3'KB9PH&MO;4B4+Y=,-Z\ M8G0YFS!.GS==4ZOJ:4[^MJ1HI:PNSE1-%.@Q9'6=N4UV83 TSL":$[@$0I,W MI\XT%9FI'+$"U8>DOM<]LUQC%H>OL?PC8QRJNT"WP+.3*8\\B;9:-V: M,5[);#*XU+T.3G&:N7@;LKZ%<;=54-I7;A?7Z7<.KJR(075X"?.$YNWHRB!@ M"):#DVG$^67E(&H]Q2?3G[-'^228DW>:[UX&Q-$V=FD96# MHF;7,W.(F$R.C$(/WJ^9G>EOE\-?XMG%>>9:TSL,\HRUIC M^":RK(>OU'U&F:@CUHZ%3%1=!'Q&&=::4\"\3%H^W]>\(H07]^XSS+#^+'$] MZ5L(HV_ 2H5XG,= ]=([]$#=(DT/ MNYP_T=N+O)Q5[=YMIZ'J,BKQ?.)YZ/F_GN#?8#92\(!V^Q!M$%Y7'V"VC0.P MB1/Z'B*19?Y$+VYT"S]51;B6F+C+!+W1&*DS2D=-\XB'=K779N4X-UB[1^FO MUPDDJQ!B*&;W>$7.93N4YG>&SP.-'1-G+9)/3S;X6X"*CT&"OYZ%YV<#DD;V M*"49V"X@QF*NW$1_BD/<38BRX]R7*8?CUU.$4GY0_%?JZ:5F;/3E M3 (4>[^'*<2#V.+N+^$S#.,]V:8F1)B8H'4=/,O(CW=P[;U_D^: M(1]#&-O=V*>+1(=U!KTE/6Z<)+.-XUG"^;F)TQ3DW8*\7^P/O;2>+7'KU8R" M#MMWT9]+ TN!^$=Q1&I)EHQ@XH72/L*@MT1LAO$(9Q%^DI-B$W(2 ]>MG%XN8FH@3PVI 6(.("7FB .I2O$13#WV M=9P+4,G)L0DJB:'K@HIV2;1C K>X3^QBY= EEA.F-(4++J#FQ/OF\\,!U3K. MO-"Y:STLM)Y7/3!2(V=*FPWTLZI[W#4YTR;A\2U?%X!(O]/CR2V#@Y&'K(O.R Y7QLVH;WG=0LM^= V@#C M'/7HS;JNOJU7W2++$O1XR&C?\9U'S(9)@D]<8@[0+N:(@V?JQ3_F7CS*89G- MP(N7$V4_&"4<_3A<$?2VD,NQ0Q?9-0Q(@+5:[RWT3Q4#-<*;_2Q9H_SS8JP5 MKDLS%?BEDO8RJIO32C?7BX"FS9(/WIW]WUDL!\,(9(9RC8E!,RE69LNPN\), M<&1_71G@FFW,"_--(BC:^FZ.A:>$2W69:8K)-7#, MW&;@8DOR0I=1&=7!'RS2%&9I==N,9)9](D64[!AB*@S9CM",9YD7;*8]X/V! M)D#GWK%7MG$=(C2'' D#2G4N]1<$.8./\?J*#C!8[6%2.-%E%P@[Q''=;(-13C4N MG 8XE5B5B&T^H*<(;9!/+JBT#[:K8Y].MH?3R*467MA!2_69U*J#UR?SF-)2 M*5)V.K^U112*.9$Y-?1HBQ_DAPW<4)N M+Z6&=9J D/5S02XKO!*<, ,A"5/[C8_=)GX/BJUU/"@>\ B3KPM)/%,3I2JT M2#A,4&CR(3I!!D%?S7SIU"P3R(J5CM ;J-8F\S&B/\&@5%;O3J6V%U8[NZ$< M!@<<>3L+N @FM]HU>,/0+%_40$?#)"G[EI/M4!]6"XD/,"-C0X1UNQ\<5K25 M% W+GN".7-N18G?^/HZ#3R@D-S^6488G%)$B6U3+='^>;AO1Y,?MGJ/'-/?( M/7HZ"=$S.7VDWP$O02G)$B%P I[_CP/^D=Y>=WO]WQB*.!OL: M/$R$>28I)S$O 4/RME1#W7[I^%1<1I@LZ'$G0%O?WL/0RTC]B20[KA,O2K$* M)^MW^CMP*I1=@$Z!/]X=X*N;Q?KJ$MPM[M>_@/7]XO9A<;%>KFX?P.+V$IPO M;A:W%\W+Y*/B6G 5\W:3KZPG4D9I2IEYTGQJQB/O;JTVZRVDO4OAJM?( M*GRZU'DA*?H9P0A)'MN3+]W%,'G37+_KPAJ4GD@I6(AJVJ+]SRC;XB[?)_%A M+R5:;F.[H04>&]P:%/7GX!,JJOS0%@[=S2%!5,(7CG9T%>6F\B@>IS*WF7 Z MM(L6%=84]Y0C:&[V+E_0TQ'HP%8BF"'=X-P![NX$O+" MBWL=8!XC2 H4[?-F/S@S0*1D4L>\!L>L#XUU/ X8W/:62[,+6!&@(HOYF' ! MBB%I-"$A'.Z88JV57OK)2Q!10V7EYJLHR\_R)\\@&:;LMCC(('\26]K"]TE" M9TKNPT'T3)]8[#X5*\L6[[V6$EU) MW<$)7]/US]Y2,&'+CZB<#.[?V+(9&U-FSA4'43>LX/*8I@FF*H/J+\4F[]7L R M(#=.-]2!+Y+V27)50I^=;&;=D7>#8%"8N8T_4%O8,/YL<&PLE/U]CN.(/L,9 MB)!L85A\MRPY8(.A+,Q-3^=CT@#X1=7#1M*2TP5C$:W-I6=+-B."M499]/8H M\\(;B"VJU6.(GJ:XZVJ!89-&O*.%S!P8+R^6?/5Y+E4A("=;J?S)U_8H3/+' MS@2>\3+E,/SZERE[8"J7+]RD/]E'Y51K52"!6:S5_JY?1HSOO"/I8\;+=ICW MS\Y<[@QPZ#QCGW_F^/#""5[MF("-VQ6I'#S5#1U>6HK M%E<3*H*!:D*EJI)V'2>7\>$QVQS";J+"1(DL"I3=['L*'/(,P;('L(D3X&.; M!N4E5QS'8#2DWM)8BA.CO0'>)?$>)MGQ#L]JAO?8*VP8T@<]*35L^!UV!WJF M>PGW"?31%/%(/1[<(%:+5V[4,$U_ %[=!@2-1JZWUU'(:&)9?\JT47V-[<0, MWI!"!=T[^ UZBUV<9.B?4T!:@P[CR<%;G4QK+7J.14U6L#X8FBC5G2JOV M46U\Q)LPCIXRF&#/YQFF-*%!*J5ZH NK8)-@2(BJNJG39&DYJ509TA(#UBFM M3J9DF;\ 42;V2P&"U3$652\2A&\QK8U,H\167B^G1,^I>12EY80#5U?8:^] MEPL:A6B62YW\"0=9J@Z."R59XR#NI_F]PJ HX:8F4YD+C0,VBFOZ;L,GB!Z. M:09W:^AOHSB,GXB*C)ZV'KJ(;[+@ R3@E])5*OW9O+NARISHP0_< \B[ '4? MX$W9RQ?@(O[R+>?X[B#QCHOA?6 M5&Y0NCWD-.@W^<\*4-3KV3HHM=CDQ;?)=P!W=E+TU@)HWD$3GF_^\/OOWKT[ M_7/>+O\[_=79G[_H8]>%'S4*'O7]8^TY-HMI7:VJU*'=\BXJK&FA5DJMS@F9 M,JI5>=8TZ\50.G7O'Q\6-=8_/J@B<*@CN_46)#@2 JX!,MR8JQ4_/@@THA/0 M2^@O MV$3G@2XE$=95]Z1G1M<'+O?<#X=_H.B)HOA'Z(79MB94*\S\(R6XZ?9N'8*: MC')AF?<'\F\+!9AWV00G;^/-F_$W7_OP'0F3!J3'S+0NS!?1WD,EZ9R>[R7P M@Q=Y>6 \O_J>'D*2$JSNHNCV;AGFVHQRC4G<7]--J?L$=:"O67ZP;?2( M9K\"!G>0.F=I>6>UJL0]YK]2%CV_#ZN>[ S VAH[*2X8;V)YEV(HGENH#(H MN YJQ/.BY[+FW=S$3RC-D)_JJ U&8[M.*8^- ;A4#=@*Q TF^)+H@($S7$V? M,N_SQVL=^3=;6;9@>@P,B/S':\YFX4;8C/GN2+D[-&W+((Z#1R^%.K8!NZEM M23.YX(F[^%AD'UB7N% "M=CYXQQG%5[]I\[:;K9RLK8;# RL[:O_G-7:9LQW M9VUWAS9.OLMH$R<[F@^A(VAF

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

HGBU MA?$7^5'395/3UP>E/(>UJX&J \HJR9P'$SBZGRM_*I]E1975J&.3B.>Z,.;! M1(RJ@JY*,N7!A(H<%^6K]3?6M: 8_DSDA3GWD.W92NQ#!\*H!Q,MJC(**\F\ M!Q0P6LF*@WZ&\XFLDZ^R*C_1=.:).CW35,-:F(#T--9479CW@&)'U45A%9EW M=#!A)%]-RY4Z.9BRX='!1(WVAZ!*,M[!!(D87CWC")#+?G4XH=O1P82'JH&L M2C+DP02&&$*_:$^*82H3(XVPK0L?'DPT:*\XJB3['4P(B*'V\V4R3NO"=0<3 MVMD':BK); <3LKG4M.FC;)"4;D5=..Y@XC%[PT\5V6Y\8,&6B_\<#,>-#RS, MLEO45)+9#BS \13)=GPP,(J%Q-MN23ZA(1^ M/""&/+ @2R4P5DG6/)B0RZ?[J^O/O]BM[)^N[J\/I 5K?#"1ESUBJ)*L=S ! MF,^6_(=FW<^)^G1IF99.3HGRIZ(^A8JE#B8?/SZ8T$P%,5=%5A4[&+4Y#)1_ MLF05?N5AV$;Y8;&HV!$;C+T-UI1JB>AJCL<)\N3X2.H7RI/=6J+J3E:?B(>> MKXJJ+*WEVS9>Q4[O(' IOS:X%#O]W>-RNYL+[9-,=W.A+Q5R]ZAA7#MJV,3K#G;=7[]QJ3PNR(EA$-,X73-[ MGFXZ]4EH2X>O6#JY5%[Q/\C=N*MCA0<]E!9/4:QG(&V+Y$)#-05037T#=-E1 M^E4S-?T[F2N3!=FA>BX9@_4,JNT[05PN4J0]A,.VN(+." L7"KZ"^H:,J!#A MKP'#$ES?7]+X>YG/@WU\? 7Z<]O#VMC,7R>_--9_-O\T;PG__YGV/WK59Q\,3O_ MN;R4[G_Y\?GU].R/SO/T7I?_^>.?K^KRY.FF\\^YWKLAWWZ]5D_4R^]F[W0F M7YQ\'RB_O^J]\>SBZX_2U_.;.^/7J?SK^7^^W/]B?I'F_RTJO^F]WI>O%ZOO MZORWS[=__O@?X^OK_--_+DY^->3_[MR>WIMWAFH]+,CSV?QR_=5:C<;CAX?! M/[U?_O/X27LQOUN_/C_T5TOUOW_OB/]]UG_Z?7#Q^X_?.I_^_GOV]^+L7/UZ M+Q/MQ7@8?_[>&W7._EC_>G%E7"O#/VY??OV/^?VL.W[Z??C[ZVJMRW^N9_\] M/;TE_SR?K:=GGS^-Q6OE[-.GGO[G]/.WLZ?GI]/?E+_^>_GO@7%O+3Y?=9]N M_GN^_NO+4!S^T9]\-I=_/GX?_?;[KT^=7_[^6^U_6OXV[AGZ]^^7OPY^'9R3 M?W_KF]>+T2]?OY]HW^_^N/[QG^']R__\/^'L_N[HZ..^!5I]8WYOD9MK&"^0 MZAM'C*$PUCN5GL;RA*XJ2F4E"Z3ZQAH;ZMCH7:2=[> MH=-6_<*\*6@K_*53^D6,P;.&TYOIV(=.5"6["\'3]L%Z1PM*+]9&RW?H& M#M,C,U-BL4:XJV](+CWN[K69^8*K3@X';?4-C=V1!:C[Z2V8"FM?M9UQNO;_ MQ8>]._),5(L8#W-%IW]44C!@_IC9#>!"Q@TX)P#7LX)ONV<'#D;0[%^>*P:B M1@$(I_97X3!OO'R\6]^86D.>AQ^QZ=8W+)>;/'U_3D.@;Y5$*R-!ZQM4;$CT MC4C1^H9##X(.*B.JZAMD/0@ZJ(H\Z-4W"%M7.O %&4)-2D4$&7KU#=(> $)+ MB!KU]A"HW5K'#:O0K]>K;Y@T4P^-RPYVQ/0<3/.%EB9A41NA5M_(:9TQ688T MJU^0D8TQG9.IM2 W,TQ8F.NOQ)QK@-!G8ICXR.AO";F6E_Y\QLGT658G9/I% MF9&'.6BI%;%P52:=?.O_XPY[& -B&^S1?F:Q3;\D]@L5VWL(]&W))?TCJ5_4(PAXO'WA)$<[^^P9/,Z-U"&->'7>M;Y%9_?);!GWN(Z&QS!2)& MPB2IT"O80RAD:[_2?PFI_4K_EXKP*_OU##U4:LM#97!9OV*@*@S7J28NZQ?L MJ'K/=L"JZL#_%;KZJ+^' ,9V6A@,2[%80V0/;OZVW!ZXA+3<'OA2$=P^J,,$ MKG ZLWLD#K*F,P-?*N3F]N"<;L%VXA@HYT@L-+HVJ*\_5U55X2=UAK*,*: P MG@LA]?IF[K/A^?2-X[E^>?TJF/'!((M4M)!M_.0*(J5^#F^=-%\89:GK<:6B M)>);<8;WH_FJ@^?Z%0'4BI\KX^[6MQZ@%GBNBG,^K%U8HXN7D'7M<.A+A=Q< M?7/N5>60H"G:+3BI/JQ?$*8*3ELUF:\."?6PP.\=28U >9;=C0EPHA]3H4Y%?SYMZ*-[\_#AGEZ:8?%:U&&V^^ MW!*&L<]=*T1UU2%_'[R"4<%F_*B^I>Q5I=F ;.K02JE1-MD4^E(1LFG4^-=E M1Y3[1V)V5\[_I4+P7+LY 96YN;=2;; W*RW0V+&W>1"C^E4;U K/59EI-&KB M$F7C>9 /SYUQH7BN7TT$;:1V<'P_(:H,1_:"TLYO+C6=3&0C>=[\H1)8]O(T M]J6"!4E]PS=9V@>=[["N?4U/V2]X"&07=+&[!4<91O4-"S7T4X%VUU%]BT<: M^JEO+W0W?1Q_>J(&C&SE74MN?*B".MH7-^P;4,_.:VC;O::CF[1 M8JL.A5]1!9^C2J)?<,G<> ]QV2UEEO\*"I%9]0M9-C*K2O331"3?&/T4&U$: MUS/I-UD'XC%O]#OE:1[:!V'_;3^X*GQXX?AM1/_8\$)%)0ZS)VWN.$Q6 M+YI\I$Y]HWA515C8JLZSR:OHJA:I4X>Q0.&;&Q]U,@Z>"WVID)NK0\5,H,VM6QE=Y9(1=9\2)WZ1GCJ@K"".6P/ M(94"E(J4O4[ _Z5"E$K-YL 67^$E=>KKHU>5VZ-)GQRIBX)+8B2Q#N-=@L5H MHV)''DMBCPUNN"ETQ(HGU MS5-7%6'1*6HY_*I>L6-P);$.9'WZL%Z1H$B](X:I*Q.33*F\_:8JIG%W_VU?F:#BFP$EJ;ZI MVC--G<"W=1F+@.X4XZ_3]2E1)_.EK/_E*P*Z6*X6VIJ0I *@$I5BGHJ.HAMC M)*G&3G0],%V1%BA)JF]V-R6FKS4U-;(+%<;5Y.SZQAMJA>_*\'=]XPZ?,-)) M"'JSEA&TM>[GLDY.90/+>-?XBA,,BSY1I]=!_EL7[/6-7^1$/# ^28G[-\#W M]2T+J+J<+[=HOEO?HOD:(:X$[[A;O^J$RBTEJ8J5W*UO="ISX]/MW=F^9NQ5 M0U5VZQO6NE(GVI*X^9XOVH3*WG +JTET8ICLPXUIU*UO<(NA\$%^/;',N:8K M#2,'$%N_6%9@&NLGHCWI\FJN3.0%P^M$L\">6O_T[?[-XK1^\:K*XK0RUE7] M8E().#7,E?[3]1\Q6O70V;1^T::JHK0R7%J_"%(:E)Y?O%TN[=4OME15E%:% M2WOUBSHE1"I\'LTEN*USZ8%,YJJVT)X48H #E'(2TP%S_6)6Z5%\LH+WJNLT+O"!H[E?OSA6>C3?::_DLP9/4Y]2H/K0,7W(X:US M_6RN*\89".ZG/Y(D]\%CNGY1K?28/KN[MUDZ303ST#%=WUA7,J;_K0=9F4\7QK?@]E>C&7%E=8,AD!=R?I@;VT FBOM&Q6(+@?2B=Z58 M")L+/O=B1Y9;--^O;Y2MH:!*5._WZQO(JR,%[+":JW\N24*'\" M5O=7]EF5"K+!@0:D*X3JJF2O!@<:.::H_OW;5%.?SO=45E89;C[0N&X%4%P9 M+JYOU!77DY*_+7C Q3/\3W0R=>@#^RL_&>;!]/!(&A:*Z?J%1@/M<_<3HLIP M9&]FE_.;2TTG$]E(1'!V$@N-/*=RXT8E5^I4>5:FEKQ(15.9B+JB.RR"'L+X M2!H7Z2$,ZQMQK8\4 J3U,TLA_Y?R22%+56PTJ^MW0;"71#8LG7Q4#*TGB<.? MSIRY$]Z?&'C.;_%9D>=:QO2=>XP-3_YV?Y[OR;=8MB;KQ'CW,?@&*@%(Z,KQ MF]?6DNBRJ3GLEQ6F &$'AAYV3E1M:6BVG_=\$(;Y?08_%L(OS+T6#_"W7,G MW)WOUJ)HB84H_KE 127B9 ,%'@A.5O#T=Q\WX@/_S#U]\*$_*J\_ =2:I4^( MP7Z<$WE*]0U\%(#YZ/SOHS9=?X3?SOO_WUS$CR M$T-X.(9[:W>))OI6/_ZP?W;XM[B\^OODZ,^U3A@D[T2M.DC$E=>7L3B5-^(B[-N!I7ZP MQ*6,O,X:?4B?GIOO$ODSV;1]KQN\$Y'7[27OQ:)-O1=].^IZ]"%>K:Y]_+#_ M\>AGSVM[B=C=K=0_O-VG89^/=7COUO\(VO'@_0,V2,/]NG>Z]_GHZ]'IU1]1 M_-\T?'\I#H\O#[Y=7AZ?G8J]TT/ZS][)WY?'E^+LD_AT?+IW>G"\=R(.SDX/ MCZ_HG7()+UT<77X[N>)WSLZ/+O;PY%(\\/QIN(8$#]WNGC@;R,A.O* K+F2< M^DF\W(OW7A3Y]C]IG'B=H?[1"UR)1JN5+2^@Z1U_O.K)R%@; #E_YC^\/8BT78$6$:B8X7V('CV;YPPL#U$GZ/G_X[#:1H5"U1K]8; M_&VDB,6?*@J&04P"%(FD)T7L_11]FF O%I(&Y7(#Y=)("\4VZR+NA:GOBK:D MEFU7)&%74D.1N/&2'@\.0Y)!3&UY04*$Z>.7./0]UT[HQWSL<4(_](D0L1ZH MSR\$84)$]@+'3VE Y9+T8WE#/4CZC<9,5.AX/HB$C]"AG1()Z,/;NS&-HB5\ MN1<$*;UQ(0=AE @BXJ/E;Y;)"S."D$:V)5-,Z^NGT[* KQ4'8[WMJ3=?_\%T6Y:.#/R+^:P.]?[6' MHM;2E%]'@_H][BL;F_FD4BX1VXBI7$.T2&Q/+?2-';F;?AC^P#L%:B0].R&J M=WSI)&KETBBB)V+@VP%QM226[=N)GD=;^I[LJ+^]X#KTKXD#O/@'_U(NI8$C M(W2)B5?$&=;%24!=PX!]FIWK=3I$/[0:T=KX0]&)PCZ-)(RE&;Y:GH1G-FOL M%?&)6@\C/0F'6=*QTYAX-V063"*OG2:2^%/$J=/3/4L:9<8&$]W2%,,;GN!< MGKN=>9@B(8N%^BZ^,X]4/KP]?CCM]EZT;>='-PK3P-UT0C^,WHF;'DG-(ZB] MF3V1%C^F=0G=U($2>E#U_9037%BO'P<"*DVIBAM)_-6U W!D$I& L=HF-B%6 M:J>Q%\@XQK-VZA$OV\3#_4$D>Z1)/9*T_?J^D#2Q?E]&CH2$)AVP&[.539)" M+"S8"I"98"-)8I?8*75$O'D3R AL+V()89"[LR/.'Y1*_3=]# MJZ=]N^UK6>G0Q'JJ05K>ON[@IA?2"[;/XJQDG[2#!2I(GR67)M%'SSE=8A&P M-;SQ7,F]WRB!=\*(1)JMB$<+A-GO0UBIV[\\<((XCDE#NDS1?]ND!:(AK7&M M"AN\%YS;CMCWPLVOTO4#62_TV]2/)J9SJ>R*:-IZ*JI:VF^?5&CO^2QN._*#33']C!T#PJE_0S M#.5@])DH6&Q>0_,[UCMOTOS*@XUGK;M%4CV#Z_20RB4V1L3&<=J.211)<&3\ M[C=CA[6/%X2JB)\/Y369WP&;]^?@P&>%_WL.L;"R"/$#&_Z[#,/0X'D&0.;R MC$ = +:VF.72B#:V14!]9MP^M(SD7$FG%Y#1[P[%<>!4,GRM'F<0&UB0S)*$ MGH:LAIE'J46*43^D'N8V4[#ETAF!.]F.6-$KZ-^P8-!MAS6/*SX?7YZ*]2__ MNR%.CK\>7QT=9D/ $S, R'2"H;)=(%\E38R'%Z9)9A[9XOD\+F-%RR5E;@$H M8>IA.!1&=KVNE]B^I9RM0"; %Y@>\>S)",8)9OI0!E5>D&Y MD30NB8;($,=84C:N7Z.*^&*'9+'$_Z46$XBZ#DC_;1X]1# '" MD;5#PN[XATLD8K!>$5<$I4EOY=PN;F@M".Q TX$H7D!_T"BO9>:!:2W+L#L" M!6@9O3[H(?FY@2O.$)U!'Q: 4N[R/IR=_"V42I%E=Z:P;+G$PB'JXB@C%LD. M6/20'''RNV!JE>@5758M<=E'.6]GK/)_:46,OR8\++-AR,TDW,R816U[9PC2;61WNO96.ZMVANC/;!BM/I$$^<'?KL(?TKQ)?39XQA1\GA2 MU+!N#B2@Y]VER-'7V,G(31IRB MYT"S&4@905SPOX9C!_:09T?,W(WL/M2J5 0Z#FC&].12)HG/H1):Q.0&$UN_ M($NTP9VW)2EO$@):,.5@R #^5;F4!\T\:LA+4A4LI#>TW-"TXB1W$,U(U!0# MA,H\/8(X&X&BF@Y>QZ(PT1MR%G7?H@^+1X(4TX>CS4ZV"!&'18!@0MQ<[10Y MY$3N@2SD] 6)I4C2T\;>;GN^EPQ50(B_4V;1=M0D85YH-,:_V5M5T:=Z!^04XI^9MQ..PPDKJ;<>1@\*[, '$*%9$5\=)SQ. MO2+IH%QJUL6,U<@U1QAU[<#[1X=T2=GH4:!7ZGX6W<<6)%/$I*(+3$$>N)ZV MF1[8V00$/#+M T(0P_'(A&E-N6"D(T%UQ UB:??9B3/<.T)]#N,E]@^V ;#; MK,01SC/Z& %)L(KVY>/QKFRGYY'4*"Z,I.UO)J2S1O@0Z".;"72 _B<'OED, M8E+H@@RD\X/(JP?*V(LP&'76A8OIIHYTBZ,7'19KEO* N ./'1M!"O !S AH M5)SN"\,B69__L[DI/GG2=]^)0O:*'*\% YA36W[<5C4 MHU!%I N+VJ6 H,HE9895[)]TH^_],Z;R,DV3FQQ(XVB0LVA-M90K!5DIT0K4$W8OON'O_8BX=H)F?708\!H$"6-(*5_ MFK'$PQBQ34OKWBYI'<^,D504O\-V@+=3%'2DZ;L(FRJO4[XYB[BPZ=[N Y. 5P:VYZZPD_ =8NZH[80;J<;9=:EXOR+7&V18&^T/'3N (,H# !BB0"W5T M:5_;06#WQ E!E%C\1<"5='2Y5-RDO3SY2YQ'X7_(F)-,1,8LR,2*@<,%XG8B<@/-)O:KDRD0K.9/U!D[H/#/;&O'^3.-N]1>JQF M.V+=VYBR^Y6'9DE:3KRXE])K^5:8$57UH7I>=.;S8*_VS$D8U5N6..@1=UO4 M+W<\H.\+<>!OEWOBX S=7!V.=5,NTDE;#QYJ*O,-+HWZ@1]E^R)".2 Y9R2/' M:J,-U O")-.Y19_3%NPFT)^!0G8F".GU,5D8D4X*G63AJP+=\!["_8CLVP8_ M!IZOXBF>SQO8Z(_4FC^LE$LD]+:K0O5W6'M;46O*ZNO%)V;Z8<>V-\*[E\R@ M]E1YS;X88=_SBP/1\[J]32QMMOR8 -$7^!3S)7*'V=(C? +31+)%2ZI9S4:\ MU5'$G\$:8C9G$ ;.6$/+F")[-DET&(2CA%=!-(=X@"%A/++.A< $4 MI6H\I.6<=W+F$+3K*4;P?#85/& [FG%!@S30 MIPO+I?Q;@S;Y"<0B+^",8^&HZ<*\,/>H M;796EYU"+^"H,D+IB3%'[&]J[N#35@6[A#4'V/O)1[/($EQ\W6\V*EOP=GW> MM?MV^:]6I6K^3?89+7-P,M7P8K)I($+E9'A*BZI6MV>V2G9I;_+T,<\(EI>\ M'J)CVD_5^5Y7(O*2Z(9;S9U*8Z3EG=U*,V]:?+4#7#M,U$L'4QT5[2(VW>[0A'6#^M8WLD!,&.<)2.AR?!2#8S/5"W\5& M XV<.H#CYV?[.(AD?>\A\,&'#YEXAK.O/4,3/8\XP2$+M?W$X$%MKN>Q-]X+ MS4[7C7@*K,',MH?:Z4247!U8TWS,D2R];3^V)&K]#*ZAJ7;(!,:,9K!I1_S3 MAK9B%1HI;SE4:E1V.B2O%E29^J&P(FI4;3"&@\!>)_41/2"\@+.WO+67Q0"Y M0[4U%,/2%8^'/'Z\_IDM7BSS:P13A*E<&I-D;$>CRH*QU!*O MHFOQE'?C<>O)?-:WAWSJ(/43G'%$/WZ'SBY5<.2]^,OV4SQ^JNTJ-7,-U18A0''&#BOR MT0VKZI11\<94D1J&#N_%U7! T]V#,#GOQ:G=EXI6IR$H4!_9MS)?X_WB1W^PZRTS5$WF(3^6.3C=:1ZSN$> NA$#*I0QU$DHA"Z'"DM!NZ@)$ MSQL(LWL0FUL\?!1C\Y:0:(+]AEEQT7)I/#"JW#6<;,SN,^3A/'Q\+D-2UIG] MO)"#M.V3KN:(!9G'D2[.+\PE,1BK+'A(KXU=!%.!$8PZ(D<3D0MC6Q0]U+T- M]CP+T5S1E^HEG,'$K2R^A"(S*\BN*XY5D3>9H=(,&H%0%K]@S*&5]=#.R*+G MV2/P&$8<^\M!@+D>AOC4A/^EC]'K[V_SOXH'F(J7"VX8WLBO"R;L MU\=I'RSZ#V(*$(CY]T410PWYYHN^GI&=JLF/%]]Z0_2^ZSCSDNB4^WJVNIT7 M\>T\Y;WE[JV9HSY'IB:517@#"7=!7T/2$V5=T]'H4GUL<" FF@4+>D^+Z":]=QQO7?P:_AK;X@]7%Z8#0N=\WMO,1-GW-6.RKPZ+=-J\D;CU MC[=\-Y_8U>''>2^^)TCA A[GX $(:^3[O+N#,]#A],^UUMJ<%J=AJ]O!W*<9 M : /^QNRQK\6S/P[(XI)E?$&S/T@ MP-NKBSN+VN]'0MP.>D$< UC[@J:[?BB52&R\3GHI%<$#DV?MX\77_;MUNO2C MNW4,<][_U<_OL_1YV[7MC#[3B+%^#'P=IC'?1%9;.!;!7[[B / [R,Q;O''' M\4S; (^Z[?5ZM6G5&SM6?6MK8PI$U(ATJ_YFJE1_3SY#)K6;J/U.O[?BH/>/( L M?E>'428F.,.&'N"J&&F(:(8 WL7TCOJE,^WHXA2^6TOS"3_#0B\ZE-^/#NM- MJ]K8O3<9%H,XKQ18:@K\JBP\A$): !S<@O'46#Y'81SCF'W'2^9#L"G(:!YE M%Z?;;2T^UG!V=K=?AW+_17I,LSK96YX!$_'F(.9L/X],B5M??-)U>1W-@X[F ML;7O>.]YO 7_(H +(W>I$V]@>T==PRIR^&.3;;W9F@BNS3'8CS:,EE7=KB[# M0+:L5G4!1?SH ZE9]5JML@!)GE('3V7@SS) $A&5J=?M>X''IZ^P9?AD7+QC MU5K+L&KK#>*?G:5@Y/JVM55;!MEN-%J5"5_AV1#Q0BQ](6-I1[B:SN=@\FNI M3\702P:3U^M6H[H,O+0T UD*B+R0=W<"YTX=FB^.WC:1ALYF>5D &S+U5VH5>O[W4T]QO-LX/D M8Y.V0S,QWT1[?)VS@)P_@>:K+@#_G@(0[RS!,'9V6Y4%QK%,:/A3&!'&"+#- MK)*YQ2P_,[H0! M#Z;-V=_:CZZP:Y.[PDN_B?54FG(1TCR^C"VWPA[;-Y_"Z6=\ET9YA2,8Q#3^ M\LX2K,JYFOJ$M_)*@I='@E4Z69/'7J=FL!'J]K>)<27VSR?8*MNUJHUEP%D( MS6XMATU$:+;:7(*1-'9J3[55]HNV&1$MP[3$QH$LG!U[N;IG573P]OW/=KZ2 M8&5(\((L\8NRNLW64FS-DM5MUI>!)K"ZSWS0:@$>GFF(<];.DWR,XC\ M#46$^?LJIO7&KK4]>:$]+PD$M1JULZD3GUQ5GJ]OCNYH;@X M'RR3D3[56S./;P1WK)W:,IB>]>V:U:PNQ4CJ=6MK=QF 0;-566!_36J\YHO/&M1H794'IEF)B[ML(T;S7:M)7G./\LEO5ZWMUJVLO**3)SC4VKE5FZWFY)O;E5L3C,V8^;CZ>LN) M%S\B!Z/Z_]^D'"-G^;V<5[*BK@J81%PB1PV)WB^79M>X6+'U>F(OU4N=2[7 MEY$O^"RE10\3SJ.KV'Q\"Z%<*KIYG-A3K1UJQE1V1TO&[-2L:K6ZL7!%G#Q[ M=B1U603#0WH\:C@H<:BJX? *F%50VGT7DCLS!*[*:1DQ52X2*M.H,P*D6@V.Q0VM$R)/U] M/+5GDCN]#/5WQA4R1M-9,4=P5;!I 8]Q2:B.2,+6UO9=) $9S)WB\H1US0T'@T[<^J M\V^79SO@V=Y%B^_L,J\RW];JS4?@6Z'9ME(NJ251TT0!A=I.I?YFP=Y>4'&: MQFL=FM$Z-(W7.C3/Q:[[4*5Y9JJC+$$$%.IJU IE:W%;FJ)5MQ_QM/F72X8 M\T[Y>CK'O2O:0Z'S^KS1YJ55J8U6?VS<#1IQMX!8K0:^@P,XT\ 4/0HWY9AM M'\>/R2CV0VW\:'9FIMG4LK*<7F#>Q02)*,;O9,?!]N,P?S>OTT8> QR4,M"X\$2J0K-*!/$-I-ZS@KL")0N&HP,:<*=[ME^1\_SL2WA<\.V1=(M MK;HT=F<2X1XBR0F*C$ VML8JO1;<^#M)9;D$]%BI9XW=33+S$0*SRCA6-0_9 ML?=9@CI2"Q6*(H=#*3-IRDH@$Y:-$ETAF=TC+TCLH,O7 4VUY%@$M$)95(GC M3ZLM00MD=UIU^8EFD& QZ1ESD>IC%8P;M9U?=)/N:L;P)A?#BG5<=K1^K8G4 MBKPR'<=QM4W[)-M1BHU+-AZB2!]56W0*CXP81?3&.P(W*,&5A1U4J2X$IN%G1H-NX%"!L<;)YA M=+A6Y'RKDXU_8'N\G> %9!I\GX4@*[ =JSKJ67F\%"&U6)5-[W@_N7@BFYD" M8,LG0-IF2AQ#G*(.-*N[ M5J,''7FI9AJT"7BP/;81UK@+HA83"V)G;,&0%KINM[+S8A9HL1!I\S5$.AHB M;;Z&2)\O1+I?$2<> 6X7V9: J _L@8=]=7+%>#?Y9=3M!C8DR$689H#2OFKF MO&MNB%,N\;9[6\I .';5 Z]R*0GYR$@8)6R1;\+H!SIT MU )6Q!Y/8.SD0GZ[I*&;NUL9GFUIYQ#9B3!#/JZ /]#YM>UGM8[M\<[( MYLB.YWB)+KS6J(^9^F;^[XV*F%5W=O9@,Y\.QF6N"VPLSWRT@5ED;:K84FMV M;(ESDW55)(\)TO'#FWF#J(CC@!Q4##7F>P1$N(R3+.+2C ]H^EX2ZC,_]+,_ M_$?&4RJ,<[=AL-GCLN9HCY2I#Y8@-C"L2/S0P3*@87,.1?,RZD6KH"S7?[84 M!5!-.^=47FXE_>P:T6!3YL9^WU/)URKB.TIE$S0$]Z)K\T$G#5Q5P)I9F-\N M+F [=;N2*VB;+V+N@3Y1!>@1'0@88 I%-U5:&Y&Q!($PA3#@P2@6E8Z"BJD:O5H!^A4?^*?K M8B;#I8IJ3FU@6B=C[>T;/N;X;CN\E@5.MD!O[*-DLP:]B:-O>K1$9BW:^%"? MV6_S2VH?)?.V307X(:M_"-TTW3\BA44'/Z!A$_XQ2E?=C8(4F34Q5>D+'J"2 MXCAM$W,1IU#K.)^<8(9I@@67ZKAM,,R454$US>,N&B!-D0/=.C X;2RKX!G, MD.Z 6AB0P+9QVG3+6+T;[)1PC(=C/>16$:]T(ZD,Q@T4L*V"/J2?U4:>3I ) MLQIFH1Y!:I?^2<8LW^D82SQ(H@Q<V,W6V(R[(!6,G)P=(R&07X$[(2/AFOUK3>& MT]XA33IY:)#S,!LILC_XU00ZG$T2M9WVG M8;5V=LHET$4HLK2V&]9VZWYD&27'3R9'LZ;(,=P0VUN5G<8(W3+"8,;Y?D!" M>FR]1O!Q9,)>OR]=C^9'[\^>O 7]\A\-*7)[HE#*NJ?XK&:U9G,:K'Z.CXG#\F<9XAZ$ MN'(PXA<0/.\(0M\1LTW?)M34([&A'RQU$L.X>?E!#/6UCO1S*F\&QB9L!^#G MZ?VRB!P$K(+-"VF3XD(4;$HC;8VCTN>.Y4JN9.)7DN728 M]O*G%R>*Z#0T#SLA!>\B"^ M(DJ!&WB5JF4BO6C[Y"L?TR@5VW6*XY@Z7/7CIN\%/Z1;>&9A&(;\X^E]B^\I MK.=Z?DH,!.]&VE' \(YX3:EL99.UAZK'QXL=F$+=Y,76'(]QV*(J#/?\ RL4<&0"6-YZ1%R1W983.> M@6'W#%T8=@>O2_+4BNRN;R#16I'EG<_[)/"!9 4!P*/@?DK$O@!':9-<(T.9QNS@C.D)T8X\+GD>S^ &3!O(A?-B3]UB>\Q-#*DQ&PTV53?CH*UF.(&KS K04%T0I\L#GMW MO+B\H4O VOY[HF)QQ=2 MQ<'1RGG/]>J:_SOR_.] _/OT=NS#E' 'L3RG3!_O1>FWGRU^N:] M6'3$:XM=ZK\E)\G$U$:OZDZYVW^7- H'9Z#$Z9]KM9P.T[9JIG1S^W;1S*#L MAWW<&#:AV07S)TP,890D"R=16 YZU\?9;D[BB5OR-Z@U6ON(7<^'H>7O,MV) MU$&OTUUB25F<: N2A#SDNW7Z.KIL=-\N_W7'T3TRV_R*?5K[N,[N6IC&!-WB MJ5G+'CW+CL8(K>:;&=@$YVH8.:7JS-W4+5WQ1\")>.>GKAWKL_9F?H*1[+7% M4XGH3W;'/LGR'FU;VY.I[.;V,Y$GY=D&C[K-DV7J?I/!-ZW=VD3:M47&_NC9 M\S+?8DX"O<7Y?U:"O95(&F8U=R>,>1-X?&($_%.K^M?6^I?&\8JM%J/Z^H'XAP7A1Y-RVII1]?27G/ML*%S1VK45N*0M(M0@@3NO'93.&][-ZZ MYKL-7.O%[A3?0)[+A".HMYBJ9@40ST[M16/>NE6=K'G[XC(FUV_/L[H0#9ZC M,LN= >\T47_)D&)Q#? *SVZC9;-EU6NM5W(^$#E;5F/[WOLKS^BCSP>^1=PQ M]43:LX+?1M7:J2]-#?&=71*H!:JS/,UH:G6K,1D;> :;^$L&<"[/K7*$U]KZ M!9RS F!WO6YM_T)]D%6@0&-G4>N\Y '>.]B3^^YC+S:>>6NTF)FODXZ?#&H] M9+?//,&=EM6<1(4K-,%:S=I]@ D^71#R2!\L[>"&!L[A2\''_-7?,2?OGW4U M^M&#;(T[A-@><1AUJ]E)K'N2O77!K#6,W*159NL MA/8,R]>$#!*[^A#W;\_0".NW5IT M\W5UX[$+AY!6EP0/PP3+@=5GU/&;*]VX)CE3KA>( ?YZ?;.'#@#>H>T,5M[& M!,V%(W_W/EJ^"H1LWK[']4K)A2C9NO4HR_T(.;U>6, M#:N0V3O/:3Q1H+B04;9C:C.4F+Y=&O9)%I@9K+9)B67U:S()H./>>)&ZIL M(9S06POF-4BT(ED96.\?9P=]7JS>S\XZW4T\BFJ_V2I44%%*N'D/M9_GJ,ER M1N^,55[:RNW+!B>(&[VPC)[\;>/U+1G5S*W4JK M^<8D?#$I]CFQS(>WZ.4CP;0XME-QA&O N..Z/5JGI-\.I\6 M"X3>2*FI]6>SYXC>MJ^>I9\=?30S-T ]$Y!T]RU BY_J8ATZBF,7]!>]=V[HE).[F/65-O8PLJ42Q.\0M,/ M.QTR31CT@BIP*J;->>UIE[_YM#K1),T_*J1:>Q$ZD>N/3\LSA[) Y1+J*FLO M>03!+,CQG)>3 93...Y=2W^(Y.JZW)A*5#9U #I#M:M*HHR4/YJ!M%1.^'%H MMG"Q,"1[5%G]B^6:5%USDY9O;(0JT>*F3M4F<^E!IG-D5U0YF[78JJR, Y74 MJQN%-\GC)CY_/HVJ9*HB#I PT:&5W7,<9+J##CH/?>264^;GB%Y'VSLWUD0G(40% M,95S_X>D\;E=;1FD(;JJ68"D\AH%((4A639]AHHS@R*%MW1UID+.KLEB90G? M4RDA.2&F+E9@J=RW2BYUM4-+5T;(43E$T ]CR%!%[/E()-/MF>2!^*\@S#(& M$EWTR2T3T>"\B3D[S9Z,3BDZL&/(822E(M10VI'*VS^4(=.K$ M6:V62UFU S3>I^ER8N$@@=W.$CP6TO.ILV]H<*Q:G M^0:%CSC*OCD99=?C5(502,Q"&AY^KY1+5RRGTVC$RB>77TZQ'#L$J!7L/0U) MRNO&'G_+5/%!5ISC4\;]E^-Y2._/'G.W&:?M3SX<9_Y>7;<>>??Z(O7EIMGQ MG+5+/7/$A=2D:R-?%P.2A=UL;FW*5K8A,'9D]7\7=V1'!ODXV[)O]\\._P9+ MO_UR]?6$_OA_4$L! A0#% @ 8*V!5YGHL9D4) %<\! !$ M ( ! &%N<&,M,C R,S V,S N>'-D4$L! A0#% @ 8*V!5^+' M(OP<$@ ".T !4 ( !0R0 &%N<&,M,C R,S V,S!?8V%L M+GAM;%!+ 0(4 Q0 ( &"M@5?[]_CP>G$ %1]!P 5 " M 9(V !A;G!C+3(P,C,P-C,P7V1E9BYX;6Q02P$"% ,4 " !@K8%7_=CZ MX>46 0 #VPT %0 @ $_J 86YP8RTR,#(S,#8S,%]L86(N M>&UL4$L! A0#% @ 8*V!5Q8A%M!6

R @!E83$X.3$W-BTV:V$Q7V9R97-H M,BYH=&U02P$"% ,4 " !@K8%7,:,MJ5M+ 0#P/!$ &0 M@ 'W0P( 96$Q.#DQ-S9E>#DY+3%?9G)E/-:?0N2D ($A 0 9 " 8F/ P!E83$X.3$W-F5X.3DM B,E]F